<SEC-DOCUMENT>0001628280-22-012614.txt : 20220506
<SEC-HEADER>0001628280-22-012614.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505160058
ACCESSION NUMBER:		0001628280-22-012614
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		52
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35558
		FILM NUMBER:		22896006

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>crdf-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:5214d653-0d65-43f4-9358-98c3966fcc60,g:7d826e52-41b1-4720-8d3a-56dea8b8a1bc,d:43edf2a30c6642969a7b68c1e523baa5--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:crdf="http://www.cardiffoncology.com/20220331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>crdf-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80L2ZyYWc6OGIyYjczNGU0ZGJjNDAyNjg1ZWEyYjk3ZjA2MmQ2YWYvdGFibGU6ODBkMzg0MTg0MjBkNGEyZjhjZDlhYzhiZTFmM2Q2MjAvdGFibGVyYW5nZTo4MGQzODQxODQyMGQ0YTJmOGNkOWFjOGJlMWYzZDYyMF80LTEtMS0xLTI3NzQy_afa3e69a-116a-4cb8-abc9-13a091b58940">0001213037</ix:nonNumeric><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80L2ZyYWc6OGIyYjczNGU0ZGJjNDAyNjg1ZWEyYjk3ZjA2MmQ2YWYvdGFibGU6ODBkMzg0MTg0MjBkNGEyZjhjZDlhYzhiZTFmM2Q2MjAvdGFibGVyYW5nZTo4MGQzODQxODQyMGQ0YTJmOGNkOWFjOGJlMWYzZDYyMF83LTEtMS0xLTI3NzQy_05a2fc3b-6df4-4bcc-b15a-b87a02b0007b">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80L2ZyYWc6OGIyYjczNGU0ZGJjNDAyNjg1ZWEyYjk3ZjA2MmQ2YWYvdGFibGU6ODBkMzg0MTg0MjBkNGEyZjhjZDlhYzhiZTFmM2Q2MjAvdGFibGVyYW5nZTo4MGQzODQxODQyMGQ0YTJmOGNkOWFjOGJlMWYzZDYyMF84LTEtMS0xLTI3NzQy_4fa6862c-03a0-42c8-b090-80a464fd4f5f">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80L2ZyYWc6OGIyYjczNGU0ZGJjNDAyNjg1ZWEyYjk3ZjA2MmQ2YWYvdGFibGU6ODBkMzg0MTg0MjBkNGEyZjhjZDlhYzhiZTFmM2Q2MjAvdGFibGVyYW5nZTo4MGQzODQxODQyMGQ0YTJmOGNkOWFjOGJlMWYzZDYyMF8xMi0xLTEtMS0yNzc0Mg_26d4020a-0c05-42ae-b99d-ed9fd4985dad">2022</ix:nonNumeric><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80L2ZyYWc6OGIyYjczNGU0ZGJjNDAyNjg1ZWEyYjk3ZjA2MmQ2YWYvdGFibGU6ODBkMzg0MTg0MjBkNGEyZjhjZDlhYzhiZTFmM2Q2MjAvdGFibGVyYW5nZTo4MGQzODQxODQyMGQ0YTJmOGNkOWFjOGJlMWYzZDYyMF8xMy0xLTEtMS0yNzc0Mg_ae5df74f-28b0-4ea3-962d-73353e9972f0">Q1</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="crdf-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d160d05433642bf890809b8d47f76c6_I20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i3e26e9a60f67478f930bec7f58534ab7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i80a10fb9a55041acbf4471eb9962b140_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i032d3c2391934b749d64c1001f146392_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i530e82542d9e45d284f2f86beacf61bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3746cafcf2464a6a8c86d7eeb2da15d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbd660f941704d6eab498635e1633e0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0a34f4133324ecabf8ccf476f867efd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4da4e68a38249baac1d08460527a5c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i695a8c3be21242d3b5f355d90d3cee60_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64b5359a6ff94b8faf437365a08b98b6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00db47d4a17244ed896d6417ea6ac008_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68f4a1bcda064a5784195b33875c7f57_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3f2263cd87445ec9f6781abaf9f567f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5fe0cd6cb50486ea568f476234e2e09_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie675592e1c2a40919a88e24c67261742_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fcbabbd465940f7b361a479d927b2ca_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70185ba0bc824fbeb9be808cdb911645_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i545e543142c7462abbd863aff074c5b1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cc592d0c43c4571aca1097e49d8d129_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91922e2e89cf4c61aa12f0520d1a5742_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibad6d99cf2f840ce9e7bed2d46e20230_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3bfbf7525a84c06a46b8b822cc8c9fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0ece49122944a43b7c858a41e13bb5f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a5aae261a9942dea72ffd742b0669b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62458f79e8c5489190ae1d0a860182dc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i750dda3cd9b44f1d95a8ef8698d47bcd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf90f6cfceb846aba68cc0e11216576a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2e7fab3163147ac9e9e0c75f6a432ba_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i206e5d41255345cda79ffb2da56624ac_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i012412a3facb44e1a372eb4e99387bea_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00079f3fd1654534b9dde967f3160fd3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d9db9e17c6040a4b40aed1bd2c626fd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4756a6ec761647b6a76e977ae5e7ba32_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c9b59d1f3d947e2bf304d747c2fdeaa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd5fcea7daf5472c942b8b78378634ef_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i337b2454b9f14ec396bcb5ac1c5a5a1b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2fa9347524245c1b46dea90d3bd28ac_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60d1d6fb130c4369b0c92df1975e7d55_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6173183c9dc4f8f8a0e7a419a06718b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if15a941225894f6199ee7c21ae8d06e0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i295d5bedf87e4485addec2ccf76b8eb2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i292c08a55ac045e4b69997f574dcf6c0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadba25c9d3794ecf9349907eb7230ee7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4754a5ec9f3b4484a5792b7e7576b9b2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa80755e562d42a3862c7b9fb1a195f6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i402afd8930894e8dad31ee8ead92c780_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie176e42f42d040008fabaab3e6fc944b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5f29ec37e5044118f1345ab67b4bfe0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i858aaf4aebaa477690f541f5cef242e3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice8e727de3934bce8949d0a1f8de0a1f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa2aec20dcbb4e11a14fa3594fae5f15_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec0c5fbc68b74c27a7ff40151b92b5ee_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeaaebfbfd564b33828c67ca78b8c766_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i760860b7d95142e6a5f23bd5db8a0e83_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0c6edc4fe34456ca0daf70b67b95445_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bc7648a25f047e89409bd461a324502_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib787e125147a4fae952c9425271b6f7c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie08212cc90ef4e709206336ccf149313_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b8194a586f841738340b39f3d565848_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacb52739ae184a00938aabdbe0bb4cdd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4acf9b35e314e309ef0816d4754a15a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia453d0061bfb48fcaaabd8e50791523b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18725cb77e8f4c02b2f1432d16e20612_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16a7736ec34f4acb84606918dacb73af_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74a2163cb8414bdcba39fea19a1148e6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd7a7fe09574445a9ea6fbc3ee035b54_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1047e58df41b40d0b4e2422be90e9b1c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7137fd6fa9e84f46828d43b1c2cccb6e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if75dd8412dd548f2b9e9b67adbe7e3d5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id749a1f0c6be4b368e444ace5f891487_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38ee8c9b1c2244608a7990d422050c94_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9512c3da93e34771b7bdaff0723660ea_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d4747ed58c947ea9a3f145a4ab45200_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i572626db256d435291fe5c0afb9d041f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6e2de4855d74f7d86a9c98ab283751a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28c89bf87ce14cca9b2b800346e0f3cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i876b48d168b94c078324d718cfdcc6b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99895349e572414c90c807f0e0e17ebb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i547b6800236a4e0caab1382e2230e08a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c4033bd7f2c4aeb9ee5d73233cec607_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4977728e4fe6441a934b69b20c984428_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ff28c3628c9439f9476dce8d023e9a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f1aebf312994daaa324ca44ae909873_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie28739979eeb42ef9ba44e6345bbce01_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0548bc72c9014a57a21548990a80dc6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i966397496b06482ea36f27e6d9813468_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8358790f990b4c0eb465115ec36b4bad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i141fc564298749ef90e593b383c7b4dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i703f601f436b43d49b1a487d4d19c8db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i457626d4907642ed957f6fa275972b86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf6c73f105ea4cf5b84fc6c9051918ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88f18fc910f945858e3b8bc20c69c3a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fc6fa6aba914b51a5f862c4592ff78c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaad7930c0f094358b1f79e8717bc3ded_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb33f7c370f04ac9b542a1d9ce2740d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d8ce90d2f4242aebc0947a200a14d74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i978107023461439f9c9388246fe5f1d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i077d5e0a95724189b2ed4ff9de4ca7b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53718eacdc59401eb030bde33ae601c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67fc8a821a934707ad82e4a6523c6f04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i045f3a1f97f64eebba51a12fff7e25ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeff0db315444d1fa011989d0832b897_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80595d8a12bd44fdbc458c86f92eaf8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fedefbb21504c7c9d24ef677e84d271_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a1e4ef065b44bde91fa2353faafba2d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab946214765844419385e846f2f071c4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c3e566014904bf0849ff752d63a833b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cc8b81d6dec439faf2b7a1516cbae4f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaf3870ca7e245d39bb917baeb589cfd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ea1c1903a66482189db39519fa9ab69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i147c926c319848eda463b6b78b8ba88c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d9c1d34a1db4e9fb7d337599646fa44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad1db42d1d374f53989a2e7eb3b57555_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76184d10cb394f4ea42385613d47f3a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fec98606e0d4c2f815d907fbfd712cd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafe44b0f34c648c084e4cb969b1c99e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86dfda88f61d4ab88a4b5f4a3dea2526_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4794d63837f04ab3a7126147249402b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="lease"><xbrli:measure>crdf:lease</xbrli:measure></xbrli:unit><xbrli:context id="idf31e53b9d2d45af97ed7cc8c45e4d49_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaba2a240dd3945df929b606e4db832e0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5acd44d9cbae440c822b1c7ee063d0e2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7a9e753b3734856bcedf3f9838179e0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i893461f644cf442b9cd2137dff555003_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b15932b484a471ebbfef330aba8275d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7a27c0297d5482cbcaf83e2e3556d4b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2401c06088e64dc38c0c80a779717d55_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crdf:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75f4f015594a4bbf8dbbe4dfa4bb7c12_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crdf:InducementGrantStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i005b644829964efaa7d10c5ad40cdf4e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdc2b0e256004062aef3e08c666721e1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59573fd142404a38a175c7870f55419f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc3f3107c69b4f6b8dd87b5fdf51dfff_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b017a6f753f436d9ec2f214f9ebe2f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bbf49ad684a421fbea0a38b95540cc1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5be5174c9fb344c9a625c79d662f8c80_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49b6a8dfc660406a91d6569610ca4915_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8d76d5beb354ae2a99c506c37bfe260_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e7fca4604c9471d93e4d2007ee915b4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b1336fa1dbf42329f000675cc7b21f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i43edf2a30c6642969a7b68c1e523baa5_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGV4dHJlZ2lvbjo5ZmQwNjQwYjZkMzE0MDlkYmYxMTQ2ZjMyZTUzZjgyOF8xODYx_f283d735-fdf2-4076-a0a7-e41f86e9efd1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6Mjc2MWY0MTZkZTkxNDdhZmI0ODg2OTU3YjdiMjEyODEvdGFibGVyYW5nZToyNzYxZjQxNmRlOTE0N2FmYjQ4ODY5NTdiN2IyMTI4MV8wLTAtMS0xLTI3NzQy_0efb0016-190f-4cc3-a197-e0f7d3e960eb">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT UNDER SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGV4dHJlZ2lvbjo5ZmQwNjQwYjZkMzE0MDlkYmYxMTQ2ZjMyZTUzZjgyOF8xMzc_f8adc57f-a7f9-4fe3-ac82-263b91790572">March 31, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6MjdkY2Y1MjZhMDk5NDdjZjk1NGMyOWY5ZTY3Zjk5MTUvdGFibGVyYW5nZToyN2RjZjUyNmEwOTk0N2NmOTU0YzI5ZjllNjdmOTkxNV8wLTAtMS0xLTI3NzQy_66be2e11-d9dd-494a-803f-e5f37285af22">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT UNDER SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGV4dHJlZ2lvbjo5ZmQwNjQwYjZkMzE0MDlkYmYxMTQ2ZjMyZTUzZjgyOF8xODU1_ab4b75b4-83a1-45fe-a534-18c5eae0c3b6">001-35558</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGV4dHJlZ2lvbjo5ZmQwNjQwYjZkMzE0MDlkYmYxMTQ2ZjMyZTUzZjgyOF8xODU3_efa40115-1138-484a-8fc9-fdea64d44f0c">CARDIFF ONCOLOGY,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact Name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:48.552%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NTQ3OGZjMDExZDcyNDk4YWFmZWFlN2QxZDZmNmVhNjgvdGFibGVyYW5nZTo1NDc4ZmMwMTFkNzI0OThhYWZlYWU3ZDFkNmY2ZWE2OF8wLTAtMS0xLTI3NzQy_15c1d12e-e3d3-48d2-a15f-868f2b0f98cb">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NTQ3OGZjMDExZDcyNDk4YWFmZWFlN2QxZDZmNmVhNjgvdGFibGVyYW5nZTo1NDc4ZmMwMTFkNzI0OThhYWZlYWU3ZDFkNmY2ZWE2OF8wLTItMS0xLTI3NzQy_52e76b47-f19e-43f1-8a0a-201aeff8e2b7">27-2004382</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NTQ3OGZjMDExZDcyNDk4YWFmZWFlN2QxZDZmNmVhNjgvdGFibGVyYW5nZTo1NDc4ZmMwMTFkNzI0OThhYWZlYWU3ZDFkNmY2ZWE2OF8zLTAtMS0xLTI3NzQyL3RleHRyZWdpb246MjM5M2MwMWQxNjc0NGFjMzkwZjI4YjBkMmI3MGVmM2JfNA_958b9ece-1db2-4ddc-88e1-7ac728fa8ff2">11055 Flintkote Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NTQ3OGZjMDExZDcyNDk4YWFmZWFlN2QxZDZmNmVhNjgvdGFibGVyYW5nZTo1NDc4ZmMwMTFkNzI0OThhYWZlYWU3ZDFkNmY2ZWE2OF8zLTAtMS0xLTI3NzQyL3RleHRyZWdpb246MjM5M2MwMWQxNjc0NGFjMzkwZjI4YjBkMmI3MGVmM2JfOA_f2ff40e6-1d23-463c-b835-5fbe24358a5d">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NTQ3OGZjMDExZDcyNDk4YWFmZWFlN2QxZDZmNmVhNjgvdGFibGVyYW5nZTo1NDc4ZmMwMTFkNzI0OThhYWZlYWU3ZDFkNmY2ZWE2OF8zLTAtMS0xLTI3NzQyL3RleHRyZWdpb246MjM5M2MwMWQxNjc0NGFjMzkwZjI4YjBkMmI3MGVmM2JfMTI_4085b380-3977-4886-a9a4-618f8d102fcc">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NTQ3OGZjMDExZDcyNDk4YWFmZWFlN2QxZDZmNmVhNjgvdGFibGVyYW5nZTo1NDc4ZmMwMTFkNzI0OThhYWZlYWU3ZDFkNmY2ZWE2OF8zLTItMS0xLTI3NzQy_fa436533-090d-49e5-a649-2ef291f1bdef">92121</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NTQ3OGZjMDExZDcyNDk4YWFmZWFlN2QxZDZmNmVhNjgvdGFibGVyYW5nZTo1NDc4ZmMwMTFkNzI0OThhYWZlYWU3ZDFkNmY2ZWE2OF82LTAtMS0xLTI3NzQyL3RleHRyZWdpb246OTQ3YTMyYjIwODAzNDM3MzhkZDIyMzM1NzIzYjYyZjhfNQ_bc0bba89-b18d-4f36-8a9f-b0275fce9d83">858</ix:nonNumeric>) <ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NTQ3OGZjMDExZDcyNDk4YWFmZWFlN2QxZDZmNmVhNjgvdGFibGVyYW5nZTo1NDc4ZmMwMTFkNzI0OThhYWZlYWU3ZDFkNmY2ZWE2OF82LTAtMS0xLTI3NzQyL3RleHRyZWdpb246OTQ3YTMyYjIwODAzNDM3MzhkZDIyMzM1NzIzYjYyZjhfOQ_782f5b6c-1066-40b3-a5d0-4e655370855f">952-7570</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:31.862%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.725%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title&#160;of&#160;each&#160;class:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading&#160;Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NWRjNDBhMWU2MjcxNDg3NzlkYjk3MGY4NTMzZmYzNTUvdGFibGVyYW5nZTo1ZGM0MGExZTYyNzE0ODc3OWRiOTcwZjg1MzNmZjM1NV8xLTAtMS0xLTI3NzQy_3bc09a64-4e3c-4eaa-a7e3-56deba502a95">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NWRjNDBhMWU2MjcxNDg3NzlkYjk3MGY4NTMzZmYzNTUvdGFibGVyYW5nZTo1ZGM0MGExZTYyNzE0ODc3OWRiOTcwZjg1MzNmZjM1NV8xLTItMS0xLTI3NzQy_db089ddf-22aa-429c-99e6-b2bccb39ca06">CRDF</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Capital Market</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the issuer (1)&#160;filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGV4dHJlZ2lvbjo5ZmQwNjQwYjZkMzE0MDlkYmYxMTQ2ZjMyZTUzZjgyOF8xODU4_affb7cdb-78d7-4429-a58e-27fbfea254f4">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGV4dHJlZ2lvbjo5ZmQwNjQwYjZkMzE0MDlkYmYxMTQ2ZjMyZTUzZjgyOF8xODU5_05c8fb9a-0b3b-4092-ab06-d39d44ada568">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:17.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.999%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6YmI0MDY5YjhhMmU5NDYwM2E3ZjZiNTA2MGEyYTk0YTIvdGFibGVyYW5nZTpiYjQwNjliOGEyZTk0NjAzYTdmNmI1MDYwYTJhOTRhMl8wLTQtMS0xLTI3NzQyL3RleHRyZWdpb246ZjA5NzE2ZDk4Y2JjNDRlYWEyOTE4ZTM0MmFkNzAxZjBfNA_8c48dc79-a6f4-40b2-8bc6-8838a7d190a7">Non-accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company&#160;<ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6YmI0MDY5YjhhMmU5NDYwM2E3ZjZiNTA2MGEyYTk0YTIvdGFibGVyYW5nZTpiYjQwNjliOGEyZTk0NjAzYTdmNmI1MDYwYTJhOTRhMl8wLTYtMS0xLTI3NzQyL3RleHRyZWdpb246ZDE1YjMxOGE4YjgxNDZlZDhkZGViNDM2ODJiNDQ1ZDZfMzA_52f8dec1-358a-4388-9d6d-a0d2a30ed004">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6YmI0MDY5YjhhMmU5NDYwM2E3ZjZiNTA2MGEyYTk0YTIvdGFibGVyYW5nZTpiYjQwNjliOGEyZTk0NjAzYTdmNmI1MDYwYTJhOTRhMl8wLTgtMS0xLTI3NzQyL3RleHRyZWdpb246MzgzZmM5NDI1NjJiNDIwYzliMDM3YjcwZWUyNjhiZjBfMjg_128997b7-6237-436f-adae-533abd6de05b">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGV4dHJlZ2lvbjo5ZmQwNjQwYjZkMzE0MDlkYmYxMTQ2ZjMyZTUzZjgyOF8xODYw_755e9135-f9f4-418e-bf97-4c553b79d0bc">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;28, 2022, the issuer had <ix:nonFraction unitRef="shares" contextRef="i0d160d05433642bf890809b8d47f76c6_I20220428" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGV4dHJlZ2lvbjo5ZmQwNjQwYjZkMzE0MDlkYmYxMTQ2ZjMyZTUzZjgyOF8xODA1_d2416f8a-33d6-4597-8253-11af7b3b32c7">43,306,061</ix:nonFraction> shares of Common Stock issued and outstanding.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i43edf2a30c6642969a7b68c1e523baa5_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_10">PART&#160;I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_13">Item 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_13">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_16">Condensed Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_16">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_19">Condensed Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_19">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_22">Condensed Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_22">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_25">Condensed Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_25">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_31">Condensed Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_31">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_37">Notes to Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_37">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_73">Item 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_73">17</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_97">Item 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_97">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_94">22</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_100">Item 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_100">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_100">22</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_103">PART&#160;II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_103">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_106">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_106">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_106">23</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_109">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_109">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_109">23</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_112">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_112">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_112">23</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_115">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_115">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_115">23</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_118">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_118">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_118">23</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_121">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_121">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_121">23</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_124">Item 6:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_124">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_124">23</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_127">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i43edf2a30c6642969a7b68c1e523baa5_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except par value)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMy0xLTEtMS0yNzc0Mg_d014f03f-8550-4349-8169-6e407862cdfa">20,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMy0zLTEtMS0yNzc0Mg_4e7ab58b-199d-40a1-80bd-4e18bb8fd17e">11,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNC0xLTEtMS0yNzc0Mg_9431aca9-27ed-48e4-88e8-d994274a372b">109,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNC0zLTEtMS0yNzc0Mg_63dab31a-7bc5-43ed-bbd4-ac5b38852d7f">128,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNS0xLTEtMS0yNzc0Mg_509ab6c9-0fb0-4751-873e-266b8bbc64cf">447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNS0zLTEtMS0yNzc0Mg_552fcfdf-f2df-4551-9b84-a77c28567551">535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNi0xLTEtMS0yNzc0Mg_28d5f3b2-ac45-4bec-bb73-7353dca4a872">5,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNi0zLTEtMS0yNzc0Mg_0f9f5fd4-4a66-441d-8bd4-f1535ea36c83">4,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNy0xLTEtMS0yNzc0Mg_dc78184f-fff6-4a9e-a1d5-6f4cce40d61f">135,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNy0zLTEtMS0yNzc0Mg_af89bb44-7304-4794-987b-a33b71be8a74">146,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfOC0xLTEtMS0yNzc0Mg_e8bc074d-e0e0-4ff7-80f0-0b3251db2d99">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfOC0zLTEtMS0yNzc0Mg_9dfe0c7a-42d6-4678-bde3-b25a229b8c9d">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTAtMS0xLTEtMjc3NDI_f5f5783f-60a3-45fe-9faf-5925ebb199d1">2,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTAtMy0xLTEtMjc3NDI_f28f39fe-3d46-4805-bab9-542fa53256a4">2,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTEtMS0xLTEtMjc3NDI_fe86f228-6795-43de-896b-03b6a4701c40">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTEtMy0xLTEtMjc3NDI_c747fea3-2f91-4614-b42e-c054e36484bd">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTItMS0xLTEtMjc3NDI_26cc10f0-eaa4-49b7-bf13-63c25f4bb42f">139,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTItMy0xLTEtMjc3NDI_64a33051-7e23-43ce-9001-20ffa09325b9">149,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTYtMS0xLTEtMjc3NDI_fbba2c60-b056-485d-be4d-3e1a5f9181b3">1,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTYtMy0xLTEtMjc3NDI_6978e481-f9cd-4dba-93c2-c70cfb77280b">1,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTctMS0xLTEtMjc3NDI_a9b58811-56ed-4b23-a0da-314ee1c041d5">4,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTctMy0xLTEtMjc3NDI_979edc9b-ed32-460a-b0ba-c9effe88bec4">4,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTktMS0xLTEtMjc3NDI_80b4a593-f02a-4062-8f1c-44941068d40d">665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTktMy0xLTEtMjc3NDI_ad17a05f-e041-449f-90ba-fbc4d115e063">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMjAtMS0xLTEtMjc3NDI_91e59107-d263-4e68-bba2-0cf791618991">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMjAtMy0xLTEtMjc3NDI_060facc1-bbaa-449e-b46b-1850585bdc90">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMjItMS0xLTEtMjc3NDI_92f02734-abb4-42c2-b4cb-b2d792827bb2">6,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMjItMy0xLTEtMjc3NDI_54ee48d9-ba6d-46df-8165-170c7dd56f20">6,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMjUtMS0xLTEtMjc3NDI_6ac5f46e-c306-4df6-8d42-3619c8cfbc65">2,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMjUtMy0xLTEtMjc3NDI_5a54e493-3b4f-4730-a826-7f0063c4a9e3">2,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMjgtMS0xLTEtMjc3NDI_e8b8e96a-d306-4e3c-aef7-241bd2148f92">9,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMjgtMy0xLTEtMjc3NDI_e0faad71-23fe-475b-a1da-25f2042631dc">9,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzAtMS0xLTEtMjc3NDI_a6e983d7-3a54-478d-ac2d-b9847b91c70b"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzAtMy0xLTEtMjc3NDI_48a689c7-18f1-4a12-ade9-969e37b814c6"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, <ix:nonFraction unitRef="shares" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzMtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo0OTY4Zjc5NzYxMzA0ZWEwOTNlMDA2NGJlN2VhZDk1YV8yMQ_02992d4f-09da-4c52-b556-e338cc7b3230"><ix:nonFraction unitRef="shares" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzMtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo0OTY4Zjc5NzYxMzA0ZWEwOTNlMDA2NGJlN2VhZDk1YV8yMQ_8939a8b6-f53b-4f01-bb34-2ecae60bb133">20,000</ix:nonFraction></ix:nonFraction> shares authorized; (Note 6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzMtMS0xLTEtMjc3NDI_06e2117d-d27f-4426-8430-edc46bd616f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzMtMy0xLTEtMjc3NDI_68476268-3eb0-4a65-880b-0f6a8e1e0fc6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo1Y2U0Njc4ZjhkZTQ0YWNlYWI4NmFlNmI4OTU1OTlkOF8xOQ_0a517e67-c062-47dd-acae-d171b76541be"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo1Y2U0Njc4ZjhkZTQ0YWNlYWI4NmFlNmI4OTU1OTlkOF8xOQ_52306382-c9d7-463e-a56e-65d10a0aacfc">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo1Y2U0Njc4ZjhkZTQ0YWNlYWI4NmFlNmI4OTU1OTlkOF8zMw_5e4517c2-2100-4bb7-8737-ea4867bf0541"><ix:nonFraction unitRef="shares" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo1Y2U0Njc4ZjhkZTQ0YWNlYWI4NmFlNmI4OTU1OTlkOF8zMw_c0bb1f4d-e702-4e20-a768-76b526552843">150,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo1Y2U0Njc4ZjhkZTQ0YWNlYWI4NmFlNmI4OTU1OTlkOF81NQ_4d391a9a-c7a6-4d2e-b160-1de360ed6cc4"><ix:nonFraction unitRef="shares" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo1Y2U0Njc4ZjhkZTQ0YWNlYWI4NmFlNmI4OTU1OTlkOF81NQ_d3d4d4e3-3ed4-40ff-a5f1-f188d0496d2f">43,306</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo1Y2U0Njc4ZjhkZTQ0YWNlYWI4NmFlNmI4OTU1OTlkOF82Mg_570d180f-1d69-4a00-90a6-01c08cfb6961"><ix:nonFraction unitRef="shares" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo1Y2U0Njc4ZjhkZTQ0YWNlYWI4NmFlNmI4OTU1OTlkOF82Mg_a296f947-0e7a-4693-9e86-5f5867c95dd7">41,964</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMS0xLTEtMjc3NDI_569ce56c-67b3-4d15-a791-a4779f923239">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMy0xLTEtMjc3NDI_871c4a60-e484-4ab2-b3b0-e2eacf1effd0">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzUtMS0xLTEtMjc3NDI_152336e5-2cbb-48f3-878f-653b58512922">401,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzUtMy0xLTEtMjc3NDI_fa72d935-1dff-4273-8158-8015f4967a35">400,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="crdf:ServiceReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzYtMS0xLTEtMjc3NDI_70416c45-dbca-48ec-b7cf-a7e73bb90edb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="crdf:ServiceReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzYtMy0xLTEtMjc3NDI_e45b9110-2245-475c-93dc-5536601d89b6">139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzctMS0xLTEtMjc3NDI_0ac2f92c-0899-44e2-8970-5aaa039c3ef6">748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzctMy0xLTEtMjc3NDI_806ac7be-48d1-4dca-b58e-34bd0be12e27">142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzgtMS0xLTEtMjc3NDI_fc58a78b-3f1a-4680-bd79-4042a6485fbe">270,809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzgtMy0xLTEtMjc3NDI_a9ff7d51-b9ea-4be5-a004-ecee4f9f9ea2">259,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzktMS0xLTEtMjc3NDI_8f692760-1f3a-4bec-8127-90bda5c50643">130,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzktMy0xLTEtMjc3NDI_70ecaf7f-6e87-4127-b681-cd3ea9a11db3">140,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNDAtMS0xLTEtMjc3NDI_3a4cade2-269a-4c0d-98a2-f398ee332201">139,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNDAtMy0xLTEtMjc3NDI_678f076f-9824-4a32-8acb-84d2b34eae6e">149,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i43edf2a30c6642969a7b68c1e523baa5_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfNS01LTEtMS0yNzc0Mg_36c762c5-bda5-4441-bc3e-e9cb2c0be8dc">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfNS03LTEtMS0yNzc0Mg_75b45710-7d53-499d-8c1f-9b0a1f2274fa">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfOC01LTEtMS0yNzc0Mg_a6a28489-43f7-4d48-b4f2-828f6158976a">7,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfOC03LTEtMS0yNzc0Mg_fea98dbb-5428-4024-8b16-58ac411b81b8">3,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfOS01LTEtMS0yNzc0Mg_9d56d0bf-b14d-4017-885b-b20c06922dce">3,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfOS03LTEtMS0yNzc0Mg_07079bf9-2231-494e-85a6-e95df7db06dd">2,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMTItNS0xLTEtMjc3NDI_4ab318ea-07c9-4952-babc-f02dd8910de9">11,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMTItNy0xLTEtMjc3NDI_3b253042-22d7-4010-9780-bbbe9b0e03f4">5,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMTQtNS0xLTEtMjc3NDI_593e22e2-88b9-43b6-affe-4b2bb5b1d1ea">11,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMTQtNy0xLTEtMjc3NDI_2910b449-9024-4d98-a4c9-5793617aa9f8">5,442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMTYtNS0xLTEtMjc3NDI_7ab046ae-b82d-4737-a4e4-ada791077af3">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMTYtNy0xLTEtMjc3NDI_11b60baf-9556-4ac9-9480-57b5c2b5cebd">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from change in fair value of derivative financial instruments&#8212;warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMTgtNS0xLTEtMjc3NDI_8cf7bff5-ee5a-4953-bd30-4881d5bc3fbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMTgtNy0xLTEtMjc3NDI_c9b4b1fa-22cb-4d08-b29a-33d7b72b34b9">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjAtNS0xLTEtMjc3NDI_e3e27d52-893d-4100-946d-1ba8c77197dc">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjAtNy0xLTEtMjc3NDI_b547eeba-cfa5-44cf-a5d5-3a51167c2706">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjItNS0xLTEtMzM2NTc_8922e125-33bb-4d8e-8c19-88c4983d2147">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjItNy0xLTEtMzM2NTc_f593fe63-0181-4d7d-861b-cca6ff5cc251">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjEtNS0xLTEtMjc3NDI_723f9813-be87-4362-9eb8-355512136eb9">10,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjEtNy0xLTEtMjc3NDI_8e41f0af-bd04-4065-9201-502ddcad3f51">5,179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjMtNS0xLTEtMjc3NDI_a7915f8b-f14f-4132-a10b-b85b88dd838d">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjMtNy0xLTEtMjc3NDI_f68ebca5-a2a3-4ecd-a70b-b2f7ff93f8e3">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjktNS0xLTEtMjc3NDI_03a342fd-0edc-4318-a26b-bfb23bd97586">10,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjktNy0xLTEtMjc3NDI_48b2c98c-2453-48d2-94f1-7d80eedfd78f">5,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMzEtNS0xLTEtMjc3NDI_6841c21e-6536-4642-a7c5-e5c866cb607f"><ix:nonFraction unitRef="usdPerShare" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMzEtNS0xLTEtMjc3NDI_9ee5cdce-38b2-41bc-915c-493b4ffede70">0.25</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMzEtNy0xLTEtMjc3NDI_6faf2512-c865-4aff-9adf-818480822026"><ix:nonFraction unitRef="usdPerShare" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMzEtNy0xLTEtMjc3NDI_e4aabe0b-0584-445f-ba4a-dd9119182fea">0.14</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8212; basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMzQtNS0xLTEtMjc3NDI_e4626c0f-b5e2-4317-a80d-e099b1d1493f"><ix:nonFraction unitRef="shares" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMzQtNS0xLTEtMjc3NDI_ef5fe2c1-b922-4e3b-bc0f-1cd01244598b">43,231</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMzQtNy0xLTEtMjc3NDI_56d1e2d9-0662-4639-9029-e8591c9d3a26"><ix:nonFraction unitRef="shares" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMzQtNy0xLTEtMjc3NDI_6679e0a3-258c-4c9e-81c5-882361934e83">37,164</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfMi01LTEtMS0yNzc0Mg_940143f0-aae0-4432-a8f0-b7b2a5dfa9b7">10,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfMi03LTEtMS0yNzc0Mg_aa46d316-44b6-4e3d-8bef-6f50a67d18bd">5,179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Unrealized loss on securities available-for-sale</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfNC01LTEtMS0yNzc0Mg_34a65e1b-989d-4e02-a65d-b99b0e37b2dd">606</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfNC03LTEtMS0yNzc0Mg_2c31aa35-0c40-43d8-82be-48a93f963a92">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfNS01LTEtMS0yNzc0Mg_3d58170e-e867-4b5b-b90a-f1f825789deb">11,599</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfNS03LTEtMS0yNzc0Mg_e7a232e0-10f1-40b3-b0c6-eff692b24350">5,246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfNy01LTEtMS0yNzc0Mg_c6431fd6-dbff-4e15-9ce6-274f02bafdc7">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfNy03LTEtMS0yNzc0Mg_d2a45eec-6ea2-4102-9c3b-3f03517ae0fb">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to common stockholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfMTMtNS0xLTEtMjc3NDI_8c380662-ea80-46ab-b0fb-4459bd0ee7bd">11,605</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfMTMtNy0xLTEtMjc3NDI_d5d62360-e25d-4a4e-9851-700cfa3b0ee1">5,252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i43edf2a30c6642969a7b68c1e523baa5_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Service Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i032d3c2391934b749d64c1001f146392_I20211231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMS0xLTEtMS0yODI4MA_03bb8929-e5cc-43a4-9049-64e91aa3e0ce">716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i032d3c2391934b749d64c1001f146392_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMS0zLTEtMS0yODI4MA_18303ab6-622a-4edc-84f6-e4d9c07e2ec7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i530e82542d9e45d284f2f86beacf61bd_I20211231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMS01LTEtMS0yODI4MA_007142d9-6035-4bc2-ac08-0e34a7c40a41">41,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530e82542d9e45d284f2f86beacf61bd_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMS03LTEtMS0yODI4MA_0681dbb2-25bd-412e-853f-e6a29d9a92c3">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3746cafcf2464a6a8c86d7eeb2da15d0_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMS05LTEtMS0yODI4MA_cd773448-08be-421d-a9e5-6cc7aa7f6b96">400,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbd660f941704d6eab498635e1633e0e_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMS0xMS0xLTEtMjgyODA_eb3b58e2-6464-4c3d-91dd-cdd28818ab1f">139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0a34f4133324ecabf8ccf476f867efd_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMS0xMy0xLTEtMjgyODA_9ef6a814-21f8-449a-b524-71a9851ca893">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4da4e68a38249baac1d08460527a5c9_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMS0xNS0xLTEtMjgyODA_bd6f9638-f58f-4430-888b-8f2646b96321">259,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMS0xNy0xLTEtMjgyODA_eca4f187-a3e5-4abc-96e4-8827c691117f">140,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i695a8c3be21242d3b5f355d90d3cee60_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMi05LTEtMS0yODI4MA_db7ba5d4-1780-42ce-8916-1b9d0c184922">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMi0xNy0xLTEtMjgyODA_8265b469-3005-496f-b61d-cbdc20de7920">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64b5359a6ff94b8faf437365a08b98b6_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfNi0xMy0xLTEtMjgyODA_00a6a72b-8a5a-4905-8d85-b9d4e165a9c5">606</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfNi0xNy0xLTEtMjgyODA_3135d9eb-9a7b-4776-b1a5-4fe8fb3d5fcf">606</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of common stock upon conversion of Series E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i00db47d4a17244ed896d6417ea6ac008_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfNy0xLTEtMS0zMjE1Mg_0c0d040d-9c9d-499d-bc03-9f28eb7e1187">328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00db47d4a17244ed896d6417ea6ac008_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfNy0zLTEtMS0zMjE1Mg_c90941f7-49ed-423f-bc00-8cfa5751fd95">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68f4a1bcda064a5784195b33875c7f57_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfNy01LTEtMS0zMjE1Mg_09c69ca7-680f-4e89-846c-7b8424e55837">1,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfNy0xNy0xLTEtMzIxNTI_338f8fb6-1f91-4386-bf2b-36f63b32acfe">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3f2263cd87445ec9f6781abaf9f567f_D20220101-20220331" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfNy0xNS0xLTEtMjgyODA_7ce46e1d-7b8e-409d-b1d1-77ee5b79b376">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfNy0xNy0xLTEtMjgyODA_5fad9686-9c63-4dd5-a5a1-35b2db97d3e0">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5fe0cd6cb50486ea568f476234e2e09_D20220101-20220331" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfOC0xMS0xLTEtMjgyODA_0f355af8-1a8a-4af4-8923-8cf558def832">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfOC0xNy0xLTEtMjgyODA_544b45e5-646c-474c-a948-386ec3dcee2c">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3f2263cd87445ec9f6781abaf9f567f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfOS0xNS0xLTEtMjgyODA_860c4ae6-fd2c-4d7c-8787-91811f0552cb">10,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfOS0xNy0xLTEtMjgyODA_b2c9e5e6-bbb3-4172-97f0-5b38f5f36a38">10,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie675592e1c2a40919a88e24c67261742_I20220331" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMTAtMS0xLTEtMjgyODA_11c2fe42-0e7d-4556-afc8-011d551913ae">388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie675592e1c2a40919a88e24c67261742_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMTAtMy0xLTEtMjgyODA_4ab02b33-5008-48a5-a18c-68e228f1f4c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1fcbabbd465940f7b361a479d927b2ca_I20220331" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMTAtNS0xLTEtMjgyODA_182acb2d-385e-4eaf-95c0-c1a8695ebcaf">43,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fcbabbd465940f7b361a479d927b2ca_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMTAtNy0xLTEtMjgyODA_65223587-c605-40b5-8146-cdec054e3623">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70185ba0bc824fbeb9be808cdb911645_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMTAtOS0xLTEtMjgyODA_d9998cbc-3d2f-4b9a-8712-eab4d097bcdc">401,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i545e543142c7462abbd863aff074c5b1_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMTAtMTEtMS0xLTI4Mjgw_1ed7fc1d-2b22-49f2-887e-ea8f8a3593e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cc592d0c43c4571aca1097e49d8d129_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMTAtMTMtMS0xLTI4Mjgw_e8794d99-55ad-4ffe-a32d-69ebb7622381">748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91922e2e89cf4c61aa12f0520d1a5742_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMTAtMTUtMS0xLTI4Mjgw_21c6a5b3-3f68-4b6a-88eb-62e761a60895">270,809</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMTAtMTctMS0xLTI4Mjgw_86d543fb-2d32-4bd6-b62e-b4f8ba774a15">130,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Service Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibad6d99cf2f840ce9e7bed2d46e20230_I20201231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMS0xLTEtMS0yNzc0Mg_2816be60-3115-49d0-b124-9c57ff3f0d29">716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibad6d99cf2f840ce9e7bed2d46e20230_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMS0zLTEtMS0yNzc0Mg_7c1fb65e-896f-4a9a-a2ec-5a566cf6dbe3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3bfbf7525a84c06a46b8b822cc8c9fd_I20201231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMS01LTEtMS0yNzc0Mg_0583a6a5-61a6-4982-b49d-f501569b4d69">36,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3bfbf7525a84c06a46b8b822cc8c9fd_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMS03LTEtMS0yNzc0Mg_88d49f82-ae66-4481-9b08-fcff6bb6306d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ece49122944a43b7c858a41e13bb5f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMS05LTEtMS0yNzc0Mg_45744436-8d45-4aaa-8404-822d9f54c4d3">361,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5aae261a9942dea72ffd742b0669b2_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMS0xMS0xLTEtMjc3NDI_7a5e8d59-27ff-411f-848f-04409dc68438">2,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62458f79e8c5489190ae1d0a860182dc_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMS0xMy0xLTEtMjc3NDI_4c269515-62e5-4b7e-934e-5122da37c94e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i750dda3cd9b44f1d95a8ef8698d47bcd_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMS0xNS0xLTEtMjc3NDI_06536a27-f69d-4406-bc34-ea0a67744d68">231,495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf90f6cfceb846aba68cc0e11216576a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMS0xNy0xLTEtMjc3NDI_d06ec284-eb42-41f7-b563-25a0d74de38a">128,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e7fab3163147ac9e9e0c75f6a432ba_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMi05LTEtMS0yNzc0Mg_cbf1fffb-5f86-4258-a855-3608b2a24feb">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMi0xNy0xLTEtMjc3NDI_774292c7-c573-4705-b651-5fa9b91b1f13">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i206e5d41255345cda79ffb2da56624ac_D20210101-20210331" decimals="-3" name="crdf:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfNC01LTEtMS0yNzc0Mg_1afce3ee-6567-48c1-b801-50d4067d02e6">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e7fab3163147ac9e9e0c75f6a432ba_D20210101-20210331" decimals="-3" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfNC05LTEtMS0yNzc0Mg_99d96581-a199-4f91-bf52-cd49350ac02a">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfNC0xNy0xLTEtMjc3NDI_eee811d3-9c60-4079-ab6b-77c3781563e5">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i012412a3facb44e1a372eb4e99387bea_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfNi0xMy0xLTEtMjc3NDI_0ed5966a-0b88-40e9-9b32-6a79c9d44526">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfNi0xNy0xLTEtMjc3NDI_7e26ddeb-3f69-4023-a10d-4e5be501dc03">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00079f3fd1654534b9dde967f3160fd3_D20210101-20210331" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfNy0xNS0xLTEtMjc3NDI_0cfaee65-2871-4f82-9575-76b7d2e2d5c9">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfNy0xNy0xLTEtMjc3NDI_b3abd638-6885-4e19-a0cf-3d28c283ce54">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d9db9e17c6040a4b40aed1bd2c626fd_D20210101-20210331" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfOC0xMS0xLTEtMjc3NDI_ac55e4ce-3bdb-4184-a2c7-82cf4ddfeb9d">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfOC0xNy0xLTEtMjc3NDI_a1a40109-5f36-4abf-b6d3-fadd11e0412c">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00079f3fd1654534b9dde967f3160fd3_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfOS0xNS0xLTEtMjc3NDI_2c96ab44-a655-4f51-ad0d-e047c03bb867">5,179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfOS0xNy0xLTEtMjc3NDI_60c9384d-b15b-4ab0-bd52-e6e458fd54b7">5,179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4756a6ec761647b6a76e977ae5e7ba32_I20210331" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMTAtMS0xLTEtMjc3NDI_c9f8767f-6abb-4dcd-86e3-32c1ffcc6c13">716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4756a6ec761647b6a76e977ae5e7ba32_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMTAtMy0xLTEtMjc3NDI_8fd2763c-9760-4605-89b7-830bb0180ee1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c9b59d1f3d947e2bf304d747c2fdeaa_I20210331" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMTAtNS0xLTEtMjc3NDI_5818606b-aafd-421b-89a5-8aa9b50816b9">37,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c9b59d1f3d947e2bf304d747c2fdeaa_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMTAtNy0xLTEtMjc3NDI_44a181db-e74e-4ca0-adb1-3cbe89fe891e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5fcea7daf5472c942b8b78378634ef_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMTAtOS0xLTEtMjc3NDI_7dfdb102-060e-4e12-8c6e-27583c9963a2">363,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i337b2454b9f14ec396bcb5ac1c5a5a1b_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMTAtMTEtMS0xLTI3NzQy_664b6b2f-c068-4773-b5cc-74949759e85c">1,791</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2fa9347524245c1b46dea90d3bd28ac_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMTAtMTMtMS0xLTI3NzQy_98a8c6da-cab2-41fe-8203-f7b0ef1fd75b">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60d1d6fb130c4369b0c92df1975e7d55_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMTAtMTUtMS0xLTI3NzQy_efd2b8da-88af-443f-85ab-34dbfbed7c54">236,680</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6173183c9dc4f8f8a0e7a419a06718b_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMTAtMTctMS0xLTI3NzQy_9d462325-ff7a-4915-9f76-c22334a58647">124,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i43edf2a30c6642969a7b68c1e523baa5_31"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMy0xLTEtMS0yNzc0Mg_ca7c9f25-6783-41f7-bbc0-db59b0dc458b">10,993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMy0zLTEtMS0yNzc0Mg_948a0b81-22c3-46ef-a489-b8cb08b3dbe3">5,179</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNS0xLTEtMS0yNzc0Mg_41d9281d-0326-4089-a73d-3c96ee8ec69e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNS0zLTEtMS0yNzc0Mg_fe5078e3-d969-4819-9297-0287ffd8ee52">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNy0xLTEtMS0yNzc0Mg_b28c8ad2-cd98-4e00-a3e4-b31f3b8e6bdd">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNy0zLTEtMS0yNzc0Mg_37391206-7a71-4c81-959f-de821b8c098c">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfOC0xLTEtMS0yNzc0Mg_ca37add7-ec2b-4ac8-8ba0-f6fb3d718509">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfOC0zLTEtMS0yNzc0Mg_67765936-f3c9-487a-b5f2-69bec76c0cba">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums on short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMTMtMS0xLTEtMjc3NDI_87a7eee6-fbc8-4d2b-95f5-f3b5dfea316c">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMTMtMy0xLTEtMjc3NDI_bea478e4-8c17-4631-bea4-41795086acec">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments&#8212;warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMTYtMS0xLTEtMjc3NDI_e76d2bc5-3cff-4f7d-a16a-72d9c839b88f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMTYtMy0xLTEtMjc3NDI_9b4dd5c3-a824-4fc6-85be-2834cf5229b9">207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMTctMS0xLTEtMjc3NDI_039eabc7-716f-4fc0-95aa-bf7c58a30a34">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMTctMy0xLTEtMjc3NDI_21534b10-4971-4b14-bf38-ff980ef2ba43">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMTktMS0xLTEtMjc3NDI_629556dc-eb34-46cb-81cd-d0b01c6097d9">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMTktMy0xLTEtMjc3NDI_fdf41472-9cf8-4a17-bb59-8badf5bbf432">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjAtMS0xLTEtMjc3NDI_46966115-730b-4082-b753-116302cdb1e7">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjAtMy0xLTEtMjc3NDI_66056d6e-c8f9-4db5-96e2-5e34aa9ac022">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjEtMS0xLTEtMjc3NDI_ba892da0-0c1f-4cc5-86b8-da25a9af65cb">1,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjEtMy0xLTEtMjc3NDI_3a1381ad-986f-43fe-8b9f-24faeba65a41">183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjItMS0xLTEtMjc3NDI_30c0be77-2f94-4ea9-888c-73ab2ef80a64">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjItMy0xLTEtMjc3NDI_ee979b1e-b6da-4f47-948f-4a79b75d23f7">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjMtMS0xLTEtMjc3NDI_b3310107-b8ef-4642-abf9-13ecf15605cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjMtMy0xLTEtMjc3NDI_b3abd001-1313-46e7-aa4e-57596ee0858a">1,421</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="crdf:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjQtMS0xLTEtMjc3NDI_454c0fda-6700-4c72-9288-5d947547551c">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="crdf:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjQtMy0xLTEtMjc3NDI_e025542d-e3cc-478e-8531-b490ba9d7dee">227</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjUtMS0xLTEtMjc3NDI_dd9deb63-99ac-4a87-9f89-48d5aa4b0f8d">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjUtMy0xLTEtMjc3NDI_4321e024-7086-4fb8-8623-77f185b0795f">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjYtMS0xLTEtMjc3NDI_149707b8-642d-45d7-b8ab-f66beddfc1a7">10,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjYtMy0xLTEtMjc3NDI_9da333c2-c38d-4a05-bfe2-fc7c12eea2f4">5,884</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzAtMS0xLTEtMjc3NDI_dd667722-770d-4c89-8805-3e1277a064c7">171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzAtMy0xLTEtMjc3NDI_b99310d5-4d6a-44dc-9663-f7f25f3ea571">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzEtMS0xLTEtMjc3NDI_ed0934d4-0fbd-4571-a6f7-26f8f0839b3f">38,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzEtMy0xLTEtMjc3NDI_0e7bd9c2-d73e-4110-bd11-ff0f8619a874">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzItMS0xLTEtMjc3NDI_58a498c4-9265-412f-ad74-8e607c109ec9">36,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzItMy0xLTEtMjc3NDI_8dd8e441-d6bf-40d2-8dc4-2f56130caf25">114,195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzMtMS0xLTEtMjc3NDI_01d24559-e486-4030-a976-d859b66da0e2">17,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzMtMy0xLTEtMjc3NDI_c66685c9-7d3f-478e-9655-b46aad7ce5dc">2,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzQtMS0xLTEtMjc3NDI_74b42d19-59b9-4a09-9a89-ad5cb9a61470">18,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzQtMy0xLTEtMjc3NDI_8304f6fa-9789-4be9-9fed-65bbd8d7bf17">111,698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNDEtMS0xLTEtMjc3NDI_9d2f70c6-e598-4445-a69e-c9f8b435816b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNDEtMy0xLTEtMjc3NDI_75322bc4-55d4-410b-9f01-86ab69017887">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNDctMS0xLTEtMjc3NDI_8484635b-4c6f-4e81-8232-d3b3bdce9d08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNDctMy0xLTEtMjc3NDI_e7485b2c-ee05-4678-8ac5-9e2f6199d5bc">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNDktMS0xLTEtMjc3NDI_4529816a-7d5d-4a77-a4b0-a2e4f759595a">8,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNDktMy0xLTEtMjc3NDI_88149ce1-e1dd-4674-9ef3-2905954c2e0c">116,319</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;Beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNTAtMS0xLTEtMjc3NDI_ae4c0608-9398-4ed1-971b-f4da73221e84">11,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf90f6cfceb846aba68cc0e11216576a_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNTAtMy0xLTEtMjc3NDI_8a7b9998-67b4-4d41-8687-d87aa635b376">130,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;End of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNTEtMS0xLTEtMjc3NDI_d34bc2e8-dca9-4849-bae4-e58b98f584d2">20,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6173183c9dc4f8f8a0e7a419a06718b_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNTEtMy0xLTEtMjc3NDI_87ebed16-fe96-414f-b63b-22ce45118a72">14,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplementary disclosure of cash flow activity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNTQtMS0xLTEtMjc3NDI_56fd10db-e0d2-4d83-a065-5c593dd2d63d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNTQtMy0xLTEtMjc3NDI_9fcf9058-2f0a-4023-8cc8-8d264eb5bdba">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of property and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNTctMS0xLTEtMjc3NDI_b73dd51d-70ab-4a74-a9d4-da083d11efe0">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNTctMy0xLTEtMjc3NDI_f7d5df85-9af6-4829-9db5-f53fc7d1920a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="crdf:PreferredStockDividendAccrued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNjAtMS0xLTEtMjc3NDI_2fffb02a-b6a8-44de-9dc0-de448ec14d19">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="crdf:PreferredStockDividendAccrued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNjAtMy0xLTEtMjc3NDI_c40e4ef4-e7c1-4a9f-a690-35881cc1b99c">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:83.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i43edf2a30c6642969a7b68c1e523baa5_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80MC9mcmFnOjQ5MTczOWQ1NGQ0NDQ5MjU5MWZjNTJmYTU3OWRjZDhmL3RleHRyZWdpb246NDkxNzM5ZDU0ZDQ0NDkyNTkxZmM1MmZhNTc5ZGNkOGZfMzA5OA_2c903ab2-3600-49c0-a72a-4b56c1222b3b" continuedAt="id1556575721348e38b71e1b54b6a1903" escape="true">Organization and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="id1556575721348e38b71e1b54b6a1903" continuedAt="i79b5ea51fdb4437290efe4f15c9ce4e3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Organization and Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology, Inc. (&#8220;Cardiff Oncology&#8221; or the &#8220;Company&#8221;) headquartered in San Diego, California, is a clinical-stage biotechnology company leveraging Polo-like Kinase 1 (&#8220;PLK1&#8221;) inhibition to develop novel therapies across a range of cancers with the greatest unmet medical need, including KRAS-mutated metastatic colorectal cancer, metastatic pancreatic cancer and metastatic castration-resistant prostate cancer. The Company's common stock is listed on the Nasdaq Capital Market under the ticker symbol "CRDF".</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and the rules&#160;and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form&#160;10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules&#160;and regulations. The unaudited interim condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company&#8217;s financial position and the results of its operations and cash flows for the periods presented. The unaudited condensed balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December&#160;31, 2021 included in the Company&#8217;s annual report on Form&#160;10-K filed with the SEC on February&#160;24, 2022.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net losses since its inception and has negative operating cash flows. As of March&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80MC9mcmFnOjQ5MTczOWQ1NGQ0NDQ5MjU5MWZjNTJmYTU3OWRjZDhmL3RleHRyZWdpb246NDkxNzM5ZDU0ZDQ0NDkyNTkxZmM1MmZhNTc5ZGNkOGZfMjIzOQ_af73af88-8e1a-4477-8030-78962138f410">129.4</ix:nonFraction>&#160;million in cash, cash equivalents and short-term investments and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.  </span></div></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i79b5ea51fdb4437290efe4f15c9ce4e3">For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#8217;s stockholders may experience additional dilution.</ix:continuation> </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_43"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RleHRyZWdpb246NDI5NGVlODFiMjc3NDdmOGI2NjM0NmQwZGUwMjBhMjZfNDMxNg_4588119e-0dba-449c-a163-18b7a6ba9a82" continuedAt="i83a72221f29640f884f6b12364c6018f" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i83a72221f29640f884f6b12364c6018f" continuedAt="i4fdf0b913bce43169f60178825b77674"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, there have been no changes to the Company&#8217;s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RleHRyZWdpb246NDI5NGVlODFiMjc3NDdmOGI2NjM0NmQwZGUwMjBhMjZfNDMxNQ_5a2bafc3-193c-4684-94a2-98b7b3f01f97" continuedAt="icf44f9d3a1b34f3b8853edf69791d298" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icf44f9d3a1b34f3b8853edf69791d298">Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.</ix:continuation> </span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><ix:continuation id="i4fdf0b913bce43169f60178825b77674"><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RleHRyZWdpb246NDI5NGVlODFiMjc3NDdmOGI2NjM0NmQwZGUwMjBhMjZfNDMyNA_81488359-a2b5-428f-b344-b51aa49e190d" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if15a941225894f6199ee7c21ae8d06e0_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfMi0xLTEtMS0yNzc0Mg_5a72d2fb-69a7-4ae0-9cea-f21703d9072d">5,467,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i295d5bedf87e4485addec2ccf76b8eb2_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfMi0zLTEtMS0yNzc0Mg_cc2a971c-cd72-4278-adc0-f1b2aa91ab36">1,849,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i292c08a55ac045e4b69997f574dcf6c0_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfMy0xLTEtMS0yNzc0Mg_aed1e1af-ce62-45dc-8578-e8c4a8d53c45">4,490,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iadba25c9d3794ecf9349907eb7230ee7_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfMy0zLTEtMS0yNzc0Mg_d9f22823-2f79-419f-a03c-4f14445e8ed5">4,490,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4754a5ec9f3b4484a5792b7e7576b9b2_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfNS0xLTEtMS0yNzc0Mg_f2eb98f4-b2e8-41c8-8220-f75e2ea9d0ca">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa80755e562d42a3862c7b9fb1a195f6_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfNS0zLTEtMS0yNzc0Mg_3feb9ef7-c64c-483f-9f6a-d6cdc2cb77f9">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i402afd8930894e8dad31ee8ead92c780_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfNy0xLTEtMS0yNzc0Mg_4abaa8d8-4e76-4a12-b96d-76ebd022c2e1">1,342,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie176e42f42d040008fabaab3e6fc944b_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfNy0zLTEtMS0yNzc0Mg_925549b4-97e6-4d3d-b03e-f731c7cedfef">2,684,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfOC0xLTEtMS0yNzc0Mg_652fc612-f3d4-4da3-9e63-6e60bca6040d">11,300,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfOC0zLTEtMS0yNzc0Mg_cac6a07f-29db-4018-b547-fbd8d1f4afdc">9,025,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RleHRyZWdpb246NDI5NGVlODFiMjc3NDdmOGI2NjM0NmQwZGUwMjBhMjZfNDMxMQ_0ef4c902-3200-4b8b-9c7f-09a76fe1ac87" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncement</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04 ("ASU 2021-04"), Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company has prospectively adopted this standard as of January 1, 2022 for periods presented after the adoption. The adoption of ASU 2021-04 did not have a material impact on the Company's financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncement Not Yet Adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023 for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i43edf2a30c6642969a7b68c1e523baa5_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;<ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RleHRyZWdpb246NTVjNjU1NjIxZjBlNDFmOGI1MjhmY2JhYTBiNzMyNjNfMTExMA_4b4e3480-7462-452e-827a-7d52128d29f0" continuedAt="i42e8ec85c54a4b19b83c6c0e3baa4ccf" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i42e8ec85c54a4b19b83c6c0e3baa4ccf"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RleHRyZWdpb246NTVjNjU1NjIxZjBlNDFmOGI1MjhmY2JhYTBiNzMyNjNfMTEwMg_a460410b-c842-4946-903f-5af84f2727ee" continuedAt="i31f59da753ac4d4daa18f3189306f995" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of March&#160;31, 2022 and December&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5f29ec37e5044118f1345ab67b4bfe0_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMy0xLTEtMS0yNzc0Mg_37197ab1-7f52-43e0-8d6d-886e877c228d">15,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i858aaf4aebaa477690f541f5cef242e3_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMy0zLTEtMS0yNzc0Mg_f7d00c62-73bb-4df3-94fc-4feeae680421">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice8e727de3934bce8949d0a1f8de0a1f_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMy01LTEtMS0yNzc0Mg_0eeab402-c0ca-44e3-a9e4-ca737e32504f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2aec20dcbb4e11a14fa3594fae5f15_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMy03LTEtMS0yNzc0Mg_57709c8a-9f81-4b73-93ac-2ce64557db5c">15,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec0c5fbc68b74c27a7ff40151b92b5ee_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfNC0xLTEtMS0yNzc0Mg_333a1914-f6b9-4354-983d-0807ea3fc3ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaaebfbfd564b33828c67ca78b8c766_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfNC0zLTEtMS0yNzc0Mg_3c6afdb6-c5e2-4390-b399-7463e02d8d16">3,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i760860b7d95142e6a5f23bd5db8a0e83_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfNC01LTEtMS0yNzc0Mg_ce22dc13-b235-409c-a946-2d3b41006b9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c6edc4fe34456ca0daf70b67b95445_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfNC03LTEtMS0yNzc0Mg_54197668-fd44-4ace-a807-cdace067a10a">3,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bc7648a25f047e89409bd461a324502_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfNS0xLTEtMS0yNzc0Mg_f47d0ff2-8b5d-47b3-8f69-7a21e307208b">15,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib787e125147a4fae952c9425271b6f7c_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfNS0zLTEtMS0yNzc0Mg_92c3134f-571c-4bcf-a4e4-cce10e6798c7">3,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie08212cc90ef4e709206336ccf149313_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfNS01LTEtMS0yNzc0Mg_b8c01db8-2222-438e-8441-2febb7405702">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b8194a586f841738340b39f3d565848_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfNS03LTEtMS0yNzc0Mg_6bcd0e0a-cdfb-4714-b48b-8e07a8d42766">19,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacb52739ae184a00938aabdbe0bb4cdd_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfOC0xLTEtMS0yNzc0Mg_10b6c560-3d88-4aa8-8c97-ebb1bb17e778">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4acf9b35e314e309ef0816d4754a15a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfOC0zLTEtMS0yNzc0Mg_8e9ad839-07f9-4a51-b528-f3b11f91ce79">9,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia453d0061bfb48fcaaabd8e50791523b_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfOC01LTEtMS0yNzc0Mg_1170a44a-3bf3-42a9-b6a4-91264d054a66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18725cb77e8f4c02b2f1432d16e20612_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfOC03LTEtMS0yNzc0Mg_0ab6e86a-a532-4b91-bee7-c68f64250db3">9,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16a7736ec34f4acb84606918dacb73af_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfOS0xLTEtMS0yNzc0Mg_52d1b5d0-3889-4621-bdd2-05d9bb188ce9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a2163cb8414bdcba39fea19a1148e6_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfOS0zLTEtMS0yNzc0Mg_f8cae598-6181-4ac5-a7c8-eaa1b9e57c29">69,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd7a7fe09574445a9ea6fbc3ee035b54_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfOS01LTEtMS0yNzc0Mg_73581bec-730b-45f5-b075-8587a7787b64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1047e58df41b40d0b4e2422be90e9b1c_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfOS03LTEtMS0yNzc0Mg_07891aed-c799-4546-b85c-fb1c50be8775">69,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7137fd6fa9e84f46828d43b1c2cccb6e_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTAtMS0xLTEtMjc3NDI_9dde1ab3-9d9e-43fc-8f4c-495f61bf449f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if75dd8412dd548f2b9e9b67adbe7e3d5_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTAtMy0xLTEtMjc3NDI_50160532-72e4-4813-9999-caf26862b245">10,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id749a1f0c6be4b368e444ace5f891487_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTAtNS0xLTEtMjc3NDI_77bbe233-a544-4726-93d5-5f16c5034544">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ee8c9b1c2244608a7990d422050c94_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTAtNy0xLTEtMjc3NDI_1c358d1a-4d2c-4758-be03-d95c229ad483">10,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9512c3da93e34771b7bdaff0723660ea_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTItMS0xLTEtMjc3NDI_7f8c4299-6dd3-4ccb-8032-6282edda6287">19,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d4747ed58c947ea9a3f145a4ab45200_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTItMy0xLTEtMjc3NDI_1654e88a-944b-4bf7-85fe-eef47810d2aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i572626db256d435291fe5c0afb9d041f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTItNS0xLTEtMjc3NDI_7bd15312-55e3-4b5e-aa5e-ecb261bec48a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6e2de4855d74f7d86a9c98ab283751a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTItNy0xLTEtMjc3NDI_4d4b8724-1bfd-4882-8d37-fde41c8f061d">19,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments (1)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bc7648a25f047e89409bd461a324502_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTMtMS0xLTEtMjc3NDI_5834d8d1-29d0-4fad-aa9a-2508323ace22">19,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib787e125147a4fae952c9425271b6f7c_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTMtMy0xLTEtMjc3NDI_2ca66340-028c-4d4b-a807-af37bf5ee6ef">89,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie08212cc90ef4e709206336ccf149313_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTMtNS0xLTEtMjc3NDI_8596547b-9cc8-42b7-87c9-5247cf8394a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b8194a586f841738340b39f3d565848_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTMtNy0xLTEtMjc3NDI_16b99d68-cbe7-4b29-abe3-023d49d9178f">109,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bc7648a25f047e89409bd461a324502_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTUtMS0xLTEtMjc3NDI_93b61fbc-c4f5-4dad-a34a-e759fd362411">35,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib787e125147a4fae952c9425271b6f7c_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTUtMy0xLTEtMjc3NDI_87a30762-0890-4f8a-8e01-ee4d9da0e509">92,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie08212cc90ef4e709206336ccf149313_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTUtNS0xLTEtMjc3NDI_b525c64c-39a6-4b60-9869-9f9cbf2802d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b8194a586f841738340b39f3d565848_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTUtNy0xLTEtMjc3NDI_ca692478-6aae-42f1-9d6f-b29c178ce0ca">128,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28c89bf87ce14cca9b2b800346e0f3cf_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMy0xLTEtMS0zMzY0MQ_540ac90d-4654-42e5-836b-7b8a0a056a0c">10,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876b48d168b94c078324d718cfdcc6b4_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMy0zLTEtMS0zMzY0MQ_e4466f17-5fb3-4cc4-9d3c-7b8956299ab6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99895349e572414c90c807f0e0e17ebb_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMy01LTEtMS0zMzY0MQ_de04730e-d349-4d8d-8855-1ff814c7ca5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i547b6800236a4e0caab1382e2230e08a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMy03LTEtMS0zMzY0MQ_8d8e4e64-dc25-4aba-8cb7-e3578c070e89">10,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c4033bd7f2c4aeb9ee5d73233cec607_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfNS0xLTEtMS0zMzg3OA_6b2cd01a-acc5-49a4-a5f1-0d0ee3112b0b">10,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4977728e4fe6441a934b69b20c984428_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfNS0zLTEtMS0zMzg3OA_5274969f-431d-4b20-a88c-e287357c6f23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff28c3628c9439f9476dce8d023e9a6_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfNS01LTEtMS0zMzg3OA_9bd033fe-442e-4576-8c79-0d7dd6c8e4ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f1aebf312994daaa324ca44ae909873_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfNS03LTEtMS0zMzg3OA_861c5dcd-e967-4806-9c97-26c38839e6ec">10,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie28739979eeb42ef9ba44e6345bbce01_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfOC0xLTEtMS0zMzg4MQ_4e5f5e9f-7a44-4851-bcfa-65f4ad7bb98e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0548bc72c9014a57a21548990a80dc6d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfOC0zLTEtMS0zMzg4MQ_df3271ad-141c-4c5d-a29f-f5ed8d7049d1">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966397496b06482ea36f27e6d9813468_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfOC01LTEtMS0zMzg4MQ_2c72540e-fd8f-4d11-96c2-90d6b5128990">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8358790f990b4c0eb465115ec36b4bad_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfOC03LTEtMS0zMzg4MQ_d4bb6238-8e32-4222-a12d-bc4be5b0107e">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141fc564298749ef90e593b383c7b4dd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfOS0xLTEtMS0zMzg4MQ_8692ccf1-990a-4b1f-ae3d-8f17c57f9f84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i703f601f436b43d49b1a487d4d19c8db_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfOS0zLTEtMS0zMzg4MQ_447c3813-d977-47f0-8e8b-d681dbb4b12c">88,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i457626d4907642ed957f6fa275972b86_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfOS01LTEtMS0zMzg4MQ_a8c58d48-eb7d-45ec-ad15-452e1af39ff0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf6c73f105ea4cf5b84fc6c9051918ae_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfOS03LTEtMS0zMzg4MQ_af5a2fb4-ccf1-4a88-a976-e8c20dad79df">88,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88f18fc910f945858e3b8bc20c69c3a8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTAtMS0xLTEtMzM4ODE_b97c8510-4567-4f2a-b683-ecdc339349a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fc6fa6aba914b51a5f862c4592ff78c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTAtMy0xLTEtMzM4ODE_bc95e116-6be2-4de7-b499-872438a5a03a">14,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaad7930c0f094358b1f79e8717bc3ded_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTAtNS0xLTEtMzM4ODE_55112b93-c17c-4695-87b7-d0b6cbb7273f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb33f7c370f04ac9b542a1d9ce2740d0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTAtNy0xLTEtMzM4ODE_0e5922e0-2dfb-4039-b27f-f35ec26e2f17">14,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d8ce90d2f4242aebc0947a200a14d74_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTEtMS0xLTEtMzM4ODU_dca81588-fc3f-407b-a428-b3fde0399a71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i978107023461439f9c9388246fe5f1d0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTEtMy0xLTEtMzM4ODU_d8690f6b-55d2-41f8-bc4f-97013ac38e1b">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i077d5e0a95724189b2ed4ff9de4ca7b1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTEtNS0xLTEtMzM4ODU_5d2c19cd-53e6-455d-83f4-9a20d6a7464a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53718eacdc59401eb030bde33ae601c2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTEtNy0xLTEtMzM4ODU_69f4a2c0-5559-4997-8c47-b2158c82cf40">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67fc8a821a934707ad82e4a6523c6f04_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTItMS0xLTEtMzM4ODM_d4a82d01-15a2-4edc-aaf1-1eb4908e2246">24,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i045f3a1f97f64eebba51a12fff7e25ba_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTItMy0xLTEtMzM4ODM_adde056e-0547-4eb0-8401-2d5d926707ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeff0db315444d1fa011989d0832b897_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTItNS0xLTEtMzM4ODM_d7c23840-7976-4b74-b777-994f01801263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80595d8a12bd44fdbc458c86f92eaf8d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTItNy0xLTEtMzM4ODM_090f6f29-e33f-40d1-9c06-d609ae13db8f">24,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments (1)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c4033bd7f2c4aeb9ee5d73233cec607_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTMtMS0xLTEtMzM4ODM_c95e1654-87b7-4003-8e0e-48e94116a7ec">24,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4977728e4fe6441a934b69b20c984428_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTMtMy0xLTEtMzM4ODM_59d84fad-3154-4ff4-8da1-3a8759ea42e8">104,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff28c3628c9439f9476dce8d023e9a6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTMtNS0xLTEtMzM4ODM_abcc07bc-6562-4f82-a78d-b9bba85a9598">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f1aebf312994daaa324ca44ae909873_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTMtNy0xLTEtMzM4ODM_0033bd4a-2aa0-43e4-96f7-11428363cc30">128,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c4033bd7f2c4aeb9ee5d73233cec607_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTUtMS0xLTEtMzM4ODM_70a46d6c-6cba-49f9-8405-be55498e4f52">35,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4977728e4fe6441a934b69b20c984428_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTUtMy0xLTEtMzM4ODM_8f7459c8-92d6-4f65-9330-8039064de498">104,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff28c3628c9439f9476dce8d023e9a6_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTUtNS0xLTEtMzM4ODM_61adb558-e6c7-46dd-afcc-e046292d4bbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f1aebf312994daaa324ca44ae909873_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTUtNy0xLTEtMzM4ODM_e7b3e06c-7d1d-491e-aa3a-12d9cbbd19a3">139,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i31f59da753ac4d4daa18f3189306f995">(1) Included in short-term investments in the accompanying balance sheets.</ix:continuation> </span></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 3 during the three months ended March 31, 2022 and 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i43edf2a30c6642969a7b68c1e523baa5_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RleHRyZWdpb246Y2I1ZGFlMGMyZDM0NDc5MjliYzE3YjBkMmI2ZTRjNTBfMTcz_0ca90a8d-b98b-4349-8857-1e1f9e7640c3" continuedAt="i90a25e3f3ae0483b83e1472c2faee45c" escape="true">Supplementary Balance Sheet Information</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i90a25e3f3ae0483b83e1472c2faee45c" continuedAt="ia2825c83cfdd4958b056c7c27ec0dc66"><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RleHRyZWdpb246Y2I1ZGFlMGMyZDM0NDc5MjliYzE3YjBkMmI2ZTRjNTBfMTY3_f03484c2-05c6-4c4f-b7d3-51121f6b8f67" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available for sale consist of the following: </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity less than 1 year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fedefbb21504c7c9d24ef677e84d271_I20220331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMi0xLTEtMS0yNzc0Mg_d90047cb-9fe5-4a77-8045-89f9fd816e7e">9,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fedefbb21504c7c9d24ef677e84d271_I20220331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMi0zLTEtMS0yNzc0Mg_999fd708-6c3b-4307-ac35-4363c97d88f8">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fedefbb21504c7c9d24ef677e84d271_I20220331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMi01LTEtMS0yNzc0Mg_4e672a99-db8f-4c3b-adb1-3c4f04f9acf5">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fedefbb21504c7c9d24ef677e84d271_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMi03LTEtMS0yNzc0Mg_e9ad8eaf-9871-48ba-aff3-610a77b3b997">9,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1e4ef065b44bde91fa2353faafba2d_I20220331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMy0xLTEtMS0yNzc0Mg_bc8d6097-8b67-465d-8582-38e053d385f6">55,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1e4ef065b44bde91fa2353faafba2d_I20220331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMy0zLTEtMS0yNzc0Mg_ff20bf3d-4330-4850-afc5-4b24f43965a4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a1e4ef065b44bde91fa2353faafba2d_I20220331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMy01LTEtMS0yNzc0Mg_fa869b33-4d75-46ee-89f4-f42345e9fde4">293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1e4ef065b44bde91fa2353faafba2d_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMy03LTEtMS0yNzc0Mg_763dc714-309c-4748-8d2f-3f69b52d51eb">54,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab946214765844419385e846f2f071c4_I20220331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNC0xLTEtMS0yNzc0Mg_36ed1574-ea8d-459b-883c-5f8f7972fc03">10,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab946214765844419385e846f2f071c4_I20220331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNC0zLTEtMS0yNzc0Mg_a3b0f423-f85d-4683-b301-dedd26b82995">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab946214765844419385e846f2f071c4_I20220331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNC01LTEtMS0yNzc0Mg_c6b51af2-9cfe-48bd-9f13-8d10574990bc">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab946214765844419385e846f2f071c4_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNC03LTEtMS0yNzc0Mg_3109ac55-8238-4db6-b8b4-98dae77dc496">10,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c3e566014904bf0849ff752d63a833b_I20220331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNi0xLTEtMS0yNzc0Mg_878a13ff-4194-4186-a645-50bc621eb7a0">20,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c3e566014904bf0849ff752d63a833b_I20220331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNi0zLTEtMS0yNzc0Mg_0eedfb96-fd5f-41a0-a143-eaa4e2158528">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c3e566014904bf0849ff752d63a833b_I20220331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNi01LTEtMS0yNzc0Mg_9b9854ac-7ce4-44bf-b183-56cfb5477e65">122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c3e566014904bf0849ff752d63a833b_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNi03LTEtMS0yNzc0Mg_70ae7cf9-db0e-4bca-a51c-3f93fc13b761">19,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfOC0xLTEtMS0yODc1Mw_4fc29732-e74b-47f5-824b-bf8d53f3e195">94,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfOC0zLTEtMS0yODc1Mw_fc318395-bf69-48e8-90c0-259a39105f77">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfOC01LTEtMS0yODc1Mw_7b71c4d7-c2ea-437b-bc8c-b53656927c7f">501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfOC03LTEtMS0yODc1Mw_39bc228c-9136-4a91-b49c-34b92d23e3da">94,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity 1 to 2 years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1e4ef065b44bde91fa2353faafba2d_I20220331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMTAtMS0xLTEtMjg3NTM_72826127-ac86-4b1c-a58b-a52e411df766">15,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1e4ef065b44bde91fa2353faafba2d_I20220331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMTAtMy0xLTEtMjg3NTM_d1cb32f5-ab72-40ee-a127-93dedf4af145">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a1e4ef065b44bde91fa2353faafba2d_I20220331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMTAtNS0xLTEtMjg3NTM_592516b2-00af-4ca4-af96-19a4c33d5ab9">252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1e4ef065b44bde91fa2353faafba2d_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMTAtNy0xLTEtMjg3NTM_d7d58636-90f9-4ade-9361-0be6c1819cc4">14,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity 1 to 2 years</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMTItMS0xLTEtMjg3NTM_30c65e8e-0066-4709-9b1d-7f547ddaccce">15,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMTItMy0xLTEtMjg3NTM_03c6033d-e14d-435f-ab2d-de7bffadc214">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMTItNS0xLTEtMjg3NTM_737a410e-10d8-4a21-8477-4fc0c89e2661">252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMTItNy0xLTEtMjg3NTM_de3fc48f-9c9f-4e9f-a697-2d086c00df3c">14,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNy0xLTEtMS0yNzc0Mg_d32af426-81cb-4199-83b8-f245423825b5">110,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNy0zLTEtMS0yNzc0Mg_a7f8b25d-6238-4041-85de-cbddb68eecf2">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNy01LTEtMS0yNzc0Mg_63b5c874-342a-4f15-a20c-3849de1dff45">753</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNy03LTEtMS0yNzc0Mg_623317af-9869-4807-ac53-bde0fbed434f">109,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity less than 1 year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc8b81d6dec439faf2b7a1516cbae4f_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMy0xLTEtMS0yODY0OA_a03f939d-6d63-4dce-95eb-081cb25217ca">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc8b81d6dec439faf2b7a1516cbae4f_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMy0zLTEtMS0yODY0OA_ecbb3de1-0e51-4606-a5ec-59a4898a80ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc8b81d6dec439faf2b7a1516cbae4f_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMy01LTEtMS0yODY0OA_ade2da37-8e52-4f41-9f24-baf4349b0452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc8b81d6dec439faf2b7a1516cbae4f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMy03LTEtMS0yODY0OA_4be45e08-337c-4d9b-9697-66c8f9c829cc">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaf3870ca7e245d39bb917baeb589cfd_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNC0xLTEtMS0yODY0OA_0ae1a190-88d1-4a66-84fb-e457e9495688">58,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaf3870ca7e245d39bb917baeb589cfd_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNC0zLTEtMS0yODY0OA_6a17750d-978c-4abf-b89b-22d1f274a392">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaf3870ca7e245d39bb917baeb589cfd_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNC01LTEtMS0yODY0OA_4a23e8ae-2a99-42d7-a5c4-680833c56217">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaf3870ca7e245d39bb917baeb589cfd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNC03LTEtMS0yODY0OA_996ad7b9-ab92-4541-ba4b-141a5a6a3c7c">58,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ea1c1903a66482189db39519fa9ab69_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNS0xLTEtMS0yODY0OA_7bf835be-09bf-4767-8de9-85ef034c4f61">14,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ea1c1903a66482189db39519fa9ab69_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNS0zLTEtMS0yODY0OA_8ee08bc0-9926-435f-8b20-56e52ea16f04">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ea1c1903a66482189db39519fa9ab69_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNS01LTEtMS0yODY0OA_005d270e-f6b5-4da1-b1f4-c8c92d8b65ec">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ea1c1903a66482189db39519fa9ab69_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNS03LTEtMS0yODY0OA_7aa8d24a-cd59-4371-b7c9-0c8133b8fdab">14,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i147c926c319848eda463b6b78b8ba88c_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNi0xLTEtMS0yODY0OA_341a8579-6858-412d-973a-0c247dc29e0d">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i147c926c319848eda463b6b78b8ba88c_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNi0zLTEtMS0yODY0OA_808cb568-f6f3-4be4-a1cf-83349bb15421">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i147c926c319848eda463b6b78b8ba88c_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNi01LTEtMS0yODY0OA_73a3fb4a-6777-4415-a6e9-bac6204d369e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i147c926c319848eda463b6b78b8ba88c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNi03LTEtMS0yODY0OA_ea4b6a47-e61e-4acb-9eee-4fdfaaf47098">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d9c1d34a1db4e9fb7d337599646fa44_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNy0xLTEtMS0yODY0OA_0c9d29be-fa95-4ceb-96db-a86dc74014da">20,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d9c1d34a1db4e9fb7d337599646fa44_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNy0zLTEtMS0yODY0OA_4fdaded8-59f9-4bbd-afde-4fe50b2dbfd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d9c1d34a1db4e9fb7d337599646fa44_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNy01LTEtMS0yODY0OA_cedf3e6a-7519-4f81-82d6-adf68ac2b476">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d9c1d34a1db4e9fb7d337599646fa44_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNy03LTEtMS0yODY0OA_9d4f2379-098b-4725-a75f-7ab62ed90980">20,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfOC0xLTEtMS0yODY0OA_4e71bc34-1bc6-4b22-9085-6924605ec112">95,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfOC0zLTEtMS0yODY0OA_31bced97-f66a-4b75-a205-1b71514d363f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfOC01LTEtMS0yODY0OA_1bf357f8-18e2-477c-8080-002ec04b18c1">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfOC03LTEtMS0yODY0OA_735333a4-3857-4d54-9ba6-fd805c0bbf1c">95,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity 1 to 2 years:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaf3870ca7e245d39bb917baeb589cfd_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTAtMS0xLTEtMjg2NDg_c5c9a21d-83ab-433b-8f18-632a494ded0f">29,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaf3870ca7e245d39bb917baeb589cfd_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTAtMy0xLTEtMjg2NDg_a9e3b5d8-5851-40a6-b168-52f825c5686f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaf3870ca7e245d39bb917baeb589cfd_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTAtNS0xLTEtMjg2NDg_5563d5bf-60ad-4001-8a44-8b12315c6f56">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaf3870ca7e245d39bb917baeb589cfd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTAtNy0xLTEtMjg2NDg_fa96686d-1cf8-442f-881f-20a8c61fc969">29,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d9c1d34a1db4e9fb7d337599646fa44_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTEtMS0xLTEtMjg2NDg_e67e62cd-7d0a-4703-9840-d30d0cee802f">3,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d9c1d34a1db4e9fb7d337599646fa44_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTEtMy0xLTEtMjg2NDg_70e949c6-1ed0-43cd-a4cd-ccf113436d25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d9c1d34a1db4e9fb7d337599646fa44_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTEtNS0xLTEtMjg2NDg_509e6a9a-2fc5-44df-a64d-a5939c8ad38e">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d9c1d34a1db4e9fb7d337599646fa44_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTEtNy0xLTEtMjg2NDg_a56f982c-a8fd-44e7-9015-c50c899c6203">3,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity 1 to 2 years</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTItMS0xLTEtMjg2NDg_2df49b68-c155-4dd6-abde-596a801b1fde">33,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTItMy0xLTEtMjg2NDg_410fe84c-f349-40c7-9b99-ff3276288519">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTItNS0xLTEtMjg2NDg_8386ab22-211e-43e8-9611-50b7bf0d1337">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTItNy0xLTEtMjg2NDg_ac50c2eb-f660-40a2-8baf-e65eed2f7cdb">33,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTQtMS0xLTEtMjg2NDg_ce5dcb40-5dbe-4b6d-a165-a78ed34dacbf">129,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTQtMy0xLTEtMjg2NDg_d8dd29b6-8231-43f5-8592-3605aa211c6c">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTQtNS0xLTEtMjg2NDg_03639a94-b1d2-4076-81c1-8e72468d6cd5">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTQtNy0xLTEtMjg2NDg_de8a96ad-9c8e-4c98-9f76-b869632f4d35">128,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RleHRyZWdpb246Y2I1ZGFlMGMyZDM0NDc5MjliYzE3YjBkMmI2ZTRjNTBfMTcw_b3804f21-927b-49a9-bf8a-736072044d80" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1db42d1d374f53989a2e7eb3b57555_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfMS0xLTEtMS0yNzc0Mg_43b20823-64b6-494d-a360-be3ae1e0f35b">1,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76184d10cb394f4ea42385613d47f3a0_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfMS0zLTEtMS0yNzc0Mg_a3fd2afa-3f27-4807-9b5e-cdb98bf0c06d">955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fec98606e0d4c2f815d907fbfd712cd_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfMi0xLTEtMS0yNzc0Mg_c07cb67f-554a-46bc-9550-e844616ed31a">2,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe44b0f34c648c084e4cb969b1c99e0_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfMi0zLTEtMS0yNzc0Mg_dcd97e2b-9448-4791-934a-d96768d22104">1,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86dfda88f61d4ab88a4b5f4a3dea2526_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfMy0xLTEtMS0yNzc0Mg_b17e9b73-24ce-4a73-9a92-406cbed973f8">912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4794d63837f04ab3a7126147249402b5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfMy0zLTEtMS0yNzc0Mg_5d71eeb6-aa34-4ab7-88e1-551d3d345424">906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfNC0xLTEtMS0yNzc0Mg_045024f6-72c7-4351-9177-d189fefe941d">4,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfNC0zLTEtMS0yNzc0Mg_e1678bc8-a4f8-4035-9894-4cb341b1f03f">3,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfNS0xLTEtMS0yNzc0Mg_3a47d3df-7163-46d4-8150-ab1a1a74ec6b">3,472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfNS0zLTEtMS0yNzc0Mg_78e4e718-c099-4dc3-8e3f-c33118b6be65">3,441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfNi0xLTEtMS0yNzc0Mg_f1698f72-c044-41c2-8e36-4c0d178df9b6">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfNi0zLTEtMS0yNzc0Mg_566d83dc-6b28-48eb-8d2b-9a1e78b59aab">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><ix:continuation id="ia2825c83cfdd4958b056c7c27ec0dc66"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Liabilities</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RleHRyZWdpb246Y2I1ZGFlMGMyZDM0NDc5MjliYzE3YjBkMmI2ZTRjNTBfNjA0NzMxMzk1MzA0NQ_069660e8-e175-4c70-90c0-796feb83b5c7" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:64.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfMi0xLTEtMS0zMzM5Mg_622b38c7-0284-4ea6-973c-79d74fe16332">878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfMi0zLTEtMS0zMzM5Mg_cdd2c02d-0845-4a61-bb1b-7922afee76a8">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="crdf:AccruedPreferredStockDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfMy0xLTEtMS0zMzM5Mg_d793b434-3ac8-4f37-ad1d-d33a67c65a08">420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="crdf:AccruedPreferredStockDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfMy0zLTEtMS0zMzM5Mg_5990b270-ae02-4f25-81ed-ba02487907aa">414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="crdf:AccruedClinicalTrial" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfNC0xLTEtMS0zMzM5Mg_8ed8fc04-2ffb-48ff-a0a4-2927362202ee">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="crdf:AccruedClinicalTrial" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfNC0zLTEtMS0zMzM5Mg_16c87909-0bbd-4725-a527-a4e565ff6322">1,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research agreements and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="crdf:AccruedResearchAgreements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfNS0xLTEtMS0zMzM5Mg_8b04a76c-0cf4-4f24-a725-70bc3ba0b5b0">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="crdf:AccruedResearchAgreements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfNS0zLTEtMS0zMzM5Mg_6cc7bd5a-1067-40e8-a74a-d7209faa3ac8">726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="crdf:AccruedDirectorFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfNi0xLTEtMS0zMzM5Mg_d7cc646e-4656-494f-99df-e4e58b49d67c">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="crdf:AccruedDirectorFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfNi0zLTEtMS0zMzM5Mg_0077b41a-0965-4d8b-9395-e89ed256f77c">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and outside services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfNy0xLTEtMS0zMzM5Mg_688bc432-02bc-4c73-aa32-31cd29e4cb96">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfNy0zLTEtMS0zMzM5Mg_cc7bb9c2-75c2-47ea-95f5-a5a57bf9d885">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent, license and other fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="crdf:PatentLicenseAndOtherFeesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfOC0xLTEtMS0zMzM5Mg_05895f52-f074-43ad-8e8c-5e6f290adae9">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="crdf:PatentLicenseAndOtherFeesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfOC0zLTEtMS0zMzM5Mg_e21a914b-a826-4302-8934-40fcb085b391">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfMTAtMS0xLTEtMzMzOTI_f8831d5e-8711-44c1-a64c-4748a93a6d4e">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfMTAtMy0xLTEtMzMzOTI_4fa9b6e9-c14d-4806-bacf-a45230356c1d">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfMTEtMS0xLTEtMzMzOTI_8ce33ed5-18f2-46d2-903e-f0dcfd35fafa">4,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfMTEtMy0xLTEtMzMzOTI_9870e56d-224a-4004-9288-ed975207fd4f">4,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfMTg4MQ_62c8a59a-2a14-4d4e-a85f-b8f2849925a3" continuedAt="i5a965a007db74f08bab9c50026d5030f" escape="true"><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfMTg5NQ_5803b629-df1f-4b69-8582-4525a4776c83" continuedAt="i2f4e4b7e69014ed5b79d56836fee4b58" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:continuation id="i5a965a007db74f08bab9c50026d5030f" continuedAt="ia1f1e1556a2847ca99dc12d764ec1282"><ix:continuation id="i2f4e4b7e69014ed5b79d56836fee4b58" continuedAt="i3a8535ec701e4f7a9cc85375fbf9bc21"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As a lessee, the Company&#8217;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Facility Lease</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently leases <ix:nonFraction unitRef="sqft" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="0" name="crdf:LesseeOperatingLeaseAreaOfLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfODAz_32ba87c7-6589-4451-b007-354b3e338951">12,300</ix:nonFraction> square feet of office and lab space in San Diego that expires on February 28, 2027. The lease currently requires monthly payments of approximately $<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="crdf:LesseeOperatingLeaseMonthlyRentPayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfMTE0OQ_cf37dd0b-a0bb-4af9-a5cf-4d63008b8ac0">60,000</ix:nonFraction> per month with <ix:nonFraction unitRef="number" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="INF" name="crdf:LesseeOperatingLeaseAnnualRentIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfMTA5OTUxMTYzMTI5MQ_642e6f65-3547-4f2e-a3f0-b001eb9fe0ce">3</ix:nonFraction>% annual escalation.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Subleases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and subleased the space to third parties under <ix:nonFraction unitRef="lease" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="INF" name="crdf:LessorNumberOfSubleases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfMTM0MQ_e09e7f87-f6ad-49ee-85d3-6ea430b06bec">three</ix:nonFraction> separate sublease agreements, which all expired on December 31, 2021. Prior to the expiration of the sublease agreements, the Company as a sublessor was leasing approximately <ix:nonFraction unitRef="sqft" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="0" name="crdf:LessorAreaOfSublease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfMTQ2NQ_88a2cdcb-852b-48a2-ab59-0af49efe8eb7">16,600</ix:nonFraction> square feet of space to third parties.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfMTg5NA_3ef574bf-399c-4b9b-865a-85d12f0972cb" continuedAt="i1508750eea144d4cb4021b0e794c34d4" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmIyN2U0OTU4MDc1MTRjYzZhYzlmMDVhNzE3N2UyZGFjL3RhYmxlcmFuZ2U6YjI3ZTQ5NTgwNzUxNGNjNmFjOWYwNWE3MTc3ZTJkYWNfMi01LTEtMS0yNzc0Mg_c6145582-d9af-470e-9142-6ce04012fe19">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmIyN2U0OTU4MDc1MTRjYzZhYzlmMDVhNzE3N2UyZGFjL3RhYmxlcmFuZ2U6YjI3ZTQ5NTgwNzUxNGNjNmFjOWYwNWE3MTc3ZTJkYWNfMi03LTEtMS0yNzc0Mg_fa690d36-2c26-4409-a5e3-7e122ccaeb66">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmIyN2U0OTU4MDc1MTRjYzZhYzlmMDVhNzE3N2UyZGFjL3RhYmxlcmFuZ2U6YjI3ZTQ5NTgwNzUxNGNjNmFjOWYwNWE3MTc3ZTJkYWNfMy01LTEtMS0yNzc0Mg_4fb1e0fc-ffa8-420e-b4ec-f66a893f2d54">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmIyN2U0OTU4MDc1MTRjYzZhYzlmMDVhNzE3N2UyZGFjL3RhYmxlcmFuZ2U6YjI3ZTQ5NTgwNzUxNGNjNmFjOWYwNWE3MTc3ZTJkYWNfMy03LTEtMS0yNzc0Mg_eff7faef-765a-4e39-b6f9-a8833e12cf0e">101</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmIyN2U0OTU4MDc1MTRjYzZhYzlmMDVhNzE3N2UyZGFjL3RhYmxlcmFuZ2U6YjI3ZTQ5NTgwNzUxNGNjNmFjOWYwNWE3MTc3ZTJkYWNfNC01LTEtMS0yNzc0Mg_9325fb3c-19e6-4480-9ec7-aa88a3570264">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmIyN2U0OTU4MDc1MTRjYzZhYzlmMDVhNzE3N2UyZGFjL3RhYmxlcmFuZ2U6YjI3ZTQ5NTgwNzUxNGNjNmFjOWYwNWE3MTc3ZTJkYWNfNC03LTEtMS0yNzc0Mg_58251a82-4922-4fe6-ab33-b14148ffdd27">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="crdf:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfMTg4Mw_0c23400d-f45e-4f00-84c6-07d573da787d" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfMS0xLTEtMS0yNzc0Mg_dacb1518-0249-4dca-8b0e-f535e5fb6c99">2,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfMS0zLTEtMS0yNzc0Mg_851e5f3b-1bf9-4265-baf5-0dfbe0882e21">2,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfMy0xLTEtMS0yNzc0Mg_4cb91254-1f01-4cf3-9b3d-e06741eeaef5">665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfMy0zLTEtMS0yNzc0Mg_9d4ba6ec-e30e-452b-8539-a369e0a44067">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfNC0xLTEtMS0yNzc0Mg_b7bb9539-6737-4ede-8894-ca7c9bbdcf31">2,438</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfNC0zLTEtMS0yNzc0Mg_811715d1-bcb6-4c1e-84e5-44ad0e007e93">2,568</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfNS0xLTEtMS0yNzc0Mg_1c3f0a2e-2611-42b1-8914-1a8ae3229484">3,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfNS0zLTEtMS0yNzc0Mg_93fc07c9-f386-4dbd-86b8-0b7cf41f4795">3,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfNy0xLTEtMS0yNzc0Mg_362f5340-b195-4636-8964-aa0862427930">4.9</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfNy0zLTEtMS0yNzc0Mg_9fbfb6d5-22af-463e-b510-1299b1ad2dd4">5.2</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfOC0xLTEtMS0yNzc0Mg_24890805-4332-499d-96d9-273eb0f366d6">7.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfOC0zLTEtMS0yNzc0Mg_b16e43e5-4cbe-4281-bb95-40abc446022f">7.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><ix:continuation id="ia1f1e1556a2847ca99dc12d764ec1282"><ix:continuation id="i3a8535ec701e4f7a9cc85375fbf9bc21"><ix:continuation id="i1508750eea144d4cb4021b0e794c34d4"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ4ZDU4MDZmZDYxZTQ2YWQ5NDBkNjVmMzNlODMzZmVjL3RhYmxlcmFuZ2U6ZDhkNTgwNmZkNjFlNDZhZDk0MGQ2NWYzM2U4MzNmZWNfMy01LTEtMS0yNzc0Mg_f1826213-bd98-4bb5-a29e-89fdaca49ca2">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ4ZDU4MDZmZDYxZTQ2YWQ5NDBkNjVmMzNlODMzZmVjL3RhYmxlcmFuZ2U6ZDhkNTgwNmZkNjFlNDZhZDk0MGQ2NWYzM2U4MzNmZWNfMy03LTEtMS0yNzc0Mg_3790b3f3-993f-47c6-9f99-fb29f7b17a4f">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfMTg5MQ_a08eef14-e42e-469d-9ea4-f1097c8286ae" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the three months ended March&#160;31, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOjA0YmQ2MmEyNDk5NTQzMGJhMTAwYmZiNjRkZTc3OTkxL3RhYmxlcmFuZ2U6MDRiZDYyYTI0OTk1NDMwYmExMDBiZmI2NGRlNzc5OTFfMy0xLTEtMS0yNzc0Mg_95e61cc2-e6a4-4eb2-8278-591bc43880c0">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOjA0YmQ2MmEyNDk5NTQzMGJhMTAwYmZiNjRkZTc3OTkxL3RhYmxlcmFuZ2U6MDRiZDYyYTI0OTk1NDMwYmExMDBiZmI2NGRlNzc5OTFfNC0xLTEtMS0yNzc0Mg_dc36c5cf-0c68-45f1-9f68-0c489e83ba91">737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOjA0YmQ2MmEyNDk5NTQzMGJhMTAwYmZiNjRkZTc3OTkxL3RhYmxlcmFuZ2U6MDRiZDYyYTI0OTk1NDMwYmExMDBiZmI2NGRlNzc5OTFfNS0xLTEtMS0yNzc0Mg_e8a3e511-6ff5-44b1-adfa-6e28436da837">754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOjA0YmQ2MmEyNDk5NTQzMGJhMTAwYmZiNjRkZTc3OTkxL3RhYmxlcmFuZ2U6MDRiZDYyYTI0OTk1NDMwYmExMDBiZmI2NGRlNzc5OTFfNi0xLTEtMS0yNzc0Mg_fcaa3e94-7011-451d-8598-c3ca097dd674">775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOjA0YmQ2MmEyNDk5NTQzMGJhMTAwYmZiNjRkZTc3OTkxL3RhYmxlcmFuZ2U6MDRiZDYyYTI0OTk1NDMwYmExMDBiZmI2NGRlNzc5OTFfNy0xLTEtMS0yNzc0Mg_104f264e-1959-4cda-aaeb-fbcce6ce726d">796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="crdf:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOjA0YmQ2MmEyNDk5NTQzMGJhMTAwYmZiNjRkZTc3OTkxL3RhYmxlcmFuZ2U6MDRiZDYyYTI0OTk1NDMwYmExMDBiZmI2NGRlNzc5OTFfOS0xLTEtMS0yNzc0Mg_d319290e-66e8-4c5b-b67a-a68cff4da92d">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOjA0YmQ2MmEyNDk5NTQzMGJhMTAwYmZiNjRkZTc3OTkxL3RhYmxlcmFuZ2U6MDRiZDYyYTI0OTk1NDMwYmExMDBiZmI2NGRlNzc5OTFfMTAtMS0xLTEtMjc3NDI_deeeeab3-6d90-4080-a4a8-9c3b090a268f">3,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOjA0YmQ2MmEyNDk5NTQzMGJhMTAwYmZiNjRkZTc3OTkxL3RhYmxlcmFuZ2U6MDRiZDYyYTI0OTk1NDMwYmExMDBiZmI2NGRlNzc5OTFfMTEtMS0xLTEtMjc3NDI_c47b66cf-33ba-48d0-9f67-d811114974d5">576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOjA0YmQ2MmEyNDk5NTQzMGJhMTAwYmZiNjRkZTc3OTkxL3RhYmxlcmFuZ2U6MDRiZDYyYTI0OTk1NDMwYmExMDBiZmI2NGRlNzc5OTFfMTItMS0xLTEtMjc3NDI_b1dcccee-7839-4e40-8ee9-99390039da44">3,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;<ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMjc0Ng_48f37604-873f-468c-9fe3-659271d7b667" continuedAt="iaceda25975bf4d3db2ba2161632b9c7f" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="iaceda25975bf4d3db2ba2161632b9c7f" continuedAt="ib716fa03a0a24e02945b2840592ba6c2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMjc0NA_57b72d32-1ef0-4b18-9b67-f698b137189e" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in research and development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf31e53b9d2d45af97ed7cc8c45e4d49_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjViMGU0YTUwMzc1YTQ4NzBiNmIwMDU2N2RhODAxYjM2L3RhYmxlcmFuZ2U6NWIwZTRhNTAzNzVhNDg3MGI2YjAwNTY3ZGE4MDFiMzZfMy01LTEtMS0yNzc0Mg_bb866467-0e57-408e-9046-ad124f0e51f2">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2a240dd3945df929b606e4db832e0_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjViMGU0YTUwMzc1YTQ4NzBiNmIwMDU2N2RhODAxYjM2L3RhYmxlcmFuZ2U6NWIwZTRhNTAzNzVhNDg3MGI2YjAwNTY3ZGE4MDFiMzZfMy03LTEtMS0yNzc0Mg_17160957-8eab-40c7-915a-b37dea53c57b">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in selling, general and administrative expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5acd44d9cbae440c822b1c7ee063d0e2_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjViMGU0YTUwMzc1YTQ4NzBiNmIwMDU2N2RhODAxYjM2L3RhYmxlcmFuZ2U6NWIwZTRhNTAzNzVhNDg3MGI2YjAwNTY3ZGE4MDFiMzZfNC01LTEtMS0yNzc0Mg_f7c81acf-13a4-4da5-87eb-e67a19ead8c9">817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a9e753b3734856bcedf3f9838179e0_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjViMGU0YTUwMzc1YTQ4NzBiNmIwMDU2N2RhODAxYjM2L3RhYmxlcmFuZ2U6NWIwZTRhNTAzNzVhNDg3MGI2YjAwNTY3ZGE4MDFiMzZfNC03LTEtMS0yNzc0Mg_03996feb-2d1d-4844-9be2-7c97891057b6">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjViMGU0YTUwMzc1YTQ4NzBiNmIwMDU2N2RhODAxYjM2L3RhYmxlcmFuZ2U6NWIwZTRhNTAzNzVhNDg3MGI2YjAwNTY3ZGE4MDFiMzZfNy01LTEtMS0yNzc0Mg_41baefc9-1d4e-49ae-8941-fbe8eaef47d1">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjViMGU0YTUwMzc1YTQ4NzBiNmIwMDU2N2RhODAxYjM2L3RhYmxlcmFuZ2U6NWIwZTRhNTAzNzVhNDg3MGI2YjAwNTY3ZGE4MDFiMzZfNy03LTEtMS0yNzc0Mg_fc3ae4fb-f8a9-46f3-b290-e911ddd502df">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized compensation cost related to non-vested stock options outstanding at March&#160;31, 2022, net of estimated forfeitures, was $<ix:nonFraction unitRef="usd" contextRef="i893461f644cf442b9cd2137dff555003_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMzA2_866fc458-70b4-4811-91ac-6043b827ee75">13.3</ix:nonFraction> million, which is expected to be recognized over a weighted-average remaining vesting period of <ix:nonNumeric contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMzk3_68214cff-eaf2-468f-bb73-defb9c17e9c4">3.2</ix:nonNumeric> years.&#160;The weighted-average remaining contractual term of outstanding options as of March&#160;31, 2022 was approximately <ix:nonNumeric contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfNDk5_e41d5d3a-e114-426e-ba19-0348805125df">8.3</ix:nonNumeric> years. The total fair value of stock options vested during the three months ended March 31, 2022 and 2021 were $<ix:nonFraction unitRef="usd" contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfNTc0_f205dde3-16bf-4502-8dff-f1d881e70522">1,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfNTgx_7aa0aaf9-3323-4848-9e25-d5e92fdd6d56">24,000</ix:nonFraction>, respectively.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMjczOQ_609d396e-9652-406d-bc7a-1ca3c815d1f0" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmU2ODNlZTk0ZDJkMjRiY2ZiNTYyMzg4YzM2ZjQyMDI5L3RhYmxlcmFuZ2U6ZTY4M2VlOTRkMmQyNGJjZmI1NjIzODhjMzZmNDIwMjlfMi0xLTEtMS0yNzc0Mg_69276f84-f9d1-4903-82e7-8c5316adcda0">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmU2ODNlZTk0ZDJkMjRiY2ZiNTYyMzg4YzM2ZjQyMDI5L3RhYmxlcmFuZ2U6ZTY4M2VlOTRkMmQyNGJjZmI1NjIzODhjMzZmNDIwMjlfMy0xLTEtMS0yNzc0Mg_204bf7b5-aebc-47c3-a051-703baabaf2b5">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmU2ODNlZTk0ZDJkMjRiY2ZiNTYyMzg4YzM2ZjQyMDI5L3RhYmxlcmFuZ2U6ZTY4M2VlOTRkMmQyNGJjZmI1NjIzODhjMzZmNDIwMjlfNC0xLTEtMS0yNzc0Mg_bea89c61-3ba1-4f98-939f-fa7b5a977a7e">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmU2ODNlZTk0ZDJkMjRiY2ZiNTYyMzg4YzM2ZjQyMDI5L3RhYmxlcmFuZ2U6ZTY4M2VlOTRkMmQyNGJjZmI1NjIzODhjMzZmNDIwMjlfNS0xLTEtMS0yNzc0Mg_060bf5df-23c3-424b-9faf-c687a3686cdb">6.0</ix:nonNumeric> years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3b15932b484a471ebbfef330aba8275d_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMTA5OTUxMTYzMDcyNQ_e35f811c-6c36-4a1e-853c-c25b97201aba">No</ix:nonFraction> stock options were granted during the three months ended March 31, 2021. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="ib716fa03a0a24e02945b2840592ba6c2" continuedAt="i2a18d8b3a8df438b80a192b01049f376"><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMjczNw_7437fa82-10a1-43b3-b8dc-d74df3bf9435" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and changes in stock options outstanding is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7a27c0297d5482cbcaf83e2e3556d4b_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfMS0xLTEtMS0yNzc0Mg_f6153314-04eb-41ad-a92a-7ee485b879ef">3,771,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic7a27c0297d5482cbcaf83e2e3556d4b_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfMS0zLTEtMS0yNzc0Mg_45d10aee-85eb-46cf-af9f-45217b8b8755">7.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a27c0297d5482cbcaf83e2e3556d4b_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfMS01LTEtMS0yNzc0Mg_a4e8961e-a317-4551-81e5-670de36cbe67">6,405,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfMi0xLTEtMS0yNzc0Mg_bf5b938b-0d23-4343-88e3-4f820dc6c771">1,697,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfMi0zLTEtMS0yNzc0Mg_7b3112d5-96e5-4920-be6a-8cdab63150ae">3.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled / Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNC0xLTEtMS0yNzc0Mg_776522c2-03e5-41d1-9e60-8f84f0f0d973">1,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNC0zLTEtMS0yNzc0Mg_d617bbdf-dac5-4f16-9c2a-dbf2f5547ba8">31.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331" decimals="INF" name="crdf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNS0xLTEtMS0yNzc0Mg_0b43beab-88e7-459f-b16e-9438b6a1b253">800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331" decimals="2" name="crdf:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNS0zLTEtMS0yNzc0Mg_470f7a52-307d-47db-9e30-b2a0bcb80d82">165.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i893461f644cf442b9cd2137dff555003_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNi0xLTEtMS0yNzc0Mg_cd5229ce-f928-4dac-aeeb-19bd74f27ae9">5,467,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i893461f644cf442b9cd2137dff555003_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNi0zLTEtMS0yNzc0Mg_c30c2b5e-6d0b-4d6a-92ee-aac4f50c1d71">5.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i893461f644cf442b9cd2137dff555003_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNi01LTEtMS0yNzc0Mg_3501020f-0e92-4c56-a931-e02c6b347ec7">65,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i893461f644cf442b9cd2137dff555003_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNy0xLTEtMS0yNzc0Mg_1f32e994-6a51-428c-a4f6-ce457e65b109">1,281,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i893461f644cf442b9cd2137dff555003_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNy0zLTEtMS0yNzc0Mg_156031fc-b65a-448a-b9f8-9d656ab5da56">8.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i893461f644cf442b9cd2137dff555003_I20220331" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNy01LTEtMS0yNzc0Mg_3721f6cd-2032-465c-aa73-fa06cfdc5d9f">25,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i893461f644cf442b9cd2137dff555003_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfOC0xLTEtMS0yNzc0Mg_b68ee0d5-752b-402e-ac32-a268e7e68ec5">5,331,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i893461f644cf442b9cd2137dff555003_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfOC0zLTEtMS0yNzc0Mg_d1efa5d1-cee9-444d-957c-994bb3b42895">5.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i893461f644cf442b9cd2137dff555003_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfOC01LTEtMS0yNzc0Mg_3c5bb024-6c22-45af-ba7e-29629d90300f">61,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Equity Incentive Plan</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 the Company's stockholders approved the 2021 Omnibus Equity Incentive Plan ("2021 Plan"). The number of authorized shares in the 2021 Plan is equal to the sum of (i) <ix:nonFraction unitRef="shares" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMTEzMw_7ae42ec6-0088-4462-abc2-2a73b5c12ab2">3,150,000</ix:nonFraction> shares, plus (ii) the number of shares of Common Stock reserved, but unissued under the 2014 Plan; and (iii) the number of shares of Common Stock underlying forfeited awards under the 2014 Plan. As of March&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i2401c06088e64dc38c0c80a779717d55_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMTM1Mg_ac3f7457-2724-4ef6-8a5a-5e8d5abab8aa">918,865</ix:nonFraction> shares available for issuance under the 2021 Plan. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2014 Equity Incentive Plan</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the adoption of the 2021 Plan, no additional equity awards can be made under the terms of the 2014 Plan. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inducement Grants</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company began issuing equity awards to certain new employees as inducement grants outside of its 2021 Plan. As of March&#160;31, 2022, an aggregate of <ix:nonFraction unitRef="shares" contextRef="i75f4f015594a4bbf8dbbe4dfa4bb7c12_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMTcyOA_7e49089e-8f9c-4c23-a044-4a825c67f734">1,120,208</ix:nonFraction> shares were issuable upon the exercise of inducement grant stock options approved by the Company.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMjc0MQ_14a97087-6f99-4b4d-be6d-b5b2f9a5c860" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining&#160;Contractual<br/>Term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjhlMTZlNjRmYjJkOTQ4ZDRiOTU0NGQyNjdhYTMwZDc1L3RhYmxlcmFuZ2U6OGUxNmU2NGZiMmQ5NDhkNGI5NTQ0ZDI2N2FhMzBkNzVfMS0xLTEtMS0yNzc0Mg_fee8898e-bc2a-475a-a7d5-dca0618a3098">4,490,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231" decimals="2" name="crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjhlMTZlNjRmYjJkOTQ4ZDRiOTU0NGQyNjdhYTMwZDc1L3RhYmxlcmFuZ2U6OGUxNmU2NGZiMmQ5NDhkNGI5NTQ0ZDI2N2FhMzBkNzVfMS0zLTEtMS0yNzc0Mg_bba82dec-eb0a-4db0-968c-b463b6fafbbf">5.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i005b644829964efaa7d10c5ad40cdf4e_D20210101-20211231" name="crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjhlMTZlNjRmYjJkOTQ4ZDRiOTU0NGQyNjdhYTMwZDc1L3RhYmxlcmFuZ2U6OGUxNmU2NGZiMmQ5NDhkNGI5NTQ0ZDI2N2FhMzBkNzVfMS01LTEtMS0yNzc0Mg_3c818778-bd07-4396-b631-2c3a05744ac5">3.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjhlMTZlNjRmYjJkOTQ4ZDRiOTU0NGQyNjdhYTMwZDc1L3RhYmxlcmFuZ2U6OGUxNmU2NGZiMmQ5NDhkNGI5NTQ0ZDI2N2FhMzBkNzVfNS0xLTEtMS0yNzc0Mg_e80c2172-871d-4f86-9726-169c417bcc4b">4,490,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331" decimals="2" name="crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjhlMTZlNjRmYjJkOTQ4ZDRiOTU0NGQyNjdhYTMwZDc1L3RhYmxlcmFuZ2U6OGUxNmU2NGZiMmQ5NDhkNGI5NTQ0ZDI2N2FhMzBkNzVfNS0zLTEtMS0yNzc0Mg_95a45148-2ae0-418e-9a18-9cf8904f1c31">5.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjhlMTZlNjRmYjJkOTQ4ZDRiOTU0NGQyNjdhYTMwZDc1L3RhYmxlcmFuZ2U6OGUxNmU2NGZiMmQ5NDhkNGI5NTQ0ZDI2N2FhMzBkNzVfNS01LTEtMS0yNzc0Mg_8b3f4db8-8a9c-4189-81a7-93ed244de2b0">2.7</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><ix:continuation id="i2a18d8b3a8df438b80a192b01049f376"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMjczOA_f4e5fc29-3a79-4549-b32f-4633c123ff84" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our Company's classes of preferred stock is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares designated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation preference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifdc2b0e256004062aef3e08c666721e1_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfMi0yLTEtMS0yNzc0Mg_29b60fb6-5a41-4484-9a46-b932aa762293">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdc2b0e256004062aef3e08c666721e1_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfMi00LTEtMS0yNzc0Mg_8187b118-11c2-402c-9c05-533e753e0097">277,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc2b0e256004062aef3e08c666721e1_I20220331" decimals="INF" name="us-gaap:PreferredStockLiquidationPreferenceValue" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfMi02LTEtMS0yNzc0Mg_f9c4cf1f-a0a3-4547-ae7f-f66c37455887">606,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdc2b0e256004062aef3e08c666721e1_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfMi04LTEtMS0yNzc0Mg_a2375b5e-916f-4804-a548-cfd856f572c2">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59573fd142404a38a175c7870f55419f_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfMi0xMC0xLTEtMjc3NDI_882b305b-6c48-42e7-bc65-eaa0f9d8e2c3">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc3f3107c69b4f6b8dd87b5fdf51dfff_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfMy0yLTEtMS0yNzc0Mg_3ed9cd38-3e9f-48ae-878a-6b95d4c7a6b2">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc3f3107c69b4f6b8dd87b5fdf51dfff_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfMy00LTEtMS0yNzc0Mg_f83fcd5f-dc27-4c35-8646-adf8933dda09">8,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc3f3107c69b4f6b8dd87b5fdf51dfff_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfMy04LTEtMS0yNzc0Mg_6f90e1c5-fe7c-4edc-a49a-6ba5f11b8733">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b017a6f753f436d9ec2f214f9ebe2f7_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfMy0xMC0xLTEtMjc3NDI_5baa2966-5d09-4fe3-b740-7007be7f15e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bbf49ad684a421fbea0a38b95540cc1_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNC0yLTEtMS0yNzc0Mg_14cc7879-b6e4-4912-b693-634fed3e45a9">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bbf49ad684a421fbea0a38b95540cc1_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNC00LTEtMS0yNzc0Mg_56743a2d-6bb1-4b18-b683-d7529137779d">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bbf49ad684a421fbea0a38b95540cc1_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNC04LTEtMS0yNzc0Mg_b730728e-78c5-4ad2-8e10-7df781e5113f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5be5174c9fb344c9a625c79d662f8c80_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNC0xMC0xLTEtMjc3NDI_22e6f438-a830-4805-8707-6a11af1dfc96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i49b6a8dfc660406a91d6569610ca4915_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNS0yLTEtMS0yNzc0Mg_9f752d1a-04a4-4b9e-835c-14164ad75eda">0.0001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49b6a8dfc660406a91d6569610ca4915_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNS00LTEtMS0yNzc0Mg_6d83ee11-ae04-4a74-bade-8c28879807e2">154,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49b6a8dfc660406a91d6569610ca4915_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNS04LTEtMS0yNzc0Mg_a6d6569f-d46a-479d-8b66-8e21db8dde40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8d76d5beb354ae2a99c506c37bfe260_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNS0xMC0xLTEtMjc3NDI_9c6d473c-a2e1-4b9f-b76f-344d61ee7da9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e7fca4604c9471d93e4d2007ee915b4_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNi0yLTEtMS0yNzc0Mg_91a6625a-36aa-4af0-aead-125cf77852bf">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e7fca4604c9471d93e4d2007ee915b4_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNi00LTEtMS0yNzc0Mg_20c904e2-3ae2-4526-9c70-4286d18a99b7">865,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e7fca4604c9471d93e4d2007ee915b4_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNi04LTEtMS0yNzc0Mg_3fdca934-09fc-4685-a9e7-74772702128e">327,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b1336fa1dbf42329f000675cc7b21f0_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNi0xMC0xLTEtMjc3NDI_4cb8487f-8920-401d-a437-5a91d377a5f3">655,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV82MS9mcmFnOjlhODFiOTQ4MjgzMzRjMmRhZTY0M2E3NjhjY2RiNGNlL3RleHRyZWdpb246OWE4MWI5NDgyODMzNGMyZGFlNjQzYTc2OGNjZGI0Y2VfMjE3MQ_39bc103c-5c23-457c-9730-6eb2fe856c51" continuedAt="ia054189241314e388d5729fd7b45f359" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ia054189241314e388d5729fd7b45f359"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development and Clinical Trial Agreements</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib. Onvansertib, an investigational drug, is an oral, and a highly selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK1. The Company is developing onvansertib in cancer indications with the greatest medical need for new treatment options. Terms of the agreement provide for the Company to pay development milestones and royalties based on sales volume.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of oncology therapeutics. These agreements include License fees, Royalties and Milestone payments. The Company also has a legacy license agreement in the field of oncology diagnostics under which royalty payments are due. These royalty payments are calculated as a percent of revenue. For the three months ended March&#160;31, 2022 and 2021, payments have not been material.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm the Company&#8217;s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company&#8217;s business or financial condition.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i43edf2a30c6642969a7b68c1e523baa5_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form&#160;10-Q includes forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).&#160;All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.&#160;These forward-looking statements are subject to a number of risks, uncertainties and assumptions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our business and financial performance may be affected by the factors that are discussed under &#8220;Risk Factors&#8221; in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021, filed on February&#160;24, 2022.&#160;Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for us to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events.&#160;We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur.&#160;Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis is qualified in its entirety by, and should be read in conjunction with, the more detailed information set forth in the financial statements and the notes thereto appearing elsewhere in this Quarterly Report on Form&#160;10-Q. This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future.&#160;Such discussion represents only the best present assessment of our management.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations that overcome disease resistance and improve disease response to standard treatment regimens and to increase overall survival. We are developing onvansertib, an oral and highly selective PLK1 inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Our clinical development programs incorporate tumor genomics and biomarker assays to refine assessment of patient response to treatment.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Drug Candidate, Onvansertib</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onvansertib, our lead compound, is a novel, highly potent, highly selective PLK1 inhibitor.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PLK1, a serine/threonine kinase, has a well-understood mechanism of action within tumor cell proliferation and is overexpressed in a number of tumors (including colorectal, pancreatic, prostate, ovarian, breast and lung cancer). In particular, PLK1&#8217;s activity in various phases of the cell cycle provide multiple targets for a PLK1 inhibitor to inhibit DNA repair and interrupt cell division, thereby killing tumor cells.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PLK1 inhibition has been considered an attractive target of cancer therapeutics for the last two decades, however past PLK1 drug candidates have failed to show acceptable tolerability and efficacy. We believe the attributes of onvansertib described below, as well as clinical evidence of favorable safety and efficacy, with expected on-target, easy to manage and reversible side effects, may prove beneficial in addressing clinical therapeutic needs across a variety of cancers:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Onvansertib is highly potent and highly selective against the PLK1 enzyme (IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> = 2nM; IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is the concentration for 50% inhibition), compared to prior PLK1 inhibitors that were pan-inhibitors of several PLK targets.  Low or no </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">activity of onvansertib was observed on a panel of 63 kinases (IC50&gt;500 nM), including the PLK members PLK2 and PLK3 (IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&gt;10,000 nM).</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Onvansertib has a relatively short drug half-life of 24 hours, compared to a half-life of approximately 5 days for prior PLK1 inhibitors.  A short half-life allows for flexible dosing and improved managing of drug concentrations to reduce dose-related toxicities.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Onvansertib is orally bioavailable, compared to prior PLK1 inhibitors that were delivered intravenously, allowing for relative ease and flexibility of dosing.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies have shown synergistic effects when onvansertib was administered in combination with different cytotoxic agents including antimicrotubule agents, topoisomerase 1 inhibitors, antimetabolites, alkylating agents, proteasome inhibitors, kinase inhibitors, BCL-2 inhibitors, and androgen biosynthesis inhibitors.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> combination studies have confirmed the positive results obtained </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and synergistic effects have been observed in xenograft models of onvansertib in combination with irinotecan, 5-fluorouracil ("5-FU"), abiraterone, PARP inhibitors, venetoclax, and paclitaxel, while additive effects in combination with cytarabine or bevacizumab have been demonstrated.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are three ongoing clinical trials in onvansertib in combination treatment: second line treatment in patients with KRAS-mutated Metastatic Colorectal Cancer ("mCRC"), second line treatment in patients with Metastatic Pancreatic Ductal Adenocarcinoma ("mPDAC"), and in patients with Metastatic Castration-Resistant Prostate Cancer ("mCRPC") showing early signs of resistance to abiraterone.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:102%">Phase 1b/2 Clinical Trial in KRAS-mutated mCRC</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TROV-054 is a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with standard of care FOLFIRI and bevacizumab (Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the second line treatment of patients with KRAS-mutated mCRC, which is being conducted at seven clinical trial sites across the U.S. - USC Norris Comprehensive Cancer Center, The Mayo Clinic Cancer Centers (Arizona, Minnesota, and Florida), Kansas University Medical Center, Inova Schar Cancer Institute and CARTI Cancer Center.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The primary objective of this trial is to evaluate the Dose-Limiting Toxicities ("DLTs") and maximum tolerated dose ("MTD") or recommended Phase 2 dose ("RP2D") of onvansertib in combination with FOLFIRI and bevacizumab (Phase 1b) and to continue to assess the safety and preliminary efficacy of onvansertib in combination with FOLFIRI and bevacizumab (Phase 2).</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scientific rationale for this clinical trial is based on the two key principles of synthetic lethality and synergy, with the objective of demonstrating a proof-of-concept of clinical benefit within this phase1b/2 trial. Synthetic lethality refers to a critical vulnerability to tumor cell death by way of PLK1 inhibition within CRC tumor cells harboring KRAS mutations versus KRAS wild-type isogenic cells. Synergy occurs when the combination of two drugs results in an unexpected greater activity than an expected additive effect of the two drugs. Onvansertib in combination with two DNA-damaging agents, irinotecan, and 5-FU (two components of FOLFIRI), demonstrated synergy in colorectal cancer cell lines and both combinations have demonstrated significantly greater tumor growth inhibition than either drug alone in CRC </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> models. We believe this synergy occurs because PLK1 can promote the repair of DNA damage caused by chemotherapeutic agents and by inhibiting PLK1, onvansertib leaves damaged tumor cells unable to replicate.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data we presented on January 18, 2022 provided an update of the ongoing phase 1b/2 clinical trial in KRAS-mutated metastatic colorectal cancer. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">34% (12 of 35) of patients treated per protocol at the RP2D in combination with FOLFIRI and bevacizumab achieved a Complete Response ("CR") or Partial Response ("PR") (CR: 1 patient; PR: 11 patients);</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">35% (17 of 48) of patients across all dose levels achieved a CR or PR. Historically, Objective Response Rates ("ORR") of 5-13% have been reported in similar second line patient populations treated with various different drug combinations, including the standard of care chemotherapy of FOLFIRI with bevacizumab;</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">10% (5 of 48) of patients discontinued the trial to pursue potentially curative metastasis-directed therapy (surgical resection or microwave ablation);</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Median Progression-Free Survival ("mPFS") across all response-evaluable patients (n=48) is 9.4 months and has not yet been reached in those treated per protocol at the RP2D. Historically, mPFS of ~4.5-5.7 months has been reported in a similar patient population treated with standard of care chemotherapy of FOLFIRI with bevacizumab;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The combination regimen of onvansertib plus FOLFIRI/bevacizumab is well tolerated with no major or unexpected toxicities attributed to onvansertib.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:102%">Phase 2 Clinical Trial in mPDAC</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRDF-001 is a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan (Onivyde</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), leucovorin, and fluorouracil for second line treatment of patients with mPDAC, which is being conducted at six clinical trial sites across the U.S. &#8211; The Mayo Clinic Cancer Centers (Arizona, Minnesota, and Florida), Kansas University Medical Center, Inova Schar Cancer Institute, and the University of Nebraska Medical Center.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first patient was dosed in June 2021. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of this trial is to assess the safety and preliminary efficacy of onvansertib in combination with nanoliposomal irinotecan (Onyvide</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), 5-FU and leucovorin as a second-line treatment in patients with mPDAC who have failed first-line gemcitabine-based therapy. The trial is expected to enroll approximately 45 patients.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 2 Clinical Trial in mCRPC</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TROV-053 is a Phase 2 open-label multi-center clinical trial of onvansertib in combination with abiraterone acetate and prednisone in patients with mCRPC, which is being conducted at three clinical trial sites - Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute and Massachusetts General Hospital.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of this trial is to observe the effects of onvansertib in combination with abiraterone and prednisone on disease control as assessed by Prostate Specific Antigen ("PSA") decline or stabilization after 12 weeks of treatment in patients with mCRPC showing early signs of resistance to abiraterone.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rationale for this trial is based on the Mechanism of Action ("MOA") of onvansertib and abiraterone acetate and the synergy of these two drugs when used in combination in pre-clinical experiments. Onvansertib inhibits tumor cell proliferation by inducing G2/M (mitosis) arrest and consequently cell death. The combination of onvansertib and abiraterone acetate synergistically increases mitotic arrest and cell death in prostate cancer cells and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has demonstrated significantly greater tumor growth inhibition than either drug alone </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data as of April 8, 2022, presented at American Association for Cancer Research ("AACR") Annual Meeting provided evidence of the safety and efficacy of onvansertib in combination with abiraterone. Disease control increased with increasing dose density of onvansertib from 29% to 45% of patients achieving PSA stabilization and from 53% to 75% of patients with radiographic stable disease; Arm A (n=17) &#8211; onvansertib 24mg/m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> days 1-5 in 21-day cycle to Arm C (n=20) &#8211; 12mg/m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> days 1-14 in 21-day cycle. Median progression-free survival ("mPFS") has increased with increasing onvansertib dose density from 4.1 months in Arm A to 13.2 months to-date in Arm C patients. Genomic analysis of ctDNA showed a correlation between alterations in two key genes of the PI3K signaling pathway&#8212;MTOR and PTEN, which appears to underly increased pathway activity, and sensitivity to onvansertib/abiraterone combination in mCRPC patients with early abiraterone resistance. The treatment regimen of onvansertib in combination with abiraterone/prednisone has been well tolerated. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborative Relationship with Pfizer</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we entered into a collaborative relationship with Pfizer Inc. as part of the Pfizer Breakthrough Growth Initiative, pursuant to which Pfizer purchased 2.4 million shares of our common stock for gross proceeds of approximately $15.0 million. In connection with the stock purchase, we and Pfizer entered into an Information Rights Agreement pursuant to which Adam Schayowitz, Ph.D., MBA, Vice President &amp; Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Melanoma at Pfizer joined our Scientific Advisory Board, and until May 17, 2024 we agreed to provide Pfizer with rights of first access to any preclinical or clinical data and results generated as part of the onvansertib development program at least two business days prior to us providing such data to a third party.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Company Update</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 11, 2022 we announced the appointment of Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, R.Ph., as Senior Vice President, Regulatory Affairs. </span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accumulated deficit through March&#160;31, 2022 is $270.8 million.&#160;To date, we have generated minimal revenues and expect to incur additional losses to perform further research and development activities.&#160;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug development efforts are in their early stages, and we cannot make estimates of the costs or the time that our development efforts will take to complete, or the timing and amount of revenues related to the sale of our drug candidates.&#160;The risk of completion of any program is high because of the many uncertainties involved in developing new drug candidates to market, including the long duration of clinical testing, the specific performance of proposed products under stringent clinical trial protocols, extended regulatory approval and review cycles, our ability to raise additional capital, the nature and timing of research and development expenses, and competing technologies being developed by organizations with significantly greater resources.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting policies are described in ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS of our Annual Report on Form&#160;10-K as of and for the year ended December&#160;31, 2021, filed with the SEC on February&#160;24, 2022.&#160;There have been no changes to our critical accounting policies since December&#160;31, 2021.</span></div><div><span><br/></span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2022 and 2021 </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues were $74,000 for the three months ended March 31, 2022 as compared to $72,000 for the prior period. Revenues are from our sales-based or usage-based royalties on other intellectual property licenses, unrelated to onvansertib. Revenue recognition of the royalty depends on the timing and overall sales activities of the licensees. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and staff costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials, outside services, and lab supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,208&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $3.9 million for the three months ended March 31, 2022 compared to the same period in 2021.&#160;The overall increase in research and development expenses was primarily due to costs associated with an increase in outside service costs related to chemistry, manufacturing, and controls ("CMC") and pharmacology for the development of our lead drug candidate, onvansertib. Salaries and staff costs increased primarily due to a higher headcount in the current period, as compared to the prior period. The increase in stock-based compensation is primarily due to additional stock option grants to employees granted subsequent to the prior period.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and staff costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside services and professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,940&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,235&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $1.7 million for the three months ended March 31, 2022 compared to the same period in 2021.&#160;The significant components of the increase were outside services and stock-based compensation. The increase in outside services is primarily related to strategic valuation consulting related to our lead drug candidate, onvansertib. The increase in stock-based compensation is primarily due to additional stock option grants to employees and directors granted subsequent to the prior period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss and per share amounts were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,993)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,179)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common&#160;shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,999)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,185)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $5.8 million increase</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in net loss attributable to common shareholders was primarily the result of an increase in operating expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March 31, 2022 compared to the same period in the prior year. The $0.11 increase in basic net loss per share was impacted by the increased net loss attributable to common shareholders and the increase in weighted average shares outstanding resulting primarily from the issuance of approximately 5.8 million shares of common stock from April 1, 2021 through March&#160;31, 2022. </span></div><div><span><br/></span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March 31, 2022 was $10.2 million, compared to $5.9 million for the three months ended March&#160;31, 2021.&#160;Our use of cash was primarily a result of the net loss of $11.0 million for the three months ended March 31, 2022, adjusted for non-cash items related to stock-based compensation of $1.2 million, amortization of premiums on short-term investments $0.3 million, and release of clinical trial funding commitment of $0.1 million.&#160;The net change in our operating assets and liabilities was $0.9 million increasing cash used in operations.&#160;At our current and anticipated level of operating loss, we expect to continue to incur an operating cash outflow for the next several years.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $18.4 million primarily related to net purchases of marketable securities during the three months ended March 31, 2022, compared to net cash used in investing activities of $111.7 million for net purchases of marketable securities during the same period in 2021. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided in financing activities was $0.0 million during the three months ended March 31, 2022, compared to $1.3 million of proceeds from warrant exercises for the same period in 2021.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, and December&#160;31, 2021, we had working capital of $129.1 million and $139.6 million, respectively.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception and have negative operating cash flows. As of March&#160;31, 2022, we had $129.4 million in cash, cash equivalents and short-term investments and we believe we have sufficient cash to meet our funding requirements for at least the next 12 months following the issuance date of this Quarterly Report on Form 10-Q. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the foreseeable future, we expect to continue to incur losses and require additional capital to further advance our clinical trial programs and support our other operations. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we can raise additional funds by issuing equity securities, our stockholders may experience additional dilution. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have performed an evaluation under the supervision and with the participation of our management, including our principal executive officer (CEO) and principal financial officer (CFO), of the effectiveness of our disclosure controls and procedures, as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).&#160;Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of March&#160;31, 2022 to provide reasonable assurance that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as specified above. Management does not expect, however, that our disclosure controls and procedures will prevent or detect all errors and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within our company have been detected.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control&#160;over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting during the three months ended March&#160;31, 2022 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i43edf2a30c6642969a7b68c1e523baa5_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II.&#160; OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes from the risk factors disclosed in our Form&#160;10-K for the year ended December&#160;31, 2021.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div><span><br/></span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_118"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_121"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i43edf2a30c6642969a7b68c1e523baa5_124"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description&#160;of&#160;Exhibit</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf-033122exhibit311.htm">Certification of Principal Executive Officer required by Rule&#160;13a-14(a)/15d-14(a)&#160;under the Exchange Act.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf-033122exhibit312.htm">Certification of Principal Financial Officer required by Rule&#160;13a-14(a)/15d-14(a)&#160;under the Exchange Act.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf-033122exhibit321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf-033122exhibit322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - the cover page from the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 is formatted in Inline XBRL</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i43edf2a30c6642969a7b68c1e523baa5_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i43edf2a30c6642969a7b68c1e523baa5_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY,&#160;INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY,&#160;INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Levine</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Levine</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>crdf-033122exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id651744945d24dc6a87fb884b8e0c20f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark Erlander, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form&#160;10-Q of Cardiff Oncology,&#160;Inc. (the &#8220;Registrant&#8221;)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer </font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>crdf-033122exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7f590b30cc3b4c97a54e1bafdb078d5b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Levine, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form&#160;10-Q of Cardiff Oncology,&#160;Inc. (the &#8220;Registrant&#8221;)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; James Levine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Levine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>crdf-033122exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id79ea47ee2aa4da5b8f4806673c3979b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Cardiff Oncology,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the three months ended March&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I, Mark Erlander, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;&#160;1350, as adopted pursuant to &#167;&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer </font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>crdf-033122exhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5d9ad7a30fbb4b6fba692f9bd4f26e7a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Cardiff Oncology,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the three months ended March&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I, James Levine, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;&#160;1350, as adopted pursuant to &#167;&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;James Levine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Levine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>crdf-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5214d653-0d65-43f4-9358-98c3966fcc60,g:7d826e52-41b1-4720-8d3a-56dea8b8a1bc-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:crdf="http://www.cardiffoncology.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardiffoncology.com/20220331">
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cardiffoncology.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETS" roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETSParenthetical" roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>1004005 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetails" roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.cardiffoncology.com/role/FairValueMeasurements">
        <link:definition>2107103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsTables">
        <link:definition>2308302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails">
        <link:definition>2409403 - Disclosure - Fair Value Measurements - Fair Value of Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformation" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation">
        <link:definition>2110104 - Disclosure - Supplementary Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationTables" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables">
        <link:definition>2311303 - Disclosure - Supplementary Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails">
        <link:definition>2412404 - Disclosure - Supplementary Balance Sheet Information - Investments Available-for-sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1">
        <link:definition>2412404 - Disclosure - Supplementary Balance Sheet Information - Investments Available-for-sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails">
        <link:definition>2413405 - Disclosure - Supplementary Balance Sheet Information - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails">
        <link:definition>2414406 - Disclosure - Supplementary Balance Sheet Information - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cardiffoncology.com/role/Leases">
        <link:definition>2115105 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cardiffoncology.com/role/LeasesTables">
        <link:definition>2316304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cardiffoncology.com/role/LeasesNarrativeDetails">
        <link:definition>2417407 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>2418408 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationDetails" roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>2419409 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationDetails" roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails">
        <link:definition>2420410 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>2421411 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>2421411 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.cardiffoncology.com/role/StockholdersEquity">
        <link:definition>2122106 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityTables">
        <link:definition>2323305 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockbasedCompensationExpenseDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails">
        <link:definition>2424412 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionActivityDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails">
        <link:definition>2425413 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityWarrantsDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails">
        <link:definition>2426414 - Disclosure - Stockholders' Equity - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityPreferredStockDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails">
        <link:definition>2427415 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingencies">
        <link:definition>2128107 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="crdf_SeriesBConvertiblePreferredStockMember" abstract="true" name="SeriesBConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_LessorNumberOfSubleases" abstract="false" name="LessorNumberOfSubleases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="crdf_PreferredStockDividendAccrued" abstract="false" name="PreferredStockDividendAccrued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_PatentLicenseAndOtherFeesPayable" abstract="false" name="PatentLicenseAndOtherFeesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseAreaOfLease" abstract="false" name="LesseeOperatingLeaseAreaOfLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_WarrantsAndRightsRollForward" abstract="true" name="WarrantsAndRightsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_SeriesDConvertiblePreferredStockMember" abstract="true" name="SeriesDConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="crdf_SeriesCConvertiblePreferredStockMember" abstract="true" name="SeriesCConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" abstract="true" name="ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_AccruedClinicalTrial" abstract="false" name="AccruedClinicalTrial" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" abstract="false" name="ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_AccruedPreferredStockDividend" abstract="false" name="AccruedPreferredStockDividend" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_SeriesAConvertiblePreferredStockMember" abstract="true" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ServiceReceivableMember" abstract="true" name="ServiceReceivableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_LessorAreaOfSublease" abstract="false" name="LessorAreaOfSublease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="crdf_EquityIncentivePlan2021Member" abstract="true" name="EquityIncentivePlan2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="crdf_InducementGrantStockOptionsMember" abstract="true" name="InducementGrantStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_ReleaseOfClinicalTrialFundingCommitment" abstract="false" name="ReleaseOfClinicalTrialFundingCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseMonthlyRentPayment" abstract="false" name="LesseeOperatingLeaseMonthlyRentPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_SeriesEConvertiblePreferredStockMember" abstract="true" name="SeriesEConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_AccruedDirectorFees" abstract="false" name="AccruedDirectorFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract" abstract="true" name="DebtSecuritiesAvailableForSaleNoncurrentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_IncreaseDecreaseInOperatingLeaseLiability" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ServiceReceivable" abstract="false" name="ServiceReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" abstract="false" name="ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_FurnitureAndOfficeEquipmentMember" abstract="true" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" abstract="false" name="LesseeOperatingLeaseAnnualRentIncreasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="crdf_AccruedResearchAgreements" abstract="false" name="AccruedResearchAgreements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" abstract="true" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>crdf-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5214d653-0d65-43f4-9358-98c3966fcc60,g:7d826e52-41b1-4720-8d3a-56dea8b8a1bc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="crdf-20220331.xsd#CONDENSEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0e72aee1-7e0a-440f-81bd-68d70bec125d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_247b52e8-0caf-44be-a7f0-85947f326441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0e72aee1-7e0a-440f-81bd-68d70bec125d" xlink:to="loc_us-gaap_AccountsPayableCurrent_247b52e8-0caf-44be-a7f0-85947f326441" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b1ef5f13-8631-46d4-97f6-59678287368e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0e72aee1-7e0a-440f-81bd-68d70bec125d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b1ef5f13-8631-46d4-97f6-59678287368e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_206a1b1e-95e1-46ed-9733-feb8734cafd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0e72aee1-7e0a-440f-81bd-68d70bec125d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_206a1b1e-95e1-46ed-9733-feb8734cafd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4f1aadaa-05a1-4af9-a0b9-b3cb8fa2837c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0e72aee1-7e0a-440f-81bd-68d70bec125d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4f1aadaa-05a1-4af9-a0b9-b3cb8fa2837c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7c64fcfd-48a2-4ef8-8272-d505850a4f27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_457340ea-64d8-438d-9a73-3250a7f6fd71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7c64fcfd-48a2-4ef8-8272-d505850a4f27" xlink:to="loc_us-gaap_PreferredStockValue_457340ea-64d8-438d-9a73-3250a7f6fd71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_dcc58d21-ee48-4a25-aec9-79fa9b49c77f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7c64fcfd-48a2-4ef8-8272-d505850a4f27" xlink:to="loc_us-gaap_CommonStockValue_dcc58d21-ee48-4a25-aec9-79fa9b49c77f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_cf0fe0e4-4600-4696-816b-ad140c122c59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7c64fcfd-48a2-4ef8-8272-d505850a4f27" xlink:to="loc_us-gaap_AdditionalPaidInCapital_cf0fe0e4-4600-4696-816b-ad140c122c59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivable_cf7cab0f-78fc-4950-babe-aedbdd292838" xlink:href="crdf-20220331.xsd#crdf_ServiceReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7c64fcfd-48a2-4ef8-8272-d505850a4f27" xlink:to="loc_crdf_ServiceReceivable_cf7cab0f-78fc-4950-babe-aedbdd292838" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_94349fac-a7d0-47b5-a5e2-36b7eca9c451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7c64fcfd-48a2-4ef8-8272-d505850a4f27" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_94349fac-a7d0-47b5-a5e2-36b7eca9c451" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_044f127d-17fa-4861-a7f7-756b9ac3c01f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7c64fcfd-48a2-4ef8-8272-d505850a4f27" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_044f127d-17fa-4861-a7f7-756b9ac3c01f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b2396804-b6ca-4922-88c5-540d47b929b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5196711d-cb06-415a-ac1f-710f995c89a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b2396804-b6ca-4922-88c5-540d47b929b5" xlink:to="loc_us-gaap_AssetsCurrent_5196711d-cb06-415a-ac1f-710f995c89a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a0da75c2-a070-4c72-be01-f0eefd467a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b2396804-b6ca-4922-88c5-540d47b929b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a0da75c2-a070-4c72-be01-f0eefd467a34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c26110ef-0e61-454f-ac5a-e4ce5097e4a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b2396804-b6ca-4922-88c5-540d47b929b5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c26110ef-0e61-454f-ac5a-e4ce5097e4a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0dfc2cea-a7cd-4a8c-ae99-74c703577d76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b2396804-b6ca-4922-88c5-540d47b929b5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0dfc2cea-a7cd-4a8c-ae99-74c703577d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_73623d2d-e94e-4905-96ad-595a9f85e8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2be8d63b-51ac-4ea0-ad43-16b50db3fde9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_73623d2d-e94e-4905-96ad-595a9f85e8c2" xlink:to="loc_us-gaap_Liabilities_2be8d63b-51ac-4ea0-ad43-16b50db3fde9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_aad61bd5-0241-45a1-ba58-54e98a4ac740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_73623d2d-e94e-4905-96ad-595a9f85e8c2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_aad61bd5-0241-45a1-ba58-54e98a4ac740" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a6e59576-515a-4594-94ee-e1a4789d9ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_73623d2d-e94e-4905-96ad-595a9f85e8c2" xlink:to="loc_us-gaap_StockholdersEquity_a6e59576-515a-4594-94ee-e1a4789d9ec0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b97ed1b2-c84d-4bbc-8e70-b274fe409ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d1a52b79-0a3a-48ae-8102-1678181e30dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b97ed1b2-c84d-4bbc-8e70-b274fe409ed0" xlink:to="loc_us-gaap_LiabilitiesCurrent_d1a52b79-0a3a-48ae-8102-1678181e30dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_981ac62e-0813-465e-a933-16b2cbdbcc85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b97ed1b2-c84d-4bbc-8e70-b274fe409ed0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_981ac62e-0813-465e-a933-16b2cbdbcc85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c14fbc1d-b2d1-4f86-b0e0-1bd4c68894b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b8f9674-a10c-4ffc-854f-6ef4aaddd8e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c14fbc1d-b2d1-4f86-b0e0-1bd4c68894b3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b8f9674-a10c-4ffc-854f-6ef4aaddd8e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6b7f0263-dffc-4061-95b1-cd6c8c1f3a5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c14fbc1d-b2d1-4f86-b0e0-1bd4c68894b3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6b7f0263-dffc-4061-95b1-cd6c8c1f3a5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_43c31288-6b37-4293-b864-8da4a6d62708" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c14fbc1d-b2d1-4f86-b0e0-1bd4c68894b3" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_43c31288-6b37-4293-b864-8da4a6d62708" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_3a82fbdb-2570-46a5-bf26-99ad39abadfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c14fbc1d-b2d1-4f86-b0e0-1bd4c68894b3" xlink:to="loc_us-gaap_ShortTermInvestments_3a82fbdb-2570-46a5-bf26-99ad39abadfb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="crdf-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7b9d9f69-09e1-40cb-a4c8-51cb0d8b0216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_906c3215-5792-41f2-a972-b0c292be34dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7b9d9f69-09e1-40cb-a4c8-51cb0d8b0216" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_906c3215-5792-41f2-a972-b0c292be34dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_4a600ea2-90b6-48b4-9843-bf097dea8f34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7b9d9f69-09e1-40cb-a4c8-51cb0d8b0216" xlink:to="loc_us-gaap_InterestIncomeOperating_4a600ea2-90b6-48b4-9843-bf097dea8f34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_22935ca3-edfa-4624-8b68-fea184913d73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7b9d9f69-09e1-40cb-a4c8-51cb0d8b0216" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_22935ca3-edfa-4624-8b68-fea184913d73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_79ca3e66-b481-445c-9410-b74527f3e72f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f4062e89-fbaf-4bf5-8dcc-9b1405cc91f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_79ca3e66-b481-445c-9410-b74527f3e72f" xlink:to="loc_us-gaap_OperatingExpenses_f4062e89-fbaf-4bf5-8dcc-9b1405cc91f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b69da7d7-b173-4edc-9b4a-534621e6fe8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_79ca3e66-b481-445c-9410-b74527f3e72f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b69da7d7-b173-4edc-9b4a-534621e6fe8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e376005-69c9-460e-9da3-292734099ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_361e4a1d-e370-4b32-944d-04471da3e9d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9e376005-69c9-460e-9da3-292734099ca7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_361e4a1d-e370-4b32-944d-04471da3e9d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6b60f57b-fbed-46ea-a7e6-10bd16dd4be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9e376005-69c9-460e-9da3-292734099ca7" xlink:to="loc_us-gaap_OperatingIncomeLoss_6b60f57b-fbed-46ea-a7e6-10bd16dd4be3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_757b8a3f-74f1-4c6c-85e2-37e26a77e6f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_6281abd3-87e7-4057-b50f-c2b2c21a98c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_757b8a3f-74f1-4c6c-85e2-37e26a77e6f7" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_6281abd3-87e7-4057-b50f-c2b2c21a98c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5ac2b7f2-3557-46e8-8443-b65df03d02db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_757b8a3f-74f1-4c6c-85e2-37e26a77e6f7" xlink:to="loc_us-gaap_NetIncomeLoss_5ac2b7f2-3557-46e8-8443-b65df03d02db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7cd28188-a8ce-4d28-be0a-40584182740d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5ddf357f-2633-4422-8b94-ca19832427ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7cd28188-a8ce-4d28-be0a-40584182740d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5ddf357f-2633-4422-8b94-ca19832427ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_08dd616c-b99d-4f7c-ad44-9d44c3c909ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7cd28188-a8ce-4d28-be0a-40584182740d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_08dd616c-b99d-4f7c-ad44-9d44c3c909ee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="crdf-20220331.xsd#CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_64946b7b-21e0-43d4-915e-896a30b98570" xlink:href="crdf-20220331.xsd#crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_320a78f4-b4be-4fd1-addb-f748ee9208f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_64946b7b-21e0-43d4-915e-896a30b98570" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_320a78f4-b4be-4fd1-addb-f748ee9208f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_852d0eaf-27c1-4516-bb57-3289aea6071c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_64946b7b-21e0-43d4-915e-896a30b98570" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_852d0eaf-27c1-4516-bb57-3289aea6071c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_818dff65-80db-458e-8d6a-3699b059aa12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7f35c6cc-b9bb-458b-86d6-43b4422d7703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_818dff65-80db-458e-8d6a-3699b059aa12" xlink:to="loc_us-gaap_NetIncomeLoss_7f35c6cc-b9bb-458b-86d6-43b4422d7703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e7c067cb-64ba-4eea-890f-0004b324b2ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_818dff65-80db-458e-8d6a-3699b059aa12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e7c067cb-64ba-4eea-890f-0004b324b2ec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="crdf-20220331.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_50b6cabb-2522-4570-a0d9-a9334bbb48e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_39df880f-eda7-4cf5-884f-c361748f2fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_50b6cabb-2522-4570-a0d9-a9334bbb48e9" xlink:to="loc_us-gaap_NetIncomeLoss_39df880f-eda7-4cf5-884f-c361748f2fbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_adbde0cf-4879-44bf-afc2-94cbaee63bc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_50b6cabb-2522-4570-a0d9-a9334bbb48e9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_adbde0cf-4879-44bf-afc2-94cbaee63bc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_be8ae909-ea1a-4d1c-a22f-b79028cf6f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_50b6cabb-2522-4570-a0d9-a9334bbb48e9" xlink:to="loc_us-gaap_ShareBasedCompensation_be8ae909-ea1a-4d1c-a22f-b79028cf6f0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_7254709a-fe62-408a-b993-0f658ef59a07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_50b6cabb-2522-4570-a0d9-a9334bbb48e9" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_7254709a-fe62-408a-b993-0f658ef59a07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_583f1a52-f054-42fa-b297-fe633a9a02ae" xlink:href="crdf-20220331.xsd#crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_50b6cabb-2522-4570-a0d9-a9334bbb48e9" xlink:to="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_583f1a52-f054-42fa-b297-fe633a9a02ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_dc301786-e9de-42a9-8da5-be6c6576b04a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_50b6cabb-2522-4570-a0d9-a9334bbb48e9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_dc301786-e9de-42a9-8da5-be6c6576b04a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5ba41330-4d58-4cae-91c0-5b3e40476d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_50b6cabb-2522-4570-a0d9-a9334bbb48e9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5ba41330-4d58-4cae-91c0-5b3e40476d48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_c81bd59f-bbe6-423b-a6a1-85a2cb90dc20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_50b6cabb-2522-4570-a0d9-a9334bbb48e9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_c81bd59f-bbe6-423b-a6a1-85a2cb90dc20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_078673ac-803f-4f11-a3b4-436689905d40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_50b6cabb-2522-4570-a0d9-a9334bbb48e9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_078673ac-803f-4f11-a3b4-436689905d40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability_ef469047-73a4-4525-9ac7-d199dc285155" xlink:href="crdf-20220331.xsd#crdf_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_50b6cabb-2522-4570-a0d9-a9334bbb48e9" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability_ef469047-73a4-4525-9ac7-d199dc285155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_92503207-09b6-4886-8be4-7ff51c6a95f2" xlink:href="crdf-20220331.xsd#crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_50b6cabb-2522-4570-a0d9-a9334bbb48e9" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_92503207-09b6-4886-8be4-7ff51c6a95f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_cc9c6c4b-62b3-47a8-a71c-327e79f6e914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_50b6cabb-2522-4570-a0d9-a9334bbb48e9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_cc9c6c4b-62b3-47a8-a71c-327e79f6e914" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_240ee70e-f578-4511-9f18-ef220788d52a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_50b6cabb-2522-4570-a0d9-a9334bbb48e9" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_240ee70e-f578-4511-9f18-ef220788d52a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_0ea04cc5-850a-46e7-af74-fdc4720e6023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_50b6cabb-2522-4570-a0d9-a9334bbb48e9" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_0ea04cc5-850a-46e7-af74-fdc4720e6023" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68885fb1-6da8-4e30-913a-ce53f2d06fc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_714fcd81-0a87-453f-8608-8f701a87510d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68885fb1-6da8-4e30-913a-ce53f2d06fc9" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_714fcd81-0a87-453f-8608-8f701a87510d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_417d5204-caa1-456d-afce-a70799ccb066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68885fb1-6da8-4e30-913a-ce53f2d06fc9" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_417d5204-caa1-456d-afce-a70799ccb066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_e0fe3d3d-b536-4f96-ba19-2f33a39a3f71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68885fb1-6da8-4e30-913a-ce53f2d06fc9" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_e0fe3d3d-b536-4f96-ba19-2f33a39a3f71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c9012919-bf5a-4a03-bea9-b5015395eee8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68885fb1-6da8-4e30-913a-ce53f2d06fc9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c9012919-bf5a-4a03-bea9-b5015395eee8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d30b1e2e-0888-450d-987f-1c6f92b8070e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_03696e21-63ef-4cb9-b717-dad2e7741e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d30b1e2e-0888-450d-987f-1c6f92b8070e" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_03696e21-63ef-4cb9-b717-dad2e7741e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d2f64c30-0afc-4b70-9309-822cd0459f76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8adc6f-4bb2-4481-bed9-a0e898ae0fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d2f64c30-0afc-4b70-9309-822cd0459f76" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8adc6f-4bb2-4481-bed9-a0e898ae0fbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55b23f22-3578-43a8-971d-e1f0dfa736f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d2f64c30-0afc-4b70-9309-822cd0459f76" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55b23f22-3578-43a8-971d-e1f0dfa736f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_db0124c2-a359-45a5-99d8-5948b0bcd474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d2f64c30-0afc-4b70-9309-822cd0459f76" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_db0124c2-a359-45a5-99d8-5948b0bcd474" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3e647b5a-04d1-4c49-b47f-a59218635818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3d0a5564-32b5-4c4b-84ae-ed0a3c25f7f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3e647b5a-04d1-4c49-b47f-a59218635818" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3d0a5564-32b5-4c4b-84ae-ed0a3c25f7f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f21a15e1-e12b-40bb-a2bd-b73b88baa4a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3e647b5a-04d1-4c49-b47f-a59218635818" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f21a15e1-e12b-40bb-a2bd-b73b88baa4a4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_a07a13ed-c8d1-4514-85a7-77d927800e3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_30411d59-ec78-4576-a1d7-a443e8402b17" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_a07a13ed-c8d1-4514-85a7-77d927800e3f" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_30411d59-ec78-4576-a1d7-a443e8402b17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_fbbd1f24-1de0-40e9-91de-87eae2750541" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_a07a13ed-c8d1-4514-85a7-77d927800e3f" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_fbbd1f24-1de0-40e9-91de-87eae2750541" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_863aff64-605e-4ef7-ace2-8204751efd98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_a07a13ed-c8d1-4514-85a7-77d927800e3f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_863aff64-605e-4ef7-ace2-8204751efd98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_446544c7-d3eb-4318-b183-deebdd6d5e51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_33eac998-2ff1-4097-8595-de844bbf7106" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_446544c7-d3eb-4318-b183-deebdd6d5e51" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_33eac998-2ff1-4097-8595-de844bbf7106" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_48230d8a-959a-4beb-b220-d6906ffcb540" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_446544c7-d3eb-4318-b183-deebdd6d5e51" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_48230d8a-959a-4beb-b220-d6906ffcb540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b84b1555-74c7-40e8-ad58-3911634209b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_456b97d1-02c4-4321-a844-87b95107bb4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b84b1555-74c7-40e8-ad58-3911634209b9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_456b97d1-02c4-4321-a844-87b95107bb4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_36a4a029-2531-46b5-99f1-31e753620e04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b84b1555-74c7-40e8-ad58-3911634209b9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_36a4a029-2531-46b5-99f1-31e753620e04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_88da16c2-3340-4542-b85d-3a78a2f23d1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4cd6111e-9a5d-4bd2-9c24-4349bb1a31d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_88da16c2-3340-4542-b85d-3a78a2f23d1a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4cd6111e-9a5d-4bd2-9c24-4349bb1a31d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_4be6546e-7912-446f-9103-ed018e7f7d76" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_88da16c2-3340-4542-b85d-3a78a2f23d1a" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_4be6546e-7912-446f-9103-ed018e7f7d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_0479f76e-e118-4072-9655-4977978e2aa2" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_88da16c2-3340-4542-b85d-3a78a2f23d1a" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_0479f76e-e118-4072-9655-4977978e2aa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fda7d744-6412-4ab8-8070-ab9c3c37c839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_59bbfbd6-0b2f-4e2d-8789-5a03bb891812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fda7d744-6412-4ab8-8070-ab9c3c37c839" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_59bbfbd6-0b2f-4e2d-8789-5a03bb891812" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_7b768db2-082f-4131-bcf2-4cd53cf0c994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fda7d744-6412-4ab8-8070-ab9c3c37c839" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_7b768db2-082f-4131-bcf2-4cd53cf0c994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_88c511b3-4a7a-4b47-8cef-ef17c9832dad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_d9322c0e-2398-49c2-ae80-ec0001c6ef92" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_88c511b3-4a7a-4b47-8cef-ef17c9832dad" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_d9322c0e-2398-49c2-ae80-ec0001c6ef92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_daca5893-fd15-43e7-894c-5eaa5cc26b2c" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_88c511b3-4a7a-4b47-8cef-ef17c9832dad" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_daca5893-fd15-43e7-894c-5eaa5cc26b2c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1" xlink:type="simple" xlink:href="crdf-20220331.xsd#SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0fa121af-b176-4d16-8edc-d78d8d4c1dbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_643e66c7-d989-4039-996c-9d5d344237bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0fa121af-b176-4d16-8edc-d78d8d4c1dbb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_643e66c7-d989-4039-996c-9d5d344237bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_46a8d3cb-ee4c-478f-bcdf-153f5d9b7887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0fa121af-b176-4d16-8edc-d78d8d4c1dbb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_46a8d3cb-ee4c-478f-bcdf-153f5d9b7887" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fdd90988-ee25-49d2-8d2f-65c5c101a643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0fa121af-b176-4d16-8edc-d78d8d4c1dbb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fdd90988-ee25-49d2-8d2f-65c5c101a643" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_051c501d-ebd4-4ea6-be99-6314c36221ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5df7f35d-f095-45e5-9b4b-ec638e3b4fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_051c501d-ebd4-4ea6-be99-6314c36221ce" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5df7f35d-f095-45e5-9b4b-ec638e3b4fde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_593fb6e8-bc26-481d-84c6-8e45e11ec5b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_051c501d-ebd4-4ea6-be99-6314c36221ce" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_593fb6e8-bc26-481d-84c6-8e45e11ec5b6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_47a2d894-5034-4bc0-b8fd-43e9ba978371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b710a63c-da1e-4370-b520-fca6d943e6cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_47a2d894-5034-4bc0-b8fd-43e9ba978371" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b710a63c-da1e-4370-b520-fca6d943e6cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a90d88ad-e2b0-4994-87c9-add008753d99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_47a2d894-5034-4bc0-b8fd-43e9ba978371" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a90d88ad-e2b0-4994-87c9-add008753d99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedPreferredStockDividend_9d1ee74e-afc0-4b54-afd1-b84d3c4de0cc" xlink:href="crdf-20220331.xsd#crdf_AccruedPreferredStockDividend"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_47a2d894-5034-4bc0-b8fd-43e9ba978371" xlink:to="loc_crdf_AccruedPreferredStockDividend_9d1ee74e-afc0-4b54-afd1-b84d3c4de0cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedDirectorFees_d2758a78-c4ad-4091-a719-52c1ad8ff337" xlink:href="crdf-20220331.xsd#crdf_AccruedDirectorFees"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_47a2d894-5034-4bc0-b8fd-43e9ba978371" xlink:to="loc_crdf_AccruedDirectorFees_d2758a78-c4ad-4091-a719-52c1ad8ff337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_6e420218-4c36-4c2b-b717-1d5271ebeff2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_47a2d894-5034-4bc0-b8fd-43e9ba978371" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_6e420218-4c36-4c2b-b717-1d5271ebeff2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedClinicalTrial_0eac8809-a987-489b-998d-5c9d5581a00a" xlink:href="crdf-20220331.xsd#crdf_AccruedClinicalTrial"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_47a2d894-5034-4bc0-b8fd-43e9ba978371" xlink:to="loc_crdf_AccruedClinicalTrial_0eac8809-a987-489b-998d-5c9d5581a00a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedResearchAgreements_cf8e4aec-3bb9-44c6-82ff-ab759e4e1dd9" xlink:href="crdf-20220331.xsd#crdf_AccruedResearchAgreements"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_47a2d894-5034-4bc0-b8fd-43e9ba978371" xlink:to="loc_crdf_AccruedResearchAgreements_cf8e4aec-3bb9-44c6-82ff-ab759e4e1dd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PatentLicenseAndOtherFeesPayable_b7d8eda0-404a-4f71-ba51-b773ff35c80b" xlink:href="crdf-20220331.xsd#crdf_PatentLicenseAndOtherFeesPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_47a2d894-5034-4bc0-b8fd-43e9ba978371" xlink:to="loc_crdf_PatentLicenseAndOtherFeesPayable_b7d8eda0-404a-4f71-ba51-b773ff35c80b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_898e7b65-1e68-480a-a521-6fb29b594eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_a80a15ad-7441-4846-92ae-fc5c6392bd2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_898e7b65-1e68-480a-a521-6fb29b594eb1" xlink:to="loc_us-gaap_OperatingLeaseCost_a80a15ad-7441-4846-92ae-fc5c6392bd2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_9d764c81-c12f-4ed1-afb1-3a0e7f4c8973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_898e7b65-1e68-480a-a521-6fb29b594eb1" xlink:to="loc_us-gaap_SubleaseIncome_9d764c81-c12f-4ed1-afb1-3a0e7f4c8973" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2071460e-87f7-4768-adfd-44fef8456cf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7d467b7a-9697-4a41-9836-2bf6c847eccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_2071460e-87f7-4768-adfd-44fef8456cf9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7d467b7a-9697-4a41-9836-2bf6c847eccd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e2c72810-469a-4cd1-9e61-74b04fdf4e60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_2071460e-87f7-4768-adfd-44fef8456cf9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e2c72810-469a-4cd1-9e61-74b04fdf4e60" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_01830df1-8436-47f1-af76-1ce354e3763a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d1eb0061-2242-4a67-8c49-63aeb73452b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_01830df1-8436-47f1-af76-1ce354e3763a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d1eb0061-2242-4a67-8c49-63aeb73452b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_895b0e1e-c2e3-4b7c-b28f-c34d3c3048d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_01830df1-8436-47f1-af76-1ce354e3763a" xlink:to="loc_us-gaap_OperatingLeaseLiability_895b0e1e-c2e3-4b7c-b28f-c34d3c3048d4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="crdf-20220331.xsd#LeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_234b5ce7-0b1e-421b-92d7-9fae92b1c26f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1aebedeb-20ef-417a-a9ea-2584da93137c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_234b5ce7-0b1e-421b-92d7-9fae92b1c26f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1aebedeb-20ef-417a-a9ea-2584da93137c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a3029fc1-b8e5-4288-bc16-04d3e2dfaf7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_234b5ce7-0b1e-421b-92d7-9fae92b1c26f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a3029fc1-b8e5-4288-bc16-04d3e2dfaf7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bc36957e-139f-486f-a45c-4e9f80920a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_234b5ce7-0b1e-421b-92d7-9fae92b1c26f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bc36957e-139f-486f-a45c-4e9f80920a6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_152f321d-9e36-4999-a034-15cc74f62ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_234b5ce7-0b1e-421b-92d7-9fae92b1c26f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_152f321d-9e36-4999-a034-15cc74f62ec6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ab9d84d-d64c-4b50-bc63-2f952080871d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_234b5ce7-0b1e-421b-92d7-9fae92b1c26f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ab9d84d-d64c-4b50-bc63-2f952080871d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_271e9e8a-4a42-413a-95a3-273e1a95dee8" xlink:href="crdf-20220331.xsd#crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_234b5ce7-0b1e-421b-92d7-9fae92b1c26f" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_271e9e8a-4a42-413a-95a3-273e1a95dee8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>crdf-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5214d653-0d65-43f4-9358-98c3966fcc60,g:7d826e52-41b1-4720-8d3a-56dea8b8a1bc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="crdf-20220331.xsd#CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="ie9e478537d89477e84c490fd8a418c13_CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f5cf5b66-c240-4049-afe7-f16aa246439f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f5cf5b66-c240-4049-afe7-f16aa246439f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c762b1b9-4a82-4ee1-baff-8cff305ee58f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_us-gaap_SharesIssued_c762b1b9-4a82-4ee1-baff-8cff305ee58f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3462fd21-2e70-4efb-8e6d-008a236cdd79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_us-gaap_StockholdersEquity_3462fd21-2e70-4efb-8e6d-008a236cdd79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_547aba5f-ed8d-4b7a-8611-9b3c9d97a81f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_547aba5f-ed8d-4b7a-8611-9b3c9d97a81f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_10b09ee5-bfa6-4bc3-bd10-9e0b2e79fa8d" xlink:href="crdf-20220331.xsd#crdf_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_10b09ee5-bfa6-4bc3-bd10-9e0b2e79fa8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised_b1ee337e-e44c-4526-a7f6-4e00ea0b49c2" xlink:href="crdf-20220331.xsd#crdf_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised_b1ee337e-e44c-4526-a7f6-4e00ea0b49c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ba123665-020c-4073-9a39-229d38a81d78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ba123665-020c-4073-9a39-229d38a81d78" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3a34b722-f270-4242-a543-acd99d1c5766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3a34b722-f270-4242-a543-acd99d1c5766" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_01f58545-c5c3-4b3e-b299-d7c5c1420263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_01f58545-c5c3-4b3e-b299-d7c5c1420263" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_fcfb44dd-34c2-434e-b8c7-3dc5bcc7c1aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_us-gaap_DividendsPreferredStock_fcfb44dd-34c2-434e-b8c7-3dc5bcc7c1aa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_d4f03208-27fd-473d-8bf7-21987f75afd9" xlink:href="crdf-20220331.xsd#crdf_ReleaseOfClinicalTrialFundingCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_d4f03208-27fd-473d-8bf7-21987f75afd9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_db1b026f-87e6-48ff-82ff-ead80e25580a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_us-gaap_NetIncomeLoss_db1b026f-87e6-48ff-82ff-ead80e25580a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c8653284-b65e-4f0c-adfd-e3fbd1c5a953" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e284a076-bda2-41c6-8eef-36b2c6c6cd0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ac78da2c-644f-4d50-889f-d9d6ee521ce9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f5cf5b66-c240-4049-afe7-f16aa246439f" xlink:to="loc_us-gaap_StatementTable_ac78da2c-644f-4d50-889f-d9d6ee521ce9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_20dfdf77-a56e-4ad8-abc4-3dedcb076588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ac78da2c-644f-4d50-889f-d9d6ee521ce9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_20dfdf77-a56e-4ad8-abc4-3dedcb076588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_20dfdf77-a56e-4ad8-abc4-3dedcb076588_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_20dfdf77-a56e-4ad8-abc4-3dedcb076588" xlink:to="loc_us-gaap_EquityComponentDomain_20dfdf77-a56e-4ad8-abc4-3dedcb076588_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d3d6d67c-d7b4-4a57-9af1-7cd1764c0f63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_20dfdf77-a56e-4ad8-abc4-3dedcb076588" xlink:to="loc_us-gaap_EquityComponentDomain_d3d6d67c-d7b4-4a57-9af1-7cd1764c0f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_1cf67248-61a4-4cca-beb5-992c457d56c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d3d6d67c-d7b4-4a57-9af1-7cd1764c0f63" xlink:to="loc_us-gaap_PreferredStockMember_1cf67248-61a4-4cca-beb5-992c457d56c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_89052e30-fb1f-4968-a8b8-18d76a70ce8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d3d6d67c-d7b4-4a57-9af1-7cd1764c0f63" xlink:to="loc_us-gaap_CommonStockMember_89052e30-fb1f-4968-a8b8-18d76a70ce8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_24569c69-67c9-46c8-8551-024182349e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d3d6d67c-d7b4-4a57-9af1-7cd1764c0f63" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_24569c69-67c9-46c8-8551-024182349e72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivableMember_6747a797-020f-4f16-843d-3bb68a403d30" xlink:href="crdf-20220331.xsd#crdf_ServiceReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d3d6d67c-d7b4-4a57-9af1-7cd1764c0f63" xlink:to="loc_crdf_ServiceReceivableMember_6747a797-020f-4f16-843d-3bb68a403d30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8a524437-7bcc-44c0-b0ab-6559b315eeaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d3d6d67c-d7b4-4a57-9af1-7cd1764c0f63" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8a524437-7bcc-44c0-b0ab-6559b315eeaf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_02133d3f-414d-48a7-a200-4b7e2d33464a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d3d6d67c-d7b4-4a57-9af1-7cd1764c0f63" xlink:to="loc_us-gaap_RetainedEarningsMember_02133d3f-414d-48a7-a200-4b7e2d33464a" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended" id="i8cd8f8dd846c48de96f59e2d5030fffd_SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ff0ea11d-1e0e-468d-8644-96639ad66e0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_de4d6b24-bed9-4d2c-9379-3193cb72b620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ff0ea11d-1e0e-468d-8644-96639ad66e0c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_de4d6b24-bed9-4d2c-9379-3193cb72b620" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_95a86f05-bf89-40e4-b9ee-c98017eb938b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ff0ea11d-1e0e-468d-8644-96639ad66e0c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_95a86f05-bf89-40e4-b9ee-c98017eb938b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_75576fdf-2abd-45e3-aeb2-71d9d27afcb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_95a86f05-bf89-40e4-b9ee-c98017eb938b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_75576fdf-2abd-45e3-aeb2-71d9d27afcb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75576fdf-2abd-45e3-aeb2-71d9d27afcb6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_75576fdf-2abd-45e3-aeb2-71d9d27afcb6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75576fdf-2abd-45e3-aeb2-71d9d27afcb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_335f5f64-0e9a-47b4-8f26-9b8836529f05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_75576fdf-2abd-45e3-aeb2-71d9d27afcb6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_335f5f64-0e9a-47b4-8f26-9b8836529f05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_745b77ca-26d9-422a-81d4-dccd64dafda5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_335f5f64-0e9a-47b4-8f26-9b8836529f05" xlink:to="loc_us-gaap_EmployeeStockOptionMember_745b77ca-26d9-422a-81d4-dccd64dafda5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_55b33f38-5f47-4a81-b666-029902937ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_335f5f64-0e9a-47b4-8f26-9b8836529f05" xlink:to="loc_us-gaap_WarrantMember_55b33f38-5f47-4a81-b666-029902937ec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_bee68dd0-6d6d-48a9-842f-02398d89892d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_335f5f64-0e9a-47b4-8f26-9b8836529f05" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_bee68dd0-6d6d-48a9-842f-02398d89892d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_3ffbe990-90af-4f64-9a66-4ec48567253c" xlink:href="crdf-20220331.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_335f5f64-0e9a-47b4-8f26-9b8836529f05" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_3ffbe990-90af-4f64-9a66-4ec48567253c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="extended" id="i5bf9838535644c5888af1d2f16f928c1_FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1162278-067e-4090-877a-5a0eb07cd05a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_6a94284e-97b1-4607-9abe-0b2d4447d5e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1162278-067e-4090-877a-5a0eb07cd05a" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_6a94284e-97b1-4607-9abe-0b2d4447d5e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1661e072-e9a3-41ab-8c06-5d51051b8ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6a94284e-97b1-4607-9abe-0b2d4447d5e0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1661e072-e9a3-41ab-8c06-5d51051b8ec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aa911822-fe0f-474d-8a77-88e91d200250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6a94284e-97b1-4607-9abe-0b2d4447d5e0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aa911822-fe0f-474d-8a77-88e91d200250" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8c4f0b08-6cf4-4696-9dae-94a0b555d3b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6a94284e-97b1-4607-9abe-0b2d4447d5e0" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8c4f0b08-6cf4-4696-9dae-94a0b555d3b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75303e37-f618-4448-a816-508c44828a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1162278-067e-4090-877a-5a0eb07cd05a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75303e37-f618-4448-a816-508c44828a4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d7257bf-4a7d-4867-8f32-cc276ef28270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75303e37-f618-4448-a816-508c44828a4e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d7257bf-4a7d-4867-8f32-cc276ef28270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6d7257bf-4a7d-4867-8f32-cc276ef28270_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d7257bf-4a7d-4867-8f32-cc276ef28270" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6d7257bf-4a7d-4867-8f32-cc276ef28270_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7073ef17-8e99-4a33-a29c-bf692c407fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d7257bf-4a7d-4867-8f32-cc276ef28270" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7073ef17-8e99-4a33-a29c-bf692c407fed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_83b4fa10-cdbd-408e-89c2-ab8792aecaa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7073ef17-8e99-4a33-a29c-bf692c407fed" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_83b4fa10-cdbd-408e-89c2-ab8792aecaa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9d68bf28-4ac4-4a7c-a9d2-764fed06361f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75303e37-f618-4448-a816-508c44828a4e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9d68bf28-4ac4-4a7c-a9d2-764fed06361f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9d68bf28-4ac4-4a7c-a9d2-764fed06361f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9d68bf28-4ac4-4a7c-a9d2-764fed06361f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9d68bf28-4ac4-4a7c-a9d2-764fed06361f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5520f918-2cbe-40c8-a3e9-0a72e5b41cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9d68bf28-4ac4-4a7c-a9d2-764fed06361f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5520f918-2cbe-40c8-a3e9-0a72e5b41cb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_75ec25d1-daab-4cc7-8134-2dcf3c6665c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5520f918-2cbe-40c8-a3e9-0a72e5b41cb4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_75ec25d1-daab-4cc7-8134-2dcf3c6665c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_aacda7db-7ee8-43e6-9af8-22f7fc4e6a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5520f918-2cbe-40c8-a3e9-0a72e5b41cb4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_aacda7db-7ee8-43e6-9af8-22f7fc4e6a68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_30a83726-7aca-4c22-8233-e64b67893224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5520f918-2cbe-40c8-a3e9-0a72e5b41cb4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_30a83726-7aca-4c22-8233-e64b67893224" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_378addbd-ff4e-4d62-ae3d-57b078f392d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75303e37-f618-4448-a816-508c44828a4e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_378addbd-ff4e-4d62-ae3d-57b078f392d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_378addbd-ff4e-4d62-ae3d-57b078f392d1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_378addbd-ff4e-4d62-ae3d-57b078f392d1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_378addbd-ff4e-4d62-ae3d-57b078f392d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_39ee5bdb-9ba5-4750-b0f9-ad34a5dab4a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_378addbd-ff4e-4d62-ae3d-57b078f392d1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_39ee5bdb-9ba5-4750-b0f9-ad34a5dab4a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_185bb6d9-c987-4166-a001-3cb516120534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_39ee5bdb-9ba5-4750-b0f9-ad34a5dab4a5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_185bb6d9-c987-4166-a001-3cb516120534" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_2d3e97b2-8912-44cf-baf0-740a18e9feab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_39ee5bdb-9ba5-4750-b0f9-ad34a5dab4a5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_2d3e97b2-8912-44cf-baf0-740a18e9feab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e1ddc2e7-56d0-404e-bc9d-28810e5005f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75303e37-f618-4448-a816-508c44828a4e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e1ddc2e7-56d0-404e-bc9d-28810e5005f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1ddc2e7-56d0-404e-bc9d-28810e5005f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e1ddc2e7-56d0-404e-bc9d-28810e5005f4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1ddc2e7-56d0-404e-bc9d-28810e5005f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ddbcd58-339e-468b-83cb-93cdd285a25b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e1ddc2e7-56d0-404e-bc9d-28810e5005f4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ddbcd58-339e-468b-83cb-93cdd285a25b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_1d0a90d1-0222-463c-a642-66f64bab9cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ddbcd58-339e-468b-83cb-93cdd285a25b" xlink:to="loc_us-gaap_CertificatesOfDepositMember_1d0a90d1-0222-463c-a642-66f64bab9cd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_fee6167b-6ada-4294-9929-b845e9062fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ddbcd58-339e-468b-83cb-93cdd285a25b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_fee6167b-6ada-4294-9929-b845e9062fb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_ac32ce90-cdd4-43b1-bbd6-b9d544354746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ddbcd58-339e-468b-83cb-93cdd285a25b" xlink:to="loc_us-gaap_CommercialPaperMember_ac32ce90-cdd4-43b1-bbd6-b9d544354746" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_580b8ddb-7d1a-4e2e-bc24-15b9af572c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ddbcd58-339e-468b-83cb-93cdd285a25b" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_580b8ddb-7d1a-4e2e-bc24-15b9af572c69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_97153abe-57db-4115-9210-8d7048168311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ddbcd58-339e-468b-83cb-93cdd285a25b" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_97153abe-57db-4115-9210-8d7048168311" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" xlink:type="extended" id="i430222088b97470bbc56de0e055aa5ca_SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0560c6f-a913-4561-8ddc-1afb7e498785" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a104a88e-7a62-4dce-a02c-ea1328ef1b25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0560c6f-a913-4561-8ddc-1afb7e498785" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a104a88e-7a62-4dce-a02c-ea1328ef1b25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_9041ecc1-0493-4e91-af6c-e9a542bbd34b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a104a88e-7a62-4dce-a02c-ea1328ef1b25" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_9041ecc1-0493-4e91-af6c-e9a542bbd34b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_94ceb069-9282-40b8-8b10-f4682fca421b" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a104a88e-7a62-4dce-a02c-ea1328ef1b25" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_94ceb069-9282-40b8-8b10-f4682fca421b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_b2c1686d-0309-4f70-a507-a64e67accb77" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a104a88e-7a62-4dce-a02c-ea1328ef1b25" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_b2c1686d-0309-4f70-a507-a64e67accb77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_99ae72f0-eb95-471c-8def-cdb012ec3e24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a104a88e-7a62-4dce-a02c-ea1328ef1b25" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_99ae72f0-eb95-471c-8def-cdb012ec3e24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_9d1a92b5-1894-43f6-b431-8f542d5aa7f7" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0560c6f-a913-4561-8ddc-1afb7e498785" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_9d1a92b5-1894-43f6-b431-8f542d5aa7f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_a03c4f0c-386b-4a97-b748-3be1673ed9e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_9d1a92b5-1894-43f6-b431-8f542d5aa7f7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_a03c4f0c-386b-4a97-b748-3be1673ed9e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_5ad1634c-0624-4214-967b-a2b73fddf75a" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_9d1a92b5-1894-43f6-b431-8f542d5aa7f7" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_5ad1634c-0624-4214-967b-a2b73fddf75a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_2a5d62e3-8eab-4cc4-bc2a-a223103a59d6" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_9d1a92b5-1894-43f6-b431-8f542d5aa7f7" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_2a5d62e3-8eab-4cc4-bc2a-a223103a59d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_287f2795-0068-4516-8dd8-f5cb2ad600ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_9d1a92b5-1894-43f6-b431-8f542d5aa7f7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_287f2795-0068-4516-8dd8-f5cb2ad600ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_efd98f03-3ca5-4499-9dd0-670e87b9e31f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0560c6f-a913-4561-8ddc-1afb7e498785" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_efd98f03-3ca5-4499-9dd0-670e87b9e31f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0ae34668-df83-425d-b47c-3cd3cda78aad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0560c6f-a913-4561-8ddc-1afb7e498785" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0ae34668-df83-425d-b47c-3cd3cda78aad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7e7dc632-4482-4c3d-8c7d-b847f6af5a01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0560c6f-a913-4561-8ddc-1afb7e498785" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7e7dc632-4482-4c3d-8c7d-b847f6af5a01" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0651d3eb-7805-47f5-932e-be330d73d12f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0560c6f-a913-4561-8ddc-1afb7e498785" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0651d3eb-7805-47f5-932e-be330d73d12f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_476c94b6-c781-47f1-ac60-56ef8d67bb58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0560c6f-a913-4561-8ddc-1afb7e498785" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_476c94b6-c781-47f1-ac60-56ef8d67bb58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_30bbeed0-9221-4113-ab2c-958683bfb6df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_476c94b6-c781-47f1-ac60-56ef8d67bb58" xlink:to="loc_us-gaap_FinancialInstrumentAxis_30bbeed0-9221-4113-ab2c-958683bfb6df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_30bbeed0-9221-4113-ab2c-958683bfb6df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_30bbeed0-9221-4113-ab2c-958683bfb6df" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_30bbeed0-9221-4113-ab2c-958683bfb6df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_49a24f74-2b70-493d-a743-dfeb284c4adf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_30bbeed0-9221-4113-ab2c-958683bfb6df" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_49a24f74-2b70-493d-a743-dfeb284c4adf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_da5daeed-5c30-4657-93bc-a44b55e40f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_49a24f74-2b70-493d-a743-dfeb284c4adf" xlink:to="loc_us-gaap_CertificatesOfDepositMember_da5daeed-5c30-4657-93bc-a44b55e40f6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6c864631-5ae9-4704-93d7-da50a3d98576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_49a24f74-2b70-493d-a743-dfeb284c4adf" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6c864631-5ae9-4704-93d7-da50a3d98576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_647b9348-f274-476c-9f92-b6f793a8cf07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_49a24f74-2b70-493d-a743-dfeb284c4adf" xlink:to="loc_us-gaap_CommercialPaperMember_647b9348-f274-476c-9f92-b6f793a8cf07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_f253decb-97c8-4c90-ae31-c45afe9e2d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_49a24f74-2b70-493d-a743-dfeb284c4adf" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_f253decb-97c8-4c90-ae31-c45afe9e2d4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_56c7b275-a2bf-4b2c-86fb-ba6e826509a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_49a24f74-2b70-493d-a743-dfeb284c4adf" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_56c7b275-a2bf-4b2c-86fb-ba6e826509a0" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="extended" id="ib975014b9a39429c8eab6896833100dd_SupplementaryBalanceSheetInformationPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5bd95e20-9bf4-4081-9e1c-081d98d37d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7572d306-f03d-408f-8eee-4cbd22a4f67d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5bd95e20-9bf4-4081-9e1c-081d98d37d0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7572d306-f03d-408f-8eee-4cbd22a4f67d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_841a2125-b710-4ba2-aa16-3dff2a7aa155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5bd95e20-9bf4-4081-9e1c-081d98d37d0d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_841a2125-b710-4ba2-aa16-3dff2a7aa155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c77419e1-30dc-46ec-8efe-5adbe6354f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5bd95e20-9bf4-4081-9e1c-081d98d37d0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c77419e1-30dc-46ec-8efe-5adbe6354f6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fc0ff5b-9bc6-4b6b-8415-2acb8e7a4a31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5bd95e20-9bf4-4081-9e1c-081d98d37d0d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fc0ff5b-9bc6-4b6b-8415-2acb8e7a4a31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3c0890a7-b4ac-4f8b-9f98-f5f0b895cd87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fc0ff5b-9bc6-4b6b-8415-2acb8e7a4a31" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3c0890a7-b4ac-4f8b-9f98-f5f0b895cd87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3c0890a7-b4ac-4f8b-9f98-f5f0b895cd87_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3c0890a7-b4ac-4f8b-9f98-f5f0b895cd87" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3c0890a7-b4ac-4f8b-9f98-f5f0b895cd87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64116dee-afc9-495b-b56d-08d09b1d7c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3c0890a7-b4ac-4f8b-9f98-f5f0b895cd87" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64116dee-afc9-495b-b56d-08d09b1d7c8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_FurnitureAndOfficeEquipmentMember_7376e810-6c09-46b0-a071-c7391d9ded58" xlink:href="crdf-20220331.xsd#crdf_FurnitureAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64116dee-afc9-495b-b56d-08d09b1d7c8b" xlink:to="loc_crdf_FurnitureAndOfficeEquipmentMember_7376e810-6c09-46b0-a071-c7391d9ded58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_f6856e25-ff2c-4383-8825-be3a02cd3993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64116dee-afc9-495b-b56d-08d09b1d7c8b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_f6856e25-ff2c-4383-8825-be3a02cd3993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_8d399025-1e70-45ad-9bd4-feef9c8e0ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64116dee-afc9-495b-b56d-08d09b1d7c8b" xlink:to="loc_us-gaap_EquipmentMember_8d399025-1e70-45ad-9bd4-feef9c8e0ed1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#StockholdersEquityStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="extended" id="i49840905f7a9463380616d65e9cf9ef5_StockholdersEquityStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_341a8ebe-f91b-4579-a700-d006109ca06e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a528e434-3890-4f1b-81e0-0d777324554e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_341a8ebe-f91b-4579-a700-d006109ca06e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a528e434-3890-4f1b-81e0-0d777324554e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3228de3e-8a9b-46ea-9ebe-02db6f49b8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_341a8ebe-f91b-4579-a700-d006109ca06e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3228de3e-8a9b-46ea-9ebe-02db6f49b8d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2ea49ba2-cb5b-4b3e-b38a-d65b9509145d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_341a8ebe-f91b-4579-a700-d006109ca06e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2ea49ba2-cb5b-4b3e-b38a-d65b9509145d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b7c78b40-7f61-435f-85ad-8fe455189ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_341a8ebe-f91b-4579-a700-d006109ca06e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b7c78b40-7f61-435f-85ad-8fe455189ccc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2982b12c-5ac0-483c-9a02-8853879dc688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_341a8ebe-f91b-4579-a700-d006109ca06e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2982b12c-5ac0-483c-9a02-8853879dc688" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cbcc39f6-c2a7-4a7c-8d67-1f35f887c341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_341a8ebe-f91b-4579-a700-d006109ca06e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cbcc39f6-c2a7-4a7c-8d67-1f35f887c341" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0d935e4f-4935-4353-a3eb-0b9d14b5c939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cbcc39f6-c2a7-4a7c-8d67-1f35f887c341" xlink:to="loc_us-gaap_AwardTypeAxis_0d935e4f-4935-4353-a3eb-0b9d14b5c939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d935e4f-4935-4353-a3eb-0b9d14b5c939_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0d935e4f-4935-4353-a3eb-0b9d14b5c939" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d935e4f-4935-4353-a3eb-0b9d14b5c939_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8ff0f79-d450-4ac9-a6b9-665a8a95e171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0d935e4f-4935-4353-a3eb-0b9d14b5c939" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8ff0f79-d450-4ac9-a6b9-665a8a95e171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cec26356-fdb3-44a2-a48a-eb48fa68f97e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8ff0f79-d450-4ac9-a6b9-665a8a95e171" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cec26356-fdb3-44a2-a48a-eb48fa68f97e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_21ac1e4b-1742-48ad-884f-f05852436450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cbcc39f6-c2a7-4a7c-8d67-1f35f887c341" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_21ac1e4b-1742-48ad-884f-f05852436450" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_21ac1e4b-1742-48ad-884f-f05852436450_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_21ac1e4b-1742-48ad-884f-f05852436450" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_21ac1e4b-1742-48ad-884f-f05852436450_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b74444ff-b040-48ce-840b-8be1ee54f0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_21ac1e4b-1742-48ad-884f-f05852436450" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b74444ff-b040-48ce-840b-8be1ee54f0aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b350abf8-af76-4965-a339-a38ef8cbd631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b74444ff-b040-48ce-840b-8be1ee54f0aa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b350abf8-af76-4965-a339-a38ef8cbd631" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_669d71f5-b55a-4a1e-bf9a-a503a0a0337e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b74444ff-b040-48ce-840b-8be1ee54f0aa" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_669d71f5-b55a-4a1e-bf9a-a503a0a0337e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#StockholdersEquityStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="extended" id="ib5f7bad8d018495bbbff074de5f69f87_StockholdersEquityStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_41f85842-6122-49f8-a0af-08f8d15edfa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_41f85842-6122-49f8-a0af-08f8d15edfa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41b2732c-2f42-47a9-9976-e5ebcac7bed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_41f85842-6122-49f8-a0af-08f8d15edfa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41b2732c-2f42-47a9-9976-e5ebcac7bed0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d18cd2c1-d477-479f-9bbc-f84a6570d2ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_41f85842-6122-49f8-a0af-08f8d15edfa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d18cd2c1-d477-479f-9bbc-f84a6570d2ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9dcd14ed-9b5a-48ac-9667-d35a8858685f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_41f85842-6122-49f8-a0af-08f8d15edfa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9dcd14ed-9b5a-48ac-9667-d35a8858685f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_24ffb7ef-0f1f-46d0-a5ce-5e637b373d92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_41f85842-6122-49f8-a0af-08f8d15edfa2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_24ffb7ef-0f1f-46d0-a5ce-5e637b373d92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7adcdcb1-8fc3-42f9-974d-6f203427b164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7adcdcb1-8fc3-42f9-974d-6f203427b164" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_261ef723-6605-4fe7-b7ac-91aeea52e8d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7adcdcb1-8fc3-42f9-974d-6f203427b164" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_261ef723-6605-4fe7-b7ac-91aeea52e8d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1085b501-c3e3-44cd-8e33-5a7445e6adf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7adcdcb1-8fc3-42f9-974d-6f203427b164" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1085b501-c3e3-44cd-8e33-5a7445e6adf7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9e4f643f-24be-4710-b672-a5f9b2aa622d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7adcdcb1-8fc3-42f9-974d-6f203427b164" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9e4f643f-24be-4710-b672-a5f9b2aa622d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_60be9f76-10c1-4af4-8efc-8a0b682cdcc7" xlink:href="crdf-20220331.xsd#crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7adcdcb1-8fc3-42f9-974d-6f203427b164" xlink:to="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_60be9f76-10c1-4af4-8efc-8a0b682cdcc7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_39a93375-6b45-4ef2-ae1a-ef807dc00ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a4ee3a66-ea7c-48f3-8043-dc57bbcf6bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a4ee3a66-ea7c-48f3-8043-dc57bbcf6bf3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_52b56a08-152f-4484-aa6e-0fef06b774aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_52b56a08-152f-4484-aa6e-0fef06b774aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_306c4e68-48f6-40dc-99c0-d2d367772bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_306c4e68-48f6-40dc-99c0-d2d367772bdd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4955be17-7f0f-4dbe-93bf-6af6f29adb0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_306c4e68-48f6-40dc-99c0-d2d367772bdd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4955be17-7f0f-4dbe-93bf-6af6f29adb0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_568db20e-763b-4330-9cbc-dc610427c694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_306c4e68-48f6-40dc-99c0-d2d367772bdd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_568db20e-763b-4330-9cbc-dc610427c694" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_076c1d82-1c1b-4647-bca4-74aa36931b8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_306c4e68-48f6-40dc-99c0-d2d367772bdd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_076c1d82-1c1b-4647-bca4-74aa36931b8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_5b6d0b07-4c20-4c28-b3b6-062374c3a201" xlink:href="crdf-20220331.xsd#crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_306c4e68-48f6-40dc-99c0-d2d367772bdd" xlink:to="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_5b6d0b07-4c20-4c28-b3b6-062374c3a201" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11dd3beb-c118-4d3d-be7d-82b726dceed3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_91bcc323-8c54-40ed-b15b-d72cc71e0753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_91bcc323-8c54-40ed-b15b-d72cc71e0753" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b8da8546-6ebb-4169-b640-201af8786002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b8da8546-6ebb-4169-b640-201af8786002" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1f8b4e8f-0de5-4b43-a011-f36d17bb1f3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1f8b4e8f-0de5-4b43-a011-f36d17bb1f3c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3fd78181-ad6d-4ea2-85ef-2827239c2bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1f8b4e8f-0de5-4b43-a011-f36d17bb1f3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3fd78181-ad6d-4ea2-85ef-2827239c2bfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_97c47ac5-ed87-47e2-b105-5b7d8a8834b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1f8b4e8f-0de5-4b43-a011-f36d17bb1f3c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_97c47ac5-ed87-47e2-b105-5b7d8a8834b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_619740f7-5a13-4c36-8aff-037728df4d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1f8b4e8f-0de5-4b43-a011-f36d17bb1f3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_619740f7-5a13-4c36-8aff-037728df4d57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_77cc7a3f-2ea8-409f-ad6b-639b4db21689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_77cc7a3f-2ea8-409f-ad6b-639b4db21689" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b81b16d0-8ec7-4fde-a096-27d79a971109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b81b16d0-8ec7-4fde-a096-27d79a971109" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1353ac01-861d-4aa7-91f8-dda40f97c72c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1353ac01-861d-4aa7-91f8-dda40f97c72c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b9f6a8a9-1be0-46c2-b585-dcc0b8952201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1353ac01-861d-4aa7-91f8-dda40f97c72c" xlink:to="loc_us-gaap_PlanNameAxis_b9f6a8a9-1be0-46c2-b585-dcc0b8952201" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b9f6a8a9-1be0-46c2-b585-dcc0b8952201_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b9f6a8a9-1be0-46c2-b585-dcc0b8952201" xlink:to="loc_us-gaap_PlanNameDomain_b9f6a8a9-1be0-46c2-b585-dcc0b8952201_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_06a52d62-0e75-4d60-8373-a026e2bfd451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b9f6a8a9-1be0-46c2-b585-dcc0b8952201" xlink:to="loc_us-gaap_PlanNameDomain_06a52d62-0e75-4d60-8373-a026e2bfd451" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityIncentivePlan2021Member_caea44a8-767b-4619-8ffc-c1494dd1195b" xlink:href="crdf-20220331.xsd#crdf_EquityIncentivePlan2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_06a52d62-0e75-4d60-8373-a026e2bfd451" xlink:to="loc_crdf_EquityIncentivePlan2021Member_caea44a8-767b-4619-8ffc-c1494dd1195b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_23956523-e1ab-4ccb-9c0f-fb1c8362c909" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1353ac01-861d-4aa7-91f8-dda40f97c72c" xlink:to="loc_us-gaap_AwardTypeAxis_23956523-e1ab-4ccb-9c0f-fb1c8362c909" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23956523-e1ab-4ccb-9c0f-fb1c8362c909_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_23956523-e1ab-4ccb-9c0f-fb1c8362c909" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23956523-e1ab-4ccb-9c0f-fb1c8362c909_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ea58c02-a737-4b2e-b8d7-b2dd241fa685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_23956523-e1ab-4ccb-9c0f-fb1c8362c909" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ea58c02-a737-4b2e-b8d7-b2dd241fa685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1759ff51-b587-4b1b-8ff0-9f47b70d5f18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ea58c02-a737-4b2e-b8d7-b2dd241fa685" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1759ff51-b587-4b1b-8ff0-9f47b70d5f18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_InducementGrantStockOptionsMember_07998213-d4d6-4d66-a032-8cc8de0cb400" xlink:href="crdf-20220331.xsd#crdf_InducementGrantStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ea58c02-a737-4b2e-b8d7-b2dd241fa685" xlink:to="loc_crdf_InducementGrantStockOptionsMember_07998213-d4d6-4d66-a032-8cc8de0cb400" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended" id="i13369009035a44f4ab3ac65e352132f3_StockholdersEquityPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_18cf1321-28ae-476c-8ed3-a921fc1710b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7567cbb3-084c-40f5-b3b0-843d7b99ace1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18cf1321-28ae-476c-8ed3-a921fc1710b2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7567cbb3-084c-40f5-b3b0-843d7b99ace1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c3b7d7ec-95d1-4717-9e53-58d15831a0a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18cf1321-28ae-476c-8ed3-a921fc1710b2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c3b7d7ec-95d1-4717-9e53-58d15831a0a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_87bdd132-021e-41ae-9c28-7b8c3ad78a3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18cf1321-28ae-476c-8ed3-a921fc1710b2" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_87bdd132-021e-41ae-9c28-7b8c3ad78a3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6af82d1f-1587-4a20-b15c-1c7bed00659e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18cf1321-28ae-476c-8ed3-a921fc1710b2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6af82d1f-1587-4a20-b15c-1c7bed00659e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_459dba2d-deb7-4371-b75d-8c3ce5e0af97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_18cf1321-28ae-476c-8ed3-a921fc1710b2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_459dba2d-deb7-4371-b75d-8c3ce5e0af97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_655b5733-d0ee-45c1-8d14-58a0324b13d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_459dba2d-deb7-4371-b75d-8c3ce5e0af97" xlink:to="loc_us-gaap_StatementClassOfStockAxis_655b5733-d0ee-45c1-8d14-58a0324b13d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_655b5733-d0ee-45c1-8d14-58a0324b13d9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_655b5733-d0ee-45c1-8d14-58a0324b13d9" xlink:to="loc_us-gaap_ClassOfStockDomain_655b5733-d0ee-45c1-8d14-58a0324b13d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1b57d584-e736-4800-98a8-21262d896b63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_655b5733-d0ee-45c1-8d14-58a0324b13d9" xlink:to="loc_us-gaap_ClassOfStockDomain_1b57d584-e736-4800-98a8-21262d896b63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesAConvertiblePreferredStockMember_a481938b-5a1d-4f5d-902e-99daaa17383d" xlink:href="crdf-20220331.xsd#crdf_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1b57d584-e736-4800-98a8-21262d896b63" xlink:to="loc_crdf_SeriesAConvertiblePreferredStockMember_a481938b-5a1d-4f5d-902e-99daaa17383d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesBConvertiblePreferredStockMember_aa36d1a6-8099-4bc1-b294-db17a3f6567b" xlink:href="crdf-20220331.xsd#crdf_SeriesBConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1b57d584-e736-4800-98a8-21262d896b63" xlink:to="loc_crdf_SeriesBConvertiblePreferredStockMember_aa36d1a6-8099-4bc1-b294-db17a3f6567b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_1b7d0621-1ea2-4b1f-af86-9a17200356ad" xlink:href="crdf-20220331.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1b57d584-e736-4800-98a8-21262d896b63" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_1b7d0621-1ea2-4b1f-af86-9a17200356ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_fe870016-72a4-495e-ae7e-a222c0951f9a" xlink:href="crdf-20220331.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1b57d584-e736-4800-98a8-21262d896b63" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_fe870016-72a4-495e-ae7e-a222c0951f9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_24cf2d36-8d94-4cdd-a014-3e41e0436216" xlink:href="crdf-20220331.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1b57d584-e736-4800-98a8-21262d896b63" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_24cf2d36-8d94-4cdd-a014-3e41e0436216" xlink:type="arc" order="4"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>crdf-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5214d653-0d65-43f4-9358-98c3966fcc60,g:7d826e52-41b1-4720-8d3a-56dea8b8a1bc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_2bdda5ad-27f1-46cd-ad83-9978571f8ab6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_91155fdd-59fc-4835-a77d-485e673ad6e2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_31089c80-5352-4b85-b1ba-95c7e668c2bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_964a6757-9ff3-456b-bf05-ac72e00c7243_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_d8bf7683-634b-49c3-844d-bbfa1e2e993e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_33d1520e-2ed1-425b-9dc3-de3e69350f0f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d3379e87-0a29-4b3e-962f-f7a06419190d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9341ba07-aef1-4e86-b11c-8118d9829d2c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums on short-term investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_c711f9f2-29a4-41a6-9fbc-2a4ac9607d82_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series&#160;A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b07263bf-c11b-4d90-ad36-c544d697e2da_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2db89dab-7a78-44ad-9b58-327f2dfa5c2a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fa243c3e-0efc-4a8e-be43-91da52f72cc5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total available for sale investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6853d6f0-19ee-4c5f-9d2c-09b02856b62c_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Market Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0a6850e7-f415-4f96-bc65-9f58c01e579d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ServiceReceivable_4377b89e-90db-4378-ac2e-64399aebdb81_negatedTerseLabel_en-US" xlink:label="lab_crdf_ServiceReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service receivables</link:label>
    <link:label id="lab_crdf_ServiceReceivable_label_en-US" xlink:label="lab_crdf_ServiceReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable</link:label>
    <link:label id="lab_crdf_ServiceReceivable_documentation_en-US" xlink:label="lab_crdf_ServiceReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivable" xlink:href="crdf-20220331.xsd#crdf_ServiceReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ServiceReceivable" xlink:to="lab_crdf_ServiceReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_bd42fc9e-b12d-4572-be0f-e231bce3e101_totalLabel_en-US" xlink:label="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to common stockholders</link:label>
    <link:label id="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Available To Common Stockholders, Basic</link:label>
    <link:label id="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_documentation_en-US" xlink:label="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Available To Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" xlink:href="crdf-20220331.xsd#crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_57c96f3b-21c3-4aca-b1ce-ec244e2afabd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised_ff16418d-1fbc-4a64-befb-4ec89593c8da_terseLabel_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of warrants</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The equity impact during the period due to the cash exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="crdf-20220331.xsd#crdf_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5f1dca05-d058-4768-aa1d-3cf8fb8efc49_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5689ee2e-88e3-4bac-b78c-d5f5fb27d9ca_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_e6249168-30f6-43a9-a493-7dd8e55e17ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Warrant Activity and Changes in Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_18cc89cf-d354-4de2-92ab-fcf9450ff701_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_c2b4a9ea-b1fa-4797-83ff-c152ab25248c_terseLabel_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of clinical trial funding commitment</link:label>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_label_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release Of Clinical Trial Funding Commitment For Services Received</link:label>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_documentation_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release Of Clinical Trial Funding Commitment For Services Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" xlink:href="crdf-20220331.xsd#crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" xlink:to="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2eb7caa4-b982-40bb-ac25-bb0fddf3b482_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_adbd0b2e-510b-456f-9a00-ec7cba5812f3_negatedTerseLabel_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_label_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Current</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_documentation_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:to="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14c60ad7-8ab2-4576-92ca-9271d29273cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability_802d5047-3053-4b1d-ab77-946861d4295f_terseLabel_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Liability</link:label>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability_documentation_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="crdf-20220331.xsd#crdf_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_c3b492f5-afe6-4aeb-930f-d979c81e437f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Company&#8217;s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ddbc3547-faa2-42fb-9fff-6e0605983b73_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions to Estimate Fair Value of Stock Option Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_af048b99-2eae-4306-84be-fb942fca7f8b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_PatentLicenseAndOtherFeesPayable_429a76f1-6650-4286-a4d7-45e8b95f38ee_terseLabel_en-US" xlink:label="lab_crdf_PatentLicenseAndOtherFeesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent, license and other fees</link:label>
    <link:label id="lab_crdf_PatentLicenseAndOtherFeesPayable_label_en-US" xlink:label="lab_crdf_PatentLicenseAndOtherFeesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent, license and other fees payable</link:label>
    <link:label id="lab_crdf_PatentLicenseAndOtherFeesPayable_documentation_en-US" xlink:label="lab_crdf_PatentLicenseAndOtherFeesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent, license and other fees payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PatentLicenseAndOtherFeesPayable" xlink:href="crdf-20220331.xsd#crdf_PatentLicenseAndOtherFeesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_PatentLicenseAndOtherFeesPayable" xlink:to="lab_crdf_PatentLicenseAndOtherFeesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_72dd62d3-7581-4b3a-a7ee-78ea1a1ad41c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c28335d3-5efa-4dc7-b7cc-08705127aebb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d9148c06-2a14-4c27-90a3-61d3e7a87755_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_602fe07a-183e-41fc-bdfa-09fe1e24d270_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity and of Changes in Stock Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2e3b2617-2a9b-46b9-ad92-4c5c52b12ac2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b57c25f4-967c-4611-8a53-1967e5394368_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e1107e37-4fdf-49d6-af9c-c59172d186ad_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_c7580493-7db8-40f7-96ad-63cf7f6ce1c1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation preference</link:label>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8d0626cc-85e6-4764-81b7-e074ec58e854_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_93f2ac7a-34ef-4fc7-a319-98a54d582e78_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_12401c84-4d6b-477b-b392-297c82c7a72d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate&#8211;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_3381df5f-a485-411e-8bd8-c206a37d697d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a166bcc2-625d-40ba-a2da-9925df7292f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_f9ca832a-b414-45bd-85de-87bb20baea55_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees and outside services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_eee6270f-2b0d-4c16-a1ad-321574b61294_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AccruedClinicalTrial_eb5fdca3-b1d7-4f34-bef0-488999686ffd_terseLabel_en-US" xlink:label="lab_crdf_AccruedClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trials</link:label>
    <link:label id="lab_crdf_AccruedClinicalTrial_label_en-US" xlink:label="lab_crdf_AccruedClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial</link:label>
    <link:label id="lab_crdf_AccruedClinicalTrial_documentation_en-US" xlink:label="lab_crdf_AccruedClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedClinicalTrial" xlink:href="crdf-20220331.xsd#crdf_AccruedClinicalTrial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AccruedClinicalTrial" xlink:to="lab_crdf_AccruedClinicalTrial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a1fedc64-6b1f-4936-95fc-4083bdbf9d1b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Market Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_07b90225-d4f0-4478-8955-628052ac1534_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ee0d58c0-cd9e-4e29-a52f-611d7aa962a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_75eaf465-c07d-420a-9510-bb1b79d54607_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_02f61016-6ea4-48e3-83be-f2ff04453834_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c11586f4-da1b-48de-a871-8948772f63d9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_b3ed95da-a6bb-45ca-883e-b65dfa2ebbe7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_958fb5fd-2b78-4678-bbe2-1ad36557d89a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_37d65a48-4675-4168-8827-706364aedaca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1c045333-d25c-449e-8c00-0dae2b045c9d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_88a9bf69-d8ea-4411-86fd-d7cd0109589b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_8084bf53-5b67-45c9-8416-a937d945ee6a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon conversion of Series E Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7b01785d-56e1-4bd1-9163-be32fc884eed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_520173e9-9471-435a-9ad5-74a98d477e21_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease ROU assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1d60512f-7978-49ba-8934-7150e50a6152_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f2aaaa89-710e-4950-87c1-48057b10fb74_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and unbilled receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ea01b003-c5da-42c3-855b-109ddd48b7c9_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_f1fd14fb-0b21-4994-9570-9cdc76ae2160_negatedLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend payable on Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_bbce145e-23f9-4403-b66a-67c1d85d254c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend payable on Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5492fddc-d27f-4d25-9690-93e7220d3d1a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_62404375-f984-49ea-809a-162d3648c028_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cfc4f217-67f2-4fed-932e-70e76942de82_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4203e0f0-8ec9-471c-8dc1-fd74777c3391_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f33616e4-3f35-48ea-ba21-e437bf5254ff_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0eda6e39-0439-4b02-bd12-d20b38f179c8_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_56f17dfa-3d43-4eeb-b8a4-b417abb3881d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_b2707119-b4b2-472c-8053-0c31467a6566_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, 20,000 shares authorized; (Note 6)</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b17885b0-8e60-4f8f-9875-2e6efa5fedc1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_fe76e53b-35ec-44c8-8ac8-bc8730ba034c_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_88bc8260-7e16-47da-ad9a-08d1e3d690d1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_27a71166-1a2b-42e6-b990-37abcf95f235_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_77159cfc-1777-4c85-b016-9683ebb8d9b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_66715327-6f9a-47c4-970d-1cc67186ae7d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cb8b9df4-299a-4f5d-a7d8-e7988bb790d8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_a81e14a0-e3a2-41f7-a2bd-325d0581a745_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of warrants outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0cd1aaaf-d295-4e39-963f-4c484caae03f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of warrants outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_229dd59f-0345-43fe-a01e-d1c2c451e185_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_a439b5d1-ac4a-45ca-a618-4273178aa62b_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_EquityIncentivePlan2021Member_80ff3e87-cd11-450e-973c-d53aa39515e1_terseLabel_en-US" xlink:label="lab_crdf_EquityIncentivePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2021</link:label>
    <link:label id="lab_crdf_EquityIncentivePlan2021Member_label_en-US" xlink:label="lab_crdf_EquityIncentivePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2021 [Member]</link:label>
    <link:label id="lab_crdf_EquityIncentivePlan2021Member_documentation_en-US" xlink:label="lab_crdf_EquityIncentivePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityIncentivePlan2021Member" xlink:href="crdf-20220331.xsd#crdf_EquityIncentivePlan2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_EquityIncentivePlan2021Member" xlink:to="lab_crdf_EquityIncentivePlan2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2768975a-df1d-47f0-9c56-751fcd60c947_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested, fair value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_PreferredStockDividendAccrued_588d7c23-0bd2-4998-95ce-c0200dcc2c36_terseLabel_en-US" xlink:label="lab_crdf_PreferredStockDividendAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend payable on Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_PreferredStockDividendAccrued_label_en-US" xlink:label="lab_crdf_PreferredStockDividendAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividend Accrued</link:label>
    <link:label id="lab_crdf_PreferredStockDividendAccrued_documentation_en-US" xlink:label="lab_crdf_PreferredStockDividendAccrued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the value of preferred stock dividend accrued during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockDividendAccrued" xlink:href="crdf-20220331.xsd#crdf_PreferredStockDividendAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_PreferredStockDividendAccrued" xlink:to="lab_crdf_PreferredStockDividendAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b33af608-5450-4f8e-b31e-2220894a6677_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AccruedPreferredStockDividend_46bd0277-dfe3-4cf2-876d-678269e6f532_terseLabel_en-US" xlink:label="lab_crdf_AccruedPreferredStockDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend</link:label>
    <link:label id="lab_crdf_AccruedPreferredStockDividend_label_en-US" xlink:label="lab_crdf_AccruedPreferredStockDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Preferred Stock Dividend</link:label>
    <link:label id="lab_crdf_AccruedPreferredStockDividend_documentation_en-US" xlink:label="lab_crdf_AccruedPreferredStockDividend" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Preferred Stock Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedPreferredStockDividend" xlink:href="crdf-20220331.xsd#crdf_AccruedPreferredStockDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AccruedPreferredStockDividend" xlink:to="lab_crdf_AccruedPreferredStockDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_b7b6245e-31d7-4799-8fb0-a4b29bd4ad7b_terseLabel_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_label_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Noncurrent</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_documentation_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:to="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_bddf9cff-e337-4c97-801c-1dbbe38ff1c3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_b5af0d71-65ff-4f4b-b1f0-d0660178524e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_40273674-1da3-403a-bb8f-d37514326eb0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_eefcb61a-7905-4a36-b3ea-54d42ebfa4e1_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled / Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_29c0dd45-2b2d-406e-aca2-1232b3fbf6f4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_1f8876a8-abca-4f13-88b2-7f3f182da805_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4b500cf-a58f-481a-8cda-fd98b89e9ce4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_25c2c97a-2ff2-414e-b646-453c4ff754e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f6d1a802-eb7a-482b-a6fb-225dd4658ed5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_16a9fb16-0144-4d5f-9283-4ca19537e8b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_WarrantsAndRightsRollForward_c292171b-9728-4124-8e2a-937b1adb69a4_terseLabel_en-US" xlink:label="lab_crdf_WarrantsAndRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Warrants</link:label>
    <link:label id="lab_crdf_WarrantsAndRightsRollForward_label_en-US" xlink:label="lab_crdf_WarrantsAndRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsAndRightsRollForward" xlink:href="crdf-20220331.xsd#crdf_WarrantsAndRightsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_WarrantsAndRightsRollForward" xlink:to="lab_crdf_WarrantsAndRightsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitment_c626c285-c6eb-4718-a0c0-c8ba29fe9d18_terseLabel_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of clinical trial funding commitment</link:label>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitment_label_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release Of Clinical Trial Funding Commitment</link:label>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitment_documentation_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release Of Clinical Trial Funding Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:href="crdf-20220331.xsd#crdf_ReleaseOfClinicalTrialFundingCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:to="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_db07fc3b-ec46-44c7-b09a-ec2af8238130_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_44e5aa6c-95f0-4cdc-8db6-acf31a8148f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_a3e7fc7a-fbff-427b-8413-8604912a78a1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2b235db7-21b0-4d9d-b932-e44d075ffbb7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_aff99c69-6312-46cf-9a1e-ce5bda16eda2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8ce33aef-90d6-46cb-bf37-bf03d2bd968d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5e30c22b-ed91-4ec3-8ac5-d502710b72c9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term&#8211;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_aaa0555c-3dbd-46bc-8310-1d5d1961ac5a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e1954d6e-f553-479a-bf11-ac50331d29b1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2e1def3f-e204-450f-9a0e-5dafd175cd5f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_9b6c33a0-f672-4dc3-a5a7-6adc4c46c749_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual rent increase, percentage</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Increase, Percentage</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Increase, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:href="crdf-20220331.xsd#crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:to="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_67f12ffc-277e-439b-81a3-2671fd694ad1_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_e670a605-f285-48d9-b893-dbdf79ae0d8a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value, 150,000 shares authorized; 43,306 and 41,964 shares issued and outstanding at March&#160;31, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_d7466812-9770-4c81-bd0f-35cf7bca18ba_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_131ba757-1a9b-4006-adfb-6cf939e9924e_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_fb0f700a-5fdb-4a46-9780-45cf1bab40eb_periodStartLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of warrants at the beginning of the period (in USD per share)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_55c320b7-badd-4ea7-b78b-009bab2490ac_periodEndLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of warrants at the end of the period (in USD per share)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the weighted average exercise price of each class of warrants or rights outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:href="crdf-20220331.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:to="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_b1c94bbf-fa01-47ab-b50f-511e959d8b79_terseLabel_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of warrants (in shares)</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of shares issued during the period upon cash exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="crdf-20220331.xsd#crdf_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_359adb1a-8354-4836-a43f-149e64c1c99e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_80f22de8-6c62-47af-abc0-003e9190c7a0_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_210c8b89-7994-4729-a7f2-9f4e358d1937_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4f608236-6d1e-4a6f-8f83-873d8ed36770_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_cc1900be-df5f-44c0-a99c-c948fbf46e8d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f4484c9d-945f-4979-b275-7ac83f15841c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_947d3f41-b57d-4ff0-8f73-74510adb271c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_3a60ee1d-7f2c-401b-83e7-647b4024cf66_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5a828925-0574-4e72-9ee8-ae40635e4a50_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_dccb7b8d-a636-4077-8cc6-186681152c97_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_02b79702-0f9c-4c2f-b741-995d763709ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_82e9caf7-62f4-4c77-a3e5-b3fcf157b37f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_100c49bd-8bc2-4aa0-a656-fc39ba30b127_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average assumptions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AccruedResearchAgreements_07395736-de91-41a2-a53f-eccc5233496f_terseLabel_en-US" xlink:label="lab_crdf_AccruedResearchAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research agreements and services</link:label>
    <link:label id="lab_crdf_AccruedResearchAgreements_label_en-US" xlink:label="lab_crdf_AccruedResearchAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research agreements</link:label>
    <link:label id="lab_crdf_AccruedResearchAgreements_documentation_en-US" xlink:label="lab_crdf_AccruedResearchAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedResearchAgreements" xlink:href="crdf-20220331.xsd#crdf_AccruedResearchAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AccruedResearchAgreements" xlink:to="lab_crdf_AccruedResearchAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ServiceReceivableMember_35291dea-945f-4026-8f5f-a3835310a4b3_terseLabel_en-US" xlink:label="lab_crdf_ServiceReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable</link:label>
    <link:label id="lab_crdf_ServiceReceivableMember_label_en-US" xlink:label="lab_crdf_ServiceReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable [Member]</link:label>
    <link:label id="lab_crdf_ServiceReceivableMember_documentation_en-US" xlink:label="lab_crdf_ServiceReceivableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivableMember" xlink:href="crdf-20220331.xsd#crdf_ServiceReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ServiceReceivableMember" xlink:to="lab_crdf_ServiceReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9e382429-5a0b-4222-9a19-7f21c86ec92f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized shares under the plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e80c0602-2990-4002-8e5f-0d76d4d3c46d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c63748b9-0928-4cda-9b2e-5e318714ffda_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b7ba58db-ffee-4e9d-828e-5b64e1001371_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of remaining shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_04c53ea0-f407-4f92-be0a-873b986a39e3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_a90ce211-8a40-4b83-b68f-0f9762648df2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_39e933ec-e86f-474d-9e13-3bc2eada8cc2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c8ab6e6-7525-4d19-8d4c-27f258817ef1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8b8f9942-fef3-48ef-b831-71714beeead9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6f59fee1-83a9-451d-b126-9626fb54f261_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment_3643cc79-3a72-4309-a442-e0785717f914_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly rent payments</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Payment</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:href="crdf-20220331.xsd#crdf_LesseeOperatingLeaseMonthlyRentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:to="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ac614b7f-3de4-48ca-98ea-217c71921624_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Market Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_4e72fb6a-8e27-4671-934d-99c8ad58e59c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and unbilled receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1777549-61f7-4cce-a97d-8e2c4acd0129_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3e154dc4-8aeb-42fd-9278-fa52f90875b9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_b062fb66-3feb-439b-b7c2-b24e776207ea_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_3776ee04-0fe5-49ac-b12f-2d374255e94f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_51342dfc-ede6-4c54-9c16-b153693579f1_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_9ab8aa16-88e1-487f-b5c1-92d4423d2d8c_terseLabel_en-US" xlink:label="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="crdf-20220331.xsd#crdf_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_1d43e071-4ea6-4fd3-9aa8-954cc61c50aa_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9f4f07c8-6a06-438c-99e1-fe95fd78ae61_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0dbf7138-ec38-48c4-876a-f9355a227d64_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2f6947ae-2b73-4f8b-a15f-f3613205a0e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_6adfdeed-4543-47ad-b66d-0d561da91eb3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d7d751ca-47a6-409a-a7b2-5bce19b7405a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_2e4d8115-4acc-4bd5-acb8-efa278872196_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_7c517746-7bdf-4c48-a691-2b197c16ab42_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e69a67fe-3388-4d40-8eba-57422d48fa4a_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3a733d38-fe7b-430a-9131-33c63357caf0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b73f462c-db1f-447c-a2b9-5e0d5b349139_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_1ac768a9-68eb-403b-8c97-a74462211bcf_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining&#160;Contractual Term</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Term of Outstanding Warrants or Rights</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period over which each class of warrants or rights outstanding may be exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:href="crdf-20220331.xsd#crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:to="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6192080f-371b-4c35-9cf5-923adc312177_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_0b506673-16b2-4460-8f5e-d2382b5b0b96_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_8c2967ef-9587-4749-9ba1-7a4ff6783c55_negatedTerseLabel_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="crdf-20220331.xsd#crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c6ad6d83-1d94-40ec-9c23-1a95ef4b5684_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_11a8cba3-be50-4ccf-933c-4fc4e7567eb4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_812c563f-4626-4e3d-9a2a-7b1a007477c5_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_bd439432-12d5-45bf-be11-e589f314e3b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_cb3b2369-40fa-4c40-9d6d-4bac2231c9ca_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_487ee5c3-7a5a-4579-a2d9-fa38cf0b7985_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_0928fed9-ee27-4668-aa31-07a175b7aa50_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_58cf1b4d-3704-478d-96c9-d44675e509d2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_80b9515e-7e78-4913-bd06-cdc3e1c20184_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2865ffbe-68e1-4af1-8ff3-5e5327ca0892_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3b492746-e242-4a94-ba44-977b9ba422f0_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_97bc9fc1-bfbe-4af2-b165-285367f5e609_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_618c0c21-378c-4a61-ab91-7d6da3e7abad_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AccruedDirectorFees_9575eb9a-cacf-446e-a17c-69731840bb8e_terseLabel_en-US" xlink:label="lab_crdf_AccruedDirectorFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director fees</link:label>
    <link:label id="lab_crdf_AccruedDirectorFees_label_en-US" xlink:label="lab_crdf_AccruedDirectorFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued director fees</link:label>
    <link:label id="lab_crdf_AccruedDirectorFees_documentation_en-US" xlink:label="lab_crdf_AccruedDirectorFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued director fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedDirectorFees" xlink:href="crdf-20220331.xsd#crdf_AccruedDirectorFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AccruedDirectorFees" xlink:to="lab_crdf_AccruedDirectorFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_e1c25ebb-e135-4ed4-a5a6-56c285ee15bd_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_198a06e5-ada0-4d4a-86e6-13eaae320c71_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_2380c487-9efd-403e-ac80-d39757908593_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Expense and Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_baa8751d-b763-4f6f-9720-2e21dab5223d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_02623aeb-186a-4960-8daf-f9cdef31287f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9b4672a6-8245-45bc-b2c7-9a6cc2e11b2b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fdb281e0-06d2-49f5-9944-0447da70f449_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (excluding the three months ended March&#160;31, 2022)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_921f87da-2b0f-40ac-9eac-8b68868fc53e_terseLabel_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_label_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_documentation_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:to="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_119d888e-4ccf-40c1-8d7f-109049557235_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_c1696a8b-a0e9-47e1-9e7c-132eda5e00b7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7ed661d7-4976-4168-bf6d-816c693d6aff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_1b6f51ec-aaa1-40eb-9b0b-216dd295d40a_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a571f378-c8ec-4124-8c60-9bc8cf6e38ea_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b3accec2-1d2c-4408-8618-a274c6c0fd65_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_204008f9-f023-4125-b2ba-4c4a17532f9e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3155be01-371b-4d93-b3c8-a25976b8d30a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_935b3a8a-cef3-43ce-831c-0a5b96082003_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_4b774bbc-4d14-46a5-98b6-5d65d1e96227_terseLabel_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in USD per share)</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expired in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:href="crdf-20220331.xsd#crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_514ee22c-2e4c-4800-bd78-1ac8c4f16631_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non U.S. government</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_47ceb1bd-7f0a-42a7-8466-6591f527b4ed_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1a31c7b7-d4e9-4c8f-b632-e1adb111f982_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_489e09e4-18b9-47b0-a995-60d62477ad45_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesCConvertiblePreferredStockMember_4f2694cb-d18e-49b1-a528-1a96e20d8c25_terseLabel_en-US" xlink:label="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesCConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesCConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock that may be exchanged into common shares at the owner's option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember" xlink:href="crdf-20220331.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesCConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_42b52e29-e5e8-4fe6-b957-d126793df1c7_negatedTerseLabel_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_label_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expired in Period</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_documentation_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares under options that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:href="crdf-20220331.xsd#crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:to="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9aa3782-9840-4a7f-964e-f6ce83bbe2f8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_InducementGrantStockOptionsMember_77092edd-8398-48cb-b8ee-2f3ee1433230_terseLabel_en-US" xlink:label="lab_crdf_InducementGrantStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Grant Stock Options</link:label>
    <link:label id="lab_crdf_InducementGrantStockOptionsMember_label_en-US" xlink:label="lab_crdf_InducementGrantStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Grant Stock Options [Member]</link:label>
    <link:label id="lab_crdf_InducementGrantStockOptionsMember_documentation_en-US" xlink:label="lab_crdf_InducementGrantStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Grant Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_InducementGrantStockOptionsMember" xlink:href="crdf-20220331.xsd#crdf_InducementGrantStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_InducementGrantStockOptionsMember" xlink:to="lab_crdf_InducementGrantStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e1bde1a8-012a-4d3c-8a9b-905a7529c104_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_6c8cddc1-6111-456b-9a01-24fed00480c1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_154d9d0b-0782-46ba-8e07-31f4e278baea_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4e488d57-cd25-4cc0-8eb9-3dc01796cd55_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_83109a91-ada6-4474-b6f8-81504c5fac84_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4eab6e20-bae2-4f4f-914f-1a2a7fc0791d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_07b706fc-085b-4a17-aa63-feb5f595019b_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LessorNumberOfSubleases_b5c6c5a7-e5cd-4b6b-97e6-e755a347ec47_terseLabel_en-US" xlink:label="lab_crdf_LessorNumberOfSubleases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of subleases</link:label>
    <link:label id="lab_crdf_LessorNumberOfSubleases_label_en-US" xlink:label="lab_crdf_LessorNumberOfSubleases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Number Of Subleases</link:label>
    <link:label id="lab_crdf_LessorNumberOfSubleases_documentation_en-US" xlink:label="lab_crdf_LessorNumberOfSubleases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Number Of Subleases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorNumberOfSubleases" xlink:href="crdf-20220331.xsd#crdf_LessorNumberOfSubleases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LessorNumberOfSubleases" xlink:to="lab_crdf_LessorNumberOfSubleases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_9d64c96a-47c2-46b5-a9d6-67fb4bab6ec0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_f753804e-4d7d-4b0c-98ea-48c031cfc14b_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosure of cash flow activity:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5346abd7-d355-4778-9882-3ae547033ab7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining vesting period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5cf4f9ea-0cc5-404c-8561-6b29ad4e2d84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4d45eca7-ca47-4d66-8708-508960c16869_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_17be2a06-445c-4bfc-ae9a-d6e00ecc314b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_15207b08-1aed-4816-a27a-96241bd3721f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9330cb50-a0c8-4bcd-a3d1-186c5912c71d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_efcfd8ab-9030-4552-9d58-cf1a729c08d8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_cc75a42f-ea6d-43cb-a774-f5ca9f9b14ac_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesBConvertiblePreferredStockMember_acff85f5-9e11-44bf-9d95-23933bcb94c7_terseLabel_en-US" xlink:label="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesBConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesBConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesBConvertiblePreferredStockMember" xlink:href="crdf-20220331.xsd#crdf_SeriesBConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesBConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_29f1255f-1e69-4ea2-9343-731ffbc41f39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6a0d9540-1465-4b6a-824f-e6ff74d39596_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_480d6b49-7c2a-49a7-977c-6754a03cd58c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ef3422a6-7a95-4784-b7a5-8c600bbbed6f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_f8c73cda-5115-462a-b681-f3de9a421e2d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_144de975-e0ac-40a8-b4a4-7d0ec285c3c9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_dc747a41-d1e7-414e-91c4-712df07204a1_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_6188c920-b099-46b0-8063-270640ed082f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) from change in fair value of derivative financial instruments&#8212;warrants</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_8a41d019-0434-41dd-a0f3-238e91250b05_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative financial instruments&#8212;warrants</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_a8a9cc34-efa9-4d55-8702-8e1c38e2192a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_870f6346-a2c7-450e-990b-11d53b0cdad4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c6b9140e-dd63-4475-91cc-9727ed4e7ebb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon conversion of Series E Convertible Preferred Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_06993843-9b0d-440c-adfb-f79c01618b1a_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market fund</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6566840a-4258-4fe7-b9e3-0483762820fc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_666c80e5-c573-491e-9d7d-7f26f095edef_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less&#8212;accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_133f07f4-e107-4d96-8b07-24460b864580_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c446070a-faad-47aa-8f0d-36bb90768423_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_62a57c0e-b989-4aa1-a6a8-64d37be555f4_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9c093417-a036-43d3-8696-74401b317ad4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_246c8715-45dc-46b1-87d3-ca5f8f83c256_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_da7b7102-ee40-433f-9803-6d6d0965e7d6_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_78ab97da-887c-44a1-8eee-6a31e5f16b98_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_3c5319cc-654e-42b9-b9aa-672700d3f43f_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_8c16fa84-7c3d-4386-b22d-783cdcb0b2ed_terseLabel_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity 1 to 2 years:</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_label_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Noncurrent [Abstract]</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_documentation_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract" xlink:to="lab_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9aaf4951-170e-463d-9a31-853e1de15852_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_90227bd4-cb2e-4509-a408-b932920ec0f1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPreferredStock_fbb66848-5ac0-487e-8f28-d932bab3c15b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStock_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStock" xlink:to="lab_us-gaap_DividendsPreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_256085de-e286-4f3a-8790-f328f5e6bf3d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_8145fba3-51ba-465d-8261-e0204e47122e_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_61b283de-41a1-4218-bbb8-164e1501614a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a881f21b-300b-4c55-8751-e7990f44a592_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesAConvertiblePreferredStockMember_5a6ea2a8-6b2b-406e-9871-b598ff4ef9ad_terseLabel_en-US" xlink:label="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesAConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesAConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesAConvertiblePreferredStockMember" xlink:href="crdf-20220331.xsd#crdf_SeriesAConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesAConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_053e20f9-2682-4aa2-9968-f4c1c76c8bc0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled / Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_d3cb4972-7046-4b98-a7aa-4290993454f0_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="crdf-20220331.xsd#crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4491f02f-1de2-4fae-9755-55f3c16a3ac5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance outstanding at the beginning of the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d3305704-8c5d-4cab-8737-07c6f38acc16_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance outstanding at the end of the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_61665ae1-f841-4bc9-b909-359856409193_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_1dcd3a2d-28ea-49d3-80c6-74fda2c73ba8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_b0e97ef8-4350-4c38-823c-322c22906328_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_881d962e-a91f-4d31-8090-0da8b9cf6806_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity less than 1 year:</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_b7da763e-8c2d-4e8b-a7a0-71d0f787c56b_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_f5dffe6f-d64a-4001-9f45-b1163d4807a9_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d2fe0d12-b103-4f3e-b08f-9922097c23f7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_7a9cedf8-3733-4882-802b-0b56f0987e13_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_f01d98cd-36ae-44b6-92ad-b79c37db0f08_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b34609bd-ab0a-4ea7-8ebb-201e94d737ff_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af4b0b58-b02d-45ee-904f-fec0fd817588_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents&#8212;Beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_656920b3-04bd-4a6a-8273-88d4b36269ce_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents&#8212;End of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a07975e9-fa5a-4c03-a8b9-23dda410c74f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_121abffc-4948-497c-80d3-3689a5b81c54_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_197a68a7-e86d-46e2-9d4b-1b436aaf292b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_edb5f2e8-1d4c-4b08-9d64-846cd7db7e50_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e75c4c6a-5b01-469d-aed0-bef62906c770_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_29556b88-18e5-4982-8794-0fbe8a2ac7b2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b3839807-3ffb-48bd-a3a3-54ee4010209f_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_0ec72937-64f6-4968-abf7-b6a54736f8e3_negatedTerseLabel_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_label_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_documentation_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:to="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b62b4fb1-4228-48d9-8165-bc7ec5cdcb49_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_3747b361-6550-48b0-a4f0-90a2f30afe72_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9834e644-d23b-4254-a938-51a99e09c7e2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_FurnitureAndOfficeEquipmentMember_056a653c-3830-49d1-9051-6c7a736d89ab_terseLabel_en-US" xlink:label="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and office equipment</link:label>
    <link:label id="lab_crdf_FurnitureAndOfficeEquipmentMember_label_en-US" xlink:label="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture And Office Equipment [Member]</link:label>
    <link:label id="lab_crdf_FurnitureAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to furniture and office equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_FurnitureAndOfficeEquipmentMember" xlink:href="crdf-20220331.xsd#crdf_FurnitureAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_FurnitureAndOfficeEquipmentMember" xlink:to="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_b22ee89c-2348-495a-9046-3b0cc4805d04_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_bf15f862-b6f0-4100-a7d8-acb4d956d210_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e0b6a071-673f-467b-81eb-25388ae15d77_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0c7a0886-edc6-414f-bbec-99c20d3044df_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_203b514a-2080-4432-9808-c6e0182eb7a2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_52be067e-0250-4f2a-b203-727e76ebad3a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesDConvertiblePreferredStockMember_46f13c05-f3ce-4226-bbcc-9c608d79702d_terseLabel_en-US" xlink:label="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesDConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesDConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember" xlink:href="crdf-20220331.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesDConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_7912c7e4-f30c-4685-b7e9-a84b23f545c2_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Per Share</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights [Abstract]</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:href="crdf-20220331.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:to="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_69f75ac1-7560-4aa7-ab00-62ac1624022f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d042ad0e-89e7-4ac2-948a-d55f91ccc4cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_57f33fc9-17c8-4c5a-a720-d6a7a07a1e05_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_70a5fe51-a4ee-4cd8-af58-d77d19298486_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6a69f11f-2bc1-40f9-bfd5-115efa10df16_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_810e8cb8-77fe-4bea-9ba5-72bf0c80e209_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesEConvertiblePreferredStockMember_30480150-de03-451c-a72e-589edceecf50_terseLabel_en-US" xlink:label="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series&#160;E Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesEConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesEConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember" xlink:href="crdf-20220331.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesEConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f33d593a-aafb-4aa0-90a3-5ace1706b95d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_c60c1484-fcf4-4162-8522-4e1c30dc4231_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares designated (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LessorAreaOfSublease_bd12a3d9-8beb-487a-b44b-78f5ef1b368a_terseLabel_en-US" xlink:label="lab_crdf_LessorAreaOfSublease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of sublease</link:label>
    <link:label id="lab_crdf_LessorAreaOfSublease_label_en-US" xlink:label="lab_crdf_LessorAreaOfSublease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Area Of Sublease</link:label>
    <link:label id="lab_crdf_LessorAreaOfSublease_documentation_en-US" xlink:label="lab_crdf_LessorAreaOfSublease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Area Of Sublease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorAreaOfSublease" xlink:href="crdf-20220331.xsd#crdf_LessorAreaOfSublease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LessorAreaOfSublease" xlink:to="lab_crdf_LessorAreaOfSublease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_0de163e2-83b7-4274-a2a8-77cf2ad1d70f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d4456dd8-7cd9-4b35-a531-5d7e4daead08_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_dde92a5d-b3e2-4eca-92b7-9d1aa25adf00_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_364410eb-383f-460a-b053-d9111ef2ed9e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_00d116d8-2710-44e6-b68d-7cfb1035327b_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0661f1f0-62f7-49b2-8eb1-9f31f9358ef1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4bf3775c-17b7-4bf8-8ede-deeb7c5b3852_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1df89bbb-6153-405e-b3d1-72231d745760_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7c7ab159-e562-4e2b-a089-71950eade866_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, weighted average contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0617595e-3807-415e-9e3c-7fc1af0e2491_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseAreaOfLease_ddc0530f-199c-416d-85de-d0368c62efb3_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAreaOfLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of lease</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseAreaOfLease_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAreaOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Of Lease</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseAreaOfLease_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAreaOfLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAreaOfLease" xlink:href="crdf-20220331.xsd#crdf_LesseeOperatingLeaseAreaOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseAreaOfLease" xlink:to="lab_crdf_LesseeOperatingLeaseAreaOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_5ce09665-1f1c-4679-a5b4-cb18f8bf9a90_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_24bc6a46-629d-4a3b-b120-71100823d02e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d95b9bb3-6864-4b32-8ecc-fdf1c925da21_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_bf04e1ba-d747-495e-a3af-e09de7fc39a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a384ed9a-f262-4d5b-867e-b6c8e8eb710c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary Balance Sheet Information</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_709e16fa-cb52-4ab6-947f-8627cd9dd44b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_707ac99b-b7f0-47e5-96e6-aea36928fe72_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Term of Warrants or Rights [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:href="crdf-20220331.xsd#crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:to="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f396718-269a-448b-9760-3a1f41d311db_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_8af1814b-7994-472f-a1a5-18cf49e3d3eb_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_d6f3b11b-04eb-49ba-a91c-071099d68433_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments Available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_74b60d48-b9ba-490d-8213-dc5c516a3a1b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_e9508f25-4cf1-455a-9bb1-a5ac75c15926_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_65706a4d-904f-43a5-b02e-1ba932b04411_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_40e2c80f-6b9c-4195-ab71-b2d33d43041c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_124af96f-0061-4f37-867a-349c0f482881_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e4f8ad87-bff8-460d-981f-f3fec37da06f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f6f19fd2-ecae-494b-b3f0-9b37196ff5d2_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncement and Recent Accounting Pronouncement Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_43d45bf2-27d8-470d-8e8a-da89a8b03f22_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_79d6910b-aa89-4830-a077-f8aa0ebfe70c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_0ea8900f-a536-46dc-a81d-767b861006ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>crdf-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5214d653-0d65-43f4-9358-98c3966fcc60,g:7d826e52-41b1-4720-8d3a-56dea8b8a1bc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CoverPage" xlink:type="simple" xlink:href="crdf-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7688f6d9-4fc2-4fb6-90f3-a4a841474955" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_DocumentType_7688f6d9-4fc2-4fb6-90f3-a4a841474955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_22b2420f-575f-479a-9479-2961dfab31a8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_DocumentQuarterlyReport_22b2420f-575f-479a-9479-2961dfab31a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_641ac0e8-648d-43d7-828a-3786e4cdfc80" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_DocumentTransitionReport_641ac0e8-648d-43d7-828a-3786e4cdfc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4392157e-923f-4d48-a226-920dad56361c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_DocumentPeriodEndDate_4392157e-923f-4d48-a226-920dad56361c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d026e92d-9f44-44d9-a1cd-f775b1f27bbc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_EntityFileNumber_d026e92d-9f44-44d9-a1cd-f775b1f27bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_eb6d2a7b-91a8-467e-a2c3-f1289f036256" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_EntityRegistrantName_eb6d2a7b-91a8-467e-a2c3-f1289f036256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_365842d6-19c5-4dcd-9e46-6e45b051733b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_EntityIncorporationStateCountryCode_365842d6-19c5-4dcd-9e46-6e45b051733b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_da6a4df5-ea97-453f-af12-ae93d0458730" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_EntityTaxIdentificationNumber_da6a4df5-ea97-453f-af12-ae93d0458730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_60bedc00-73ac-45b2-bd57-803a64cb4a0c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_EntityAddressAddressLine1_60bedc00-73ac-45b2-bd57-803a64cb4a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_999d8496-e50a-4eb1-b858-02435b6c928b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_EntityAddressCityOrTown_999d8496-e50a-4eb1-b858-02435b6c928b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_dfc6827a-7626-48cc-9d5a-018243ccd64a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_EntityAddressStateOrProvince_dfc6827a-7626-48cc-9d5a-018243ccd64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_967053ca-eeb6-40d4-9cdc-eade7e67f4a7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_EntityAddressPostalZipCode_967053ca-eeb6-40d4-9cdc-eade7e67f4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5b833c6a-110a-4d91-9d55-1e38e9e9c5c3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_CityAreaCode_5b833c6a-110a-4d91-9d55-1e38e9e9c5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_da67849d-eb05-48d4-9d11-9c2ef968f438" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_LocalPhoneNumber_da67849d-eb05-48d4-9d11-9c2ef968f438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_bd89d3f9-1f15-4faa-861d-c23c129f3cf0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_Security12bTitle_bd89d3f9-1f15-4faa-861d-c23c129f3cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7a99ba6e-9aca-402f-9861-9b63d3244079" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_TradingSymbol_7a99ba6e-9aca-402f-9861-9b63d3244079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_867d4dcc-e89c-43c4-aa06-db58901b7840" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_EntityCurrentReportingStatus_867d4dcc-e89c-43c4-aa06-db58901b7840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7002e614-3ec3-42a0-8797-169e8479cd75" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_EntityInteractiveDataCurrent_7002e614-3ec3-42a0-8797-169e8479cd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e0eaa206-64ad-4ea2-8526-71cbdd9497bf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_EntityFilerCategory_e0eaa206-64ad-4ea2-8526-71cbdd9497bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b4b21f68-6dd4-4cbd-8502-bf5635cd9143" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_EntitySmallBusiness_b4b21f68-6dd4-4cbd-8502-bf5635cd9143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_36745b5d-bc31-4779-8cc3-539c27f2d9e6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_EntityEmergingGrowthCompany_36745b5d-bc31-4779-8cc3-539c27f2d9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_210f3e51-d85a-4e82-bb62-7a78f71126b3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_EntityShellCompany_210f3e51-d85a-4e82-bb62-7a78f71126b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_952234db-8577-4e97-bc97-7770509a198d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_952234db-8577-4e97-bc97-7770509a198d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bf497001-4140-4c1d-bf9a-33911865a7cb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_EntityCentralIndexKey_bf497001-4140-4c1d-bf9a-33911865a7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f0a743e0-af02-410e-8c34-57531cf642fc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_AmendmentFlag_f0a743e0-af02-410e-8c34-57531cf642fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b041bffe-4d10-49b6-8bea-672f0ae3b23d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_CurrentFiscalYearEndDate_b041bffe-4d10-49b6-8bea-672f0ae3b23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b2c6d405-1473-417d-945a-d9e739bde2d9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_DocumentFiscalYearFocus_b2c6d405-1473-417d-945a-d9e739bde2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b066702c-680b-4148-95fa-d620b3b23050" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_589b9dce-22aa-4e58-8478-289fe37e5c85" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b066702c-680b-4148-95fa-d620b3b23050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="crdf-20220331.xsd#CONDENSEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_51cba192-cfe4-4031-990d-e345ff627962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_66aa9b00-4c94-4e37-ab05-9ec2a4955e4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_51cba192-cfe4-4031-990d-e345ff627962" xlink:to="loc_us-gaap_AssetsAbstract_66aa9b00-4c94-4e37-ab05-9ec2a4955e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_ba31315d-51c6-4145-bd88-18e903fe791a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_66aa9b00-4c94-4e37-ab05-9ec2a4955e4b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_ba31315d-51c6-4145-bd88-18e903fe791a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eb23c133-1165-47b5-9728-fcdc19ea6e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ba31315d-51c6-4145-bd88-18e903fe791a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eb23c133-1165-47b5-9728-fcdc19ea6e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_bdc77195-ec47-4649-84e4-89fc7c6e1994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ba31315d-51c6-4145-bd88-18e903fe791a" xlink:to="loc_us-gaap_ShortTermInvestments_bdc77195-ec47-4649-84e4-89fc7c6e1994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_afebd414-2861-44df-bcb4-6ea86a228daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ba31315d-51c6-4145-bd88-18e903fe791a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_afebd414-2861-44df-bcb4-6ea86a228daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_a180f9d4-ad76-4218-8e47-f76a9f790906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ba31315d-51c6-4145-bd88-18e903fe791a" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_a180f9d4-ad76-4218-8e47-f76a9f790906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e9ae5582-fbf3-4701-9efa-9d9f8445dbee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ba31315d-51c6-4145-bd88-18e903fe791a" xlink:to="loc_us-gaap_AssetsCurrent_e9ae5582-fbf3-4701-9efa-9d9f8445dbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cd86a57c-9dba-4389-8348-3ddd4b28d7ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_66aa9b00-4c94-4e37-ab05-9ec2a4955e4b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cd86a57c-9dba-4389-8348-3ddd4b28d7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_96a03228-9494-4e1e-bdb8-9e14ce25176e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_66aa9b00-4c94-4e37-ab05-9ec2a4955e4b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_96a03228-9494-4e1e-bdb8-9e14ce25176e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cf75a98a-d561-452f-beeb-a8c6f7a253d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_66aa9b00-4c94-4e37-ab05-9ec2a4955e4b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cf75a98a-d561-452f-beeb-a8c6f7a253d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d55e34fe-f357-4f95-96f5-5e5d72fa19b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_66aa9b00-4c94-4e37-ab05-9ec2a4955e4b" xlink:to="loc_us-gaap_Assets_d55e34fe-f357-4f95-96f5-5e5d72fa19b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ef603f6-aef8-452f-bcf7-96b04a33847f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_51cba192-cfe4-4031-990d-e345ff627962" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ef603f6-aef8-452f-bcf7-96b04a33847f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_846abfd2-568e-4460-8a43-a06a330cd642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ef603f6-aef8-452f-bcf7-96b04a33847f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_846abfd2-568e-4460-8a43-a06a330cd642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_cc5de72f-f5f7-4f8c-9945-9959225bc4a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_846abfd2-568e-4460-8a43-a06a330cd642" xlink:to="loc_us-gaap_AccountsPayableCurrent_cc5de72f-f5f7-4f8c-9945-9959225bc4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_41ac4bad-40bc-4599-bc8d-2c626409e52b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_846abfd2-568e-4460-8a43-a06a330cd642" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_41ac4bad-40bc-4599-bc8d-2c626409e52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_58fab181-3fb2-4a40-9c56-2d5d19ba5c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_846abfd2-568e-4460-8a43-a06a330cd642" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_58fab181-3fb2-4a40-9c56-2d5d19ba5c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_044691e6-abaf-4624-8814-627e252c20c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_846abfd2-568e-4460-8a43-a06a330cd642" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_044691e6-abaf-4624-8814-627e252c20c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3ab35fa8-5886-44aa-93a7-6794a5d40799" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_846abfd2-568e-4460-8a43-a06a330cd642" xlink:to="loc_us-gaap_LiabilitiesCurrent_3ab35fa8-5886-44aa-93a7-6794a5d40799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_01b5a827-26c5-46ee-aa5b-a3d33626c171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ef603f6-aef8-452f-bcf7-96b04a33847f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_01b5a827-26c5-46ee-aa5b-a3d33626c171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6328f918-0486-40b3-aceb-8284c4a02242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ef603f6-aef8-452f-bcf7-96b04a33847f" xlink:to="loc_us-gaap_Liabilities_6328f918-0486-40b3-aceb-8284c4a02242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_cf1877db-13f9-41a6-b83d-ec4c3332caff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ef603f6-aef8-452f-bcf7-96b04a33847f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_cf1877db-13f9-41a6-b83d-ec4c3332caff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_560004fa-701d-453c-9c6e-3e30d28136ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ef603f6-aef8-452f-bcf7-96b04a33847f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_560004fa-701d-453c-9c6e-3e30d28136ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_49041d14-f12b-41ea-b129-82eb5d7c89e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_560004fa-701d-453c-9c6e-3e30d28136ec" xlink:to="loc_us-gaap_PreferredStockValue_49041d14-f12b-41ea-b129-82eb5d7c89e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2c995fc4-9cfc-4358-8aef-968c61a6f978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_560004fa-701d-453c-9c6e-3e30d28136ec" xlink:to="loc_us-gaap_CommonStockValue_2c995fc4-9cfc-4358-8aef-968c61a6f978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_be968ad1-fb51-4c42-b0a9-b3bec2801919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_560004fa-701d-453c-9c6e-3e30d28136ec" xlink:to="loc_us-gaap_AdditionalPaidInCapital_be968ad1-fb51-4c42-b0a9-b3bec2801919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivable_f6a6a56e-c10c-408f-b936-2c913810ca53" xlink:href="crdf-20220331.xsd#crdf_ServiceReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_560004fa-701d-453c-9c6e-3e30d28136ec" xlink:to="loc_crdf_ServiceReceivable_f6a6a56e-c10c-408f-b936-2c913810ca53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0b1db277-7f5e-4dbf-a14e-3d191b3a20ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_560004fa-701d-453c-9c6e-3e30d28136ec" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0b1db277-7f5e-4dbf-a14e-3d191b3a20ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_59ebb027-8255-431b-bf1e-f152a6c08f50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_560004fa-701d-453c-9c6e-3e30d28136ec" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_59ebb027-8255-431b-bf1e-f152a6c08f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b3b4599-3326-45c3-9675-0129d6599b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_560004fa-701d-453c-9c6e-3e30d28136ec" xlink:to="loc_us-gaap_StockholdersEquity_3b3b4599-3326-45c3-9675-0129d6599b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d88ff817-247a-4edf-a601-0db672ad9d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ef603f6-aef8-452f-bcf7-96b04a33847f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d88ff817-247a-4edf-a601-0db672ad9d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="crdf-20220331.xsd#CONDENSEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ae2d4734-4e1b-46e5-86be-cb30f195fbe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_64b7268a-cf56-4a7a-902d-f111e5478ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ae2d4734-4e1b-46e5-86be-cb30f195fbe9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_64b7268a-cf56-4a7a-902d-f111e5478ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9d534f2d-d35d-43a2-ad2c-3d750a50c459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ae2d4734-4e1b-46e5-86be-cb30f195fbe9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9d534f2d-d35d-43a2-ad2c-3d750a50c459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2103c198-57c4-417a-be29-b156a23bbef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ae2d4734-4e1b-46e5-86be-cb30f195fbe9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2103c198-57c4-417a-be29-b156a23bbef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6374db45-a974-474a-a19c-892409441699" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ae2d4734-4e1b-46e5-86be-cb30f195fbe9" xlink:to="loc_us-gaap_CommonStockSharesIssued_6374db45-a974-474a-a19c-892409441699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_19a01e60-ce4e-43f1-827a-59d7750868bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ae2d4734-4e1b-46e5-86be-cb30f195fbe9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_19a01e60-ce4e-43f1-827a-59d7750868bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="crdf-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_326765dc-7288-4e5e-8014-35b9704094c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_557b3fad-4c33-42ef-83d7-b9cbd56e21c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_326765dc-7288-4e5e-8014-35b9704094c0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_557b3fad-4c33-42ef-83d7-b9cbd56e21c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3bb4c6c6-3672-4ba9-a4f3-3a8c62d01cb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_326765dc-7288-4e5e-8014-35b9704094c0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_3bb4c6c6-3672-4ba9-a4f3-3a8c62d01cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c352e59c-093d-4a0f-ada4-f8a32f23a8bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3bb4c6c6-3672-4ba9-a4f3-3a8c62d01cb3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c352e59c-093d-4a0f-ada4-f8a32f23a8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2599b15d-06a6-4f40-b19c-11e6e1ea5e46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3bb4c6c6-3672-4ba9-a4f3-3a8c62d01cb3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2599b15d-06a6-4f40-b19c-11e6e1ea5e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8215aefb-8421-4be8-93f8-293b1b4df548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3bb4c6c6-3672-4ba9-a4f3-3a8c62d01cb3" xlink:to="loc_us-gaap_OperatingExpenses_8215aefb-8421-4be8-93f8-293b1b4df548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0b2bc11f-c814-43ef-83ed-53b7c41e91af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_326765dc-7288-4e5e-8014-35b9704094c0" xlink:to="loc_us-gaap_OperatingIncomeLoss_0b2bc11f-c814-43ef-83ed-53b7c41e91af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_d3c850aa-9013-4fcd-b4e1-225f8ef5b0fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_326765dc-7288-4e5e-8014-35b9704094c0" xlink:to="loc_us-gaap_InterestIncomeOperating_d3c850aa-9013-4fcd-b4e1-225f8ef5b0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_b4073a3a-4b37-4ffa-8c82-ead32f0bcd12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_326765dc-7288-4e5e-8014-35b9704094c0" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_b4073a3a-4b37-4ffa-8c82-ead32f0bcd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_90826351-9120-4ddd-89ee-066f54e08d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_326765dc-7288-4e5e-8014-35b9704094c0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_90826351-9120-4ddd-89ee-066f54e08d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_090fd5ab-80a1-42ba-aae1-af803dd95097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_326765dc-7288-4e5e-8014-35b9704094c0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_090fd5ab-80a1-42ba-aae1-af803dd95097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7165ba01-72b6-400d-aff2-0ef2a6a5e173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_326765dc-7288-4e5e-8014-35b9704094c0" xlink:to="loc_us-gaap_NetIncomeLoss_7165ba01-72b6-400d-aff2-0ef2a6a5e173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_7a7f4fdf-9d38-49d2-9e2a-f9c15faf4f0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_326765dc-7288-4e5e-8014-35b9704094c0" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_7a7f4fdf-9d38-49d2-9e2a-f9c15faf4f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9c3d0d1e-3501-4ad3-8b7f-996ac487ab5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_326765dc-7288-4e5e-8014-35b9704094c0" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9c3d0d1e-3501-4ad3-8b7f-996ac487ab5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7731d490-67c1-4795-a198-ef3b7851a1cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_326765dc-7288-4e5e-8014-35b9704094c0" xlink:to="loc_us-gaap_EarningsPerShareBasic_7731d490-67c1-4795-a198-ef3b7851a1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_faf9c85c-17bc-4528-b1c7-e79e7c93f5bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_326765dc-7288-4e5e-8014-35b9704094c0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_faf9c85c-17bc-4528-b1c7-e79e7c93f5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9485b728-c3dc-4849-8f3e-8e6116b7cecc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_326765dc-7288-4e5e-8014-35b9704094c0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9485b728-c3dc-4849-8f3e-8e6116b7cecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21e4a800-d2e9-46ad-8a25-c650aeaad03a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_326765dc-7288-4e5e-8014-35b9704094c0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21e4a800-d2e9-46ad-8a25-c650aeaad03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="crdf-20220331.xsd#CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0a763e1c-6014-4fcf-8bc0-d574337f144f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ecd7cc83-51d2-440c-b63b-118a6d653863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0a763e1c-6014-4fcf-8bc0-d574337f144f" xlink:to="loc_us-gaap_NetIncomeLoss_ecd7cc83-51d2-440c-b63b-118a6d653863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_3513d449-9309-4bc0-b74b-20dc139ed0e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0a763e1c-6014-4fcf-8bc0-d574337f144f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_3513d449-9309-4bc0-b74b-20dc139ed0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9160b30b-98ee-41b5-9a77-fca7c2f18e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_3513d449-9309-4bc0-b74b-20dc139ed0e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9160b30b-98ee-41b5-9a77-fca7c2f18e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4abad57d-88fb-4392-96fe-3e468f5e4357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0a763e1c-6014-4fcf-8bc0-d574337f144f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_4abad57d-88fb-4392-96fe-3e468f5e4357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_aee52c92-1dd2-4fbc-b9e8-f4b7098dd8e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0a763e1c-6014-4fcf-8bc0-d574337f144f" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_aee52c92-1dd2-4fbc-b9e8-f4b7098dd8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_eb2a4eda-371a-4d9f-be24-5e159cb496cf" xlink:href="crdf-20220331.xsd#crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0a763e1c-6014-4fcf-8bc0-d574337f144f" xlink:to="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_eb2a4eda-371a-4d9f-be24-5e159cb496cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="crdf-20220331.xsd#CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_edc2805a-04e5-40c4-9fcc-d866f5697960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ac78da2c-644f-4d50-889f-d9d6ee521ce9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_edc2805a-04e5-40c4-9fcc-d866f5697960" xlink:to="loc_us-gaap_StatementTable_ac78da2c-644f-4d50-889f-d9d6ee521ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_20dfdf77-a56e-4ad8-abc4-3dedcb076588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ac78da2c-644f-4d50-889f-d9d6ee521ce9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_20dfdf77-a56e-4ad8-abc4-3dedcb076588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d3d6d67c-d7b4-4a57-9af1-7cd1764c0f63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_20dfdf77-a56e-4ad8-abc4-3dedcb076588" xlink:to="loc_us-gaap_EquityComponentDomain_d3d6d67c-d7b4-4a57-9af1-7cd1764c0f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_1cf67248-61a4-4cca-beb5-992c457d56c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d3d6d67c-d7b4-4a57-9af1-7cd1764c0f63" xlink:to="loc_us-gaap_PreferredStockMember_1cf67248-61a4-4cca-beb5-992c457d56c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_89052e30-fb1f-4968-a8b8-18d76a70ce8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d3d6d67c-d7b4-4a57-9af1-7cd1764c0f63" xlink:to="loc_us-gaap_CommonStockMember_89052e30-fb1f-4968-a8b8-18d76a70ce8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_24569c69-67c9-46c8-8551-024182349e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d3d6d67c-d7b4-4a57-9af1-7cd1764c0f63" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_24569c69-67c9-46c8-8551-024182349e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivableMember_6747a797-020f-4f16-843d-3bb68a403d30" xlink:href="crdf-20220331.xsd#crdf_ServiceReceivableMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d3d6d67c-d7b4-4a57-9af1-7cd1764c0f63" xlink:to="loc_crdf_ServiceReceivableMember_6747a797-020f-4f16-843d-3bb68a403d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8a524437-7bcc-44c0-b0ab-6559b315eeaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d3d6d67c-d7b4-4a57-9af1-7cd1764c0f63" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8a524437-7bcc-44c0-b0ab-6559b315eeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_02133d3f-414d-48a7-a200-4b7e2d33464a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d3d6d67c-d7b4-4a57-9af1-7cd1764c0f63" xlink:to="loc_us-gaap_RetainedEarningsMember_02133d3f-414d-48a7-a200-4b7e2d33464a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f5cf5b66-c240-4049-afe7-f16aa246439f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ac78da2c-644f-4d50-889f-d9d6ee521ce9" xlink:to="loc_us-gaap_StatementLineItems_f5cf5b66-c240-4049-afe7-f16aa246439f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f5cf5b66-c240-4049-afe7-f16aa246439f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c762b1b9-4a82-4ee1-baff-8cff305ee58f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_us-gaap_SharesIssued_c762b1b9-4a82-4ee1-baff-8cff305ee58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3462fd21-2e70-4efb-8e6d-008a236cdd79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_us-gaap_StockholdersEquity_3462fd21-2e70-4efb-8e6d-008a236cdd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_547aba5f-ed8d-4b7a-8611-9b3c9d97a81f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_547aba5f-ed8d-4b7a-8611-9b3c9d97a81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_10b09ee5-bfa6-4bc3-bd10-9e0b2e79fa8d" xlink:href="crdf-20220331.xsd#crdf_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_10b09ee5-bfa6-4bc3-bd10-9e0b2e79fa8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised_b1ee337e-e44c-4526-a7f6-4e00ea0b49c2" xlink:href="crdf-20220331.xsd#crdf_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised_b1ee337e-e44c-4526-a7f6-4e00ea0b49c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ba123665-020c-4073-9a39-229d38a81d78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ba123665-020c-4073-9a39-229d38a81d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3a34b722-f270-4242-a543-acd99d1c5766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3a34b722-f270-4242-a543-acd99d1c5766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_01f58545-c5c3-4b3e-b299-d7c5c1420263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_01f58545-c5c3-4b3e-b299-d7c5c1420263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_fcfb44dd-34c2-434e-b8c7-3dc5bcc7c1aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_us-gaap_DividendsPreferredStock_fcfb44dd-34c2-434e-b8c7-3dc5bcc7c1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_d4f03208-27fd-473d-8bf7-21987f75afd9" xlink:href="crdf-20220331.xsd#crdf_ReleaseOfClinicalTrialFundingCommitment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_d4f03208-27fd-473d-8bf7-21987f75afd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_db1b026f-87e6-48ff-82ff-ead80e25580a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_us-gaap_NetIncomeLoss_db1b026f-87e6-48ff-82ff-ead80e25580a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c8653284-b65e-4f0c-adfd-e3fbd1c5a953" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_us-gaap_SharesIssued_c8653284-b65e-4f0c-adfd-e3fbd1c5a953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e284a076-bda2-41c6-8eef-36b2c6c6cd0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0487f7b9-d066-4d6a-bace-a93e5c69064a" xlink:to="loc_us-gaap_StockholdersEquity_e284a076-bda2-41c6-8eef-36b2c6c6cd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="crdf-20220331.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_bf0e025e-8387-4525-a273-b93186cbd107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a6b0b0f9-91e2-48cf-9944-9b44d40da482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bf0e025e-8387-4525-a273-b93186cbd107" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a6b0b0f9-91e2-48cf-9944-9b44d40da482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7eba12be-18cc-43aa-8653-bfbecd96ef3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a6b0b0f9-91e2-48cf-9944-9b44d40da482" xlink:to="loc_us-gaap_NetIncomeLoss_7eba12be-18cc-43aa-8653-bfbecd96ef3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_47c5bb9e-94fa-48b3-b533-4d14cecec7d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a6b0b0f9-91e2-48cf-9944-9b44d40da482" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_47c5bb9e-94fa-48b3-b533-4d14cecec7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_0ce2b201-e53f-4d38-af70-726c58094ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_47c5bb9e-94fa-48b3-b533-4d14cecec7d6" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_0ce2b201-e53f-4d38-af70-726c58094ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1c493152-cc11-4590-b1b9-b34409d08add" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_47c5bb9e-94fa-48b3-b533-4d14cecec7d6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1c493152-cc11-4590-b1b9-b34409d08add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f263613d-4df5-4225-a6d5-735cd838835b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_47c5bb9e-94fa-48b3-b533-4d14cecec7d6" xlink:to="loc_us-gaap_ShareBasedCompensation_f263613d-4df5-4225-a6d5-735cd838835b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_74304613-6949-4032-b495-3814597d8dae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_47c5bb9e-94fa-48b3-b533-4d14cecec7d6" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_74304613-6949-4032-b495-3814597d8dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_3e4ede48-65cf-433a-8479-4462494d9cc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_47c5bb9e-94fa-48b3-b533-4d14cecec7d6" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_3e4ede48-65cf-433a-8479-4462494d9cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_c955a508-57f6-4d04-993c-10fe99f11f55" xlink:href="crdf-20220331.xsd#crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_47c5bb9e-94fa-48b3-b533-4d14cecec7d6" xlink:to="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_c955a508-57f6-4d04-993c-10fe99f11f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a1020952-f600-4cca-967b-b87bcfabd6bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_47c5bb9e-94fa-48b3-b533-4d14cecec7d6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a1020952-f600-4cca-967b-b87bcfabd6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_83640dd9-b409-4f04-aefc-0d0dfab5c019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a1020952-f600-4cca-967b-b87bcfabd6bb" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_83640dd9-b409-4f04-aefc-0d0dfab5c019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d89f9ccb-7372-4942-94f6-481453860c12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a1020952-f600-4cca-967b-b87bcfabd6bb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d89f9ccb-7372-4942-94f6-481453860c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_585b92ab-b4c7-479d-9b4f-11ff5ac1bf1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a1020952-f600-4cca-967b-b87bcfabd6bb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_585b92ab-b4c7-479d-9b4f-11ff5ac1bf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0db79820-e906-4e15-b237-8c3e3e5a4a8a" xlink:href="crdf-20220331.xsd#crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a1020952-f600-4cca-967b-b87bcfabd6bb" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0db79820-e906-4e15-b237-8c3e3e5a4a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4dd0adb6-cc54-430a-9410-ae98e04e54e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a1020952-f600-4cca-967b-b87bcfabd6bb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4dd0adb6-cc54-430a-9410-ae98e04e54e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability_04d5f0ea-dd05-4024-8d2f-af4b2a1d937e" xlink:href="crdf-20220331.xsd#crdf_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a1020952-f600-4cca-967b-b87bcfabd6bb" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability_04d5f0ea-dd05-4024-8d2f-af4b2a1d937e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_251818c9-5d9a-48a5-9a38-ecd41081ff62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a1020952-f600-4cca-967b-b87bcfabd6bb" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_251818c9-5d9a-48a5-9a38-ecd41081ff62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d196a51-25cd-4831-a425-80f9aa29ccbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a6b0b0f9-91e2-48cf-9944-9b44d40da482" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d196a51-25cd-4831-a425-80f9aa29ccbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d17858d9-4f8d-41ec-b17e-d68877ae746b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bf0e025e-8387-4525-a273-b93186cbd107" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d17858d9-4f8d-41ec-b17e-d68877ae746b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8f94ebf5-dd13-4995-8155-d944d0a05089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d17858d9-4f8d-41ec-b17e-d68877ae746b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8f94ebf5-dd13-4995-8155-d944d0a05089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_22bc761b-fe22-463a-9edc-a5da0cbf13c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d17858d9-4f8d-41ec-b17e-d68877ae746b" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_22bc761b-fe22-463a-9edc-a5da0cbf13c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2ffbed3f-a220-4bad-891d-49f2b7bcad96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d17858d9-4f8d-41ec-b17e-d68877ae746b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2ffbed3f-a220-4bad-891d-49f2b7bcad96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_234625e8-5fb8-4690-9636-c47b2e4ca275" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d17858d9-4f8d-41ec-b17e-d68877ae746b" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_234625e8-5fb8-4690-9636-c47b2e4ca275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c695488c-b19c-492c-a995-b926b66b4063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d17858d9-4f8d-41ec-b17e-d68877ae746b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c695488c-b19c-492c-a995-b926b66b4063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6afc3e5f-dac3-420d-94be-2676ed5004f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bf0e025e-8387-4525-a273-b93186cbd107" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6afc3e5f-dac3-420d-94be-2676ed5004f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_40fe21a6-c03a-4d26-9759-5ff4929e902d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6afc3e5f-dac3-420d-94be-2676ed5004f7" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_40fe21a6-c03a-4d26-9759-5ff4929e902d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bc25ea5e-6f3f-4631-87b5-4c5735858246" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6afc3e5f-dac3-420d-94be-2676ed5004f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bc25ea5e-6f3f-4631-87b5-4c5735858246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7f33b9f3-c394-4580-a5e4-159886fb013a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bf0e025e-8387-4525-a273-b93186cbd107" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7f33b9f3-c394-4580-a5e4-159886fb013a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2c059fcc-6f37-460c-afa3-1012c8c694f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bf0e025e-8387-4525-a273-b93186cbd107" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2c059fcc-6f37-460c-afa3-1012c8c694f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b942318c-ade0-4bd6-9c8d-e5891e16ddd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bf0e025e-8387-4525-a273-b93186cbd107" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b942318c-ade0-4bd6-9c8d-e5891e16ddd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_528169cc-d30c-4770-807c-81cfa21e6b26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bf0e025e-8387-4525-a273-b93186cbd107" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_528169cc-d30c-4770-807c-81cfa21e6b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_97feab1f-b33a-4216-a77a-3079f4fa899a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_528169cc-d30c-4770-807c-81cfa21e6b26" xlink:to="loc_us-gaap_IncomeTaxesPaid_97feab1f-b33a-4216-a77a-3079f4fa899a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_fcaae267-da1e-4adc-9d48-ff6b01acff4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bf0e025e-8387-4525-a273-b93186cbd107" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_fcaae267-da1e-4adc-9d48-ff6b01acff4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f57c9496-ef83-4380-98f7-b25e35d8b68a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_fcaae267-da1e-4adc-9d48-ff6b01acff4e" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f57c9496-ef83-4380-98f7-b25e35d8b68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockDividendAccrued_a7324593-1a66-497c-9ef4-02a33038851c" xlink:href="crdf-20220331.xsd#crdf_PreferredStockDividendAccrued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_fcaae267-da1e-4adc-9d48-ff6b01acff4e" xlink:to="loc_crdf_PreferredStockDividendAccrued_a7324593-1a66-497c-9ef4-02a33038851c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="crdf-20220331.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aebf1fee-5a54-475a-b265-7f3a644294d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8e8f8101-bfe1-4741-906f-157065d6d5be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aebf1fee-5a54-475a-b265-7f3a644294d7" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8e8f8101-bfe1-4741-906f-157065d6d5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d3c9bf5c-a117-4215-917d-adae04ee5ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_fd27a28f-6945-4d37-90ca-8f0cfeb54e25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d3c9bf5c-a117-4215-917d-adae04ee5ec2" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_fd27a28f-6945-4d37-90ca-8f0cfeb54e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="crdf-20220331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_18d83007-7048-4368-94ee-9347045fc84a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3db86460-7182-4a4d-9456-dfd79b84b2d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18d83007-7048-4368-94ee-9347045fc84a" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3db86460-7182-4a4d-9456-dfd79b84b2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="crdf-20220331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_406a4267-3578-4119-b4b7-f8d3d9ad40d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_cdad13d2-d358-481b-9732-284784cee449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406a4267-3578-4119-b4b7-f8d3d9ad40d9" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_cdad13d2-d358-481b-9732-284784cee449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4c188770-ba9b-4479-91d3-04ec6d9c19d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406a4267-3578-4119-b4b7-f8d3d9ad40d9" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4c188770-ba9b-4479-91d3-04ec6d9c19d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="crdf-20220331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_698c9f56-6082-4955-bee3-e62c5f6539d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8e36c7f3-2e21-4ee3-847e-e9f77f91b3c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_698c9f56-6082-4955-bee3-e62c5f6539d5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8e36c7f3-2e21-4ee3-847e-e9f77f91b3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5b28ef43-de10-4846-a848-dd8b250b9484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_95a86f05-bf89-40e4-b9ee-c98017eb938b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b28ef43-de10-4846-a848-dd8b250b9484" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_95a86f05-bf89-40e4-b9ee-c98017eb938b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_75576fdf-2abd-45e3-aeb2-71d9d27afcb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_95a86f05-bf89-40e4-b9ee-c98017eb938b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_75576fdf-2abd-45e3-aeb2-71d9d27afcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_335f5f64-0e9a-47b4-8f26-9b8836529f05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_75576fdf-2abd-45e3-aeb2-71d9d27afcb6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_335f5f64-0e9a-47b4-8f26-9b8836529f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_745b77ca-26d9-422a-81d4-dccd64dafda5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_335f5f64-0e9a-47b4-8f26-9b8836529f05" xlink:to="loc_us-gaap_EmployeeStockOptionMember_745b77ca-26d9-422a-81d4-dccd64dafda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_55b33f38-5f47-4a81-b666-029902937ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_335f5f64-0e9a-47b4-8f26-9b8836529f05" xlink:to="loc_us-gaap_WarrantMember_55b33f38-5f47-4a81-b666-029902937ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_bee68dd0-6d6d-48a9-842f-02398d89892d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_335f5f64-0e9a-47b4-8f26-9b8836529f05" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_bee68dd0-6d6d-48a9-842f-02398d89892d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_3ffbe990-90af-4f64-9a66-4ec48567253c" xlink:href="crdf-20220331.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_335f5f64-0e9a-47b4-8f26-9b8836529f05" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_3ffbe990-90af-4f64-9a66-4ec48567253c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ff0ea11d-1e0e-468d-8644-96639ad66e0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_95a86f05-bf89-40e4-b9ee-c98017eb938b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ff0ea11d-1e0e-468d-8644-96639ad66e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_de4d6b24-bed9-4d2c-9379-3193cb72b620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ff0ea11d-1e0e-468d-8644-96639ad66e0c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_de4d6b24-bed9-4d2c-9379-3193cb72b620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="crdf-20220331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d6d0a533-5941-46c9-ba28-07a4111dbbf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_bc5f7d90-04fe-4926-a5e1-6c231754800c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d6d0a533-5941-46c9-ba28-07a4111dbbf4" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_bc5f7d90-04fe-4926-a5e1-6c231754800c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="crdf-20220331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4df09053-d8c1-4e3c-9bd7-c33a4de14433" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_f6652382-9775-4d91-bdb8-77620c82911c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4df09053-d8c1-4e3c-9bd7-c33a4de14433" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_f6652382-9775-4d91-bdb8-77620c82911c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0aa61dc1-05ee-407b-8dd4-27fe71c4a446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75303e37-f618-4448-a816-508c44828a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0aa61dc1-05ee-407b-8dd4-27fe71c4a446" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75303e37-f618-4448-a816-508c44828a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d7257bf-4a7d-4867-8f32-cc276ef28270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75303e37-f618-4448-a816-508c44828a4e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d7257bf-4a7d-4867-8f32-cc276ef28270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7073ef17-8e99-4a33-a29c-bf692c407fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d7257bf-4a7d-4867-8f32-cc276ef28270" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7073ef17-8e99-4a33-a29c-bf692c407fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_83b4fa10-cdbd-408e-89c2-ab8792aecaa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7073ef17-8e99-4a33-a29c-bf692c407fed" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_83b4fa10-cdbd-408e-89c2-ab8792aecaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9d68bf28-4ac4-4a7c-a9d2-764fed06361f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75303e37-f618-4448-a816-508c44828a4e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9d68bf28-4ac4-4a7c-a9d2-764fed06361f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5520f918-2cbe-40c8-a3e9-0a72e5b41cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9d68bf28-4ac4-4a7c-a9d2-764fed06361f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5520f918-2cbe-40c8-a3e9-0a72e5b41cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_75ec25d1-daab-4cc7-8134-2dcf3c6665c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5520f918-2cbe-40c8-a3e9-0a72e5b41cb4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_75ec25d1-daab-4cc7-8134-2dcf3c6665c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_aacda7db-7ee8-43e6-9af8-22f7fc4e6a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5520f918-2cbe-40c8-a3e9-0a72e5b41cb4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_aacda7db-7ee8-43e6-9af8-22f7fc4e6a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_30a83726-7aca-4c22-8233-e64b67893224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5520f918-2cbe-40c8-a3e9-0a72e5b41cb4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_30a83726-7aca-4c22-8233-e64b67893224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_378addbd-ff4e-4d62-ae3d-57b078f392d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75303e37-f618-4448-a816-508c44828a4e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_378addbd-ff4e-4d62-ae3d-57b078f392d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_39ee5bdb-9ba5-4750-b0f9-ad34a5dab4a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_378addbd-ff4e-4d62-ae3d-57b078f392d1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_39ee5bdb-9ba5-4750-b0f9-ad34a5dab4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_185bb6d9-c987-4166-a001-3cb516120534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_39ee5bdb-9ba5-4750-b0f9-ad34a5dab4a5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_185bb6d9-c987-4166-a001-3cb516120534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_2d3e97b2-8912-44cf-baf0-740a18e9feab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_39ee5bdb-9ba5-4750-b0f9-ad34a5dab4a5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_2d3e97b2-8912-44cf-baf0-740a18e9feab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e1ddc2e7-56d0-404e-bc9d-28810e5005f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75303e37-f618-4448-a816-508c44828a4e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e1ddc2e7-56d0-404e-bc9d-28810e5005f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ddbcd58-339e-468b-83cb-93cdd285a25b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e1ddc2e7-56d0-404e-bc9d-28810e5005f4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ddbcd58-339e-468b-83cb-93cdd285a25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_1d0a90d1-0222-463c-a642-66f64bab9cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ddbcd58-339e-468b-83cb-93cdd285a25b" xlink:to="loc_us-gaap_CertificatesOfDepositMember_1d0a90d1-0222-463c-a642-66f64bab9cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_fee6167b-6ada-4294-9929-b845e9062fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ddbcd58-339e-468b-83cb-93cdd285a25b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_fee6167b-6ada-4294-9929-b845e9062fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_ac32ce90-cdd4-43b1-bbd6-b9d544354746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ddbcd58-339e-468b-83cb-93cdd285a25b" xlink:to="loc_us-gaap_CommercialPaperMember_ac32ce90-cdd4-43b1-bbd6-b9d544354746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_580b8ddb-7d1a-4e2e-bc24-15b9af572c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ddbcd58-339e-468b-83cb-93cdd285a25b" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_580b8ddb-7d1a-4e2e-bc24-15b9af572c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_97153abe-57db-4115-9210-8d7048168311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ddbcd58-339e-468b-83cb-93cdd285a25b" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_97153abe-57db-4115-9210-8d7048168311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1162278-067e-4090-877a-5a0eb07cd05a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75303e37-f618-4448-a816-508c44828a4e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1162278-067e-4090-877a-5a0eb07cd05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_6a94284e-97b1-4607-9abe-0b2d4447d5e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1162278-067e-4090-877a-5a0eb07cd05a" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_6a94284e-97b1-4607-9abe-0b2d4447d5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1661e072-e9a3-41ab-8c06-5d51051b8ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6a94284e-97b1-4607-9abe-0b2d4447d5e0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1661e072-e9a3-41ab-8c06-5d51051b8ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aa911822-fe0f-474d-8a77-88e91d200250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6a94284e-97b1-4607-9abe-0b2d4447d5e0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aa911822-fe0f-474d-8a77-88e91d200250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8c4f0b08-6cf4-4696-9dae-94a0b555d3b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6a94284e-97b1-4607-9abe-0b2d4447d5e0" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8c4f0b08-6cf4-4696-9dae-94a0b555d3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation" xlink:type="simple" xlink:href="crdf-20220331.xsd#SupplementaryBalanceSheetInformation"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_52d2cf16-ed28-454c-88a7-786c27fb330d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_63918d76-000d-419d-b7c8-714cd61469f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_52d2cf16-ed28-454c-88a7-786c27fb330d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_63918d76-000d-419d-b7c8-714cd61469f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables" xlink:type="simple" xlink:href="crdf-20220331.xsd#SupplementaryBalanceSheetInformationTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a761435-358b-4393-af23-ca6dd23f6dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1cf55f56-d29e-4c18-a50f-38abf034d9be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a761435-358b-4393-af23-ca6dd23f6dcb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1cf55f56-d29e-4c18-a50f-38abf034d9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_15eb3786-0c29-4cee-8179-368ed32a04bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a761435-358b-4393-af23-ca6dd23f6dcb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_15eb3786-0c29-4cee-8179-368ed32a04bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7071ac2f-147c-4ba6-bff6-350e096b4bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a761435-358b-4393-af23-ca6dd23f6dcb" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7071ac2f-147c-4ba6-bff6-350e096b4bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df394997-afac-496e-801a-60fd43d25a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_476c94b6-c781-47f1-ac60-56ef8d67bb58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df394997-afac-496e-801a-60fd43d25a8b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_476c94b6-c781-47f1-ac60-56ef8d67bb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_30bbeed0-9221-4113-ab2c-958683bfb6df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_476c94b6-c781-47f1-ac60-56ef8d67bb58" xlink:to="loc_us-gaap_FinancialInstrumentAxis_30bbeed0-9221-4113-ab2c-958683bfb6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_49a24f74-2b70-493d-a743-dfeb284c4adf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_30bbeed0-9221-4113-ab2c-958683bfb6df" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_49a24f74-2b70-493d-a743-dfeb284c4adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_da5daeed-5c30-4657-93bc-a44b55e40f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_49a24f74-2b70-493d-a743-dfeb284c4adf" xlink:to="loc_us-gaap_CertificatesOfDepositMember_da5daeed-5c30-4657-93bc-a44b55e40f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6c864631-5ae9-4704-93d7-da50a3d98576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_49a24f74-2b70-493d-a743-dfeb284c4adf" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6c864631-5ae9-4704-93d7-da50a3d98576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_647b9348-f274-476c-9f92-b6f793a8cf07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_49a24f74-2b70-493d-a743-dfeb284c4adf" xlink:to="loc_us-gaap_CommercialPaperMember_647b9348-f274-476c-9f92-b6f793a8cf07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_f253decb-97c8-4c90-ae31-c45afe9e2d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_49a24f74-2b70-493d-a743-dfeb284c4adf" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_f253decb-97c8-4c90-ae31-c45afe9e2d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_56c7b275-a2bf-4b2c-86fb-ba6e826509a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_49a24f74-2b70-493d-a743-dfeb284c4adf" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_56c7b275-a2bf-4b2c-86fb-ba6e826509a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0560c6f-a913-4561-8ddc-1afb7e498785" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_476c94b6-c781-47f1-ac60-56ef8d67bb58" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0560c6f-a913-4561-8ddc-1afb7e498785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a104a88e-7a62-4dce-a02c-ea1328ef1b25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0560c6f-a913-4561-8ddc-1afb7e498785" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a104a88e-7a62-4dce-a02c-ea1328ef1b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_9041ecc1-0493-4e91-af6c-e9a542bbd34b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a104a88e-7a62-4dce-a02c-ea1328ef1b25" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_9041ecc1-0493-4e91-af6c-e9a542bbd34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_94ceb069-9282-40b8-8b10-f4682fca421b" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a104a88e-7a62-4dce-a02c-ea1328ef1b25" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_94ceb069-9282-40b8-8b10-f4682fca421b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_b2c1686d-0309-4f70-a507-a64e67accb77" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a104a88e-7a62-4dce-a02c-ea1328ef1b25" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_b2c1686d-0309-4f70-a507-a64e67accb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_99ae72f0-eb95-471c-8def-cdb012ec3e24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a104a88e-7a62-4dce-a02c-ea1328ef1b25" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_99ae72f0-eb95-471c-8def-cdb012ec3e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_9d1a92b5-1894-43f6-b431-8f542d5aa7f7" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0560c6f-a913-4561-8ddc-1afb7e498785" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_9d1a92b5-1894-43f6-b431-8f542d5aa7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_a03c4f0c-386b-4a97-b748-3be1673ed9e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_9d1a92b5-1894-43f6-b431-8f542d5aa7f7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_a03c4f0c-386b-4a97-b748-3be1673ed9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_5ad1634c-0624-4214-967b-a2b73fddf75a" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_9d1a92b5-1894-43f6-b431-8f542d5aa7f7" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_5ad1634c-0624-4214-967b-a2b73fddf75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_2a5d62e3-8eab-4cc4-bc2a-a223103a59d6" xlink:href="crdf-20220331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_9d1a92b5-1894-43f6-b431-8f542d5aa7f7" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_2a5d62e3-8eab-4cc4-bc2a-a223103a59d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_287f2795-0068-4516-8dd8-f5cb2ad600ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_9d1a92b5-1894-43f6-b431-8f542d5aa7f7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_287f2795-0068-4516-8dd8-f5cb2ad600ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_efd98f03-3ca5-4499-9dd0-670e87b9e31f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0560c6f-a913-4561-8ddc-1afb7e498785" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_efd98f03-3ca5-4499-9dd0-670e87b9e31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0ae34668-df83-425d-b47c-3cd3cda78aad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0560c6f-a913-4561-8ddc-1afb7e498785" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0ae34668-df83-425d-b47c-3cd3cda78aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7e7dc632-4482-4c3d-8c7d-b847f6af5a01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0560c6f-a913-4561-8ddc-1afb7e498785" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7e7dc632-4482-4c3d-8c7d-b847f6af5a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0651d3eb-7805-47f5-932e-be330d73d12f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0560c6f-a913-4561-8ddc-1afb7e498785" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0651d3eb-7805-47f5-932e-be330d73d12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1" xlink:type="simple" xlink:href="crdf-20220331.xsd#SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7acf6ead-1c85-4cbb-bb0f-4a80789663d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fc0ff5b-9bc6-4b6b-8415-2acb8e7a4a31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7acf6ead-1c85-4cbb-bb0f-4a80789663d5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fc0ff5b-9bc6-4b6b-8415-2acb8e7a4a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3c0890a7-b4ac-4f8b-9f98-f5f0b895cd87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fc0ff5b-9bc6-4b6b-8415-2acb8e7a4a31" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3c0890a7-b4ac-4f8b-9f98-f5f0b895cd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64116dee-afc9-495b-b56d-08d09b1d7c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3c0890a7-b4ac-4f8b-9f98-f5f0b895cd87" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64116dee-afc9-495b-b56d-08d09b1d7c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_FurnitureAndOfficeEquipmentMember_7376e810-6c09-46b0-a071-c7391d9ded58" xlink:href="crdf-20220331.xsd#crdf_FurnitureAndOfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64116dee-afc9-495b-b56d-08d09b1d7c8b" xlink:to="loc_crdf_FurnitureAndOfficeEquipmentMember_7376e810-6c09-46b0-a071-c7391d9ded58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_f6856e25-ff2c-4383-8825-be3a02cd3993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64116dee-afc9-495b-b56d-08d09b1d7c8b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_f6856e25-ff2c-4383-8825-be3a02cd3993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_8d399025-1e70-45ad-9bd4-feef9c8e0ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64116dee-afc9-495b-b56d-08d09b1d7c8b" xlink:to="loc_us-gaap_EquipmentMember_8d399025-1e70-45ad-9bd4-feef9c8e0ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5bd95e20-9bf4-4081-9e1c-081d98d37d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fc0ff5b-9bc6-4b6b-8415-2acb8e7a4a31" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5bd95e20-9bf4-4081-9e1c-081d98d37d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7572d306-f03d-408f-8eee-4cbd22a4f67d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5bd95e20-9bf4-4081-9e1c-081d98d37d0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7572d306-f03d-408f-8eee-4cbd22a4f67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_841a2125-b710-4ba2-aa16-3dff2a7aa155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5bd95e20-9bf4-4081-9e1c-081d98d37d0d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_841a2125-b710-4ba2-aa16-3dff2a7aa155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c77419e1-30dc-46ec-8efe-5adbe6354f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5bd95e20-9bf4-4081-9e1c-081d98d37d0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c77419e1-30dc-46ec-8efe-5adbe6354f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5e3a33b7-6ab3-46ab-b991-1e45963136f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4ff12cdf-10ae-46d5-81b6-24caa30ffc9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5e3a33b7-6ab3-46ab-b991-1e45963136f4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4ff12cdf-10ae-46d5-81b6-24caa30ffc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedPreferredStockDividend_1ab8ec09-09cd-424e-8a5f-b8ac928696a7" xlink:href="crdf-20220331.xsd#crdf_AccruedPreferredStockDividend"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5e3a33b7-6ab3-46ab-b991-1e45963136f4" xlink:to="loc_crdf_AccruedPreferredStockDividend_1ab8ec09-09cd-424e-8a5f-b8ac928696a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedClinicalTrial_c04ec7cc-c708-447f-8ed0-66245f717831" xlink:href="crdf-20220331.xsd#crdf_AccruedClinicalTrial"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5e3a33b7-6ab3-46ab-b991-1e45963136f4" xlink:to="loc_crdf_AccruedClinicalTrial_c04ec7cc-c708-447f-8ed0-66245f717831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedResearchAgreements_b0c624f6-f316-4acd-94d2-c673cfdd77ea" xlink:href="crdf-20220331.xsd#crdf_AccruedResearchAgreements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5e3a33b7-6ab3-46ab-b991-1e45963136f4" xlink:to="loc_crdf_AccruedResearchAgreements_b0c624f6-f316-4acd-94d2-c673cfdd77ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedDirectorFees_4e00ba41-62b1-4d79-ad73-7006dd487a6e" xlink:href="crdf-20220331.xsd#crdf_AccruedDirectorFees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5e3a33b7-6ab3-46ab-b991-1e45963136f4" xlink:to="loc_crdf_AccruedDirectorFees_4e00ba41-62b1-4d79-ad73-7006dd487a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_0df7024b-68a1-4787-b735-b1a167665ad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5e3a33b7-6ab3-46ab-b991-1e45963136f4" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_0df7024b-68a1-4787-b735-b1a167665ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PatentLicenseAndOtherFeesPayable_f14e0b9c-52f7-4450-b67d-35f6b43067af" xlink:href="crdf-20220331.xsd#crdf_PatentLicenseAndOtherFeesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5e3a33b7-6ab3-46ab-b991-1e45963136f4" xlink:to="loc_crdf_PatentLicenseAndOtherFeesPayable_f14e0b9c-52f7-4450-b67d-35f6b43067af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e0d4f9e6-698f-4422-adfd-19742053a61d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5e3a33b7-6ab3-46ab-b991-1e45963136f4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e0d4f9e6-698f-4422-adfd-19742053a61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_33244db5-a550-42a1-bf5f-9c7de9034cf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5e3a33b7-6ab3-46ab-b991-1e45963136f4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_33244db5-a550-42a1-bf5f-9c7de9034cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/Leases" xlink:type="simple" xlink:href="crdf-20220331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5d8a2f1c-bbfb-493c-a9a7-0a0d1609fadd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_9d5489aa-6a56-4ee7-ad30-c876a059b392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5d8a2f1c-bbfb-493c-a9a7-0a0d1609fadd" xlink:to="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_9d5489aa-6a56-4ee7-ad30-c876a059b392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_cedc2fdd-1330-4184-bdfb-25b9cb4876cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5d8a2f1c-bbfb-493c-a9a7-0a0d1609fadd" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_cedc2fdd-1330-4184-bdfb-25b9cb4876cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesTables" xlink:type="simple" xlink:href="crdf-20220331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f8a476a9-2b61-444e-acbe-9184708fa185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_f07b10d0-a895-4bf9-bc63-19ce2558b1b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f8a476a9-2b61-444e-acbe-9184708fa185" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_f07b10d0-a895-4bf9-bc63-19ce2558b1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_25c3a14b-948d-4a28-b20b-6ab6e2ca3bbd" xlink:href="crdf-20220331.xsd#crdf_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f8a476a9-2b61-444e-acbe-9184708fa185" xlink:to="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_25c3a14b-948d-4a28-b20b-6ab6e2ca3bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_64c64422-c3d5-4f3b-a25f-31e1a4ea49ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f8a476a9-2b61-444e-acbe-9184708fa185" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_64c64422-c3d5-4f3b-a25f-31e1a4ea49ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fd7e5018-d0b4-471c-9e44-5f0b38c5a072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAreaOfLease_9c9fd1e9-5cba-42aa-abb6-0f32409aee25" xlink:href="crdf-20220331.xsd#crdf_LesseeOperatingLeaseAreaOfLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fd7e5018-d0b4-471c-9e44-5f0b38c5a072" xlink:to="loc_crdf_LesseeOperatingLeaseAreaOfLease_9c9fd1e9-5cba-42aa-abb6-0f32409aee25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment_924a8d8b-f769-468e-bd24-d91a98431038" xlink:href="crdf-20220331.xsd#crdf_LesseeOperatingLeaseMonthlyRentPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fd7e5018-d0b4-471c-9e44-5f0b38c5a072" xlink:to="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment_924a8d8b-f769-468e-bd24-d91a98431038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_6a004ea9-c258-4322-9cc2-357c7990f893" xlink:href="crdf-20220331.xsd#crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fd7e5018-d0b4-471c-9e44-5f0b38c5a072" xlink:to="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_6a004ea9-c258-4322-9cc2-357c7990f893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorNumberOfSubleases_7f51c85b-3c25-4850-a360-8440c7ebac2d" xlink:href="crdf-20220331.xsd#crdf_LessorNumberOfSubleases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fd7e5018-d0b4-471c-9e44-5f0b38c5a072" xlink:to="loc_crdf_LessorNumberOfSubleases_7f51c85b-3c25-4850-a360-8440c7ebac2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorAreaOfSublease_3d35e2d4-fa2f-4cda-a45b-e9683e9ae649" xlink:href="crdf-20220331.xsd#crdf_LessorAreaOfSublease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fd7e5018-d0b4-471c-9e44-5f0b38c5a072" xlink:to="loc_crdf_LessorAreaOfSublease_3d35e2d4-fa2f-4cda-a45b-e9683e9ae649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8d2d90f5-6eaa-4088-a9e0-5c74f2d6d103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_fb057ad9-baa3-4b74-9356-31205ed8dabb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d2d90f5-6eaa-4088-a9e0-5c74f2d6d103" xlink:to="loc_us-gaap_OperatingLeaseCost_fb057ad9-baa3-4b74-9356-31205ed8dabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_198310c5-deba-41dd-a02d-9e56e7ee0d69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d2d90f5-6eaa-4088-a9e0-5c74f2d6d103" xlink:to="loc_us-gaap_SubleaseIncome_198310c5-deba-41dd-a02d-9e56e7ee0d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_ea985174-b12a-4fe3-a4dc-9392faf627f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d2d90f5-6eaa-4088-a9e0-5c74f2d6d103" xlink:to="loc_us-gaap_LeaseCost_ea985174-b12a-4fe3-a4dc-9392faf627f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8228f6b6-903c-4e71-910a-63afa0e8334c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4a6396c7-ed4a-4bf4-b4f3-8a4a521164a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8228f6b6-903c-4e71-910a-63afa0e8334c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4a6396c7-ed4a-4bf4-b4f3-8a4a521164a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_01613a05-a972-4df4-9c48-df2ea828cb32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8228f6b6-903c-4e71-910a-63afa0e8334c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_01613a05-a972-4df4-9c48-df2ea828cb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2aac94ba-d2c2-4b87-883d-35891f7121e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8228f6b6-903c-4e71-910a-63afa0e8334c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2aac94ba-d2c2-4b87-883d-35891f7121e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7c09a757-af93-4004-97d4-3eefd81fc9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8228f6b6-903c-4e71-910a-63afa0e8334c" xlink:to="loc_us-gaap_OperatingLeaseLiability_7c09a757-af93-4004-97d4-3eefd81fc9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ad35b2b1-6506-4f25-815d-45ea082ce784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8228f6b6-903c-4e71-910a-63afa0e8334c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ad35b2b1-6506-4f25-815d-45ea082ce784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_515f3305-cfe0-464f-a8ef-b99abe711347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8228f6b6-903c-4e71-910a-63afa0e8334c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_515f3305-cfe0-464f-a8ef-b99abe711347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#LeasesSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b31f7e7a-bb40-4364-90a1-f3a2ba6657a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_b673693e-8d3b-4b78-bc1d-a3247d8be6a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b31f7e7a-bb40-4364-90a1-f3a2ba6657a3" xlink:to="loc_us-gaap_OperatingLeasePayments_b673693e-8d3b-4b78-bc1d-a3247d8be6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_334249b2-b6f4-467c-8edb-0d2b60b9c7cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c9b4d105-a08c-4576-ad1d-c641fa79b16f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_334249b2-b6f4-467c-8edb-0d2b60b9c7cf" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c9b4d105-a08c-4576-ad1d-c641fa79b16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7441b6d9-25b5-4c2c-b696-5b26e2dc4b29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c9b4d105-a08c-4576-ad1d-c641fa79b16f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7441b6d9-25b5-4c2c-b696-5b26e2dc4b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b2dba5f9-1619-4d25-a595-3c0326bc0ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c9b4d105-a08c-4576-ad1d-c641fa79b16f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b2dba5f9-1619-4d25-a595-3c0326bc0ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_952b3dab-ddf2-4638-84f8-bfb8b9b1bc48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c9b4d105-a08c-4576-ad1d-c641fa79b16f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_952b3dab-ddf2-4638-84f8-bfb8b9b1bc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bac71930-3717-4ad2-b339-0648a95621e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c9b4d105-a08c-4576-ad1d-c641fa79b16f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bac71930-3717-4ad2-b339-0648a95621e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bf1026d1-3672-45ac-8e6c-5877246dc2e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c9b4d105-a08c-4576-ad1d-c641fa79b16f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bf1026d1-3672-45ac-8e6c-5877246dc2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_07974c37-b1c2-4791-9d9f-b8e85a4495e1" xlink:href="crdf-20220331.xsd#crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c9b4d105-a08c-4576-ad1d-c641fa79b16f" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_07974c37-b1c2-4791-9d9f-b8e85a4495e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_83d1579c-6a6e-4f65-a699-4ad57cf2ab40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c9b4d105-a08c-4576-ad1d-c641fa79b16f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_83d1579c-6a6e-4f65-a699-4ad57cf2ab40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8d1b5af7-34ae-4a59-94bd-20b9c9fa10e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c9b4d105-a08c-4576-ad1d-c641fa79b16f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8d1b5af7-34ae-4a59-94bd-20b9c9fa10e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a9d22afb-eb47-454a-9565-e15a1693d40f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c9b4d105-a08c-4576-ad1d-c641fa79b16f" xlink:to="loc_us-gaap_OperatingLeaseLiability_a9d22afb-eb47-454a-9565-e15a1693d40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="crdf-20220331.xsd#LeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquity" xlink:type="simple" xlink:href="crdf-20220331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e257a18d-6adc-47f0-8b30-1e69cbaa31bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9760f80e-9b12-4d6a-9aed-467c89830531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e257a18d-6adc-47f0-8b30-1e69cbaa31bc" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9760f80e-9b12-4d6a-9aed-467c89830531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="crdf-20220331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_19af7987-5c9e-43ee-abb8-707dc94359a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_761d83a1-a9b9-42fc-a914-1fe59313f864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_19af7987-5c9e-43ee-abb8-707dc94359a0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_761d83a1-a9b9-42fc-a914-1fe59313f864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_03500e0d-7659-4212-8027-8ecbbdbb454e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_19af7987-5c9e-43ee-abb8-707dc94359a0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_03500e0d-7659-4212-8027-8ecbbdbb454e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5b6aaf86-9bca-4e54-9832-5e2eebf2e757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_19af7987-5c9e-43ee-abb8-707dc94359a0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5b6aaf86-9bca-4e54-9832-5e2eebf2e757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_28efae26-7308-4675-b850-6ce091a735e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_19af7987-5c9e-43ee-abb8-707dc94359a0" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_28efae26-7308-4675-b850-6ce091a735e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_0929ea6d-450b-4db7-a1fc-6833d9e68bb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_19af7987-5c9e-43ee-abb8-707dc94359a0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_0929ea6d-450b-4db7-a1fc-6833d9e68bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#StockholdersEquityStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_6960acf2-e83d-43bd-b555-370d7fb7e913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cbcc39f6-c2a7-4a7c-8d67-1f35f887c341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_6960acf2-e83d-43bd-b555-370d7fb7e913" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cbcc39f6-c2a7-4a7c-8d67-1f35f887c341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0d935e4f-4935-4353-a3eb-0b9d14b5c939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cbcc39f6-c2a7-4a7c-8d67-1f35f887c341" xlink:to="loc_us-gaap_AwardTypeAxis_0d935e4f-4935-4353-a3eb-0b9d14b5c939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8ff0f79-d450-4ac9-a6b9-665a8a95e171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0d935e4f-4935-4353-a3eb-0b9d14b5c939" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8ff0f79-d450-4ac9-a6b9-665a8a95e171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cec26356-fdb3-44a2-a48a-eb48fa68f97e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8ff0f79-d450-4ac9-a6b9-665a8a95e171" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cec26356-fdb3-44a2-a48a-eb48fa68f97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_21ac1e4b-1742-48ad-884f-f05852436450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cbcc39f6-c2a7-4a7c-8d67-1f35f887c341" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_21ac1e4b-1742-48ad-884f-f05852436450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b74444ff-b040-48ce-840b-8be1ee54f0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_21ac1e4b-1742-48ad-884f-f05852436450" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b74444ff-b040-48ce-840b-8be1ee54f0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b350abf8-af76-4965-a339-a38ef8cbd631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b74444ff-b040-48ce-840b-8be1ee54f0aa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b350abf8-af76-4965-a339-a38ef8cbd631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_669d71f5-b55a-4a1e-bf9a-a503a0a0337e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b74444ff-b040-48ce-840b-8be1ee54f0aa" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_669d71f5-b55a-4a1e-bf9a-a503a0a0337e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_341a8ebe-f91b-4579-a700-d006109ca06e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cbcc39f6-c2a7-4a7c-8d67-1f35f887c341" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_341a8ebe-f91b-4579-a700-d006109ca06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a528e434-3890-4f1b-81e0-0d777324554e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_341a8ebe-f91b-4579-a700-d006109ca06e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a528e434-3890-4f1b-81e0-0d777324554e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3228de3e-8a9b-46ea-9ebe-02db6f49b8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_341a8ebe-f91b-4579-a700-d006109ca06e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3228de3e-8a9b-46ea-9ebe-02db6f49b8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2ea49ba2-cb5b-4b3e-b38a-d65b9509145d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_341a8ebe-f91b-4579-a700-d006109ca06e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2ea49ba2-cb5b-4b3e-b38a-d65b9509145d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b7c78b40-7f61-435f-85ad-8fe455189ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_341a8ebe-f91b-4579-a700-d006109ca06e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b7c78b40-7f61-435f-85ad-8fe455189ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2982b12c-5ac0-483c-9a02-8853879dc688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_341a8ebe-f91b-4579-a700-d006109ca06e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2982b12c-5ac0-483c-9a02-8853879dc688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#StockholdersEquityStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_ea8ce56f-a7e8-4ebb-8c7a-578139a57bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1353ac01-861d-4aa7-91f8-dda40f97c72c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_ea8ce56f-a7e8-4ebb-8c7a-578139a57bd9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1353ac01-861d-4aa7-91f8-dda40f97c72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b9f6a8a9-1be0-46c2-b585-dcc0b8952201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1353ac01-861d-4aa7-91f8-dda40f97c72c" xlink:to="loc_us-gaap_PlanNameAxis_b9f6a8a9-1be0-46c2-b585-dcc0b8952201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_06a52d62-0e75-4d60-8373-a026e2bfd451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b9f6a8a9-1be0-46c2-b585-dcc0b8952201" xlink:to="loc_us-gaap_PlanNameDomain_06a52d62-0e75-4d60-8373-a026e2bfd451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityIncentivePlan2021Member_caea44a8-767b-4619-8ffc-c1494dd1195b" xlink:href="crdf-20220331.xsd#crdf_EquityIncentivePlan2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_06a52d62-0e75-4d60-8373-a026e2bfd451" xlink:to="loc_crdf_EquityIncentivePlan2021Member_caea44a8-767b-4619-8ffc-c1494dd1195b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_23956523-e1ab-4ccb-9c0f-fb1c8362c909" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1353ac01-861d-4aa7-91f8-dda40f97c72c" xlink:to="loc_us-gaap_AwardTypeAxis_23956523-e1ab-4ccb-9c0f-fb1c8362c909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ea58c02-a737-4b2e-b8d7-b2dd241fa685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_23956523-e1ab-4ccb-9c0f-fb1c8362c909" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ea58c02-a737-4b2e-b8d7-b2dd241fa685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1759ff51-b587-4b1b-8ff0-9f47b70d5f18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ea58c02-a737-4b2e-b8d7-b2dd241fa685" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1759ff51-b587-4b1b-8ff0-9f47b70d5f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_InducementGrantStockOptionsMember_07998213-d4d6-4d66-a032-8cc8de0cb400" xlink:href="crdf-20220331.xsd#crdf_InducementGrantStockOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ea58c02-a737-4b2e-b8d7-b2dd241fa685" xlink:to="loc_crdf_InducementGrantStockOptionsMember_07998213-d4d6-4d66-a032-8cc8de0cb400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1353ac01-861d-4aa7-91f8-dda40f97c72c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_41f85842-6122-49f8-a0af-08f8d15edfa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_41f85842-6122-49f8-a0af-08f8d15edfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41b2732c-2f42-47a9-9976-e5ebcac7bed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_41f85842-6122-49f8-a0af-08f8d15edfa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41b2732c-2f42-47a9-9976-e5ebcac7bed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d18cd2c1-d477-479f-9bbc-f84a6570d2ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_41f85842-6122-49f8-a0af-08f8d15edfa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d18cd2c1-d477-479f-9bbc-f84a6570d2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9dcd14ed-9b5a-48ac-9667-d35a8858685f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_41f85842-6122-49f8-a0af-08f8d15edfa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9dcd14ed-9b5a-48ac-9667-d35a8858685f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_24ffb7ef-0f1f-46d0-a5ce-5e637b373d92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_41f85842-6122-49f8-a0af-08f8d15edfa2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_24ffb7ef-0f1f-46d0-a5ce-5e637b373d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7adcdcb1-8fc3-42f9-974d-6f203427b164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7adcdcb1-8fc3-42f9-974d-6f203427b164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_261ef723-6605-4fe7-b7ac-91aeea52e8d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7adcdcb1-8fc3-42f9-974d-6f203427b164" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_261ef723-6605-4fe7-b7ac-91aeea52e8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1085b501-c3e3-44cd-8e33-5a7445e6adf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7adcdcb1-8fc3-42f9-974d-6f203427b164" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1085b501-c3e3-44cd-8e33-5a7445e6adf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9e4f643f-24be-4710-b672-a5f9b2aa622d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7adcdcb1-8fc3-42f9-974d-6f203427b164" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9e4f643f-24be-4710-b672-a5f9b2aa622d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_60be9f76-10c1-4af4-8efc-8a0b682cdcc7" xlink:href="crdf-20220331.xsd#crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7adcdcb1-8fc3-42f9-974d-6f203427b164" xlink:to="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_60be9f76-10c1-4af4-8efc-8a0b682cdcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_39a93375-6b45-4ef2-ae1a-ef807dc00ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7adcdcb1-8fc3-42f9-974d-6f203427b164" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_39a93375-6b45-4ef2-ae1a-ef807dc00ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a4ee3a66-ea7c-48f3-8043-dc57bbcf6bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a4ee3a66-ea7c-48f3-8043-dc57bbcf6bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_52b56a08-152f-4484-aa6e-0fef06b774aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_52b56a08-152f-4484-aa6e-0fef06b774aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_306c4e68-48f6-40dc-99c0-d2d367772bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_306c4e68-48f6-40dc-99c0-d2d367772bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4955be17-7f0f-4dbe-93bf-6af6f29adb0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_306c4e68-48f6-40dc-99c0-d2d367772bdd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4955be17-7f0f-4dbe-93bf-6af6f29adb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_568db20e-763b-4330-9cbc-dc610427c694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_306c4e68-48f6-40dc-99c0-d2d367772bdd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_568db20e-763b-4330-9cbc-dc610427c694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_076c1d82-1c1b-4647-bca4-74aa36931b8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_306c4e68-48f6-40dc-99c0-d2d367772bdd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_076c1d82-1c1b-4647-bca4-74aa36931b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_5b6d0b07-4c20-4c28-b3b6-062374c3a201" xlink:href="crdf-20220331.xsd#crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_306c4e68-48f6-40dc-99c0-d2d367772bdd" xlink:to="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_5b6d0b07-4c20-4c28-b3b6-062374c3a201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11dd3beb-c118-4d3d-be7d-82b726dceed3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_306c4e68-48f6-40dc-99c0-d2d367772bdd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11dd3beb-c118-4d3d-be7d-82b726dceed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_91bcc323-8c54-40ed-b15b-d72cc71e0753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_91bcc323-8c54-40ed-b15b-d72cc71e0753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b8da8546-6ebb-4169-b640-201af8786002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b8da8546-6ebb-4169-b640-201af8786002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1f8b4e8f-0de5-4b43-a011-f36d17bb1f3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1f8b4e8f-0de5-4b43-a011-f36d17bb1f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3fd78181-ad6d-4ea2-85ef-2827239c2bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1f8b4e8f-0de5-4b43-a011-f36d17bb1f3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3fd78181-ad6d-4ea2-85ef-2827239c2bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_97c47ac5-ed87-47e2-b105-5b7d8a8834b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1f8b4e8f-0de5-4b43-a011-f36d17bb1f3c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_97c47ac5-ed87-47e2-b105-5b7d8a8834b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_619740f7-5a13-4c36-8aff-037728df4d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1f8b4e8f-0de5-4b43-a011-f36d17bb1f3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_619740f7-5a13-4c36-8aff-037728df4d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_77cc7a3f-2ea8-409f-ad6b-639b4db21689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_77cc7a3f-2ea8-409f-ad6b-639b4db21689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b81b16d0-8ec7-4fde-a096-27d79a971109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5605f39b-a8e4-4ca9-9e20-c503949ebfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b81b16d0-8ec7-4fde-a096-27d79a971109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#StockholdersEquityWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_49334db6-e64d-4671-a4ce-3f90a087bfc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsAndRightsRollForward_3cc98576-7bce-4058-8064-d6aa784ee352" xlink:href="crdf-20220331.xsd#crdf_WarrantsAndRightsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_49334db6-e64d-4671-a4ce-3f90a087bfc7" xlink:to="loc_crdf_WarrantsAndRightsRollForward_3cc98576-7bce-4058-8064-d6aa784ee352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_408d8ef0-f52c-4b04-bdbd-49d6f28a3ebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_WarrantsAndRightsRollForward_3cc98576-7bce-4058-8064-d6aa784ee352" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_408d8ef0-f52c-4b04-bdbd-49d6f28a3ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e279ebc7-f109-4b03-a96c-5cfda7485ebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_WarrantsAndRightsRollForward_3cc98576-7bce-4058-8064-d6aa784ee352" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e279ebc7-f109-4b03-a96c-5cfda7485ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_db696344-8660-4c4c-ae94-2735ad0dedba" xlink:href="crdf-20220331.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_49334db6-e64d-4671-a4ce-3f90a087bfc7" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_db696344-8660-4c4c-ae94-2735ad0dedba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c6cd26fc-50b6-46c8-94a4-024a9acc6e33" xlink:href="crdf-20220331.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_db696344-8660-4c4c-ae94-2735ad0dedba" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c6cd26fc-50b6-46c8-94a4-024a9acc6e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_8a52b08d-2860-49da-b3b4-02cc606bde5c" xlink:href="crdf-20220331.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_db696344-8660-4c4c-ae94-2735ad0dedba" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_8a52b08d-2860-49da-b3b4-02cc606bde5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_358920a1-afff-4e99-b4e6-ed1cf2df4e8e" xlink:href="crdf-20220331.xsd#crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_49334db6-e64d-4671-a4ce-3f90a087bfc7" xlink:to="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_358920a1-afff-4e99-b4e6-ed1cf2df4e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_df408dc5-875e-4d4d-bbf5-5307002ddd5d" xlink:href="crdf-20220331.xsd#crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_358920a1-afff-4e99-b4e6-ed1cf2df4e8e" xlink:to="loc_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_df408dc5-875e-4d4d-bbf5-5307002ddd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="crdf-20220331.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_552cc140-006d-4e46-bc8b-cac8d30bad19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_459dba2d-deb7-4371-b75d-8c3ce5e0af97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_552cc140-006d-4e46-bc8b-cac8d30bad19" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_459dba2d-deb7-4371-b75d-8c3ce5e0af97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_655b5733-d0ee-45c1-8d14-58a0324b13d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_459dba2d-deb7-4371-b75d-8c3ce5e0af97" xlink:to="loc_us-gaap_StatementClassOfStockAxis_655b5733-d0ee-45c1-8d14-58a0324b13d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1b57d584-e736-4800-98a8-21262d896b63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_655b5733-d0ee-45c1-8d14-58a0324b13d9" xlink:to="loc_us-gaap_ClassOfStockDomain_1b57d584-e736-4800-98a8-21262d896b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesAConvertiblePreferredStockMember_a481938b-5a1d-4f5d-902e-99daaa17383d" xlink:href="crdf-20220331.xsd#crdf_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1b57d584-e736-4800-98a8-21262d896b63" xlink:to="loc_crdf_SeriesAConvertiblePreferredStockMember_a481938b-5a1d-4f5d-902e-99daaa17383d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesBConvertiblePreferredStockMember_aa36d1a6-8099-4bc1-b294-db17a3f6567b" xlink:href="crdf-20220331.xsd#crdf_SeriesBConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1b57d584-e736-4800-98a8-21262d896b63" xlink:to="loc_crdf_SeriesBConvertiblePreferredStockMember_aa36d1a6-8099-4bc1-b294-db17a3f6567b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_1b7d0621-1ea2-4b1f-af86-9a17200356ad" xlink:href="crdf-20220331.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1b57d584-e736-4800-98a8-21262d896b63" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_1b7d0621-1ea2-4b1f-af86-9a17200356ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_fe870016-72a4-495e-ae7e-a222c0951f9a" xlink:href="crdf-20220331.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1b57d584-e736-4800-98a8-21262d896b63" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_fe870016-72a4-495e-ae7e-a222c0951f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_24cf2d36-8d94-4cdd-a014-3e41e0436216" xlink:href="crdf-20220331.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1b57d584-e736-4800-98a8-21262d896b63" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_24cf2d36-8d94-4cdd-a014-3e41e0436216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_18cf1321-28ae-476c-8ed3-a921fc1710b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_459dba2d-deb7-4371-b75d-8c3ce5e0af97" xlink:to="loc_us-gaap_ClassOfStockLineItems_18cf1321-28ae-476c-8ed3-a921fc1710b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7567cbb3-084c-40f5-b3b0-843d7b99ace1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18cf1321-28ae-476c-8ed3-a921fc1710b2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7567cbb3-084c-40f5-b3b0-843d7b99ace1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c3b7d7ec-95d1-4717-9e53-58d15831a0a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18cf1321-28ae-476c-8ed3-a921fc1710b2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c3b7d7ec-95d1-4717-9e53-58d15831a0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_87bdd132-021e-41ae-9c28-7b8c3ad78a3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18cf1321-28ae-476c-8ed3-a921fc1710b2" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_87bdd132-021e-41ae-9c28-7b8c3ad78a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6af82d1f-1587-4a20-b15c-1c7bed00659e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18cf1321-28ae-476c-8ed3-a921fc1710b2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6af82d1f-1587-4a20-b15c-1c7bed00659e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="crdf-20220331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e76b566a-35b6-43aa-ad9d-ed13ff7cd863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_77189401-1291-4ebd-bd6c-11d577765fce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e76b566a-35b6-43aa-ad9d-ed13ff7cd863" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_77189401-1291-4ebd-bd6c-11d577765fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655661353064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CARDIFF ONCOLOGY,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-2004382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11055 Flintkote Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">952-7570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRDF<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,306,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001213037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655660853048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 20,052<span></span>
</td>
<td class="nump">$ 11,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">109,310<span></span>
</td>
<td class="nump">128,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable and unbilled receivable</a></td>
<td class="nump">447<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,997<span></span>
</td>
<td class="nump">4,771<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">135,806<span></span>
</td>
<td class="nump">146,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">550<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,660<span></span>
</td>
<td class="nump">2,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">139,204<span></span>
</td>
<td class="nump">149,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,261<span></span>
</td>
<td class="nump">1,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">4,738<span></span>
</td>
<td class="nump">4,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">665<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,664<span></span>
</td>
<td class="nump">6,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">2,438<span></span>
</td>
<td class="nump">2,568<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">9,102<span></span>
</td>
<td class="nump">9,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, 20,000 shares authorized; (Note 6)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 150,000 shares authorized; 43,306 and 41,964 shares issued and outstanding at March&#160;31, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">401,655<span></span>
</td>
<td class="nump">400,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ServiceReceivable', window );">Service receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(748)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(270,809)<span></span>
</td>
<td class="num">(259,810)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">130,102<span></span>
</td>
<td class="nump">140,417<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 139,204<span></span>
</td>
<td class="nump">$ 149,544<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ServiceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ServiceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655661457832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">43,306,000<span></span>
</td>
<td class="nump">41,964,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">43,306,000<span></span>
</td>
<td class="nump">41,964,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655661305368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalties</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">7,208<span></span>
</td>
<td class="nump">3,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">3,940<span></span>
</td>
<td class="nump">2,235<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">11,148<span></span>
</td>
<td class="nump">5,514<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(11,074)<span></span>
</td>
<td class="num">(5,442)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income, net</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) from change in fair value of derivative financial instruments&#8212;warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,993)<span></span>
</td>
<td class="num">(5,179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (10,999)<span></span>
</td>
<td class="num">$ (5,185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding - basic (in shares)</a></td>
<td class="nump">43,231<span></span>
</td>
<td class="nump">37,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding - diluted (in shares)</a></td>
<td class="nump">43,231<span></span>
</td>
<td class="nump">37,164<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655666551960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (10,993)<span></span>
</td>
<td class="num">$ (5,179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on securities available-for-sale</a></td>
<td class="num">(606)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">(11,599)<span></span>
</td>
<td class="num">(5,246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic', window );">Comprehensive loss attributable to common stockholders</a></td>
<td class="num">$ (11,605)<span></span>
</td>
<td class="num">$ (5,252)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comprehensive Income (Loss) Available To Common Stockholders, Basic</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655662841032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Service Receivable</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income/(Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716<span></span>
</td>
<td class="nump">36,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2020</a></td>
<td class="nump">$ 128,158<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 361,819<span></span>
</td>
<td class="num">$ (2,171)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (231,495)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">1,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss)</a></td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="nump">380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,179)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,179)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716<span></span>
</td>
<td class="nump">37,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Mar. 31, 2021</a></td>
<td class="nump">124,817<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">363,350<span></span>
</td>
<td class="num">(1,791)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="num">(236,680)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716<span></span>
</td>
<td class="nump">41,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2021</a></td>
<td class="nump">140,417<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">400,503<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="num">(259,810)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss)</a></td>
<td class="num">(606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series E Convertible Preferred Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(328)<span></span>
</td>
<td class="nump">1,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series E Convertible Preferred Stock</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,993)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="nump">43,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Mar. 31, 2022</a></td>
<td class="nump">$ 130,102<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 401,655<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (748)<span></span>
</td>
<td class="num">$ (270,809)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ReleaseOfClinicalTrialFundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Release Of Clinical Trial Funding Commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ReleaseOfClinicalTrialFundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares issued during the period upon cash exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity impact during the period due to the cash exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655666585464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (10,993)<span></span>
</td>
<td class="num">$ (5,179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,152<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums on short-term investments</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative financial instruments&#8212;warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived', window );">Release of clinical trial funding commitment</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable and unbilled receivable</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other assets</a></td>
<td class="num">(1,141)<span></span>
</td>
<td class="num">(183)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,421)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(42)<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(10,249)<span></span>
</td>
<td class="num">(5,884)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(171)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of short-term investments</a></td>
<td class="nump">38,217<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of short-term investments</a></td>
<td class="num">(36,773)<span></span>
</td>
<td class="num">(114,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of short-term investments</a></td>
<td class="nump">17,085<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">18,358<span></span>
</td>
<td class="num">(111,698)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">8,109<span></span>
</td>
<td class="num">(116,319)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents&#8212;Beginning of period</a></td>
<td class="nump">11,943<span></span>
</td>
<td class="nump">130,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents&#8212;End of period</a></td>
<td class="nump">20,052<span></span>
</td>
<td class="nump">14,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flow activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Acquisition of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_PreferredStockDividendAccrued', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_PreferredStockDividendAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of preferred stock dividend accrued during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_PreferredStockDividendAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Release Of Clinical Trial Funding Commitment For Services Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655665319544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Organization and Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology, Inc. (&#8220;Cardiff Oncology&#8221; or the &#8220;Company&#8221;) headquartered in San Diego, California, is a clinical-stage biotechnology company leveraging Polo-like Kinase 1 (&#8220;PLK1&#8221;) inhibition to develop novel therapies across a range of cancers with the greatest unmet medical need, including KRAS-mutated metastatic colorectal cancer, metastatic pancreatic cancer and metastatic castration-resistant prostate cancer. The Company's common stock is listed on the Nasdaq Capital Market under the ticker symbol "CRDF".</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and the rules&#160;and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form&#160;10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules&#160;and regulations. The unaudited interim condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company&#8217;s financial position and the results of its operations and cash flows for the periods presented. The unaudited condensed balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December&#160;31, 2021 included in the Company&#8217;s annual report on Form&#160;10-K filed with the SEC on February&#160;24, 2022.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net losses since its inception and has negative operating cash flows. As of March&#160;31, 2022, the Company had $129.4&#160;million in cash, cash equivalents and short-term investments and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.  </span></div>For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#8217;s stockholders may experience additional dilution.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655665303368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, there have been no changes to the Company&#8217;s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share. </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,467,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,300,897&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,025,380&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncement</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04 ("ASU 2021-04"), Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company has prospectively adopted this standard as of January 1, 2022 for periods presented after the adoption. The adoption of ASU 2021-04 did not have a material impact on the Company's financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncement Not Yet Adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023 for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655665297448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of March&#160;31, 2022 and December&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,824&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,029&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments (1)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments (1)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,036&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,868&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Included in short-term investments in the accompanying balance sheets. </span></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 3 during the three months ended March 31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655665195928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Supplementary Balance Sheet Information</a></td>
<td class="text">Supplementary Balance Sheet Information<div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available for sale consist of the following: </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity less than 1 year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,906&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,410&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity 1 to 2 years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity 1 to 2 years</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(753)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity less than 1 year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity 1 to 2 years:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity 1 to 2 years</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,823&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,472)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Liabilities</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research agreements and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and outside services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent, license and other fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,527&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655665398488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As a lessee, the Company&#8217;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Facility Lease</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently leases 12,300 square feet of office and lab space in San Diego that expires on February 28, 2027. The lease currently requires monthly payments of approximately $60,000 per month with 3% annual escalation.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Subleases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and subleased the space to third parties under three separate sublease agreements, which all expired on December 31, 2021. Prior to the expiration of the sublease agreements, the Company as a sublessor was leasing approximately 16,600 square feet of space to third parties.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,438&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,568&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the three months ended March&#160;31, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(576)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As a lessee, the Company&#8217;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Facility Lease</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently leases 12,300 square feet of office and lab space in San Diego that expires on February 28, 2027. The lease currently requires monthly payments of approximately $60,000 per month with 3% annual escalation.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Subleases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and subleased the space to third parties under three separate sublease agreements, which all expired on December 31, 2021. Prior to the expiration of the sublease agreements, the Company as a sublessor was leasing approximately 16,600 square feet of space to third parties.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,438&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,568&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the three months ended March&#160;31, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(576)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph Note 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph Note 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888252<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655665199768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in research and development expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in selling, general and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized compensation cost related to non-vested stock options outstanding at March&#160;31, 2022, net of estimated forfeitures, was $13.3 million, which is expected to be recognized over a weighted-average remaining vesting period of 3.2 years.&#160;The weighted-average remaining contractual term of outstanding options as of March&#160;31, 2022 was approximately 8.3 years. The total fair value of stock options vested during the three months ended March 31, 2022 and 2021 were $1,000 and $24,000, respectively.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No stock options were granted during the three months ended March 31, 2021. </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and changes in stock options outstanding is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,771,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,405,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled / Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,467,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281,362&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,331,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Equity Incentive Plan</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 the Company's stockholders approved the 2021 Omnibus Equity Incentive Plan ("2021 Plan"). The number of authorized shares in the 2021 Plan is equal to the sum of (i) 3,150,000 shares, plus (ii) the number of shares of Common Stock reserved, but unissued under the 2014 Plan; and (iii) the number of shares of Common Stock underlying forfeited awards under the 2014 Plan. As of March&#160;31, 2022, there were 918,865 shares available for issuance under the 2021 Plan. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2014 Equity Incentive Plan</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the adoption of the 2021 Plan, no additional equity awards can be made under the terms of the 2014 Plan. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inducement Grants</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company began issuing equity awards to certain new employees as inducement grants outside of its 2021 Plan. As of March&#160;31, 2022, an aggregate of 1,120,208 shares were issuable upon the exercise of inducement grant stock options approved by the Company.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.008%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining&#160;Contractual<br/>Term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490,159&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 years</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our Company's classes of preferred stock is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares designated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation preference</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655665337272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development and Clinical Trial Agreements</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib. Onvansertib, an investigational drug, is an oral, and a highly selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK1. The Company is developing onvansertib in cancer indications with the greatest medical need for new treatment options. Terms of the agreement provide for the Company to pay development milestones and royalties based on sales volume.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of oncology therapeutics. These agreements include License fees, Royalties and Milestone payments. The Company also has a legacy license agreement in the field of oncology diagnostics under which royalty payments are due. These royalty payments are calculated as a percent of revenue. For the three months ended March&#160;31, 2022 and 2021, payments have not been material.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm the Company&#8217;s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company&#8217;s business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655766039160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncement and Recent Accounting Pronouncement Not Yet Adopted</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncement</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04 ("ASU 2021-04"), Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company has prospectively adopted this standard as of January 1, 2022 for periods presented after the adoption. The adoption of ASU 2021-04 did not have a material impact on the Company's financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncement Not Yet Adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023 for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655665326872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,467,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,300,897&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,025,380&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655665367032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of the Company&#8217;s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of March&#160;31, 2022 and December&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,824&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,029&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments (1)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments (1)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,036&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,868&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>(1) Included in short-term investments in the accompanying balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655746781032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Investments Available-for-sale</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available for sale consist of the following: </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity less than 1 year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,906&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,410&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity 1 to 2 years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity 1 to 2 years</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(753)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity less than 1 year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity 1 to 2 years:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity 1 to 2 years</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Components of Property and Equipment</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,823&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,472)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research agreements and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and outside services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent, license and other fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,527&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655666288280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Expense and Supplemental Cash Flow Information</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,438&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,568&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Payments</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the three months ended March&#160;31, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(576)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655660865800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in research and development expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in selling, general and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions to Estimate Fair Value of Stock Option Awards</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity and of Changes in Stock Options Outstanding</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and changes in stock options outstanding is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,771,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,405,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled / Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,467,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281,362&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,331,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrant Activity and Changes in Warrants Outstanding</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.008%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining&#160;Contractual<br/>Term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490,159&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Preferred Stock</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our Company's classes of preferred stock is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares designated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation preference</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655666682488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 129.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655662592760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">11,300,897<span></span>
</td>
<td class="nump">9,025,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">5,467,611<span></span>
</td>
<td class="nump">1,849,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">4,490,159<span></span>
</td>
<td class="nump">4,490,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember', window );">Series&#160;A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crdf_SeriesEConvertiblePreferredStockMember', window );">Series&#160;E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">1,342,250<span></span>
</td>
<td class="nump">2,684,607<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crdf_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crdf_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655657397224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value of Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">$ 109,310<span></span>
</td>
<td class="nump">$ 128,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">19,029<span></span>
</td>
<td class="nump">10,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">109,310<span></span>
</td>
<td class="nump">128,878<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">128,339<span></span>
</td>
<td class="nump">139,868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">9,239<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">69,664<span></span>
</td>
<td class="nump">88,390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">10,468<span></span>
</td>
<td class="nump">14,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">19,939<span></span>
</td>
<td class="nump">24,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Money market fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">15,824<span></span>
</td>
<td class="nump">10,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">3,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">15,824<span></span>
</td>
<td class="nump">10,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">19,939<span></span>
</td>
<td class="nump">24,046<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">35,763<span></span>
</td>
<td class="nump">35,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">19,939<span></span>
</td>
<td class="nump">24,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Money market fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">15,824<span></span>
</td>
<td class="nump">10,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">3,205<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">89,371<span></span>
</td>
<td class="nump">104,832<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">92,576<span></span>
</td>
<td class="nump">104,832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">9,239<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">69,664<span></span>
</td>
<td class="nump">88,390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">10,468<span></span>
</td>
<td class="nump">14,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Money market fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">3,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Money market fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655660119048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information - Investments Available-for-sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">$ 94,906<span></span>
</td>
<td class="nump">$ 95,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(501)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="nump">94,410<span></span>
</td>
<td class="nump">95,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract', window );"><strong>Maturity 1 to 2 years:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized Cost</a></td>
<td class="nump">15,152<span></span>
</td>
<td class="nump">33,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(252)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Fair Market Value</a></td>
<td class="nump">14,900<span></span>
</td>
<td class="nump">33,294<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">110,058<span></span>
</td>
<td class="nump">129,020<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(753)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">109,310<span></span>
</td>
<td class="nump">128,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">9,250<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="nump">9,239<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">55,056<span></span>
</td>
<td class="nump">58,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(293)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="nump">54,764<span></span>
</td>
<td class="nump">58,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract', window );"><strong>Maturity 1 to 2 years:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized Cost</a></td>
<td class="nump">15,152<span></span>
</td>
<td class="nump">29,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(252)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Fair Market Value</a></td>
<td class="nump">14,900<span></span>
</td>
<td class="nump">29,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">10,539<span></span>
</td>
<td class="nump">14,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="nump">10,468<span></span>
</td>
<td class="nump">14,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">20,061<span></span>
</td>
<td class="nump">20,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(122)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="nump">$ 19,939<span></span>
</td>
<td class="nump">20,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract', window );"><strong>Maturity 1 to 2 years:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Fair Market Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,690<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655660089256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and depreciation and amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 4,022<span></span>
</td>
<td class="nump">$ 3,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less&#8212;accumulated depreciation and amortization</a></td>
<td class="num">(3,472)<span></span>
</td>
<td class="num">(3,441)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">550<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and depreciation and amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,064<span></span>
</td>
<td class="nump">955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and depreciation and amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,046<span></span>
</td>
<td class="nump">1,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and depreciation and amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 912<span></span>
</td>
<td class="nump">$ 906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655662793256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 878<span></span>
</td>
<td class="nump">$ 1,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_AccruedPreferredStockDividend', window );">Preferred stock dividend</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_AccruedClinicalTrial', window );">Clinical trials</a></td>
<td class="nump">2,110<span></span>
</td>
<td class="nump">1,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_AccruedResearchAgreements', window );">Research agreements and services</a></td>
<td class="nump">992<span></span>
</td>
<td class="nump">726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_AccruedDirectorFees', window );">Director fees</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees and outside services</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_PatentLicenseAndOtherFeesPayable', window );">Patent, license and other fees</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 4,738<span></span>
</td>
<td class="nump">$ 4,527<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AccruedClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AccruedClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AccruedDirectorFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued director fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AccruedDirectorFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AccruedPreferredStockDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Preferred Stock Dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AccruedPreferredStockDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AccruedResearchAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AccruedResearchAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_PatentLicenseAndOtherFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent, license and other fees payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_PatentLicenseAndOtherFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655666071928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>lease</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseAreaOfLease', window );">Area of lease</a></td>
<td class="nump">12,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseMonthlyRentPayment', window );">Monthly rent payments | $</a></td>
<td class="nump">$ 60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage', window );">Annual rent increase, percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LessorNumberOfSubleases', window );">Number of subleases | lease</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LessorAreaOfSublease', window );">Area of sublease</a></td>
<td class="nump">16,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Rent Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseAreaOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area Of Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseAreaOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseMonthlyRentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Rent Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseMonthlyRentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LessorAreaOfSublease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessor, Area Of Sublease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LessorAreaOfSublease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LessorNumberOfSubleases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessor, Number Of Subleases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LessorNumberOfSubleases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655666493272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 191<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Operating sublease income</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net operating lease cost</a></td>
<td class="nump">$ 191<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655662576984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets</a></td>
<td class="nump">$ 2,660<span></span>
</td>
<td class="nump">$ 2,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">665<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">2,438<span></span>
</td>
<td class="nump">2,568<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 3,103<span></span>
</td>
<td class="nump">$ 3,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term&#8211;operating leases</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate&#8211;operating leases</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655665296600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655660092072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (excluding the three months ended March&#160;31, 2022)</a></td>
<td class="nump">$ 480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">3,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 3,103<span></span>
</td>
<td class="nump">$ 3,119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655657358952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation expense</a></td>
<td class="nump">$ 1,152<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Options vested, fair value</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation expense</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation expense</a></td>
<td class="nump">817<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 13,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining vesting period for recognition</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average contractual life</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655659893240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized shares under the plan (in shares)</a></td>
<td class="nump">3,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">106.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">3,771,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,697,536<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled / Forfeited (in shares)</a></td>
<td class="num">(1,109)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance outstanding at the end of the period (in shares)</a></td>
<td class="nump">5,467,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
<td class="nump">1,281,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">5,331,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance outstanding at the beginning of the period (in USD per share)</a></td>
<td class="nump">$ 7.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">3.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled / Forfeited (in USD per share)</a></td>
<td class="nump">31.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice', window );">Expired (in USD per share)</a></td>
<td class="nump">165.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance outstanding at the end of the period (in USD per share)</a></td>
<td class="nump">5.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in USD per share)</a></td>
<td class="nump">8.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in USD per share)</a></td>
<td class="nump">$ 5.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, intrinsic value</a></td>
<td class="nump">$ 65,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,405,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at the end of the period, intrinsic value</a></td>
<td class="nump">25,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, intrinsic value</a></td>
<td class="nump">$ 61,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=crdf_InducementGrantStockOptionsMember', window );">Inducement Grant Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,120,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=crdf_EquityIncentivePlan2021Member', window );">Equity Incentive Plan 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of remaining shares available for issuance (in shares)</a></td>
<td class="nump">918,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=crdf_InducementGrantStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=crdf_InducementGrantStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=crdf_EquityIncentivePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=crdf_EquityIncentivePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655661453592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_WarrantsAndRightsRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the end of the period (in shares)</a></td>
<td class="nump">4,490,159<span></span>
</td>
<td class="nump">4,490,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">4,490,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted average exercise price of warrants at the beginning of the period (in USD per share)</a></td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted average exercise price of warrants at the end of the period (in USD per share)</a></td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract', window );"><strong>Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights', window );">Weighted-Average Remaining&#160;Contractual Term</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period over which each class of warrants or rights outstanding may be exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of each class of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>No definition available</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_WarrantsAndRightsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_WarrantsAndRightsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140655662928232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Preferred Stock (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">277,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation preference</a></td>
<td class="nump">$ 606,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">60,600<span></span>
</td>
<td class="nump">60,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">8,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">154,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember', window );">Series&#160;E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">865,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">327,509<span></span>
</td>
<td class="nump">655,044<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>crdf-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:crdf="http://www.cardiffoncology.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="crdf-20220331.xsd" xlink:type="simple"/>
    <context id="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0d160d05433642bf890809b8d47f76c6_I20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2022-04-28</instant>
        </period>
    </context>
    <context id="i3e26e9a60f67478f930bec7f58534ab7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i80a10fb9a55041acbf4471eb9962b140_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i032d3c2391934b749d64c1001f146392_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i530e82542d9e45d284f2f86beacf61bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3746cafcf2464a6a8c86d7eeb2da15d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icbd660f941704d6eab498635e1633e0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0a34f4133324ecabf8ccf476f867efd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4da4e68a38249baac1d08460527a5c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i695a8c3be21242d3b5f355d90d3cee60_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i64b5359a6ff94b8faf437365a08b98b6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i00db47d4a17244ed896d6417ea6ac008_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i68f4a1bcda064a5784195b33875c7f57_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib3f2263cd87445ec9f6781abaf9f567f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id5fe0cd6cb50486ea568f476234e2e09_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie675592e1c2a40919a88e24c67261742_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1fcbabbd465940f7b361a479d927b2ca_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i70185ba0bc824fbeb9be808cdb911645_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i545e543142c7462abbd863aff074c5b1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3cc592d0c43c4571aca1097e49d8d129_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i91922e2e89cf4c61aa12f0520d1a5742_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibad6d99cf2f840ce9e7bed2d46e20230_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3bfbf7525a84c06a46b8b822cc8c9fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia0ece49122944a43b7c858a41e13bb5f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a5aae261a9942dea72ffd742b0669b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62458f79e8c5489190ae1d0a860182dc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i750dda3cd9b44f1d95a8ef8698d47bcd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf90f6cfceb846aba68cc0e11216576a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2e7fab3163147ac9e9e0c75f6a432ba_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i206e5d41255345cda79ffb2da56624ac_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i012412a3facb44e1a372eb4e99387bea_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i00079f3fd1654534b9dde967f3160fd3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4d9db9e17c6040a4b40aed1bd2c626fd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4756a6ec761647b6a76e977ae5e7ba32_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5c9b59d1f3d947e2bf304d747c2fdeaa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icd5fcea7daf5472c942b8b78378634ef_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i337b2454b9f14ec396bcb5ac1c5a5a1b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie2fa9347524245c1b46dea90d3bd28ac_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i60d1d6fb130c4369b0c92df1975e7d55_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if6173183c9dc4f8f8a0e7a419a06718b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if15a941225894f6199ee7c21ae8d06e0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i295d5bedf87e4485addec2ccf76b8eb2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i292c08a55ac045e4b69997f574dcf6c0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iadba25c9d3794ecf9349907eb7230ee7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4754a5ec9f3b4484a5792b7e7576b9b2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaa80755e562d42a3862c7b9fb1a195f6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i402afd8930894e8dad31ee8ead92c780_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie176e42f42d040008fabaab3e6fc944b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib5f29ec37e5044118f1345ab67b4bfe0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i858aaf4aebaa477690f541f5cef242e3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ice8e727de3934bce8949d0a1f8de0a1f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaa2aec20dcbb4e11a14fa3594fae5f15_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iec0c5fbc68b74c27a7ff40151b92b5ee_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifeaaebfbfd564b33828c67ca78b8c766_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i760860b7d95142e6a5f23bd5db8a0e83_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id0c6edc4fe34456ca0daf70b67b95445_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7bc7648a25f047e89409bd461a324502_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib787e125147a4fae952c9425271b6f7c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie08212cc90ef4e709206336ccf149313_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9b8194a586f841738340b39f3d565848_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iacb52739ae184a00938aabdbe0bb4cdd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia4acf9b35e314e309ef0816d4754a15a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia453d0061bfb48fcaaabd8e50791523b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i18725cb77e8f4c02b2f1432d16e20612_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i16a7736ec34f4acb84606918dacb73af_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i74a2163cb8414bdcba39fea19a1148e6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icd7a7fe09574445a9ea6fbc3ee035b54_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1047e58df41b40d0b4e2422be90e9b1c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7137fd6fa9e84f46828d43b1c2cccb6e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if75dd8412dd548f2b9e9b67adbe7e3d5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id749a1f0c6be4b368e444ace5f891487_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i38ee8c9b1c2244608a7990d422050c94_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9512c3da93e34771b7bdaff0723660ea_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7d4747ed58c947ea9a3f145a4ab45200_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i572626db256d435291fe5c0afb9d041f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie6e2de4855d74f7d86a9c98ab283751a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i28c89bf87ce14cca9b2b800346e0f3cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i876b48d168b94c078324d718cfdcc6b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99895349e572414c90c807f0e0e17ebb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i547b6800236a4e0caab1382e2230e08a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c4033bd7f2c4aeb9ee5d73233cec607_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4977728e4fe6441a934b69b20c984428_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6ff28c3628c9439f9476dce8d023e9a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f1aebf312994daaa324ca44ae909873_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie28739979eeb42ef9ba44e6345bbce01_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0548bc72c9014a57a21548990a80dc6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i966397496b06482ea36f27e6d9813468_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8358790f990b4c0eb465115ec36b4bad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i141fc564298749ef90e593b383c7b4dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i703f601f436b43d49b1a487d4d19c8db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i457626d4907642ed957f6fa275972b86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf6c73f105ea4cf5b84fc6c9051918ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88f18fc910f945858e3b8bc20c69c3a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0fc6fa6aba914b51a5f862c4592ff78c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaad7930c0f094358b1f79e8717bc3ded_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb33f7c370f04ac9b542a1d9ce2740d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d8ce90d2f4242aebc0947a200a14d74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i978107023461439f9c9388246fe5f1d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i077d5e0a95724189b2ed4ff9de4ca7b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53718eacdc59401eb030bde33ae601c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67fc8a821a934707ad82e4a6523c6f04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i045f3a1f97f64eebba51a12fff7e25ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieeff0db315444d1fa011989d0832b897_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80595d8a12bd44fdbc458c86f92eaf8d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3fedefbb21504c7c9d24ef677e84d271_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9a1e4ef065b44bde91fa2353faafba2d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iab946214765844419385e846f2f071c4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9c3e566014904bf0849ff752d63a833b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5cc8b81d6dec439faf2b7a1516cbae4f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibaf3870ca7e245d39bb917baeb589cfd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ea1c1903a66482189db39519fa9ab69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i147c926c319848eda463b6b78b8ba88c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d9c1d34a1db4e9fb7d337599646fa44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad1db42d1d374f53989a2e7eb3b57555_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i76184d10cb394f4ea42385613d47f3a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2fec98606e0d4c2f815d907fbfd712cd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iafe44b0f34c648c084e4cb969b1c99e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i86dfda88f61d4ab88a4b5f4a3dea2526_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4794d63837f04ab3a7126147249402b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf31e53b9d2d45af97ed7cc8c45e4d49_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaba2a240dd3945df929b606e4db832e0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5acd44d9cbae440c822b1c7ee063d0e2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic7a9e753b3734856bcedf3f9838179e0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i893461f644cf442b9cd2137dff555003_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3b15932b484a471ebbfef330aba8275d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic7a27c0297d5482cbcaf83e2e3556d4b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2401c06088e64dc38c0c80a779717d55_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crdf:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i75f4f015594a4bbf8dbbe4dfa4bb7c12_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crdf:InducementGrantStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i005b644829964efaa7d10c5ad40cdf4e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifdc2b0e256004062aef3e08c666721e1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i59573fd142404a38a175c7870f55419f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc3f3107c69b4f6b8dd87b5fdf51dfff_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3b017a6f753f436d9ec2f214f9ebe2f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2bbf49ad684a421fbea0a38b95540cc1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5be5174c9fb344c9a625c79d662f8c80_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49b6a8dfc660406a91d6569610ca4915_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic8d76d5beb354ae2a99c506c37bfe260_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e7fca4604c9471d93e4d2007ee915b4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4b1336fa1dbf42329f000675cc7b21f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="lease">
        <measure>crdf:lease</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80L2ZyYWc6OGIyYjczNGU0ZGJjNDAyNjg1ZWEyYjk3ZjA2MmQ2YWYvdGFibGU6ODBkMzg0MTg0MjBkNGEyZjhjZDlhYzhiZTFmM2Q2MjAvdGFibGVyYW5nZTo4MGQzODQxODQyMGQ0YTJmOGNkOWFjOGJlMWYzZDYyMF80LTEtMS0xLTI3NzQy_afa3e69a-116a-4cb8-abc9-13a091b58940">0001213037</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80L2ZyYWc6OGIyYjczNGU0ZGJjNDAyNjg1ZWEyYjk3ZjA2MmQ2YWYvdGFibGU6ODBkMzg0MTg0MjBkNGEyZjhjZDlhYzhiZTFmM2Q2MjAvdGFibGVyYW5nZTo4MGQzODQxODQyMGQ0YTJmOGNkOWFjOGJlMWYzZDYyMF83LTEtMS0xLTI3NzQy_05a2fc3b-6df4-4bcc-b15a-b87a02b0007b">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80L2ZyYWc6OGIyYjczNGU0ZGJjNDAyNjg1ZWEyYjk3ZjA2MmQ2YWYvdGFibGU6ODBkMzg0MTg0MjBkNGEyZjhjZDlhYzhiZTFmM2Q2MjAvdGFibGVyYW5nZTo4MGQzODQxODQyMGQ0YTJmOGNkOWFjOGJlMWYzZDYyMF84LTEtMS0xLTI3NzQy_4fa6862c-03a0-42c8-b090-80a464fd4f5f">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80L2ZyYWc6OGIyYjczNGU0ZGJjNDAyNjg1ZWEyYjk3ZjA2MmQ2YWYvdGFibGU6ODBkMzg0MTg0MjBkNGEyZjhjZDlhYzhiZTFmM2Q2MjAvdGFibGVyYW5nZTo4MGQzODQxODQyMGQ0YTJmOGNkOWFjOGJlMWYzZDYyMF8xMi0xLTEtMS0yNzc0Mg_26d4020a-0c05-42ae-b99d-ed9fd4985dad">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80L2ZyYWc6OGIyYjczNGU0ZGJjNDAyNjg1ZWEyYjk3ZjA2MmQ2YWYvdGFibGU6ODBkMzg0MTg0MjBkNGEyZjhjZDlhYzhiZTFmM2Q2MjAvdGFibGVyYW5nZTo4MGQzODQxODQyMGQ0YTJmOGNkOWFjOGJlMWYzZDYyMF8xMy0xLTEtMS0yNzc0Mg_ae5df74f-28b0-4ea3-962d-73353e9972f0">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGV4dHJlZ2lvbjo5ZmQwNjQwYjZkMzE0MDlkYmYxMTQ2ZjMyZTUzZjgyOF8xODYx_f283d735-fdf2-4076-a0a7-e41f86e9efd1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6Mjc2MWY0MTZkZTkxNDdhZmI0ODg2OTU3YjdiMjEyODEvdGFibGVyYW5nZToyNzYxZjQxNmRlOTE0N2FmYjQ4ODY5NTdiN2IyMTI4MV8wLTAtMS0xLTI3NzQy_0efb0016-190f-4cc3-a197-e0f7d3e960eb">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGV4dHJlZ2lvbjo5ZmQwNjQwYjZkMzE0MDlkYmYxMTQ2ZjMyZTUzZjgyOF8xMzc_f8adc57f-a7f9-4fe3-ac82-263b91790572">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6MjdkY2Y1MjZhMDk5NDdjZjk1NGMyOWY5ZTY3Zjk5MTUvdGFibGVyYW5nZToyN2RjZjUyNmEwOTk0N2NmOTU0YzI5ZjllNjdmOTkxNV8wLTAtMS0xLTI3NzQy_66be2e11-d9dd-494a-803f-e5f37285af22">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGV4dHJlZ2lvbjo5ZmQwNjQwYjZkMzE0MDlkYmYxMTQ2ZjMyZTUzZjgyOF8xODU1_ab4b75b4-83a1-45fe-a534-18c5eae0c3b6">001-35558</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGV4dHJlZ2lvbjo5ZmQwNjQwYjZkMzE0MDlkYmYxMTQ2ZjMyZTUzZjgyOF8xODU3_efa40115-1138-484a-8fc9-fdea64d44f0c">CARDIFF ONCOLOGY,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NTQ3OGZjMDExZDcyNDk4YWFmZWFlN2QxZDZmNmVhNjgvdGFibGVyYW5nZTo1NDc4ZmMwMTFkNzI0OThhYWZlYWU3ZDFkNmY2ZWE2OF8wLTAtMS0xLTI3NzQy_15c1d12e-e3d3-48d2-a15f-868f2b0f98cb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NTQ3OGZjMDExZDcyNDk4YWFmZWFlN2QxZDZmNmVhNjgvdGFibGVyYW5nZTo1NDc4ZmMwMTFkNzI0OThhYWZlYWU3ZDFkNmY2ZWE2OF8wLTItMS0xLTI3NzQy_52e76b47-f19e-43f1-8a0a-201aeff8e2b7">27-2004382</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NTQ3OGZjMDExZDcyNDk4YWFmZWFlN2QxZDZmNmVhNjgvdGFibGVyYW5nZTo1NDc4ZmMwMTFkNzI0OThhYWZlYWU3ZDFkNmY2ZWE2OF8zLTAtMS0xLTI3NzQyL3RleHRyZWdpb246MjM5M2MwMWQxNjc0NGFjMzkwZjI4YjBkMmI3MGVmM2JfNA_958b9ece-1db2-4ddc-88e1-7ac728fa8ff2">11055 Flintkote Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NTQ3OGZjMDExZDcyNDk4YWFmZWFlN2QxZDZmNmVhNjgvdGFibGVyYW5nZTo1NDc4ZmMwMTFkNzI0OThhYWZlYWU3ZDFkNmY2ZWE2OF8zLTAtMS0xLTI3NzQyL3RleHRyZWdpb246MjM5M2MwMWQxNjc0NGFjMzkwZjI4YjBkMmI3MGVmM2JfOA_f2ff40e6-1d23-463c-b835-5fbe24358a5d">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NTQ3OGZjMDExZDcyNDk4YWFmZWFlN2QxZDZmNmVhNjgvdGFibGVyYW5nZTo1NDc4ZmMwMTFkNzI0OThhYWZlYWU3ZDFkNmY2ZWE2OF8zLTAtMS0xLTI3NzQyL3RleHRyZWdpb246MjM5M2MwMWQxNjc0NGFjMzkwZjI4YjBkMmI3MGVmM2JfMTI_4085b380-3977-4886-a9a4-618f8d102fcc">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NTQ3OGZjMDExZDcyNDk4YWFmZWFlN2QxZDZmNmVhNjgvdGFibGVyYW5nZTo1NDc4ZmMwMTFkNzI0OThhYWZlYWU3ZDFkNmY2ZWE2OF8zLTItMS0xLTI3NzQy_fa436533-090d-49e5-a649-2ef291f1bdef">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NTQ3OGZjMDExZDcyNDk4YWFmZWFlN2QxZDZmNmVhNjgvdGFibGVyYW5nZTo1NDc4ZmMwMTFkNzI0OThhYWZlYWU3ZDFkNmY2ZWE2OF82LTAtMS0xLTI3NzQyL3RleHRyZWdpb246OTQ3YTMyYjIwODAzNDM3MzhkZDIyMzM1NzIzYjYyZjhfNQ_bc0bba89-b18d-4f36-8a9f-b0275fce9d83">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NTQ3OGZjMDExZDcyNDk4YWFmZWFlN2QxZDZmNmVhNjgvdGFibGVyYW5nZTo1NDc4ZmMwMTFkNzI0OThhYWZlYWU3ZDFkNmY2ZWE2OF82LTAtMS0xLTI3NzQyL3RleHRyZWdpb246OTQ3YTMyYjIwODAzNDM3MzhkZDIyMzM1NzIzYjYyZjhfOQ_782f5b6c-1066-40b3-a5d0-4e655370855f">952-7570</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NWRjNDBhMWU2MjcxNDg3NzlkYjk3MGY4NTMzZmYzNTUvdGFibGVyYW5nZTo1ZGM0MGExZTYyNzE0ODc3OWRiOTcwZjg1MzNmZjM1NV8xLTAtMS0xLTI3NzQy_3bc09a64-4e3c-4eaa-a7e3-56deba502a95">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6NWRjNDBhMWU2MjcxNDg3NzlkYjk3MGY4NTMzZmYzNTUvdGFibGVyYW5nZTo1ZGM0MGExZTYyNzE0ODc3OWRiOTcwZjg1MzNmZjM1NV8xLTItMS0xLTI3NzQy_db089ddf-22aa-429c-99e6-b2bccb39ca06">CRDF</dei:TradingSymbol>
    <dei:EntityCurrentReportingStatus
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGV4dHJlZ2lvbjo5ZmQwNjQwYjZkMzE0MDlkYmYxMTQ2ZjMyZTUzZjgyOF8xODU4_affb7cdb-78d7-4429-a58e-27fbfea254f4">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGV4dHJlZ2lvbjo5ZmQwNjQwYjZkMzE0MDlkYmYxMTQ2ZjMyZTUzZjgyOF8xODU5_05c8fb9a-0b3b-4092-ab06-d39d44ada568">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6YmI0MDY5YjhhMmU5NDYwM2E3ZjZiNTA2MGEyYTk0YTIvdGFibGVyYW5nZTpiYjQwNjliOGEyZTk0NjAzYTdmNmI1MDYwYTJhOTRhMl8wLTQtMS0xLTI3NzQyL3RleHRyZWdpb246ZjA5NzE2ZDk4Y2JjNDRlYWEyOTE4ZTM0MmFkNzAxZjBfNA_8c48dc79-a6f4-40b2-8bc6-8838a7d190a7">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6YmI0MDY5YjhhMmU5NDYwM2E3ZjZiNTA2MGEyYTk0YTIvdGFibGVyYW5nZTpiYjQwNjliOGEyZTk0NjAzYTdmNmI1MDYwYTJhOTRhMl8wLTYtMS0xLTI3NzQyL3RleHRyZWdpb246ZDE1YjMxOGE4YjgxNDZlZDhkZGViNDM2ODJiNDQ1ZDZfMzA_52f8dec1-358a-4388-9d6d-a0d2a30ed004">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGFibGU6YmI0MDY5YjhhMmU5NDYwM2E3ZjZiNTA2MGEyYTk0YTIvdGFibGVyYW5nZTpiYjQwNjliOGEyZTk0NjAzYTdmNmI1MDYwYTJhOTRhMl8wLTgtMS0xLTI3NzQyL3RleHRyZWdpb246MzgzZmM5NDI1NjJiNDIwYzliMDM3YjcwZWUyNjhiZjBfMjg_128997b7-6237-436f-adae-533abd6de05b">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGV4dHJlZ2lvbjo5ZmQwNjQwYjZkMzE0MDlkYmYxMTQ2ZjMyZTUzZjgyOF8xODYw_755e9135-f9f4-418e-bf97-4c553b79d0bc">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i0d160d05433642bf890809b8d47f76c6_I20220428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xL2ZyYWc6OWZkMDY0MGI2ZDMxNDA5ZGJmMTE0NmYzMmU1M2Y4MjgvdGV4dHJlZ2lvbjo5ZmQwNjQwYjZkMzE0MDlkYmYxMTQ2ZjMyZTUzZjgyOF8xODA1_d2416f8a-33d6-4597-8253-11af7b3b32c7"
      unitRef="shares">43306061</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMy0xLTEtMS0yNzc0Mg_d014f03f-8550-4349-8169-6e407862cdfa"
      unitRef="usd">20052000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMy0zLTEtMS0yNzc0Mg_4e7ab58b-199d-40a1-80bd-4e18bb8fd17e"
      unitRef="usd">11943000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNC0xLTEtMS0yNzc0Mg_9431aca9-27ed-48e4-88e8-d994274a372b"
      unitRef="usd">109310000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNC0zLTEtMS0yNzc0Mg_63dab31a-7bc5-43ed-bbd4-ac5b38852d7f"
      unitRef="usd">128878000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNS0xLTEtMS0yNzc0Mg_509ab6c9-0fb0-4751-873e-266b8bbc64cf"
      unitRef="usd">447000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNS0zLTEtMS0yNzc0Mg_552fcfdf-f2df-4551-9b84-a77c28567551"
      unitRef="usd">535000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNi0xLTEtMS0yNzc0Mg_28d5f3b2-ac45-4bec-bb73-7353dca4a872"
      unitRef="usd">5997000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNi0zLTEtMS0yNzc0Mg_0f9f5fd4-4a66-441d-8bd4-f1535ea36c83"
      unitRef="usd">4771000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNy0xLTEtMS0yNzc0Mg_dc78184f-fff6-4a9e-a1d5-6f4cce40d61f"
      unitRef="usd">135806000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNy0zLTEtMS0yNzc0Mg_af89bb44-7304-4794-987b-a33b71be8a74"
      unitRef="usd">146127000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfOC0xLTEtMS0yNzc0Mg_e8bc074d-e0e0-4ff7-80f0-0b3251db2d99"
      unitRef="usd">550000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfOC0zLTEtMS0yNzc0Mg_9dfe0c7a-42d6-4678-bde3-b25a229b8c9d"
      unitRef="usd">382000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTAtMS0xLTEtMjc3NDI_f5f5783f-60a3-45fe-9faf-5925ebb199d1"
      unitRef="usd">2660000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTAtMy0xLTEtMjc3NDI_f28f39fe-3d46-4805-bab9-542fa53256a4"
      unitRef="usd">2796000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTEtMS0xLTEtMjc3NDI_fe86f228-6795-43de-896b-03b6a4701c40"
      unitRef="usd">188000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTEtMy0xLTEtMjc3NDI_c747fea3-2f91-4614-b42e-c054e36484bd"
      unitRef="usd">239000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTItMS0xLTEtMjc3NDI_26cc10f0-eaa4-49b7-bf13-63c25f4bb42f"
      unitRef="usd">139204000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTItMy0xLTEtMjc3NDI_64a33051-7e23-43ce-9001-20ffa09325b9"
      unitRef="usd">149544000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTYtMS0xLTEtMjc3NDI_fbba2c60-b056-485d-be4d-3e1a5f9181b3"
      unitRef="usd">1261000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTYtMy0xLTEtMjc3NDI_6978e481-f9cd-4dba-93c2-c70cfb77280b"
      unitRef="usd">1439000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTctMS0xLTEtMjc3NDI_a9b58811-56ed-4b23-a0da-314ee1c041d5"
      unitRef="usd">4738000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTctMy0xLTEtMjc3NDI_979edc9b-ed32-460a-b0ba-c9effe88bec4"
      unitRef="usd">4527000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTktMS0xLTEtMjc3NDI_80b4a593-f02a-4062-8f1c-44941068d40d"
      unitRef="usd">665000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMTktMy0xLTEtMjc3NDI_ad17a05f-e041-449f-90ba-fbc4d115e063"
      unitRef="usd">551000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMjAtMS0xLTEtMjc3NDI_91e59107-d263-4e68-bba2-0cf791618991"
      unitRef="usd">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMjAtMy0xLTEtMjc3NDI_060facc1-bbaa-449e-b46b-1850585bdc90"
      unitRef="usd">42000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMjItMS0xLTEtMjc3NDI_92f02734-abb4-42c2-b4cb-b2d792827bb2"
      unitRef="usd">6664000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMjItMy0xLTEtMjc3NDI_54ee48d9-ba6d-46df-8165-170c7dd56f20"
      unitRef="usd">6559000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMjUtMS0xLTEtMjc3NDI_6ac5f46e-c306-4df6-8d42-3619c8cfbc65"
      unitRef="usd">2438000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMjUtMy0xLTEtMjc3NDI_5a54e493-3b4f-4730-a826-7f0063c4a9e3"
      unitRef="usd">2568000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMjgtMS0xLTEtMjc3NDI_e8b8e96a-d306-4e3c-aef7-241bd2148f92"
      unitRef="usd">9102000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMjgtMy0xLTEtMjc3NDI_e0faad71-23fe-475b-a1da-25f2042631dc"
      unitRef="usd">9127000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzAtMS0xLTEtMjc3NDI_a6e983d7-3a54-478d-ac2d-b9847b91c70b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzAtMy0xLTEtMjc3NDI_48a689c7-18f1-4a12-ade9-969e37b814c6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzMtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo0OTY4Zjc5NzYxMzA0ZWEwOTNlMDA2NGJlN2VhZDk1YV8yMQ_02992d4f-09da-4c52-b556-e338cc7b3230"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzMtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo0OTY4Zjc5NzYxMzA0ZWEwOTNlMDA2NGJlN2VhZDk1YV8yMQ_8939a8b6-f53b-4f01-bb34-2ecae60bb133"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzMtMS0xLTEtMjc3NDI_06e2117d-d27f-4426-8430-edc46bd616f2"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzMtMy0xLTEtMjc3NDI_68476268-3eb0-4a65-880b-0f6a8e1e0fc6"
      unitRef="usd">1000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo1Y2U0Njc4ZjhkZTQ0YWNlYWI4NmFlNmI4OTU1OTlkOF8xOQ_0a517e67-c062-47dd-acae-d171b76541be"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo1Y2U0Njc4ZjhkZTQ0YWNlYWI4NmFlNmI4OTU1OTlkOF8xOQ_52306382-c9d7-463e-a56e-65d10a0aacfc"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo1Y2U0Njc4ZjhkZTQ0YWNlYWI4NmFlNmI4OTU1OTlkOF8zMw_5e4517c2-2100-4bb7-8737-ea4867bf0541"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo1Y2U0Njc4ZjhkZTQ0YWNlYWI4NmFlNmI4OTU1OTlkOF8zMw_c0bb1f4d-e702-4e20-a768-76b526552843"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo1Y2U0Njc4ZjhkZTQ0YWNlYWI4NmFlNmI4OTU1OTlkOF81NQ_4d391a9a-c7a6-4d2e-b160-1de360ed6cc4"
      unitRef="shares">43306000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo1Y2U0Njc4ZjhkZTQ0YWNlYWI4NmFlNmI4OTU1OTlkOF81NQ_d3d4d4e3-3ed4-40ff-a5f1-f188d0496d2f"
      unitRef="shares">43306000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo1Y2U0Njc4ZjhkZTQ0YWNlYWI4NmFlNmI4OTU1OTlkOF82Mg_570d180f-1d69-4a00-90a6-01c08cfb6961"
      unitRef="shares">41964000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMC0xLTEtMjc3NDIvdGV4dHJlZ2lvbjo1Y2U0Njc4ZjhkZTQ0YWNlYWI4NmFlNmI4OTU1OTlkOF82Mg_a296f947-0e7a-4693-9e86-5f5867c95dd7"
      unitRef="shares">41964000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMS0xLTEtMjc3NDI_569ce56c-67b3-4d15-a791-a4779f923239"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzQtMy0xLTEtMjc3NDI_871c4a60-e484-4ab2-b3b0-e2eacf1effd0"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzUtMS0xLTEtMjc3NDI_152336e5-2cbb-48f3-878f-653b58512922"
      unitRef="usd">401655000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzUtMy0xLTEtMjc3NDI_fa72d935-1dff-4273-8158-8015f4967a35"
      unitRef="usd">400503000</us-gaap:AdditionalPaidInCapital>
    <crdf:ServiceReceivable
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzYtMS0xLTEtMjc3NDI_70416c45-dbca-48ec-b7cf-a7e73bb90edb"
      unitRef="usd">0</crdf:ServiceReceivable>
    <crdf:ServiceReceivable
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzYtMy0xLTEtMjc3NDI_e45b9110-2245-475c-93dc-5536601d89b6"
      unitRef="usd">139000</crdf:ServiceReceivable>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzctMS0xLTEtMjc3NDI_0ac2f92c-0899-44e2-8970-5aaa039c3ef6"
      unitRef="usd">-748000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzctMy0xLTEtMjc3NDI_806ac7be-48d1-4dca-b58e-34bd0be12e27"
      unitRef="usd">-142000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzgtMS0xLTEtMjc3NDI_fc58a78b-3f1a-4680-bd79-4042a6485fbe"
      unitRef="usd">-270809000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzgtMy0xLTEtMjc3NDI_a9ff7d51-b9ea-4be5-a004-ecee4f9f9ea2"
      unitRef="usd">-259810000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzktMS0xLTEtMjc3NDI_8f692760-1f3a-4bec-8127-90bda5c50643"
      unitRef="usd">130102000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfMzktMy0xLTEtMjc3NDI_70ecaf7f-6e87-4127-b681-cd3ea9a11db3"
      unitRef="usd">140417000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNDAtMS0xLTEtMjc3NDI_3a4cade2-269a-4c0d-98a2-f398ee332201"
      unitRef="usd">139204000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xNi9mcmFnOjNjODM1MjRjYTk3MjRmNWY5NmFmZTUwZjgwN2YzODQyL3RhYmxlOjY3ZmY2MzAyY2I4NTRiOTI4YTAyM2FjMzVkMzJkZTg0L3RhYmxlcmFuZ2U6NjdmZjYzMDJjYjg1NGI5MjhhMDIzYWMzNWQzMmRlODRfNDAtMy0xLTEtMjc3NDI_678f076f-9824-4a32-8acb-84d2b34eae6e"
      unitRef="usd">149544000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfNS01LTEtMS0yNzc0Mg_36c762c5-bda5-4441-bc3e-e9cb2c0be8dc"
      unitRef="usd">74000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfNS03LTEtMS0yNzc0Mg_75b45710-7d53-499d-8c1f-9b0a1f2274fa"
      unitRef="usd">72000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfOC01LTEtMS0yNzc0Mg_a6a28489-43f7-4d48-b4f2-828f6158976a"
      unitRef="usd">7208000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfOC03LTEtMS0yNzc0Mg_fea98dbb-5428-4024-8b16-58ac411b81b8"
      unitRef="usd">3279000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfOS01LTEtMS0yNzc0Mg_9d56d0bf-b14d-4017-885b-b20c06922dce"
      unitRef="usd">3940000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfOS03LTEtMS0yNzc0Mg_07079bf9-2231-494e-85a6-e95df7db06dd"
      unitRef="usd">2235000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMTItNS0xLTEtMjc3NDI_4ab318ea-07c9-4952-babc-f02dd8910de9"
      unitRef="usd">11148000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMTItNy0xLTEtMjc3NDI_3b253042-22d7-4010-9780-bbbe9b0e03f4"
      unitRef="usd">5514000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMTQtNS0xLTEtMjc3NDI_593e22e2-88b9-43b6-affe-4b2bb5b1d1ea"
      unitRef="usd">-11074000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMTQtNy0xLTEtMjc3NDI_2910b449-9024-4d98-a4c9-5793617aa9f8"
      unitRef="usd">-5442000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMTYtNS0xLTEtMjc3NDI_7ab046ae-b82d-4737-a4e4-ada791077af3"
      unitRef="usd">130000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMTYtNy0xLTEtMjc3NDI_11b60baf-9556-4ac9-9480-57b5c2b5cebd"
      unitRef="usd">57000</us-gaap:InterestIncomeOperating>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMTgtNS0xLTEtMjc3NDI_8cf7bff5-ee5a-4953-bd30-4881d5bc3fbc"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMTgtNy0xLTEtMjc3NDI_c9b4b1fa-22cb-4d08-b29a-33d7b72b34b9"
      unitRef="usd">207000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjAtNS0xLTEtMjc3NDI_e3e27d52-893d-4100-946d-1ba8c77197dc"
      unitRef="usd">-49000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjAtNy0xLTEtMjc3NDI_b547eeba-cfa5-44cf-a5d5-3a51167c2706"
      unitRef="usd">-1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjItNS0xLTEtMzM2NTc_8922e125-33bb-4d8e-8c19-88c4983d2147"
      unitRef="usd">81000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjItNy0xLTEtMzM2NTc_f593fe63-0181-4d7d-861b-cca6ff5cc251"
      unitRef="usd">263000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjEtNS0xLTEtMjc3NDI_723f9813-be87-4362-9eb8-355512136eb9"
      unitRef="usd">-10993000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjEtNy0xLTEtMjc3NDI_8e41f0af-bd04-4065-9201-502ddcad3f51"
      unitRef="usd">-5179000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjMtNS0xLTEtMjc3NDI_a7915f8b-f14f-4132-a10b-b85b88dd838d"
      unitRef="usd">6000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjMtNy0xLTEtMjc3NDI_f68ebca5-a2a3-4ecd-a70b-b2f7ff93f8e3"
      unitRef="usd">6000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjktNS0xLTEtMjc3NDI_03a342fd-0edc-4318-a26b-bfb23bd97586"
      unitRef="usd">-10999000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMjktNy0xLTEtMjc3NDI_48b2c98c-2453-48d2-94f1-7d80eedfd78f"
      unitRef="usd">-5185000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMzEtNS0xLTEtMjc3NDI_6841c21e-6536-4642-a7c5-e5c866cb607f"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMzEtNS0xLTEtMjc3NDI_9ee5cdce-38b2-41bc-915c-493b4ffede70"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMzEtNy0xLTEtMjc3NDI_6faf2512-c865-4aff-9adf-818480822026"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMzEtNy0xLTEtMjc3NDI_e4aabe0b-0584-445f-ba4a-dd9119182fea"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMzQtNS0xLTEtMjc3NDI_e4626c0f-b5e2-4317-a80d-e099b1d1493f"
      unitRef="shares">43231000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMzQtNS0xLTEtMjc3NDI_ef5fe2c1-b922-4e3b-bc0f-1cd01244598b"
      unitRef="shares">43231000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMzQtNy0xLTEtMjc3NDI_56d1e2d9-0662-4639-9029-e8591c9d3a26"
      unitRef="shares">37164000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8xOS9mcmFnOjIwNTdhMzliZmM4ZjQ3OGU4YWNkNGM3NGMwZTAzY2IxL3RhYmxlOmVjODg1Y2IzZTNmZjRmODg4NWYyMjEyY2JkNGRmMmNjL3RhYmxlcmFuZ2U6ZWM4ODVjYjNlM2ZmNGY4ODg1ZjIyMTJjYmQ0ZGYyY2NfMzQtNy0xLTEtMjc3NDI_6679e0a3-258c-4c9e-81c5-882361934e83"
      unitRef="shares">37164000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfMi01LTEtMS0yNzc0Mg_940143f0-aae0-4432-a8f0-b7b2a5dfa9b7"
      unitRef="usd">-10993000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfMi03LTEtMS0yNzc0Mg_aa46d316-44b6-4e3d-8bef-6f50a67d18bd"
      unitRef="usd">-5179000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfNC01LTEtMS0yNzc0Mg_34a65e1b-989d-4e02-a65d-b99b0e37b2dd"
      unitRef="usd">-606000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfNC03LTEtMS0yNzc0Mg_2c31aa35-0c40-43d8-82be-48a93f963a92"
      unitRef="usd">-67000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfNS01LTEtMS0yNzc0Mg_3d58170e-e867-4b5b-b90a-f1f825789deb"
      unitRef="usd">-11599000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfNS03LTEtMS0yNzc0Mg_e7a232e0-10f1-40b3-b0c6-eff692b24350"
      unitRef="usd">-5246000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfNy01LTEtMS0yNzc0Mg_c6431fd6-dbff-4e15-9ce6-274f02bafdc7"
      unitRef="usd">6000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfNy03LTEtMS0yNzc0Mg_d2a45eec-6ea2-4102-9c3b-3f03517ae0fb"
      unitRef="usd">6000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfMTMtNS0xLTEtMjc3NDI_8c380662-ea80-46ab-b0fb-4459bd0ee7bd"
      unitRef="usd">-11605000</crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic>
    <crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yMi9mcmFnOjY0ZTYxN2Y3ZjA3YjQzZWVhZWYzY2VhZTdhNTdmMzc5L3RhYmxlOjcxZGJiN2I0YjAzZTRmZDliZTE0MTYwZmQ1Y2JlM2Q4L3RhYmxlcmFuZ2U6NzFkYmI3YjRiMDNlNGZkOWJlMTQxNjBmZDVjYmUzZDhfMTMtNy0xLTEtMjc3NDI_d5d62360-e25d-4a4e-9851-700cfa3b0ee1"
      unitRef="usd">-5252000</crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:SharesIssued
      contextRef="i032d3c2391934b749d64c1001f146392_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMS0xLTEtMS0yODI4MA_03bb8929-e5cc-43a4-9049-64e91aa3e0ce"
      unitRef="shares">716000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i032d3c2391934b749d64c1001f146392_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMS0zLTEtMS0yODI4MA_18303ab6-622a-4edc-84f6-e4d9c07e2ec7"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i530e82542d9e45d284f2f86beacf61bd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMS01LTEtMS0yODI4MA_007142d9-6035-4bc2-ac08-0e34a7c40a41"
      unitRef="shares">41964000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i530e82542d9e45d284f2f86beacf61bd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMS03LTEtMS0yODI4MA_0681dbb2-25bd-412e-853f-e6a29d9a92c3"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3746cafcf2464a6a8c86d7eeb2da15d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMS05LTEtMS0yODI4MA_cd773448-08be-421d-a9e5-6cc7aa7f6b96"
      unitRef="usd">400503000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icbd660f941704d6eab498635e1633e0e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMS0xMS0xLTEtMjgyODA_eb3b58e2-6464-4c3d-91dd-cdd28818ab1f"
      unitRef="usd">-139000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id0a34f4133324ecabf8ccf476f867efd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMS0xMy0xLTEtMjgyODA_9ef6a814-21f8-449a-b524-71a9851ca893"
      unitRef="usd">-142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia4da4e68a38249baac1d08460527a5c9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMS0xNS0xLTEtMjgyODA_bd6f9638-f58f-4430-888b-8f2646b96321"
      unitRef="usd">-259810000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMS0xNy0xLTEtMjgyODA_eca4f187-a3e5-4abc-96e4-8827c691117f"
      unitRef="usd">140417000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i695a8c3be21242d3b5f355d90d3cee60_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMi05LTEtMS0yODI4MA_db7ba5d4-1780-42ce-8916-1b9d0c184922"
      unitRef="usd">1152000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMi0xNy0xLTEtMjgyODA_8265b469-3005-496f-b61d-cbdc20de7920"
      unitRef="usd">1152000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i64b5359a6ff94b8faf437365a08b98b6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfNi0xMy0xLTEtMjgyODA_00a6a72b-8a5a-4905-8d85-b9d4e165a9c5"
      unitRef="usd">-606000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfNi0xNy0xLTEtMjgyODA_3135d9eb-9a7b-4776-b1a5-4fe8fb3d5fcf"
      unitRef="usd">-606000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i00db47d4a17244ed896d6417ea6ac008_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfNy0xLTEtMS0zMjE1Mg_0c0d040d-9c9d-499d-bc03-9f28eb7e1187"
      unitRef="shares">-328000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i00db47d4a17244ed896d6417ea6ac008_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfNy0zLTEtMS0zMjE1Mg_c90941f7-49ed-423f-bc00-8cfa5751fd95"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i68f4a1bcda064a5784195b33875c7f57_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfNy01LTEtMS0zMjE1Mg_09c69ca7-680f-4e89-846c-7b8424e55837"
      unitRef="shares">1342000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfNy0xNy0xLTEtMzIxNTI_338f8fb6-1f91-4386-bf2b-36f63b32acfe"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:DividendsPreferredStock
      contextRef="ib3f2263cd87445ec9f6781abaf9f567f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfNy0xNS0xLTEtMjgyODA_7ce46e1d-7b8e-409d-b1d1-77ee5b79b376"
      unitRef="usd">6000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfNy0xNy0xLTEtMjgyODA_5fad9686-9c63-4dd5-a5a1-35b2db97d3e0"
      unitRef="usd">6000</us-gaap:DividendsPreferredStock>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="id5fe0cd6cb50486ea568f476234e2e09_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfOC0xMS0xLTEtMjgyODA_0f355af8-1a8a-4af4-8923-8cf558def832"
      unitRef="usd">139000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfOC0xNy0xLTEtMjgyODA_544b45e5-646c-474c-a948-386ec3dcee2c"
      unitRef="usd">139000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <us-gaap:NetIncomeLoss
      contextRef="ib3f2263cd87445ec9f6781abaf9f567f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfOS0xNS0xLTEtMjgyODA_860c4ae6-fd2c-4d7c-8787-91811f0552cb"
      unitRef="usd">-10993000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfOS0xNy0xLTEtMjgyODA_b2c9e5e6-bbb3-4172-97f0-5b38f5f36a38"
      unitRef="usd">-10993000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="ie675592e1c2a40919a88e24c67261742_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMTAtMS0xLTEtMjgyODA_11c2fe42-0e7d-4556-afc8-011d551913ae"
      unitRef="shares">388000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ie675592e1c2a40919a88e24c67261742_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMTAtMy0xLTEtMjgyODA_4ab02b33-5008-48a5-a18c-68e228f1f4c6"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i1fcbabbd465940f7b361a479d927b2ca_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMTAtNS0xLTEtMjgyODA_182acb2d-385e-4eaf-95c0-c1a8695ebcaf"
      unitRef="shares">43306000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i1fcbabbd465940f7b361a479d927b2ca_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMTAtNy0xLTEtMjgyODA_65223587-c605-40b5-8146-cdec054e3623"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i70185ba0bc824fbeb9be808cdb911645_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMTAtOS0xLTEtMjgyODA_d9998cbc-3d2f-4b9a-8712-eab4d097bcdc"
      unitRef="usd">401655000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i545e543142c7462abbd863aff074c5b1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMTAtMTEtMS0xLTI4Mjgw_1ed7fc1d-2b22-49f2-887e-ea8f8a3593e2"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3cc592d0c43c4571aca1097e49d8d129_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMTAtMTMtMS0xLTI4Mjgw_e8794d99-55ad-4ffe-a32d-69ebb7622381"
      unitRef="usd">-748000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i91922e2e89cf4c61aa12f0520d1a5742_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMTAtMTUtMS0xLTI4Mjgw_21c6a5b3-3f68-4b6a-88eb-62e761a60895"
      unitRef="usd">-270809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOmZkOTM4ZGViMjJlMDRlYmJiNDk3ZTg4OWVmN2I4YzhjL3RhYmxlcmFuZ2U6ZmQ5MzhkZWIyMmUwNGViYmI0OTdlODg5ZWY3YjhjOGNfMTAtMTctMS0xLTI4Mjgw_86d543fb-2d32-4bd6-b62e-b4f8ba774a15"
      unitRef="usd">130102000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ibad6d99cf2f840ce9e7bed2d46e20230_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMS0xLTEtMS0yNzc0Mg_2816be60-3115-49d0-b124-9c57ff3f0d29"
      unitRef="shares">716000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ibad6d99cf2f840ce9e7bed2d46e20230_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMS0zLTEtMS0yNzc0Mg_7c1fb65e-896f-4a9a-a2ec-5a566cf6dbe3"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ia3bfbf7525a84c06a46b8b822cc8c9fd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMS01LTEtMS0yNzc0Mg_0583a6a5-61a6-4982-b49d-f501569b4d69"
      unitRef="shares">36781000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ia3bfbf7525a84c06a46b8b822cc8c9fd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMS03LTEtMS0yNzc0Mg_88d49f82-ae66-4481-9b08-fcff6bb6306d"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia0ece49122944a43b7c858a41e13bb5f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMS05LTEtMS0yNzc0Mg_45744436-8d45-4aaa-8404-822d9f54c4d3"
      unitRef="usd">361819000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a5aae261a9942dea72ffd742b0669b2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMS0xMS0xLTEtMjc3NDI_7a5e8d59-27ff-411f-848f-04409dc68438"
      unitRef="usd">-2171000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i62458f79e8c5489190ae1d0a860182dc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMS0xMy0xLTEtMjc3NDI_4c269515-62e5-4b7e-934e-5122da37c94e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i750dda3cd9b44f1d95a8ef8698d47bcd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMS0xNS0xLTEtMjc3NDI_06536a27-f69d-4406-bc34-ea0a67744d68"
      unitRef="usd">-231495000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibf90f6cfceb846aba68cc0e11216576a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMS0xNy0xLTEtMjc3NDI_d06ec284-eb42-41f7-b563-25a0d74de38a"
      unitRef="usd">128158000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id2e7fab3163147ac9e9e0c75f6a432ba_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMi05LTEtMS0yNzc0Mg_cbf1fffb-5f86-4258-a855-3608b2a24feb"
      unitRef="usd">268000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMi0xNy0xLTEtMjc3NDI_774292c7-c573-4705-b651-5fa9b91b1f13"
      unitRef="usd">268000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <crdf:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i206e5d41255345cda79ffb2da56624ac_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfNC01LTEtMS0yNzc0Mg_1afce3ee-6567-48c1-b801-50d4067d02e6"
      unitRef="shares">771000</crdf:StockIssuedDuringPeriodSharesWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="id2e7fab3163147ac9e9e0c75f6a432ba_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfNC05LTEtMS0yNzc0Mg_99d96581-a199-4f91-bf52-cd49350ac02a"
      unitRef="usd">1263000</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfNC0xNy0xLTEtMjc3NDI_eee811d3-9c60-4079-ab6b-77c3781563e5"
      unitRef="usd">1263000</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i012412a3facb44e1a372eb4e99387bea_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfNi0xMy0xLTEtMjc3NDI_0ed5966a-0b88-40e9-9b32-6a79c9d44526"
      unitRef="usd">-67000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfNi0xNy0xLTEtMjc3NDI_7e26ddeb-3f69-4023-a10d-4e5be501dc03"
      unitRef="usd">-67000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsPreferredStock
      contextRef="i00079f3fd1654534b9dde967f3160fd3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfNy0xNS0xLTEtMjc3NDI_0cfaee65-2871-4f82-9575-76b7d2e2d5c9"
      unitRef="usd">6000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfNy0xNy0xLTEtMjc3NDI_b3abd638-6885-4e19-a0cf-3d28c283ce54"
      unitRef="usd">6000</us-gaap:DividendsPreferredStock>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i4d9db9e17c6040a4b40aed1bd2c626fd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfOC0xMS0xLTEtMjc3NDI_ac55e4ce-3bdb-4184-a2c7-82cf4ddfeb9d"
      unitRef="usd">380000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfOC0xNy0xLTEtMjc3NDI_a1a40109-5f36-4abf-b6d3-fadd11e0412c"
      unitRef="usd">380000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <us-gaap:NetIncomeLoss
      contextRef="i00079f3fd1654534b9dde967f3160fd3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfOS0xNS0xLTEtMjc3NDI_2c96ab44-a655-4f51-ad0d-e047c03bb867"
      unitRef="usd">-5179000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfOS0xNy0xLTEtMjc3NDI_60c9384d-b15b-4ab0-bd52-e6e458fd54b7"
      unitRef="usd">-5179000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i4756a6ec761647b6a76e977ae5e7ba32_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMTAtMS0xLTEtMjc3NDI_c9f8767f-6abb-4dcd-86e3-32c1ffcc6c13"
      unitRef="shares">716000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i4756a6ec761647b6a76e977ae5e7ba32_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMTAtMy0xLTEtMjc3NDI_8fd2763c-9760-4605-89b7-830bb0180ee1"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i5c9b59d1f3d947e2bf304d747c2fdeaa_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMTAtNS0xLTEtMjc3NDI_5818606b-aafd-421b-89a5-8aa9b50816b9"
      unitRef="shares">37552000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i5c9b59d1f3d947e2bf304d747c2fdeaa_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMTAtNy0xLTEtMjc3NDI_44a181db-e74e-4ca0-adb1-3cbe89fe891e"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icd5fcea7daf5472c942b8b78378634ef_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMTAtOS0xLTEtMjc3NDI_7dfdb102-060e-4e12-8c6e-27583c9963a2"
      unitRef="usd">363350000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i337b2454b9f14ec396bcb5ac1c5a5a1b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMTAtMTEtMS0xLTI3NzQy_664b6b2f-c068-4773-b5cc-74949759e85c"
      unitRef="usd">-1791000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie2fa9347524245c1b46dea90d3bd28ac_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMTAtMTMtMS0xLTI3NzQy_98a8c6da-cab2-41fe-8203-f7b0ef1fd75b"
      unitRef="usd">-67000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i60d1d6fb130c4369b0c92df1975e7d55_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMTAtMTUtMS0xLTI3NzQy_efd2b8da-88af-443f-85ab-34dbfbed7c54"
      unitRef="usd">-236680000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if6173183c9dc4f8f8a0e7a419a06718b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8yNS9mcmFnOmUyMDQ5OWY3YmI1ZTQzYWE5YzIxODRlNGEwMTY4MWJhL3RhYmxlOjY2YTE4MWVjNDFkYTQ1NTdhNWIxMGI5YTFlYWNlMTAyL3RhYmxlcmFuZ2U6NjZhMTgxZWM0MWRhNDU1N2E1YjEwYjlhMWVhY2UxMDJfMTAtMTctMS0xLTI3NzQy_9d462325-ff7a-4915-9f76-c22334a58647"
      unitRef="usd">124817000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMy0xLTEtMS0yNzc0Mg_ca7c9f25-6783-41f7-bbc0-db59b0dc458b"
      unitRef="usd">-10993000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMy0zLTEtMS0yNzc0Mg_948a0b81-22c3-46ef-a489-b8cb08b3dbe3"
      unitRef="usd">-5179000</us-gaap:NetIncomeLoss>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNS0xLTEtMS0yNzc0Mg_41d9281d-0326-4089-a73d-3c96ee8ec69e"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNS0zLTEtMS0yNzc0Mg_fe5078e3-d969-4819-9297-0287ffd8ee52"
      unitRef="usd">-1000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNy0xLTEtMS0yNzc0Mg_b28c8ad2-cd98-4e00-a3e4-b31f3b8e6bdd"
      unitRef="usd">31000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNy0zLTEtMS0yNzc0Mg_37391206-7a71-4c81-959f-de821b8c098c"
      unitRef="usd">119000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfOC0xLTEtMS0yNzc0Mg_ca37add7-ec2b-4ac8-8ba0-f6fb3d718509"
      unitRef="usd">1152000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfOC0zLTEtMS0yNzc0Mg_67765936-f3c9-487a-b5f2-69bec76c0cba"
      unitRef="usd">268000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMTMtMS0xLTEtMjc3NDI_87a7eee6-fbc8-4d2b-95f5-f3b5dfea316c"
      unitRef="usd">-346000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMTMtMy0xLTEtMjc3NDI_bea478e4-8c17-4631-bea4-41795086acec"
      unitRef="usd">-204000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMTYtMS0xLTEtMjc3NDI_e76d2bc5-3cff-4f7d-a16a-72d9c839b88f"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMTYtMy0xLTEtMjc3NDI_9b4dd5c3-a824-4fc6-85be-2834cf5229b9"
      unitRef="usd">207000</us-gaap:UnrealizedGainLossOnDerivatives>
    <crdf:ReleaseOfClinicalTrialFundingCommitmentForServicesReceived
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMTctMS0xLTEtMjc3NDI_039eabc7-716f-4fc0-95aa-bf7c58a30a34"
      unitRef="usd">139000</crdf:ReleaseOfClinicalTrialFundingCommitmentForServicesReceived>
    <crdf:ReleaseOfClinicalTrialFundingCommitmentForServicesReceived
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMTctMy0xLTEtMjc3NDI_21534b10-4971-4b14-bf38-ff980ef2ba43"
      unitRef="usd">380000</crdf:ReleaseOfClinicalTrialFundingCommitmentForServicesReceived>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMTktMS0xLTEtMjc3NDI_629556dc-eb34-46cb-81cd-d0b01c6097d9"
      unitRef="usd">-51000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMTktMy0xLTEtMjc3NDI_fdf41472-9cf8-4a17-bb59-8badf5bbf432"
      unitRef="usd">-166000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjAtMS0xLTEtMjc3NDI_46966115-730b-4082-b753-116302cdb1e7"
      unitRef="usd">-88000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjAtMy0xLTEtMjc3NDI_66056d6e-c8f9-4db5-96e2-5e34aa9ac022"
      unitRef="usd">-79000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjEtMS0xLTEtMjc3NDI_ba892da0-0c1f-4cc5-86b8-da25a9af65cb"
      unitRef="usd">1141000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjEtMy0xLTEtMjc3NDI_3a1381ad-986f-43fe-8b9f-24faeba65a41"
      unitRef="usd">183000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjItMS0xLTEtMjc3NDI_30c0be77-2f94-4ea9-888c-73ab2ef80a64"
      unitRef="usd">-136000</crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjItMy0xLTEtMjc3NDI_ee979b1e-b6da-4f47-948f-4a79b75d23f7"
      unitRef="usd">-82000</crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjMtMS0xLTEtMjc3NDI_b3310107-b8ef-4642-abf9-13ecf15605cb"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjMtMy0xLTEtMjc3NDI_b3abd001-1313-46e7-aa4e-57596ee0858a"
      unitRef="usd">-1421000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <crdf:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjQtMS0xLTEtMjc3NDI_454c0fda-6700-4c72-9288-5d947547551c"
      unitRef="usd">-16000</crdf:IncreaseDecreaseInOperatingLeaseLiability>
    <crdf:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjQtMy0xLTEtMjc3NDI_e025542d-e3cc-478e-8531-b490ba9d7dee"
      unitRef="usd">-227000</crdf:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjUtMS0xLTEtMjc3NDI_dd9deb63-99ac-4a87-9f89-48d5aa4b0f8d"
      unitRef="usd">-42000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjUtMy0xLTEtMjc3NDI_4321e024-7086-4fb8-8623-77f185b0795f"
      unitRef="usd">34000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjYtMS0xLTEtMjc3NDI_149707b8-642d-45d7-b8ab-f66beddfc1a7"
      unitRef="usd">-10249000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMjYtMy0xLTEtMjc3NDI_9da333c2-c38d-4a05-bfe2-fc7c12eea2f4"
      unitRef="usd">-5884000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzAtMS0xLTEtMjc3NDI_dd667722-770d-4c89-8805-3e1277a064c7"
      unitRef="usd">171000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzAtMy0xLTEtMjc3NDI_b99310d5-4d6a-44dc-9663-f7f25f3ea571"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzEtMS0xLTEtMjc3NDI_ed0934d4-0fbd-4571-a6f7-26f8f0839b3f"
      unitRef="usd">38217000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzEtMy0xLTEtMjc3NDI_0e7bd9c2-d73e-4110-bd11-ff0f8619a874"
      unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzItMS0xLTEtMjc3NDI_58a498c4-9265-412f-ad74-8e607c109ec9"
      unitRef="usd">36773000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzItMy0xLTEtMjc3NDI_8dd8e441-d6bf-40d2-8dc4-2f56130caf25"
      unitRef="usd">114195000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzMtMS0xLTEtMjc3NDI_01d24559-e486-4030-a976-d859b66da0e2"
      unitRef="usd">17085000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzMtMy0xLTEtMjc3NDI_c66685c9-7d3f-478e-9655-b46aad7ce5dc"
      unitRef="usd">2497000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzQtMS0xLTEtMjc3NDI_74b42d19-59b9-4a09-9a89-ad5cb9a61470"
      unitRef="usd">18358000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfMzQtMy0xLTEtMjc3NDI_8304f6fa-9789-4be9-9fed-65bbd8d7bf17"
      unitRef="usd">-111698000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNDEtMS0xLTEtMjc3NDI_9d2f70c6-e598-4445-a69e-c9f8b435816b"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNDEtMy0xLTEtMjc3NDI_75322bc4-55d4-410b-9f01-86ab69017887"
      unitRef="usd">1263000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNDctMS0xLTEtMjc3NDI_8484635b-4c6f-4e81-8232-d3b3bdce9d08"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNDctMy0xLTEtMjc3NDI_e7485b2c-ee05-4678-8ac5-9e2f6199d5bc"
      unitRef="usd">1263000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNDktMS0xLTEtMjc3NDI_4529816a-7d5d-4a77-a4b0-a2e4f759595a"
      unitRef="usd">8109000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNDktMy0xLTEtMjc3NDI_88149ce1-e1dd-4674-9ef3-2905954c2e0c"
      unitRef="usd">-116319000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNTAtMS0xLTEtMjc3NDI_ae4c0608-9398-4ed1-971b-f4da73221e84"
      unitRef="usd">11943000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibf90f6cfceb846aba68cc0e11216576a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNTAtMy0xLTEtMjc3NDI_8a7b9998-67b4-4d41-8687-d87aa635b376"
      unitRef="usd">130981000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNTEtMS0xLTEtMjc3NDI_d34bc2e8-dca9-4849-bae4-e58b98f584d2"
      unitRef="usd">20052000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if6173183c9dc4f8f8a0e7a419a06718b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNTEtMy0xLTEtMjc3NDI_87ebed16-fe96-414f-b63b-22ce45118a72"
      unitRef="usd">14662000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNTQtMS0xLTEtMjc3NDI_56fd10db-e0d2-4d83-a065-5c593dd2d63d"
      unitRef="usd">1000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNTQtMy0xLTEtMjc3NDI_9fcf9058-2f0a-4023-8cc8-8d264eb5bdba"
      unitRef="usd">1000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNTctMS0xLTEtMjc3NDI_b73dd51d-70ab-4a74-a9d4-da083d11efe0"
      unitRef="usd">27000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNTctMy0xLTEtMjc3NDI_f7d5df85-9af6-4829-9db5-f53fc7d1920a"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <crdf:PreferredStockDividendAccrued
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNjAtMS0xLTEtMjc3NDI_2fffb02a-b6a8-44de-9dc0-de448ec14d19"
      unitRef="usd">6000</crdf:PreferredStockDividendAccrued>
    <crdf:PreferredStockDividendAccrued
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV8zMS9mcmFnOjg2MzkzZDYzNDU1MDQ3NDk5OTY1NjIxYjMwNDI0NGQwL3RhYmxlOjI2ZDkzNGI0OGM5NjRmYzhiM2ZlOWVkYzEzZDNlZDExL3RhYmxlcmFuZ2U6MjZkOTM0YjQ4Yzk2NGZjOGIzZmU5ZWRjMTNkM2VkMTFfNjAtMy0xLTEtMjc3NDI_c40e4ef4-e7c1-4a9f-a690-35881cc1b99c"
      unitRef="usd">6000</crdf:PreferredStockDividendAccrued>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80MC9mcmFnOjQ5MTczOWQ1NGQ0NDQ5MjU5MWZjNTJmYTU3OWRjZDhmL3RleHRyZWdpb246NDkxNzM5ZDU0ZDQ0NDkyNTkxZmM1MmZhNTc5ZGNkOGZfMzA5OA_2c903ab2-3600-49c0-a72a-4b56c1222b3b">Organization and Basis of Presentation&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Organization and Overview&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardiff Oncology, Inc. (&#x201c;Cardiff Oncology&#x201d; or the &#x201c;Company&#x201d;) headquartered in San Diego, California, is a clinical-stage biotechnology company leveraging Polo-like Kinase 1 (&#x201c;PLK1&#x201d;) inhibition to develop novel therapies across a range of cancers with the greatest unmet medical need, including KRAS-mutated metastatic colorectal cancer, metastatic pancreatic cancer and metastatic castration-resistant prostate cancer. The Company's common stock is listed on the Nasdaq Capital Market under the ticker symbol "CRDF".&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and the rules&#160;and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) related to a quarterly report on Form&#160;10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules&#160;and regulations. The unaudited interim condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company&#x2019;s financial position and the results of its operations and cash flows for the periods presented. The unaudited condensed balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December&#160;31, 2021 included in the Company&#x2019;s annual report on Form&#160;10-K filed with the SEC on February&#160;24, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred net losses since its inception and has negative operating cash flows. As of March&#160;31, 2022, the Company had $129.4&#160;million in cash, cash equivalents and short-term investments and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.  &lt;/span&gt;&lt;/div&gt;For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#x2019;s stockholders may experience additional dilution.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80MC9mcmFnOjQ5MTczOWQ1NGQ0NDQ5MjU5MWZjNTJmYTU3OWRjZDhmL3RleHRyZWdpb246NDkxNzM5ZDU0ZDQ0NDkyNTkxZmM1MmZhNTc5ZGNkOGZfMjIzOQ_af73af88-8e1a-4477-8030-78962138f410"
      unitRef="usd">129400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RleHRyZWdpb246NDI5NGVlODFiMjc3NDdmOGI2NjM0NmQwZGUwMjBhMjZfNDMxNg_4588119e-0dba-449c-a163-18b7a6ba9a82">Summary of Significant Accounting Policies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, there have been no changes to the Company&#x2019;s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,467,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,849,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,300,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,025,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU No. 2021-04 ("ASU 2021-04"), Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company has prospectively adopted this standard as of January 1, 2022 for periods presented after the adoption. The adoption of ASU 2021-04 did not have a material impact on the Company's financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncement Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) (&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023 for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RleHRyZWdpb246NDI5NGVlODFiMjc3NDdmOGI2NjM0NmQwZGUwMjBhMjZfNDMxNQ_5a2bafc3-193c-4684-94a2-98b7b3f01f97">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RleHRyZWdpb246NDI5NGVlODFiMjc3NDdmOGI2NjM0NmQwZGUwMjBhMjZfNDMyNA_81488359-a2b5-428f-b344-b51aa49e190d">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,467,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,849,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,300,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,025,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if15a941225894f6199ee7c21ae8d06e0_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfMi0xLTEtMS0yNzc0Mg_5a72d2fb-69a7-4ae0-9cea-f21703d9072d"
      unitRef="shares">5467611</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i295d5bedf87e4485addec2ccf76b8eb2_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfMi0zLTEtMS0yNzc0Mg_cc2a971c-cd72-4278-adc0-f1b2aa91ab36"
      unitRef="shares">1849737</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i292c08a55ac045e4b69997f574dcf6c0_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfMy0xLTEtMS0yNzc0Mg_aed1e1af-ce62-45dc-8578-e8c4a8d53c45"
      unitRef="shares">4490159</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iadba25c9d3794ecf9349907eb7230ee7_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfMy0zLTEtMS0yNzc0Mg_d9f22823-2f79-419f-a03c-4f14445e8ed5"
      unitRef="shares">4490159</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4754a5ec9f3b4484a5792b7e7576b9b2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfNS0xLTEtMS0yNzc0Mg_f2eb98f4-b2e8-41c8-8220-f75e2ea9d0ca"
      unitRef="shares">877</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaa80755e562d42a3862c7b9fb1a195f6_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfNS0zLTEtMS0yNzc0Mg_3feb9ef7-c64c-483f-9f6a-d6cdc2cb77f9"
      unitRef="shares">877</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i402afd8930894e8dad31ee8ead92c780_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfNy0xLTEtMS0yNzc0Mg_4abaa8d8-4e76-4a12-b96d-76ebd022c2e1"
      unitRef="shares">1342250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie176e42f42d040008fabaab3e6fc944b_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfNy0zLTEtMS0yNzc0Mg_925549b4-97e6-4d3d-b03e-f731c7cedfef"
      unitRef="shares">2684607</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfOC0xLTEtMS0yNzc0Mg_652fc612-f3d4-4da3-9e63-6e60bca6040d"
      unitRef="shares">11300897</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RhYmxlOjRiY2EyZGM3MWNlOTQzYTE4ZjYyZWNlYTYzNzRjYzJkL3RhYmxlcmFuZ2U6NGJjYTJkYzcxY2U5NDNhMThmNjJlY2VhNjM3NGNjMmRfOC0zLTEtMS0yNzc0Mg_cac6a07f-29db-4018-b547-fbd8d1f4afdc"
      unitRef="shares">9025380</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80My9mcmFnOjQyOTRlZTgxYjI3NzQ3ZjhiNjYzNDZkMGRlMDIwYTI2L3RleHRyZWdpb246NDI5NGVlODFiMjc3NDdmOGI2NjM0NmQwZGUwMjBhMjZfNDMxMQ_0ef4c902-3200-4b8b-9c7f-09a76fe1ac87">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU No. 2021-04 ("ASU 2021-04"), Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company has prospectively adopted this standard as of January 1, 2022 for periods presented after the adoption. The adoption of ASU 2021-04 did not have a material impact on the Company's financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncement Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) (&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023 for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RleHRyZWdpb246NTVjNjU1NjIxZjBlNDFmOGI1MjhmY2JhYTBiNzMyNjNfMTExMA_4b4e3480-7462-452e-827a-7d52128d29f0">Fair Value Measurements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of March&#160;31, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available for sale investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available for sale investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available for sale investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non U.S. government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available for sale investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Included in short-term investments in the accompanying balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 3 during the three months ended March 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RleHRyZWdpb246NTVjNjU1NjIxZjBlNDFmOGI1MjhmY2JhYTBiNzMyNjNfMTEwMg_a460410b-c842-4946-903f-5af84f2727ee">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of March&#160;31, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available for sale investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available for sale investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available for sale investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non U.S. government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available for sale investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) Included in short-term investments in the accompanying balance sheets.</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib5f29ec37e5044118f1345ab67b4bfe0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMy0xLTEtMS0yNzc0Mg_37197ab1-7f52-43e0-8d6d-886e877c228d"
      unitRef="usd">15824000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i858aaf4aebaa477690f541f5cef242e3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMy0zLTEtMS0yNzc0Mg_f7d00c62-73bb-4df3-94fc-4feeae680421"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ice8e727de3934bce8949d0a1f8de0a1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMy01LTEtMS0yNzc0Mg_0eeab402-c0ca-44e3-a9e4-ca737e32504f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaa2aec20dcbb4e11a14fa3594fae5f15_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMy03LTEtMS0yNzc0Mg_57709c8a-9f81-4b73-93ac-2ce64557db5c"
      unitRef="usd">15824000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iec0c5fbc68b74c27a7ff40151b92b5ee_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfNC0xLTEtMS0yNzc0Mg_333a1914-f6b9-4354-983d-0807ea3fc3ca"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifeaaebfbfd564b33828c67ca78b8c766_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfNC0zLTEtMS0yNzc0Mg_3c6afdb6-c5e2-4390-b399-7463e02d8d16"
      unitRef="usd">3205000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i760860b7d95142e6a5f23bd5db8a0e83_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfNC01LTEtMS0yNzc0Mg_ce22dc13-b235-409c-a946-2d3b41006b9e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id0c6edc4fe34456ca0daf70b67b95445_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfNC03LTEtMS0yNzc0Mg_54197668-fd44-4ace-a807-cdace067a10a"
      unitRef="usd">3205000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7bc7648a25f047e89409bd461a324502_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfNS0xLTEtMS0yNzc0Mg_f47d0ff2-8b5d-47b3-8f69-7a21e307208b"
      unitRef="usd">15824000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib787e125147a4fae952c9425271b6f7c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfNS0zLTEtMS0yNzc0Mg_92c3134f-571c-4bcf-a4e4-cce10e6798c7"
      unitRef="usd">3205000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie08212cc90ef4e709206336ccf149313_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfNS01LTEtMS0yNzc0Mg_b8c01db8-2222-438e-8441-2febb7405702"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9b8194a586f841738340b39f3d565848_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfNS03LTEtMS0yNzc0Mg_6bcd0e0a-cdfb-4714-b48b-8e07a8d42766"
      unitRef="usd">19029000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iacb52739ae184a00938aabdbe0bb4cdd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfOC0xLTEtMS0yNzc0Mg_10b6c560-3d88-4aa8-8c97-ebb1bb17e778"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia4acf9b35e314e309ef0816d4754a15a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfOC0zLTEtMS0yNzc0Mg_8e9ad839-07f9-4a51-b528-f3b11f91ce79"
      unitRef="usd">9239000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia453d0061bfb48fcaaabd8e50791523b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfOC01LTEtMS0yNzc0Mg_1170a44a-3bf3-42a9-b6a4-91264d054a66"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i18725cb77e8f4c02b2f1432d16e20612_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfOC03LTEtMS0yNzc0Mg_0ab6e86a-a532-4b91-bee7-c68f64250db3"
      unitRef="usd">9239000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i16a7736ec34f4acb84606918dacb73af_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfOS0xLTEtMS0yNzc0Mg_52d1b5d0-3889-4621-bdd2-05d9bb188ce9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74a2163cb8414bdcba39fea19a1148e6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfOS0zLTEtMS0yNzc0Mg_f8cae598-6181-4ac5-a7c8-eaa1b9e57c29"
      unitRef="usd">69664000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd7a7fe09574445a9ea6fbc3ee035b54_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfOS01LTEtMS0yNzc0Mg_73581bec-730b-45f5-b075-8587a7787b64"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1047e58df41b40d0b4e2422be90e9b1c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfOS03LTEtMS0yNzc0Mg_07891aed-c799-4546-b85c-fb1c50be8775"
      unitRef="usd">69664000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7137fd6fa9e84f46828d43b1c2cccb6e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTAtMS0xLTEtMjc3NDI_9dde1ab3-9d9e-43fc-8f4c-495f61bf449f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if75dd8412dd548f2b9e9b67adbe7e3d5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTAtMy0xLTEtMjc3NDI_50160532-72e4-4813-9999-caf26862b245"
      unitRef="usd">10468000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id749a1f0c6be4b368e444ace5f891487_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTAtNS0xLTEtMjc3NDI_77bbe233-a544-4726-93d5-5f16c5034544"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i38ee8c9b1c2244608a7990d422050c94_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTAtNy0xLTEtMjc3NDI_1c358d1a-4d2c-4758-be03-d95c229ad483"
      unitRef="usd">10468000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9512c3da93e34771b7bdaff0723660ea_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTItMS0xLTEtMjc3NDI_7f8c4299-6dd3-4ccb-8032-6282edda6287"
      unitRef="usd">19939000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7d4747ed58c947ea9a3f145a4ab45200_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTItMy0xLTEtMjc3NDI_1654e88a-944b-4bf7-85fe-eef47810d2aa"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i572626db256d435291fe5c0afb9d041f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTItNS0xLTEtMjc3NDI_7bd15312-55e3-4b5e-aa5e-ecb261bec48a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie6e2de4855d74f7d86a9c98ab283751a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTItNy0xLTEtMjc3NDI_4d4b8724-1bfd-4882-8d37-fde41c8f061d"
      unitRef="usd">19939000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7bc7648a25f047e89409bd461a324502_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTMtMS0xLTEtMjc3NDI_5834d8d1-29d0-4fad-aa9a-2508323ace22"
      unitRef="usd">19939000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib787e125147a4fae952c9425271b6f7c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTMtMy0xLTEtMjc3NDI_2ca66340-028c-4d4b-a807-af37bf5ee6ef"
      unitRef="usd">89371000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie08212cc90ef4e709206336ccf149313_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTMtNS0xLTEtMjc3NDI_8596547b-9cc8-42b7-87c9-5247cf8394a9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9b8194a586f841738340b39f3d565848_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTMtNy0xLTEtMjc3NDI_16b99d68-cbe7-4b29-abe3-023d49d9178f"
      unitRef="usd">109310000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7bc7648a25f047e89409bd461a324502_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTUtMS0xLTEtMjc3NDI_93b61fbc-c4f5-4dad-a34a-e759fd362411"
      unitRef="usd">35763000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib787e125147a4fae952c9425271b6f7c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTUtMy0xLTEtMjc3NDI_87a30762-0890-4f8a-8e01-ee4d9da0e509"
      unitRef="usd">92576000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie08212cc90ef4e709206336ccf149313_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTUtNS0xLTEtMjc3NDI_b525c64c-39a6-4b60-9869-9f9cbf2802d9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9b8194a586f841738340b39f3d565848_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOmJmNzEwYjQzMGJmZjQxNWZiZDJhNTIyMzM5NTQ3ZTM4L3RhYmxlcmFuZ2U6YmY3MTBiNDMwYmZmNDE1ZmJkMmE1MjIzMzk1NDdlMzhfMTUtNy0xLTEtMjc3NDI_ca692478-6aae-42f1-9d6f-b29c178ce0ca"
      unitRef="usd">128339000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i28c89bf87ce14cca9b2b800346e0f3cf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMy0xLTEtMS0zMzY0MQ_540ac90d-4654-42e5-836b-7b8a0a056a0c"
      unitRef="usd">10990000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i876b48d168b94c078324d718cfdcc6b4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMy0zLTEtMS0zMzY0MQ_e4466f17-5fb3-4cc4-9d3c-7b8956299ab6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i99895349e572414c90c807f0e0e17ebb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMy01LTEtMS0zMzY0MQ_de04730e-d349-4d8d-8855-1ff814c7ca5c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i547b6800236a4e0caab1382e2230e08a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMy03LTEtMS0zMzY0MQ_8d8e4e64-dc25-4aba-8cb7-e3578c070e89"
      unitRef="usd">10990000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6c4033bd7f2c4aeb9ee5d73233cec607_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfNS0xLTEtMS0zMzg3OA_6b2cd01a-acc5-49a4-a5f1-0d0ee3112b0b"
      unitRef="usd">10990000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4977728e4fe6441a934b69b20c984428_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfNS0zLTEtMS0zMzg3OA_5274969f-431d-4b20-a88c-e287357c6f23"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6ff28c3628c9439f9476dce8d023e9a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfNS01LTEtMS0zMzg3OA_9bd033fe-442e-4576-8c79-0d7dd6c8e4ca"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7f1aebf312994daaa324ca44ae909873_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfNS03LTEtMS0zMzg3OA_861c5dcd-e967-4806-9c97-26c38839e6ec"
      unitRef="usd">10990000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie28739979eeb42ef9ba44e6345bbce01_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfOC0xLTEtMS0zMzg4MQ_4e5f5e9f-7a44-4851-bcfa-65f4ad7bb98e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0548bc72c9014a57a21548990a80dc6d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfOC0zLTEtMS0zMzg4MQ_df3271ad-141c-4c5d-a29f-f5ed8d7049d1"
      unitRef="usd">1260000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i966397496b06482ea36f27e6d9813468_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfOC01LTEtMS0zMzg4MQ_2c72540e-fd8f-4d11-96c2-90d6b5128990"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8358790f990b4c0eb465115ec36b4bad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfOC03LTEtMS0zMzg4MQ_d4bb6238-8e32-4222-a12d-bc4be5b0107e"
      unitRef="usd">1260000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i141fc564298749ef90e593b383c7b4dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfOS0xLTEtMS0zMzg4MQ_8692ccf1-990a-4b1f-ae3d-8f17c57f9f84"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i703f601f436b43d49b1a487d4d19c8db_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfOS0zLTEtMS0zMzg4MQ_447c3813-d977-47f0-8e8b-d681dbb4b12c"
      unitRef="usd">88390000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i457626d4907642ed957f6fa275972b86_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfOS01LTEtMS0zMzg4MQ_a8c58d48-eb7d-45ec-ad15-452e1af39ff0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaf6c73f105ea4cf5b84fc6c9051918ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfOS03LTEtMS0zMzg4MQ_af5a2fb4-ccf1-4a88-a976-e8c20dad79df"
      unitRef="usd">88390000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i88f18fc910f945858e3b8bc20c69c3a8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTAtMS0xLTEtMzM4ODE_b97c8510-4567-4f2a-b683-ecdc339349a0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0fc6fa6aba914b51a5f862c4592ff78c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTAtMy0xLTEtMzM4ODE_bc95e116-6be2-4de7-b499-872438a5a03a"
      unitRef="usd">14454000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaad7930c0f094358b1f79e8717bc3ded_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTAtNS0xLTEtMzM4ODE_55112b93-c17c-4695-87b7-d0b6cbb7273f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifb33f7c370f04ac9b542a1d9ce2740d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTAtNy0xLTEtMzM4ODE_0e5922e0-2dfb-4039-b27f-f35ec26e2f17"
      unitRef="usd">14454000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8d8ce90d2f4242aebc0947a200a14d74_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTEtMS0xLTEtMzM4ODU_dca81588-fc3f-407b-a428-b3fde0399a71"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i978107023461439f9c9388246fe5f1d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTEtMy0xLTEtMzM4ODU_d8690f6b-55d2-41f8-bc4f-97013ac38e1b"
      unitRef="usd">728000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i077d5e0a95724189b2ed4ff9de4ca7b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTEtNS0xLTEtMzM4ODU_5d2c19cd-53e6-455d-83f4-9a20d6a7464a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i53718eacdc59401eb030bde33ae601c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTEtNy0xLTEtMzM4ODU_69f4a2c0-5559-4997-8c47-b2158c82cf40"
      unitRef="usd">728000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i67fc8a821a934707ad82e4a6523c6f04_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTItMS0xLTEtMzM4ODM_d4a82d01-15a2-4edc-aaf1-1eb4908e2246"
      unitRef="usd">24046000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i045f3a1f97f64eebba51a12fff7e25ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTItMy0xLTEtMzM4ODM_adde056e-0547-4eb0-8401-2d5d926707ff"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieeff0db315444d1fa011989d0832b897_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTItNS0xLTEtMzM4ODM_d7c23840-7976-4b74-b777-994f01801263"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i80595d8a12bd44fdbc458c86f92eaf8d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTItNy0xLTEtMzM4ODM_090f6f29-e33f-40d1-9c06-d609ae13db8f"
      unitRef="usd">24046000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6c4033bd7f2c4aeb9ee5d73233cec607_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTMtMS0xLTEtMzM4ODM_c95e1654-87b7-4003-8e0e-48e94116a7ec"
      unitRef="usd">24046000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4977728e4fe6441a934b69b20c984428_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTMtMy0xLTEtMzM4ODM_59d84fad-3154-4ff4-8da1-3a8759ea42e8"
      unitRef="usd">104832000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6ff28c3628c9439f9476dce8d023e9a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTMtNS0xLTEtMzM4ODM_abcc07bc-6562-4f82-a78d-b9bba85a9598"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f1aebf312994daaa324ca44ae909873_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTMtNy0xLTEtMzM4ODM_0033bd4a-2aa0-43e4-96f7-11428363cc30"
      unitRef="usd">128878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6c4033bd7f2c4aeb9ee5d73233cec607_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTUtMS0xLTEtMzM4ODM_70a46d6c-6cba-49f9-8405-be55498e4f52"
      unitRef="usd">35036000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4977728e4fe6441a934b69b20c984428_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTUtMy0xLTEtMzM4ODM_8f7459c8-92d6-4f65-9330-8039064de498"
      unitRef="usd">104832000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6ff28c3628c9439f9476dce8d023e9a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTUtNS0xLTEtMzM4ODM_61adb558-e6c7-46dd-afcc-e046292d4bbe"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7f1aebf312994daaa324ca44ae909873_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80Ni9mcmFnOjU1YzY1NTYyMWYwZTQxZjhiNTI4ZmNiYWEwYjczMjYzL3RhYmxlOjFlMWZlODIwMjU3YTRkNjBhODBiMmUzNWE4NDcwYTcyL3RhYmxlcmFuZ2U6MWUxZmU4MjAyNTdhNGQ2MGE4MGIyZTM1YTg0NzBhNzJfMTUtNy0xLTEtMzM4ODM_e7b3e06c-7d1d-491e-aa3a-12d9cbbd19a3"
      unitRef="usd">139868000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RleHRyZWdpb246Y2I1ZGFlMGMyZDM0NDc5MjliYzE3YjBkMmI2ZTRjNTBfMTcz_0ca90a8d-b98b-4349-8857-1e1f9e7640c3">Supplementary Balance Sheet Information&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments available for sale consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Market Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity less than 1 year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity 1 to 2 years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity 1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Market Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity less than 1 year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non U.S. government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity 1 to 2 years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity 1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#x2014;accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred stock dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research agreements and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Director fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees and outside services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patent, license and other fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RleHRyZWdpb246Y2I1ZGFlMGMyZDM0NDc5MjliYzE3YjBkMmI2ZTRjNTBfMTY3_f03484c2-05c6-4c4f-b7d3-51121f6b8f67">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments available for sale consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Market Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity less than 1 year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity 1 to 2 years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity 1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Market Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity less than 1 year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non U.S. government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity 1 to 2 years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity 1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i3fedefbb21504c7c9d24ef677e84d271_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMi0xLTEtMS0yNzc0Mg_d90047cb-9fe5-4a77-8045-89f9fd816e7e"
      unitRef="usd">9250000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i3fedefbb21504c7c9d24ef677e84d271_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMi0zLTEtMS0yNzc0Mg_999fd708-6c3b-4307-ac35-4363c97d88f8"
      unitRef="usd">4000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i3fedefbb21504c7c9d24ef677e84d271_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMi01LTEtMS0yNzc0Mg_4e672a99-db8f-4c3b-adb1-3c4f04f9acf5"
      unitRef="usd">15000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3fedefbb21504c7c9d24ef677e84d271_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMi03LTEtMS0yNzc0Mg_e9ad8eaf-9871-48ba-aff3-610a77b3b997"
      unitRef="usd">9239000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i9a1e4ef065b44bde91fa2353faafba2d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMy0xLTEtMS0yNzc0Mg_bc8d6097-8b67-465d-8582-38e053d385f6"
      unitRef="usd">55056000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i9a1e4ef065b44bde91fa2353faafba2d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMy0zLTEtMS0yNzc0Mg_ff20bf3d-4330-4850-afc5-4b24f43965a4"
      unitRef="usd">1000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i9a1e4ef065b44bde91fa2353faafba2d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMy01LTEtMS0yNzc0Mg_fa869b33-4d75-46ee-89f4-f42345e9fde4"
      unitRef="usd">293000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9a1e4ef065b44bde91fa2353faafba2d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMy03LTEtMS0yNzc0Mg_763dc714-309c-4748-8d2f-3f69b52d51eb"
      unitRef="usd">54764000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="iab946214765844419385e846f2f071c4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNC0xLTEtMS0yNzc0Mg_36ed1574-ea8d-459b-883c-5f8f7972fc03"
      unitRef="usd">10539000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="iab946214765844419385e846f2f071c4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNC0zLTEtMS0yNzc0Mg_a3b0f423-f85d-4683-b301-dedd26b82995"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="iab946214765844419385e846f2f071c4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNC01LTEtMS0yNzc0Mg_c6b51af2-9cfe-48bd-9f13-8d10574990bc"
      unitRef="usd">71000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iab946214765844419385e846f2f071c4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNC03LTEtMS0yNzc0Mg_3109ac55-8238-4db6-b8b4-98dae77dc496"
      unitRef="usd">10468000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i9c3e566014904bf0849ff752d63a833b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNi0xLTEtMS0yNzc0Mg_878a13ff-4194-4186-a645-50bc621eb7a0"
      unitRef="usd">20061000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i9c3e566014904bf0849ff752d63a833b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNi0zLTEtMS0yNzc0Mg_0eedfb96-fd5f-41a0-a143-eaa4e2158528"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i9c3e566014904bf0849ff752d63a833b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNi01LTEtMS0yNzc0Mg_9b9854ac-7ce4-44bf-b183-56cfb5477e65"
      unitRef="usd">122000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9c3e566014904bf0849ff752d63a833b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNi03LTEtMS0yNzc0Mg_70ae7cf9-db0e-4bca-a51c-3f93fc13b761"
      unitRef="usd">19939000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfOC0xLTEtMS0yODc1Mw_4fc29732-e74b-47f5-824b-bf8d53f3e195"
      unitRef="usd">94906000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfOC0zLTEtMS0yODc1Mw_fc318395-bf69-48e8-90c0-259a39105f77"
      unitRef="usd">5000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfOC01LTEtMS0yODc1Mw_7b71c4d7-c2ea-437b-bc8c-b53656927c7f"
      unitRef="usd">501000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfOC03LTEtMS0yODc1Mw_39bc228c-9136-4a91-b49c-34b92d23e3da"
      unitRef="usd">94410000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i9a1e4ef065b44bde91fa2353faafba2d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMTAtMS0xLTEtMjg3NTM_72826127-ac86-4b1c-a58b-a52e411df766"
      unitRef="usd">15152000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i9a1e4ef065b44bde91fa2353faafba2d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMTAtMy0xLTEtMjg3NTM_d1cb32f5-ab72-40ee-a127-93dedf4af145"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i9a1e4ef065b44bde91fa2353faafba2d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMTAtNS0xLTEtMjg3NTM_592516b2-00af-4ca4-af96-19a4c33d5ab9"
      unitRef="usd">252000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9a1e4ef065b44bde91fa2353faafba2d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMTAtNy0xLTEtMjg3NTM_d7d58636-90f9-4ade-9361-0be6c1819cc4"
      unitRef="usd">14900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMTItMS0xLTEtMjg3NTM_30c65e8e-0066-4709-9b1d-7f547ddaccce"
      unitRef="usd">15152000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMTItMy0xLTEtMjg3NTM_03c6033d-e14d-435f-ab2d-de7bffadc214"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMTItNS0xLTEtMjg3NTM_737a410e-10d8-4a21-8477-4fc0c89e2661"
      unitRef="usd">252000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfMTItNy0xLTEtMjg3NTM_de3fc48f-9c9f-4e9f-a697-2d086c00df3c"
      unitRef="usd">14900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNy0xLTEtMS0yNzc0Mg_d32af426-81cb-4199-83b8-f245423825b5"
      unitRef="usd">110058000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNy0zLTEtMS0yNzc0Mg_a7f8b25d-6238-4041-85de-cbddb68eecf2"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNy01LTEtMS0yNzc0Mg_63b5c874-342a-4f15-a20c-3849de1dff45"
      unitRef="usd">753000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmM1NzliZTdjM2ZiNTQyMDVhY2Q1ZTE1ZGIwZTZkN2QyL3RhYmxlcmFuZ2U6YzU3OWJlN2MzZmI1NDIwNWFjZDVlMTVkYjBlNmQ3ZDJfNy03LTEtMS0yNzc0Mg_623317af-9869-4807-ac53-bde0fbed434f"
      unitRef="usd">109310000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i5cc8b81d6dec439faf2b7a1516cbae4f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMy0xLTEtMS0yODY0OA_a03f939d-6d63-4dce-95eb-081cb25217ca"
      unitRef="usd">1260000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i5cc8b81d6dec439faf2b7a1516cbae4f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMy0zLTEtMS0yODY0OA_ecbb3de1-0e51-4606-a5ec-59a4898a80ad"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i5cc8b81d6dec439faf2b7a1516cbae4f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMy01LTEtMS0yODY0OA_ade2da37-8e52-4f41-9f24-baf4349b0452"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5cc8b81d6dec439faf2b7a1516cbae4f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMy03LTEtMS0yODY0OA_4be45e08-337c-4d9b-9697-66c8f9c829cc"
      unitRef="usd">1260000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ibaf3870ca7e245d39bb917baeb589cfd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNC0xLTEtMS0yODY0OA_0ae1a190-88d1-4a66-84fb-e457e9495688"
      unitRef="usd">58822000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="ibaf3870ca7e245d39bb917baeb589cfd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNC0zLTEtMS0yODY0OA_6a17750d-978c-4abf-b89b-22d1f274a392"
      unitRef="usd">2000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="ibaf3870ca7e245d39bb917baeb589cfd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNC01LTEtMS0yODY0OA_4a23e8ae-2a99-42d7-a5c4-680833c56217"
      unitRef="usd">38000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibaf3870ca7e245d39bb917baeb589cfd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNC03LTEtMS0yODY0OA_996ad7b9-ab92-4541-ba4b-141a5a6a3c7c"
      unitRef="usd">58786000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i7ea1c1903a66482189db39519fa9ab69_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNS0xLTEtMS0yODY0OA_7bf835be-09bf-4767-8de9-85ef034c4f61"
      unitRef="usd">14453000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i7ea1c1903a66482189db39519fa9ab69_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNS0zLTEtMS0yODY0OA_8ee08bc0-9926-435f-8b20-56e52ea16f04"
      unitRef="usd">4000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i7ea1c1903a66482189db39519fa9ab69_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNS01LTEtMS0yODY0OA_005d270e-f6b5-4da1-b1f4-c8c92d8b65ec"
      unitRef="usd">3000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7ea1c1903a66482189db39519fa9ab69_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNS03LTEtMS0yODY0OA_7aa8d24a-cd59-4371-b7c9-0c8133b8fdab"
      unitRef="usd">14454000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i147c926c319848eda463b6b78b8ba88c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNi0xLTEtMS0yODY0OA_341a8579-6858-412d-973a-0c247dc29e0d"
      unitRef="usd">728000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i147c926c319848eda463b6b78b8ba88c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNi0zLTEtMS0yODY0OA_808cb568-f6f3-4be4-a1cf-83349bb15421"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i147c926c319848eda463b6b78b8ba88c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNi01LTEtMS0yODY0OA_73a3fb4a-6777-4415-a6e9-bac6204d369e"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i147c926c319848eda463b6b78b8ba88c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNi03LTEtMS0yODY0OA_ea4b6a47-e61e-4acb-9eee-4fdfaaf47098"
      unitRef="usd">728000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i5d9c1d34a1db4e9fb7d337599646fa44_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNy0xLTEtMS0yODY0OA_0c9d29be-fa95-4ceb-96db-a86dc74014da"
      unitRef="usd">20380000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i5d9c1d34a1db4e9fb7d337599646fa44_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNy0zLTEtMS0yODY0OA_4fdaded8-59f9-4bbd-afde-4fe50b2dbfd2"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i5d9c1d34a1db4e9fb7d337599646fa44_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNy01LTEtMS0yODY0OA_cedf3e6a-7519-4f81-82d6-adf68ac2b476"
      unitRef="usd">24000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5d9c1d34a1db4e9fb7d337599646fa44_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfNy03LTEtMS0yODY0OA_9d4f2379-098b-4725-a75f-7ab62ed90980"
      unitRef="usd">20356000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfOC0xLTEtMS0yODY0OA_4e71bc34-1bc6-4b22-9085-6924605ec112"
      unitRef="usd">95643000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfOC0zLTEtMS0yODY0OA_31bced97-f66a-4b75-a205-1b71514d363f"
      unitRef="usd">6000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfOC01LTEtMS0yODY0OA_1bf357f8-18e2-477c-8080-002ec04b18c1"
      unitRef="usd">65000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfOC03LTEtMS0yODY0OA_735333a4-3857-4d54-9ba6-fd805c0bbf1c"
      unitRef="usd">95584000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="ibaf3870ca7e245d39bb917baeb589cfd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTAtMS0xLTEtMjg2NDg_c5c9a21d-83ab-433b-8f18-632a494ded0f"
      unitRef="usd">29676000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="ibaf3870ca7e245d39bb917baeb589cfd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTAtMy0xLTEtMjg2NDg_a9e3b5d8-5851-40a6-b168-52f825c5686f"
      unitRef="usd">1000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="ibaf3870ca7e245d39bb917baeb589cfd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTAtNS0xLTEtMjg2NDg_5563d5bf-60ad-4001-8a44-8b12315c6f56"
      unitRef="usd">73000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ibaf3870ca7e245d39bb917baeb589cfd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTAtNy0xLTEtMjg2NDg_fa96686d-1cf8-442f-881f-20a8c61fc969"
      unitRef="usd">29604000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i5d9c1d34a1db4e9fb7d337599646fa44_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTEtMS0xLTEtMjg2NDg_e67e62cd-7d0a-4703-9840-d30d0cee802f"
      unitRef="usd">3701000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i5d9c1d34a1db4e9fb7d337599646fa44_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTEtMy0xLTEtMjg2NDg_70e949c6-1ed0-43cd-a4cd-ccf113436d25"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i5d9c1d34a1db4e9fb7d337599646fa44_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTEtNS0xLTEtMjg2NDg_509e6a9a-2fc5-44df-a64d-a5939c8ad38e"
      unitRef="usd">11000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5d9c1d34a1db4e9fb7d337599646fa44_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTEtNy0xLTEtMjg2NDg_a56f982c-a8fd-44e7-9015-c50c899c6203"
      unitRef="usd">3690000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTItMS0xLTEtMjg2NDg_2df49b68-c155-4dd6-abde-596a801b1fde"
      unitRef="usd">33377000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTItMy0xLTEtMjg2NDg_410fe84c-f349-40c7-9b99-ff3276288519"
      unitRef="usd">1000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTItNS0xLTEtMjg2NDg_8386ab22-211e-43e8-9611-50b7bf0d1337"
      unitRef="usd">84000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTItNy0xLTEtMjg2NDg_ac50c2eb-f660-40a2-8baf-e65eed2f7cdb"
      unitRef="usd">33294000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTQtMS0xLTEtMjg2NDg_ce5dcb40-5dbe-4b6d-a165-a78ed34dacbf"
      unitRef="usd">129020000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTQtMy0xLTEtMjg2NDg_d8dd29b6-8231-43f5-8592-3605aa211c6c"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTQtNS0xLTEtMjg2NDg_03639a94-b1d2-4076-81c1-8e72468d6cd5"
      unitRef="usd">149000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjBhYzM0N2Y4Nzg5NTRlMGVhZGQwNWQ2ODNjMmEwZDZmL3RhYmxlcmFuZ2U6MGFjMzQ3Zjg3ODk1NGUwZWFkZDA1ZDY4M2MyYTBkNmZfMTQtNy0xLTEtMjg2NDg_de8a96ad-9c8e-4c98-9f76-b869632f4d35"
      unitRef="usd">128878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RleHRyZWdpb246Y2I1ZGFlMGMyZDM0NDc5MjliYzE3YjBkMmI2ZTRjNTBfMTcw_b3804f21-927b-49a9-bf8a-736072044d80">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#x2014;accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iad1db42d1d374f53989a2e7eb3b57555_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfMS0xLTEtMS0yNzc0Mg_43b20823-64b6-494d-a360-be3ae1e0f35b"
      unitRef="usd">1064000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i76184d10cb394f4ea42385613d47f3a0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfMS0zLTEtMS0yNzc0Mg_a3fd2afa-3f27-4807-9b5e-cdb98bf0c06d"
      unitRef="usd">955000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2fec98606e0d4c2f815d907fbfd712cd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfMi0xLTEtMS0yNzc0Mg_c07cb67f-554a-46bc-9550-e844616ed31a"
      unitRef="usd">2046000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iafe44b0f34c648c084e4cb969b1c99e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfMi0zLTEtMS0yNzc0Mg_dcd97e2b-9448-4791-934a-d96768d22104"
      unitRef="usd">1962000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i86dfda88f61d4ab88a4b5f4a3dea2526_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfMy0xLTEtMS0yNzc0Mg_b17e9b73-24ce-4a73-9a92-406cbed973f8"
      unitRef="usd">912000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4794d63837f04ab3a7126147249402b5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfMy0zLTEtMS0yNzc0Mg_5d71eeb6-aa34-4ab7-88e1-551d3d345424"
      unitRef="usd">906000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfNC0xLTEtMS0yNzc0Mg_045024f6-72c7-4351-9177-d189fefe941d"
      unitRef="usd">4022000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfNC0zLTEtMS0yNzc0Mg_e1678bc8-a4f8-4035-9894-4cb341b1f03f"
      unitRef="usd">3823000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfNS0xLTEtMS0yNzc0Mg_3a47d3df-7163-46d4-8150-ab1a1a74ec6b"
      unitRef="usd">3472000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfNS0zLTEtMS0yNzc0Mg_78e4e718-c099-4dc3-8e3f-c33118b6be65"
      unitRef="usd">3441000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfNi0xLTEtMS0yNzc0Mg_f1698f72-c044-41c2-8e36-4c0d178df9b6"
      unitRef="usd">550000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOmFmMjg5ZjhmMDNmYzQ3NjViNmE3MTkzYzE0MWU1OWNkL3RhYmxlcmFuZ2U6YWYyODlmOGYwM2ZjNDc2NWI2YTcxOTNjMTQxZTU5Y2RfNi0zLTEtMS0yNzc0Mg_566d83dc-6b28-48eb-8d2b-9a1e78b59aab"
      unitRef="usd">382000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RleHRyZWdpb246Y2I1ZGFlMGMyZDM0NDc5MjliYzE3YjBkMmI2ZTRjNTBfNjA0NzMxMzk1MzA0NQ_069660e8-e175-4c70-90c0-796feb83b5c7">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred stock dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research agreements and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Director fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees and outside services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patent, license and other fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfMi0xLTEtMS0zMzM5Mg_622b38c7-0284-4ea6-973c-79d74fe16332"
      unitRef="usd">878000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfMi0zLTEtMS0zMzM5Mg_cdd2c02d-0845-4a61-bb1b-7922afee76a8"
      unitRef="usd">1435000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <crdf:AccruedPreferredStockDividend
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfMy0xLTEtMS0zMzM5Mg_d793b434-3ac8-4f37-ad1d-d33a67c65a08"
      unitRef="usd">420000</crdf:AccruedPreferredStockDividend>
    <crdf:AccruedPreferredStockDividend
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfMy0zLTEtMS0zMzM5Mg_5990b270-ae02-4f25-81ed-ba02487907aa"
      unitRef="usd">414000</crdf:AccruedPreferredStockDividend>
    <crdf:AccruedClinicalTrial
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfNC0xLTEtMS0zMzM5Mg_8ed8fc04-2ffb-48ff-a0a4-2927362202ee"
      unitRef="usd">2110000</crdf:AccruedClinicalTrial>
    <crdf:AccruedClinicalTrial
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfNC0zLTEtMS0zMzM5Mg_16c87909-0bbd-4725-a527-a4e565ff6322"
      unitRef="usd">1639000</crdf:AccruedClinicalTrial>
    <crdf:AccruedResearchAgreements
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfNS0xLTEtMS0zMzM5Mg_8b04a76c-0cf4-4f24-a725-70bc3ba0b5b0"
      unitRef="usd">992000</crdf:AccruedResearchAgreements>
    <crdf:AccruedResearchAgreements
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfNS0zLTEtMS0zMzM5Mg_6cc7bd5a-1067-40e8-a74a-d7209faa3ac8"
      unitRef="usd">726000</crdf:AccruedResearchAgreements>
    <crdf:AccruedDirectorFees
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfNi0xLTEtMS0zMzM5Mg_d7cc646e-4656-494f-99df-e4e58b49d67c"
      unitRef="usd">141000</crdf:AccruedDirectorFees>
    <crdf:AccruedDirectorFees
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfNi0zLTEtMS0zMzM5Mg_0077b41a-0965-4d8b-9395-e89ed256f77c"
      unitRef="usd">141000</crdf:AccruedDirectorFees>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfNy0xLTEtMS0zMzM5Mg_688bc432-02bc-4c73-aa32-31cd29e4cb96"
      unitRef="usd">53000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfNy0zLTEtMS0zMzM5Mg_cc7bb9c2-75c2-47ea-95f5-a5a57bf9d885"
      unitRef="usd">63000</us-gaap:AccruedProfessionalFeesCurrent>
    <crdf:PatentLicenseAndOtherFeesPayable
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfOC0xLTEtMS0zMzM5Mg_05895f52-f074-43ad-8e8c-5e6f290adae9"
      unitRef="usd">75000</crdf:PatentLicenseAndOtherFeesPayable>
    <crdf:PatentLicenseAndOtherFeesPayable
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfOC0zLTEtMS0zMzM5Mg_e21a914b-a826-4302-8934-40fcb085b391"
      unitRef="usd">43000</crdf:PatentLicenseAndOtherFeesPayable>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfMTAtMS0xLTEtMzMzOTI_f8831d5e-8711-44c1-a64c-4748a93a6d4e"
      unitRef="usd">69000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfMTAtMy0xLTEtMzMzOTI_4fa9b6e9-c14d-4806-bacf-a45230356c1d"
      unitRef="usd">66000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfMTEtMS0xLTEtMzMzOTI_8ce33ed5-18f2-46d2-903e-f0dcfd35fafa"
      unitRef="usd">4738000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV80OS9mcmFnOmNiNWRhZTBjMmQzNDQ3OTI5YmMxN2IwZDJiNmU0YzUwL3RhYmxlOjM2ZGNjNzRkYWZmNDRkODFhZjE0ZjY0MGQzNGE3YTc3L3RhYmxlcmFuZ2U6MzZkY2M3NGRhZmY0NGQ4MWFmMTRmNjQwZDM0YTdhNzdfMTEtMy0xLTEtMzMzOTI_9870e56d-224a-4004-9288-ed975207fd4f"
      unitRef="usd">4527000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfMTg4MQ_62c8a59a-2a14-4d4e-a85f-b8f2849925a3">Leases&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;As a lessee, the Company&#x2019;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Master Facility Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently leases 12,300 square feet of office and lab space in San Diego that expires on February 28, 2027. The lease currently requires monthly payments of approximately $60,000 per month with 3% annual escalation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Facility Subleases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and subleased the space to third parties under three separate sublease agreements, which all expired on December 31, 2021. Prior to the expiration of the sublease agreements, the Company as a sublessor was leasing approximately 16,600 square feet of space to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the three months ended March&#160;31, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfMTg5NQ_5803b629-df1f-4b69-8582-4525a4776c83">Leases&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;As a lessee, the Company&#x2019;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Master Facility Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently leases 12,300 square feet of office and lab space in San Diego that expires on February 28, 2027. The lease currently requires monthly payments of approximately $60,000 per month with 3% annual escalation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Facility Subleases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and subleased the space to third parties under three separate sublease agreements, which all expired on December 31, 2021. Prior to the expiration of the sublease agreements, the Company as a sublessor was leasing approximately 16,600 square feet of space to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the three months ended March&#160;31, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <crdf:LesseeOperatingLeaseAreaOfLease
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfODAz_32ba87c7-6589-4451-b007-354b3e338951"
      unitRef="sqft">12300</crdf:LesseeOperatingLeaseAreaOfLease>
    <crdf:LesseeOperatingLeaseMonthlyRentPayment
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfMTE0OQ_cf37dd0b-a0bb-4af9-a5cf-4d63008b8ac0"
      unitRef="usd">60000</crdf:LesseeOperatingLeaseMonthlyRentPayment>
    <crdf:LesseeOperatingLeaseAnnualRentIncreasePercentage
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfMTA5OTUxMTYzMTI5MQ_642e6f65-3547-4f2e-a3f0-b001eb9fe0ce"
      unitRef="number">0.03</crdf:LesseeOperatingLeaseAnnualRentIncreasePercentage>
    <crdf:LessorNumberOfSubleases
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfMTM0MQ_e09e7f87-f6ad-49ee-85d3-6ea430b06bec"
      unitRef="lease">3</crdf:LessorNumberOfSubleases>
    <crdf:LessorAreaOfSublease
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfMTQ2NQ_88a2cdcb-852b-48a2-ab59-0af49efe8eb7"
      unitRef="sqft">16600</crdf:LessorAreaOfSublease>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfMTg5NA_3ef574bf-399c-4b9b-865a-85d12f0972cb">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmIyN2U0OTU4MDc1MTRjYzZhYzlmMDVhNzE3N2UyZGFjL3RhYmxlcmFuZ2U6YjI3ZTQ5NTgwNzUxNGNjNmFjOWYwNWE3MTc3ZTJkYWNfMi01LTEtMS0yNzc0Mg_c6145582-d9af-470e-9142-6ce04012fe19"
      unitRef="usd">191000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmIyN2U0OTU4MDc1MTRjYzZhYzlmMDVhNzE3N2UyZGFjL3RhYmxlcmFuZ2U6YjI3ZTQ5NTgwNzUxNGNjNmFjOWYwNWE3MTc3ZTJkYWNfMi03LTEtMS0yNzc0Mg_fa690d36-2c26-4409-a5e3-7e122ccaeb66"
      unitRef="usd">95000</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmIyN2U0OTU4MDc1MTRjYzZhYzlmMDVhNzE3N2UyZGFjL3RhYmxlcmFuZ2U6YjI3ZTQ5NTgwNzUxNGNjNmFjOWYwNWE3MTc3ZTJkYWNfMy01LTEtMS0yNzc0Mg_4fb1e0fc-ffa8-420e-b4ec-f66a893f2d54"
      unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmIyN2U0OTU4MDc1MTRjYzZhYzlmMDVhNzE3N2UyZGFjL3RhYmxlcmFuZ2U6YjI3ZTQ5NTgwNzUxNGNjNmFjOWYwNWE3MTc3ZTJkYWNfMy03LTEtMS0yNzc0Mg_eff7faef-765a-4e39-b6f9-a8833e12cf0e"
      unitRef="usd">101000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmIyN2U0OTU4MDc1MTRjYzZhYzlmMDVhNzE3N2UyZGFjL3RhYmxlcmFuZ2U6YjI3ZTQ5NTgwNzUxNGNjNmFjOWYwNWE3MTc3ZTJkYWNfNC01LTEtMS0yNzc0Mg_9325fb3c-19e6-4480-9ec7-aa88a3570264"
      unitRef="usd">191000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmIyN2U0OTU4MDc1MTRjYzZhYzlmMDVhNzE3N2UyZGFjL3RhYmxlcmFuZ2U6YjI3ZTQ5NTgwNzUxNGNjNmFjOWYwNWE3MTc3ZTJkYWNfNC03LTEtMS0yNzc0Mg_58251a82-4922-4fe6-ab33-b14148ffdd27"
      unitRef="usd">-6000</us-gaap:LeaseCost>
    <crdf:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfMTg4Mw_0c23400d-f45e-4f00-84c6-07d573da787d">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</crdf:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfMS0xLTEtMS0yNzc0Mg_dacb1518-0249-4dca-8b0e-f535e5fb6c99"
      unitRef="usd">2660000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfMS0zLTEtMS0yNzc0Mg_851e5f3b-1bf9-4265-baf5-0dfbe0882e21"
      unitRef="usd">2796000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfMy0xLTEtMS0yNzc0Mg_4cb91254-1f01-4cf3-9b3d-e06741eeaef5"
      unitRef="usd">665000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfMy0zLTEtMS0yNzc0Mg_9d4ba6ec-e30e-452b-8539-a369e0a44067"
      unitRef="usd">551000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfNC0xLTEtMS0yNzc0Mg_b7bb9539-6737-4ede-8894-ca7c9bbdcf31"
      unitRef="usd">2438000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfNC0zLTEtMS0yNzc0Mg_811715d1-bcb6-4c1e-84e5-44ad0e007e93"
      unitRef="usd">2568000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfNS0xLTEtMS0yNzc0Mg_1c3f0a2e-2611-42b1-8914-1a8ae3229484"
      unitRef="usd">3103000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfNS0zLTEtMS0yNzc0Mg_93fc07c9-f386-4dbd-86b8-0b7cf41f4795"
      unitRef="usd">3119000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfNy0xLTEtMS0yNzc0Mg_362f5340-b195-4636-8964-aa0862427930">P4Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfNy0zLTEtMS0yNzc0Mg_9fbfb6d5-22af-463e-b510-1299b1ad2dd4">P5Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfOC0xLTEtMS0yNzc0Mg_24890805-4332-499d-96d9-273eb0f366d6"
      unitRef="number">0.070</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ1OTcwODJjYTkzMDRjMjFiMWI1OGYyZDljZTgyMWQ3L3RhYmxlcmFuZ2U6ZDU5NzA4MmNhOTMwNGMyMWIxYjU4ZjJkOWNlODIxZDdfOC0zLTEtMS0yNzc0Mg_b16e43e5-4cbe-4281-bb95-40abc446022f"
      unitRef="number">0.070</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ4ZDU4MDZmZDYxZTQ2YWQ5NDBkNjVmMzNlODMzZmVjL3RhYmxlcmFuZ2U6ZDhkNTgwNmZkNjFlNDZhZDk0MGQ2NWYzM2U4MzNmZWNfMy01LTEtMS0yNzc0Mg_f1826213-bd98-4bb5-a29e-89fdaca49ca2"
      unitRef="usd">70000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOmQ4ZDU4MDZmZDYxZTQ2YWQ5NDBkNjVmMzNlODMzZmVjL3RhYmxlcmFuZ2U6ZDhkNTgwNmZkNjFlNDZhZDk0MGQ2NWYzM2U4MzNmZWNfMy03LTEtMS0yNzc0Mg_3790b3f3-993f-47c6-9f99-fb29f7b17a4f"
      unitRef="usd">240000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RleHRyZWdpb246NjAxMTZiY2Y3OWM3NGJkNGJlZTY1ZTcyNDYzYmFhYjhfMTg5MQ_a08eef14-e42e-469d-9ea4-f1097c8286ae">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the three months ended March&#160;31, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOjA0YmQ2MmEyNDk5NTQzMGJhMTAwYmZiNjRkZTc3OTkxL3RhYmxlcmFuZ2U6MDRiZDYyYTI0OTk1NDMwYmExMDBiZmI2NGRlNzc5OTFfMy0xLTEtMS0yNzc0Mg_95e61cc2-e6a4-4eb2-8278-591bc43880c0"
      unitRef="usd">480000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOjA0YmQ2MmEyNDk5NTQzMGJhMTAwYmZiNjRkZTc3OTkxL3RhYmxlcmFuZ2U6MDRiZDYyYTI0OTk1NDMwYmExMDBiZmI2NGRlNzc5OTFfNC0xLTEtMS0yNzc0Mg_dc36c5cf-0c68-45f1-9f68-0c489e83ba91"
      unitRef="usd">737000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOjA0YmQ2MmEyNDk5NTQzMGJhMTAwYmZiNjRkZTc3OTkxL3RhYmxlcmFuZ2U6MDRiZDYyYTI0OTk1NDMwYmExMDBiZmI2NGRlNzc5OTFfNS0xLTEtMS0yNzc0Mg_e8a3e511-6ff5-44b1-adfa-6e28436da837"
      unitRef="usd">754000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOjA0YmQ2MmEyNDk5NTQzMGJhMTAwYmZiNjRkZTc3OTkxL3RhYmxlcmFuZ2U6MDRiZDYyYTI0OTk1NDMwYmExMDBiZmI2NGRlNzc5OTFfNi0xLTEtMS0yNzc0Mg_fcaa3e94-7011-451d-8598-c3ca097dd674"
      unitRef="usd">775000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOjA0YmQ2MmEyNDk5NTQzMGJhMTAwYmZiNjRkZTc3OTkxL3RhYmxlcmFuZ2U6MDRiZDYyYTI0OTk1NDMwYmExMDBiZmI2NGRlNzc5OTFfNy0xLTEtMS0yNzc0Mg_104f264e-1959-4cda-aaeb-fbcce6ce726d"
      unitRef="usd">796000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <crdf:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOjA0YmQ2MmEyNDk5NTQzMGJhMTAwYmZiNjRkZTc3OTkxL3RhYmxlcmFuZ2U6MDRiZDYyYTI0OTk1NDMwYmExMDBiZmI2NGRlNzc5OTFfOS0xLTEtMS0yNzc0Mg_d319290e-66e8-4c5b-b67a-a68cff4da92d"
      unitRef="usd">137000</crdf:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOjA0YmQ2MmEyNDk5NTQzMGJhMTAwYmZiNjRkZTc3OTkxL3RhYmxlcmFuZ2U6MDRiZDYyYTI0OTk1NDMwYmExMDBiZmI2NGRlNzc5OTFfMTAtMS0xLTEtMjc3NDI_deeeeab3-6d90-4080-a4a8-9c3b090a268f"
      unitRef="usd">3679000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOjA0YmQ2MmEyNDk5NTQzMGJhMTAwYmZiNjRkZTc3OTkxL3RhYmxlcmFuZ2U6MDRiZDYyYTI0OTk1NDMwYmExMDBiZmI2NGRlNzc5OTFfMTEtMS0xLTEtMjc3NDI_c47b66cf-33ba-48d0-9f67-d811114974d5"
      unitRef="usd">576000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81Mi9mcmFnOjYwMTE2YmNmNzljNzRiZDRiZWU2NWU3MjQ2M2JhYWI4L3RhYmxlOjA0YmQ2MmEyNDk5NTQzMGJhMTAwYmZiNjRkZTc3OTkxL3RhYmxlcmFuZ2U6MDRiZDYyYTI0OTk1NDMwYmExMDBiZmI2NGRlNzc5OTFfMTItMS0xLTEtMjc3NDI_b1dcccee-7839-4e40-8ee9-99390039da44"
      unitRef="usd">3103000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMjc0Ng_48f37604-873f-468c-9fe3-659271d7b667">Stockholders&#x2019; Equity&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrecognized compensation cost related to non-vested stock options outstanding at March&#160;31, 2022, net of estimated forfeitures, was $13.3 million, which is expected to be recognized over a weighted-average remaining vesting period of 3.2 years.&#160;The weighted-average remaining contractual term of outstanding options as of March&#160;31, 2022 was approximately 8.3 years. The total fair value of stock options vested during the three months ended March 31, 2022 and 2021 were $1,000 and $24,000, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No stock options were granted during the three months ended March 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity and changes in stock options outstanding is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,771,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,405,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,697,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled / Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,467,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,281,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,331,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 the Company's stockholders approved the 2021 Omnibus Equity Incentive Plan ("2021 Plan"). The number of authorized shares in the 2021 Plan is equal to the sum of (i) 3,150,000 shares, plus (ii) the number of shares of Common Stock reserved, but unissued under the 2014 Plan; and (iii) the number of shares of Common Stock underlying forfeited awards under the 2014 Plan. As of March&#160;31, 2022, there were 918,865 shares available for issuance under the 2021 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to the adoption of the 2021 Plan, no additional equity awards can be made under the terms of the 2014 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inducement Grants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company began issuing equity awards to certain new employees as inducement grants outside of its 2021 Plan. As of March&#160;31, 2022, an aggregate of 1,120,208 shares were issuable upon the exercise of inducement grant stock options approved by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&#160;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&#160;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our Company's classes of preferred stock is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Par value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares designated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidation preference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMjc0NA_57b72d32-1ef0-4b18-9b67-f698b137189e">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idf31e53b9d2d45af97ed7cc8c45e4d49_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjViMGU0YTUwMzc1YTQ4NzBiNmIwMDU2N2RhODAxYjM2L3RhYmxlcmFuZ2U6NWIwZTRhNTAzNzVhNDg3MGI2YjAwNTY3ZGE4MDFiMzZfMy01LTEtMS0yNzc0Mg_bb866467-0e57-408e-9046-ad124f0e51f2"
      unitRef="usd">335000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaba2a240dd3945df929b606e4db832e0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjViMGU0YTUwMzc1YTQ4NzBiNmIwMDU2N2RhODAxYjM2L3RhYmxlcmFuZ2U6NWIwZTRhNTAzNzVhNDg3MGI2YjAwNTY3ZGE4MDFiMzZfMy03LTEtMS0yNzc0Mg_17160957-8eab-40c7-915a-b37dea53c57b"
      unitRef="usd">40000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5acd44d9cbae440c822b1c7ee063d0e2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjViMGU0YTUwMzc1YTQ4NzBiNmIwMDU2N2RhODAxYjM2L3RhYmxlcmFuZ2U6NWIwZTRhNTAzNzVhNDg3MGI2YjAwNTY3ZGE4MDFiMzZfNC01LTEtMS0yNzc0Mg_f7c81acf-13a4-4da5-87eb-e67a19ead8c9"
      unitRef="usd">817000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic7a9e753b3734856bcedf3f9838179e0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjViMGU0YTUwMzc1YTQ4NzBiNmIwMDU2N2RhODAxYjM2L3RhYmxlcmFuZ2U6NWIwZTRhNTAzNzVhNDg3MGI2YjAwNTY3ZGE4MDFiMzZfNC03LTEtMS0yNzc0Mg_03996feb-2d1d-4844-9be2-7c97891057b6"
      unitRef="usd">228000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjViMGU0YTUwMzc1YTQ4NzBiNmIwMDU2N2RhODAxYjM2L3RhYmxlcmFuZ2U6NWIwZTRhNTAzNzVhNDg3MGI2YjAwNTY3ZGE4MDFiMzZfNy01LTEtMS0yNzc0Mg_41baefc9-1d4e-49ae-8941-fbe8eaef47d1"
      unitRef="usd">1152000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjViMGU0YTUwMzc1YTQ4NzBiNmIwMDU2N2RhODAxYjM2L3RhYmxlcmFuZ2U6NWIwZTRhNTAzNzVhNDg3MGI2YjAwNTY3ZGE4MDFiMzZfNy03LTEtMS0yNzc0Mg_fc3ae4fb-f8a9-46f3-b290-e911ddd502df"
      unitRef="usd">268000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i893461f644cf442b9cd2137dff555003_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMzA2_866fc458-70b4-4811-91ac-6043b827ee75"
      unitRef="usd">13300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMzk3_68214cff-eaf2-468f-bb73-defb9c17e9c4">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfNDk5_e41d5d3a-e114-426e-ba19-0348805125df">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfNTc0_f205dde3-16bf-4502-8dff-f1d881e70522"
      unitRef="usd">1000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="if072b714d21c47edab0c3ff058c7d009_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfNTgx_7aa0aaf9-3323-4848-9e25-d5e92fdd6d56"
      unitRef="usd">24000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMjczOQ_609d396e-9652-406d-bc7a-1ca3c815d1f0">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmU2ODNlZTk0ZDJkMjRiY2ZiNTYyMzg4YzM2ZjQyMDI5L3RhYmxlcmFuZ2U6ZTY4M2VlOTRkMmQyNGJjZmI1NjIzODhjMzZmNDIwMjlfMi0xLTEtMS0yNzc0Mg_69276f84-f9d1-4903-82e7-8c5316adcda0"
      unitRef="number">0.0184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmU2ODNlZTk0ZDJkMjRiY2ZiNTYyMzg4YzM2ZjQyMDI5L3RhYmxlcmFuZ2U6ZTY4M2VlOTRkMmQyNGJjZmI1NjIzODhjMzZmNDIwMjlfMy0xLTEtMS0yNzc0Mg_204bf7b5-aebc-47c3-a051-703baabaf2b5"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmU2ODNlZTk0ZDJkMjRiY2ZiNTYyMzg4YzM2ZjQyMDI5L3RhYmxlcmFuZ2U6ZTY4M2VlOTRkMmQyNGJjZmI1NjIzODhjMzZmNDIwMjlfNC0xLTEtMS0yNzc0Mg_bea89c61-3ba1-4f98-939f-fa7b5a977a7e"
      unitRef="number">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmU2ODNlZTk0ZDJkMjRiY2ZiNTYyMzg4YzM2ZjQyMDI5L3RhYmxlcmFuZ2U6ZTY4M2VlOTRkMmQyNGJjZmI1NjIzODhjMzZmNDIwMjlfNS0xLTEtMS0yNzc0Mg_060bf5df-23c3-424b-9faf-c687a3686cdb">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3b15932b484a471ebbfef330aba8275d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMTA5OTUxMTYzMDcyNQ_e35f811c-6c36-4a1e-853c-c25b97201aba"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMjczNw_7437fa82-10a1-43b3-b8dc-d74df3bf9435">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity and changes in stock options outstanding is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,771,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,405,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,697,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled / Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,467,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,281,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,331,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic7a27c0297d5482cbcaf83e2e3556d4b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfMS0xLTEtMS0yNzc0Mg_f6153314-04eb-41ad-a92a-7ee485b879ef"
      unitRef="shares">3771984</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic7a27c0297d5482cbcaf83e2e3556d4b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfMS0zLTEtMS0yNzc0Mg_45d10aee-85eb-46cf-af9f-45217b8b8755"
      unitRef="usdPerShare">7.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ic7a27c0297d5482cbcaf83e2e3556d4b_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfMS01LTEtMS0yNzc0Mg_a4e8961e-a317-4551-81e5-670de36cbe67"
      unitRef="usd">6405258</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfMi0xLTEtMS0yNzc0Mg_bf5b938b-0d23-4343-88e3-4f820dc6c771"
      unitRef="shares">1697536</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfMi0zLTEtMS0yNzc0Mg_7b3112d5-96e5-4920-be6a-8cdab63150ae"
      unitRef="usdPerShare">3.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNC0xLTEtMS0yNzc0Mg_776522c2-03e5-41d1-9e60-8f84f0f0d973"
      unitRef="shares">1109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNC0zLTEtMS0yNzc0Mg_d617bbdf-dac5-4f16-9c2a-dbf2f5547ba8"
      unitRef="usdPerShare">31.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <crdf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
      contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNS0xLTEtMS0yNzc0Mg_0b43beab-88e7-459f-b16e-9438b6a1b253"
      unitRef="shares">800</crdf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod>
    <crdf:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="i3fcd332e60b342cfaa0870b4636cee00_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNS0zLTEtMS0yNzc0Mg_470f7a52-307d-47db-9e30-b2a0bcb80d82"
      unitRef="usdPerShare">165.84</crdf:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i893461f644cf442b9cd2137dff555003_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNi0xLTEtMS0yNzc0Mg_cd5229ce-f928-4dac-aeeb-19bd74f27ae9"
      unitRef="shares">5467611</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i893461f644cf442b9cd2137dff555003_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNi0zLTEtMS0yNzc0Mg_c30c2b5e-6d0b-4d6a-92ee-aac4f50c1d71"
      unitRef="usdPerShare">5.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i893461f644cf442b9cd2137dff555003_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNi01LTEtMS0yNzc0Mg_3501020f-0e92-4c56-a931-e02c6b347ec7"
      unitRef="usd">65189</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i893461f644cf442b9cd2137dff555003_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNy0xLTEtMS0yNzc0Mg_1f32e994-6a51-428c-a4f6-ce457e65b109"
      unitRef="shares">1281362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i893461f644cf442b9cd2137dff555003_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNy0zLTEtMS0yNzc0Mg_156031fc-b65a-448a-b9f8-9d656ab5da56"
      unitRef="usdPerShare">8.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i893461f644cf442b9cd2137dff555003_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfNy01LTEtMS0yNzc0Mg_3721f6cd-2032-465c-aa73-fa06cfdc5d9f"
      unitRef="usd">25108</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i893461f644cf442b9cd2137dff555003_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfOC0xLTEtMS0yNzc0Mg_b68ee0d5-752b-402e-ac32-a268e7e68ec5"
      unitRef="shares">5331850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i893461f644cf442b9cd2137dff555003_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfOC0zLTEtMS0yNzc0Mg_d1efa5d1-cee9-444d-957c-994bb3b42895"
      unitRef="usdPerShare">5.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i893461f644cf442b9cd2137dff555003_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOmNhYjAzMmE3ZjZkOTQ5YjZhOGJlOWIyNmVlMzM3ZWQ2L3RhYmxlcmFuZ2U6Y2FiMDMyYTdmNmQ5NDliNmE4YmU5YjI2ZWUzMzdlZDZfOC01LTEtMS0yNzc0Mg_3c5bb024-6c22-45af-ba7e-29629d90300f"
      unitRef="usd">61800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMTEzMw_7ae42ec6-0088-4462-abc2-2a73b5c12ab2"
      unitRef="shares">3150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i2401c06088e64dc38c0c80a779717d55_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMTM1Mg_ac3f7457-2724-4ef6-8a5a-5e8d5abab8aa"
      unitRef="shares">918865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i75f4f015594a4bbf8dbbe4dfa4bb7c12_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMTcyOA_7e49089e-8f9c-4c23-a044-4a825c67f734"
      unitRef="shares">1120208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMjc0MQ_14a97087-6f99-4b4d-be6d-b5b2f9a5c860">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&#160;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&#160;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjhlMTZlNjRmYjJkOTQ4ZDRiOTU0NGQyNjdhYTMwZDc1L3RhYmxlcmFuZ2U6OGUxNmU2NGZiMmQ5NDhkNGI5NTQ0ZDI2N2FhMzBkNzVfMS0xLTEtMS0yNzc0Mg_fee8898e-bc2a-475a-a7d5-dca0618a3098"
      unitRef="shares">4490159</us-gaap:ClassOfWarrantOrRightOutstanding>
    <crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="i80a10fb9a55041acbf4471eb9962b140_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjhlMTZlNjRmYjJkOTQ4ZDRiOTU0NGQyNjdhYTMwZDc1L3RhYmxlcmFuZ2U6OGUxNmU2NGZiMmQ5NDhkNGI5NTQ0ZDI2N2FhMzBkNzVfMS0zLTEtMS0yNzc0Mg_bba82dec-eb0a-4db0-968c-b463b6fafbbf"
      unitRef="usdPerShare">5.80</crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
      contextRef="i005b644829964efaa7d10c5ad40cdf4e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjhlMTZlNjRmYjJkOTQ4ZDRiOTU0NGQyNjdhYTMwZDc1L3RhYmxlcmFuZ2U6OGUxNmU2NGZiMmQ5NDhkNGI5NTQ0ZDI2N2FhMzBkNzVfMS01LTEtMS0yNzc0Mg_3c818778-bd07-4396-b631-2c3a05744ac5">P3Y</crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjhlMTZlNjRmYjJkOTQ4ZDRiOTU0NGQyNjdhYTMwZDc1L3RhYmxlcmFuZ2U6OGUxNmU2NGZiMmQ5NDhkNGI5NTQ0ZDI2N2FhMzBkNzVfNS0xLTEtMS0yNzc0Mg_e80c2172-871d-4f86-9726-169c417bcc4b"
      unitRef="shares">4490159</us-gaap:ClassOfWarrantOrRightOutstanding>
    <crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="i3e26e9a60f67478f930bec7f58534ab7_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjhlMTZlNjRmYjJkOTQ4ZDRiOTU0NGQyNjdhYTMwZDc1L3RhYmxlcmFuZ2U6OGUxNmU2NGZiMmQ5NDhkNGI5NTQ0ZDI2N2FhMzBkNzVfNS0zLTEtMS0yNzc0Mg_95a45148-2ae0-418e-9a18-9cf8904f1c31"
      unitRef="usdPerShare">5.80</crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjhlMTZlNjRmYjJkOTQ4ZDRiOTU0NGQyNjdhYTMwZDc1L3RhYmxlcmFuZ2U6OGUxNmU2NGZiMmQ5NDhkNGI5NTQ0ZDI2N2FhMzBkNzVfNS01LTEtMS0yNzc0Mg_8b3f4db8-8a9c-4189-81a7-93ed244de2b0">P2Y8M12D</crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RleHRyZWdpb246ZDRlNmZhMzdjNDZiNDEwYzkyNmRiMWZiNDdmZDk1NDZfMjczOA_f4e5fc29-3a79-4549-b32f-4633c123ff84">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our Company's classes of preferred stock is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Par value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares designated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidation preference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ifdc2b0e256004062aef3e08c666721e1_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfMi0yLTEtMS0yNzc0Mg_29b60fb6-5a41-4484-9a46-b932aa762293"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ifdc2b0e256004062aef3e08c666721e1_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfMi00LTEtMS0yNzc0Mg_8187b118-11c2-402c-9c05-533e753e0097"
      unitRef="shares">277100</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="ifdc2b0e256004062aef3e08c666721e1_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfMi02LTEtMS0yNzc0Mg_f9c4cf1f-a0a3-4547-ae7f-f66c37455887"
      unitRef="usd">606000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ifdc2b0e256004062aef3e08c666721e1_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfMi04LTEtMS0yNzc0Mg_a2375b5e-916f-4804-a548-cfd856f572c2"
      unitRef="shares">60600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i59573fd142404a38a175c7870f55419f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfMi0xMC0xLTEtMjc3NDI_882b305b-6c48-42e7-bc65-eaa0f9d8e2c3"
      unitRef="shares">60600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ifc3f3107c69b4f6b8dd87b5fdf51dfff_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfMy0yLTEtMS0yNzc0Mg_3ed9cd38-3e9f-48ae-878a-6b95d4c7a6b2"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ifc3f3107c69b4f6b8dd87b5fdf51dfff_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfMy00LTEtMS0yNzc0Mg_f83fcd5f-dc27-4c35-8646-adf8933dda09"
      unitRef="shares">8860</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ifc3f3107c69b4f6b8dd87b5fdf51dfff_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfMy04LTEtMS0yNzc0Mg_6f90e1c5-fe7c-4edc-a49a-6ba5f11b8733"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i3b017a6f753f436d9ec2f214f9ebe2f7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfMy0xMC0xLTEtMjc3NDI_5baa2966-5d09-4fe3-b740-7007be7f15e7"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2bbf49ad684a421fbea0a38b95540cc1_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNC0yLTEtMS0yNzc0Mg_14cc7879-b6e4-4912-b693-634fed3e45a9"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2bbf49ad684a421fbea0a38b95540cc1_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNC00LTEtMS0yNzc0Mg_56743a2d-6bb1-4b18-b683-d7529137779d"
      unitRef="shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2bbf49ad684a421fbea0a38b95540cc1_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNC04LTEtMS0yNzc0Mg_b730728e-78c5-4ad2-8e10-7df781e5113f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5be5174c9fb344c9a625c79d662f8c80_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNC0xMC0xLTEtMjc3NDI_22e6f438-a830-4805-8707-6a11af1dfc96"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i49b6a8dfc660406a91d6569610ca4915_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNS0yLTEtMS0yNzc0Mg_9f752d1a-04a4-4b9e-835c-14164ad75eda"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i49b6a8dfc660406a91d6569610ca4915_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNS00LTEtMS0yNzc0Mg_6d83ee11-ae04-4a74-bade-8c28879807e2"
      unitRef="shares">154670</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i49b6a8dfc660406a91d6569610ca4915_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNS04LTEtMS0yNzc0Mg_a6d6569f-d46a-479d-8b66-8e21db8dde40"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic8d76d5beb354ae2a99c506c37bfe260_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNS0xMC0xLTEtMjc3NDI_9c6d473c-a2e1-4b9f-b76f-344d61ee7da9"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0e7fca4604c9471d93e4d2007ee915b4_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNi0yLTEtMS0yNzc0Mg_91a6625a-36aa-4af0-aead-125cf77852bf"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0e7fca4604c9471d93e4d2007ee915b4_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNi00LTEtMS0yNzc0Mg_20c904e2-3ae2-4526-9c70-4286d18a99b7"
      unitRef="shares">865824</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0e7fca4604c9471d93e4d2007ee915b4_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNi04LTEtMS0yNzc0Mg_3fdca934-09fc-4685-a9e7-74772702128e"
      unitRef="shares">327509</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i4b1336fa1dbf42329f000675cc7b21f0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV81OC9mcmFnOmQ0ZTZmYTM3YzQ2YjQxMGM5MjZkYjFmYjQ3ZmQ5NTQ2L3RhYmxlOjA3N2VhYTM3NzdiYTRjODBhNWM3NzBmMjI0ZjdhNzBkL3RhYmxlcmFuZ2U6MDc3ZWFhMzc3N2JhNGM4MGE1Yzc3MGYyMjRmN2E3MGRfNi0xMC0xLTEtMjc3NDI_4cb8487f-8920-401d-a437-5a91d377a5f3"
      unitRef="shares">655044</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzZWRmMmEzMGM2NjQyOTY5YTdiNjhjMWU1MjNiYWE1L3NlYzo0M2VkZjJhMzBjNjY0Mjk2OWE3YjY4YzFlNTIzYmFhNV82MS9mcmFnOjlhODFiOTQ4MjgzMzRjMmRhZTY0M2E3NjhjY2RiNGNlL3RleHRyZWdpb246OWE4MWI5NDgyODMzNGMyZGFlNjQzYTc2OGNjZGI0Y2VfMjE3MQ_39bc103c-5c23-457c-9730-6eb2fe856c51">Commitments and Contingencies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Executive Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development and Clinical Trial Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib. Onvansertib, an investigational drug, is an oral, and a highly selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK1. The Company is developing onvansertib in cancer indications with the greatest medical need for new treatment options. Terms of the agreement provide for the Company to pay development milestones and royalties based on sales volume.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of oncology therapeutics. These agreements include License fees, Royalties and Milestone payments. The Company also has a legacy license agreement in the field of oncology diagnostics under which royalty payments are due. These royalty payments are calculated as a percent of revenue. For the three months ended March&#160;31, 2022 and 2021, payments have not been material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm the Company&#x2019;s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company&#x2019;s business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>47
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MHTA4.F<<9I*HJBBH_',#N=@,'<]Y67A@JTR;!7<4E70%<]"/Y4SBS&U94E8
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M!.#^4@C],C$=N;V 1_\ 4$L#!!0    ( !J I50!X[RJR 0  %(0   8
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&ULE5AM;^(X$/XK%K<ZM5+;Q$["RQY%
M:FGWKM+V186]_7"Z#X888C6Q.=M ^^]OG$ "Q(FZ7TCLS(R?9SR>\3#<2O6F
M$\8,>L]2H:\[B3&KKYZGYPG+J+Z2*R;@RT*JC!H8JJ6G5XK1.%?*4H_X?M?+
M*!>=T3"?>U&CH5R;E OVHI!>9QE5'[<LE=OK#N[L)U[Y,C%VPAL-5W3))LS\
M6+TH&'FEE9AG3&@N!5)L<=VYP5_'Q+<*N<3?G&WUP3NR5&92OMG!0WS=\2TB
MEK*YL28H/#9LS-+46@(<_^V,=LHUK>+A^][ZMYP\D)E1S<8R_<ECDUQW^AT4
MLP5=I^95;O]B.T*1M3>7J<Y_T78GZW?0?*V-S';*@"#CHGC2]YTC#A3 CEN!
M[!3(J4+8H!#L%(*<:($LIW5'#1T-E=PB9:7!FGW)?9-K QLN[#9.C(*O'/3,
M:/S\='?_-+F_0_ V>?[^<'<SA<%D"H_'^Z?I!#U_0\\O]Z\WTP<00)?HQ^0.
MG7TY1SJABFG$!9HF<JVIB/4%^G(T'GH&(-J%O/D.SFT!AS3 "="C%";1Z%[$
M+#[6]X!:R8_L^=V25H./5%VA %\@XA/BP#/^O#IN@1.4[@YR>T&#O0<QEQE#
M$T,-@\-@T#\W,VT4!/._+=;#TGJ86P\;K+_*#YH:SIR.+U2[N:H]W)M1+QQZ
MFT-?.$1(*7*$*"H11:U\QU(;C2 6$'N'S*.9_MK"LUM:[;;S9)I1-4]RPS';
M0#):66^Z:!>6HB-.?O^$>%TH(+V!FWJO!-EK!3F!U,3%\@(MF6"*ICE8&L,9
MYG;';?9RX>W5H0Q"_P1O78B0('+C[9=X^ZUXI]( 2*@/%IM8EAOF MFOK8\Q
M#D^]6I>*(ARZ40Y*E(-6E-^EUFBA9+9'*H43X:"V]B7&?BWB'6)1&#8$/?:K
MI.JWHGP0AD%R-) -[7F_0((Y@W-GYLB1P>EF.X2B7@/"@[2/6Q'^"14>G:7@
MS?/"G?.$BB6SZ7M!N4(;FJX9D@LX7HIO\FA%"RZHF'.($BX@A-?VR.G??^L3
M3/[84J4H#)TL<8U C6-=A/A-)$E%DK22?#8)4[L]0&>[@#YOW@U2CX9P<(K4
M(80;@%95 0>?.7N_"#>H(>GC4[1U&=(-&N!690:WUYDGN%[:T'&B"AW^\0>#
MX!290R["34D75P4'1ZW87N :R)1B,8*[T_P-Q7S#8P:I=T4_Z"R%F!9H C$-
M5Y<;-)9BPY3A=KY2G%A%)[>HCKE[RJM5YIA45>]P>\';.QQ18Q2?K4W.Q$@$
MH9(!H9QJ(E,XK.Y-Z=8J>[XIM>!VR$6XWU!9<%4*<7LM+/%#SBXQV_LCW"?A
M$L[GZ P23RS3E*I"*/]Z[N12+-4_Q.A?D>B4BE.LJ?S@JDKB]C+91B7FZ=I
M /T"F?[GR#C%&LE4Q12W5].?>9?#XDL*QP"ZMOVE'OH];>"^8N\!ASM4?'8S
MJ9?2,"!!+2'5Q8(>[C8P(57%)>T5]W-,#C>HA0NI5UP7%X>8BXMWT)UE3"WS
MIE5#[*R%*1J9<K9LC&_R=O!D_A8:YJ*]K<P4W3:T*4NHR2AE"S#I7_4 DRH:
MV&)@Y"KO 6?20$>9OR;0]#-E!>#[0DJS']@%RK\11O\#4$L#!!0    ( !J
MI53*P>\A*P,  '((   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULC5;?
M;]HP$/Y7K&@/F[0V)"'05(!$*=,JK04UM'N8]F"2@UAU;&8;Z/;7[^S0C-(T
MV@OXQWUWWW>V[S+82_6D"P!#GDLN]- KC-E<^K[."BBI/I<;$+BSDJJD!J=J
M[>N- IH[4,G]L-/I^25EPAL-W-I<C09R:S@3,%=$;\N2JM]7P.5^Z 7>R\(]
M6Q?&+OBCP8:N(07SL)DKG/FUEYR5(#23@BA8#;UQ<#E)K+TS>&2PUT=C8I4L
MI7RRDYM\Z'4L(>"0&>N!XM\.)L"Y=80T?AU\>G5("SP>OWC_XK2CEB75,)'\
M.\M-,?0N/)+#BFZYN9?[KW#0$UM_F>3:_9)]9=N//))MM9'E 8P,2B:J?_I\
MR,,1 /TT \(#(#P%=-\!1 = Y(16S)RL:VKH:*#DGBAKC=[LP.7&H5$-$_84
M4Z-PER'.C":SN^OI73J])NEBO)C>3N\6*9E](9/9[?Q^^A6W;AZGY-LL3<D9
M>4BOR<</G\@'P@19%'*KJ<CUP#=(Q+KSLT/0JRIH^$[0B-Q*80I-IB*'_#7>
M1P&UBO!%Q578ZO"6JG,2!9])V G#!CZ3_X<'+72B.JF1\Q>]XR\UU !>=4/D
MBDQDB>^KL!=_!^1&9+($\F.\U$;A'?[9$JY;A^NZ<-UWPMWA8^=2-QY$A>PY
MI'W1N]%9T$F2:.#OCO/38!8'_:2V>L4KKGG%K6F8F0(4R5[IMSPO6S3W:M^]
M5LT/ FL69W\@=RX)5@0-V58QPT 3NJ.,TR6',ZQS9YIR:,I-%2$^%MWK]$XR
MTV34;\Y+O^;>;^6^D(;RAKPT<>R_#1\$<9*<L&PPB\-NKYGG1<WSHI7G'"LJ
M*(4IQC*4/9&<[5@.(B<;^MLFUR8]!643/L9K+G:@#+/K_X"I!3;INFA(ZXFF
M5I-7@I):4-(J:/(FY80:H]AR:YP>(^VIE/8N6=Z%Y#FHQF-)&IY5T.O$)Q(:
MS.(P#D]4^$?ENP2U=EU-(Y6M,%4-K%?KQCEV_>)D_0H;:M7__KFINC%6N#43
MFG!8H<O.>1_3JJH.5TV,W+@FL90&6XX;%OA1 ,H:X/Y*2O,RL0'JSXS17U!+
M P04    "  :@*547#\^^\T%  !:&0  &    'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;+U9:V_;-A3]*X118 E05R+U=.$8J!^I@[9)%J<;AF$?&(F.B4JB
M*]%V^N]'RJID493D8L&^V*)U[N4A>1]'\OC TF_9AA .7N(HR:X&&\ZW[PTC
M"S8DQMD[MB6)N+-F:8RY&*;/1K9-"0YSHS@RD&FZ1HQI,IB,\]_NT\F8[7A$
M$W*?@FP7QSC],241.UP-X.#G#P_T></E#\9DO,7/9$7XU^U]*D9&Z26D,4DR
MRA*0DO75X -\OT2.-,@1?U!RR$ZN@5S*$V/?Y. FO!J8DA&)2,"E"RR^]F1&
MHDAZ$CR^%TX'Y9S2\/3ZI_?K?/%B,4\X(S,6_4E#OKD:^ ,0DC7>1?R!'9:D
M6%!.,&!1EG^"0X$U!R#899S%A;%@$-/D^(U?BHTX,8!6BP$J#)!JX+886(6!
M=>X,=F%@*P;(:S%P"@-'G6'48N 6!JYB8+>MP2L,/)52V[;ZA8&?G^[Q./*S
MG&..)^.4'4 JT<*;O,@#(K<61T@3&;LKGHJ[5-CQR>SN=KZX72WF8/7XX7'Q
M97'[".ZNQ>!N]FEY]WF^>%C]!A:_?[UY_ L,P=?5'%R\N039!J<D S0!CQNV
MRW 29F_!F]IX;'!!3TYB! 65Z9$*:J'RR#B.-&:S;K-[$>PD34D(5IP%WS0.
MYMT.9BR.11:U62^ZK3^$(959B"-PCVDXO$G #&^I?BG7W;Y6)-W3@( '$A"Z
MQT\1T?CXV,,G"';Q+L)<;,@=WY 4B/6)LK:1]69/P$T2L)@8%Y]9EEUJW"_/
M=S\G:QI07G=BB  LHQ"548ARKW:+URF.<!*0M^")/-,DH<DSN!#!= RS2X"Y
MF"MX!RSX%B 3F;H@.4[@Y!/(@KV?>- =&_O3.&AB+-?S88FJ<;=*[M:O<C^#
M[_3HU#WA I$/';].>::!*8MJ(NPZ8M%$6"[TX:@.NV["A@AZRG0?FRBSCECJ
M_%C0'CGZ?;;+?;9S0ZMEGT7@BN:<$7 A]C:_NI0%)T_;#8M"DF:B4GW?4?X#
M_/W H@B(YG; :?A/1X ZY>1.YR'GLPQEDPR!R!^A'#(LLUYWLDXCRI"K'.NB
M&U.CZ)84W4Z*-UFVDX$(V%I2E"4MDZS!;BLNR0M) YKE=\6FI#CAV6F.Z<JF
MVTPIKR59O)*D]\HD=3OL-8A!Y%K*%O> :O3]DK[?2?]84(-:07T6 A%<1"WE
M=.HW: Q=3\FI;DR-Z:AD.NID6G7%X_Z&=$]#DH0ZBB/-]$I.=T)J!*%9*0^S
MD^*#$+#X>-B!N$<#T4)Y2L7G>I>$LH[*"*%<*&6N51-FLYS[2C&Z[@'5J9^(
M)MA)_58\5,@3U]*"S;URH*=4VV4OK$ZMZJ3PS%9*CGNH]-$O."W[$M2*K7,:
MJ09D>8Z#6LA7K12>V4L+\F<0GA8NZXEN^U!)LAGL;Z4:B-I+-;-9KF4YC;AK
MXH;B=-5NJH.IY6&I R'+=5OCN&JIT'Y%W:6/%_N<>&F";#AR[1;^55>&W6VY
M7WOI0Z;9?J%MVLV0<?I#I@EIA$QS-MLT'=-20Z:)&T)KI$:,#F4C-60T*.2,
M?-@6,I7*@.[_+\-@I1]@MX#X%2$&-1( .D@]GAY4G6BE%."K2P6HTP&FJP9
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M.^</HJHL^7:;"OL[F0?#"&Q^\'+:+UXA,YHLTX$VB79*1K^G9/$P+FTW'0W
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MD:6[W'&6<V4-X/>ME.;EQD[0?L0Z^P]02P,$%     @ &H"E5.*\FLTR!@
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M\'VC,:ZV+^1@_Q^0J[\ 4$L#!!0    ( !J I50B5%M-I@0  -T,   9
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M/8*W7LF;3HFS&SYN+>TL+#:=C6$TC(. *JQAZ3GW%M*G\ERFWKQ"+, YA.#
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M=,L5"@HW$]#_7"G;?;""_G[U\E]02P,$%     @ &H"E5-Z'H+]Y!P  QQ(
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M,5V(7/JD2"_4A^(U?FP#?13$QXJ^PM#Q IJ?6!OF+QQ@\5UW^3=02P,$%
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M[6ABA65-GP@TWH#N*TVU,FP\P?C1V?P&4$L#!!0    ( !J I53_[=NU500
M "L,   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;-U7;6_;-A#^*X16
M# D@Q'JS+;FV 2=9T0#-FN6E^S#L RV=+2*4J)*4W>S7[TC)BNS&28=^VQ>;
M1]X]=_?PCCY/MT(^JAQ DV\%+]7,R;6N)H.!2G,HJ#H3%91XLA*RH!I%N1ZH
M2@+-K%'!!X'GC08%9:4SG]J]&SF?BEIS5L*-)*HN"BJ?SH&+[<SQG=W&+5OG
MVFP,YM.*KN$.]$-U(U$:="@9*Z!43)1$PFKF+/S)>63TK<(7!EO56Q.3R5*(
M1R-<93/',P$!AU0;!(I?&[@ S@T0AO&UQ70ZE\:PO]ZA?["Y8RY+JN!"\#]9
MIO.9$SLD@Q6MN;X5VX_0YC,T>*G@RGZ2;:OK.22ME19%:XP1%*QLONFWEH<?
M,0A:@\#&W3BR45Y23>=3*;9$&FU$,PN;JK7&X%AI+N5.2SQE:*?G'RB3Y OE
M-9!KH*J6@(QK14[NZ9*#.IT.-'HQNH.T13QO$(,CB"&Y%J7.%?FMS"#;MQ]@
M=%V(P2[$\^!5P&LJSTCHNR3P@N 5O+!+.;1XX=LI7S*5<F&R5N2OQ5)IB57R
M]RL^HLY'9'U$1WS<8?-D-0<B5D3G0"Y$4='RZ==?XL ?OU=DH10@R[3,R"=&
MEXPSS3 &G5--J.SN(K,:MY"*=<G^,:(FO?!-59O36DI6KLDY54R1"TZ58BN&
MV@]X ]+Z7U25%)5D5 /Y!!O@N\!Z:!\92"K3_.FE.W\U7?-R3%1%4Y@Y^#0H
MD!MPYO<(OQ(<V]X$ITT]$7MJZNLE4N@S*?PE4HH^*7*/E)5)8_-,BNQ(65I2
MTF=2ZHX4VB.%]TGIH>4[4C Z<WQMA*X:;227D$*Q1,QVUY^08UV%D9ZP$GV(
M6J&I.B5_U$)C4#>2I9@JGBWL,V7\/!HR\-DE5QD:LY3R8V5SQY")%6J4FGS&
M!"3YO#278"F_*JM:[^L\E.*[\WNA.P<3T\+PA.^,"8*LD#+RCOA#-PXB7-@+
M"][OK=K#"R$K(0VA&2PU4>8:FAAWJJ$;>,,#J?'-RI37^&08%E*J<INF7<#7
MFN%U6 I;1_LP?N)Z04(6&\JX3<K0IM "L3:@M&5_0BY :LN!MHV90244TQU*
MX@9A<B"]G= H<4>CZ%#$VBY I@SSJFB%-]*%ZKG1*#X4'\[NSHB6ME:>^EXP
MLZ075"]AL]T01U]-FYSXISO].''#L=]SCK+O[6":XGKNLK?;ZAT)A^YX%.(B
M"=SA>+1?$T'LANCU_]D-GILDWK%N: [_4UT?QVN/?K*Z?3<8>0?2V]4=XQ4F
MWJ%XO+HC-QI&A^+O6#RVPM=B [(T\78JXR#>6Q_MA"!RO6CT72>TVS_<":V^
M[T5N' 9]EK%:XW'\D\W@A2-[_X?HN!<F;HRM_M)T,>@-<$CLVHZI^*LEZE(W
MLURWVTW"BV8 ?%9OQFALE34K%?Z@K=#4.QL/'2*;T;01M*CL.+@4&H=+N\QQ
MF@=I%/!\); '6\$XZ/X?S/\%4$L#!!0    ( !J I535"Z&LC@4  "(.   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;,U776_;-A3]*Q=>,=B &DO4
MEY4E 9)TZ0JT:]"TW<.P!UJB;2*2J))4TO;7[Y"R';=SW S8PQYLB5?D_3KG
M7I(G]TK?FI40ECXW=6M.1RMKN^/IU)0KT7!SI#K1XLM"Z89;#/5R:CHM>.47
M-?64A6$V;;AL1V<G7G:MSTY4;VO9BFM-IF\:KK]<B%K=GXZBT4;P3BY7U@FF
M9R<=7XH;83]TUQJCZ59+)1O1&JE:TF)Q.CJ/CB\R-]]/^"C%O=EY)Q?)7*E;
M-WA5G8Y"YY"H16F=!H['G;@4=>T4P8U/:YVCK4FW</=]H_W*QXY8YMR(2U7_
M(2N[.AW-1E2)!>]K^T[=_R;6\:1.7ZEJX__I?CTW'%'9&ZN:]6)XT,AV>/+/
MZSP\90%;+V#>[\&0]_(%M_SL1*M[TFXVM+D7'ZI?#>=DZT"YL1I?)=;9LYN^
MZVJ!+%M 0A>\YFTIZ,;SX54[@.ZR-W[/Y[4PDY.IA56W=EJN+5P,%M@C%F)Z
MHUJ[,O1K6XGJV_53>+MUF6U<OF '%;[A^HCB*" 6,G9 7[Q-0>SUQ8_H>ZN7
MO)5??9P!7:K6J%I60]B\K>A:"^/RXP5J05>R19(DK^D&0I\[0W^>SXW5X-A?
M!SQ*MAXEWJ/D,5!0>E5?"V?M57LGC!V,G-]Q63L<G@.8YX;78A\<!W6[(C\V
M'2_%Z:AS@>D[,3K;-<(W1@A&R!FA$CF1QCIW[,K):]2R;)?'=&Z<$(B4*P_)
M6+:8HGJ#Q)D)G3=*6_E55$@KUK_4RACZT*)[U%[Z$EW#_%/\&F-AZ(I+[73?
M@HL?>=T+#&ROI?U"H**!(=Y21%\$U\=T*6!I(4L@XERJ1*>,M/2,BH"E(9X)
M?N,HG0RBN(!+NE/:S:_$W)(1I=,M83A-@S#-H'K,BGA":1+D68+Y32.T![[C
MG= 4A4$*/3__-&,1^X7&>31QLB2;T8>CFR.R",CT**L=U2P,PBQZ6!,QAD5%
M4$#1>V6ANWDL1BJ2H @S2FF<AC"%81*%#SF)R"IB?JHY/A!=E 91RAY<8*ES
MP>D.OW=A5^43UID5X'YNA6Y([C#J&45(2YC.\)8Z%/(T=C!$81'$B& @T0M1
MBF:.M*Y+._H_DBD*6.;(M$G"[MOP[0"K9L&,,:1S',\F;I3/LCVD JII#+:.
MX\DP2.AW-![/J*6Z$[IU6:6<S;:V-T\G.\2\>!;NP)=,O Q$_R'QTB!+8LIH
MG*%^,$IGR;_G'2N"+/=5E2,T-PJ3Q]V-@SS<K1,0/@ZRXC!%XSB(\]R9F"$Z
MC%B1_)";\"1D#M3<=XBD\-QD0"N?T8%NGFZ[>?KD;@ZX.]5ZRQA=:QRN-()P
MV\ROGWK9.:?V]?2#%O;W]&^4BXWR [W\^W+[KK7OJ=*K7K<2. AO0RU0,6+'
ME"N),'-]MTA3>@V,Q4K5%<FFTR#R   +P@2D"(J,T6L^=]118,*#EB)BY-I>
M I08.#!C,709LZ8&+\N^Z6L0KG)UJ@5J:;MU\Z%EK(\P<9#D:%GNF8!.^Q,4
M4"N<ZZG?-.(9.T2!;$N![,D4."]+W;N^)/E<UI[L^Q _J' _XAO-]8/F#=RB
M^D\ WU@H06,<S(>\/B-7* [L)$[=:6DAM,8DG%W+6ZKDG:P$,IR@QI((VRAB
M06>M4?7H>HX V!VP.,,.^ ZA>/M\J<6:( X=%R"X9:@H&+I<1B\D@ 91:"'<
MCI9$_@=$%V &G()Z_\7SLK<&+CPH07O-8KH&91S<-62M65,8&5KKS%-"RWOK
M!7Q/8K."LDWGW/<=!XX@CV?^F;)\+XNF.^=V[ )+?SMQF/6M'8[P6^GV G0^
MG/L?I@^W)\"V=-M?+198&A[EZ!AZN)$, ZLZ?PN8*XL[A7]=X1(GM)N [PNE
M[&;@#&ROA6=_ U!+ P04    "  :@*54'>'MJ$T$  #E"@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q.2YX;6RE5FUOVS80_BL'[P4.D-J2;,EV:AM(T@8K
ML+1!DJX8AGV@Y;,E5!15DHJ3?[\[4I$=MW9;[ M%4KR'=P\?'F^Z4?JSR1 M
M/,JB-+-.9FUUUN^;-$,I3$]56-*?E=)26!KJ==]4&L72&<FB'P5!TI<B+SOS
MJ9N[T?.IJFV1EWBCP=12"OUT@87:S#IAYWGB-E]GEB?Z\VDEUGB']F-UHVG4
M;U&6N<32Y*H$C:M9YSP\NTAXO5OP5XX;L],'CF2AU&<>O%O..@$[A 6FEA$$
M?1[P$HN"@<B-+PUFI]V2#7?[S^A7+G:*92$,7JKB4[ZTV:PS[L 25Z(N[*W:
M_(%-/#'CI:HPKH6-7YL,.Y#6QBK9&),',B_]5SPV/.P8C(,#!E%C$#F__4;.
MRS?"BOE4JPUH7DUHW'&A.FMR+B_Y4.ZLIK\YV=GYGT@A&>C>BT6!YF3:MP3*
MO_II W#A :(#  .X5J7-#+PME[A\:=\G9UJ/HF>/+J*C@-="]V 0GD(41-$1
MO$$;X<#A#8Y'^,_YPEA-(OCW".:PQ1PZS.$!S#LO85 K</#P]I%N"7U%N82[
MNJH*).%:4<"E,!E<D?3A7>FO$&GQ6RP?W9"OYIFI1(JS#MT]@_H!._/[#"%5
MLE(E[678F<(Y@XTS&]3DD8&5*L@!<P;WF49\<5Y ;*>9H[N;EV S51N*P9PX
M]KD)X4.%FMPNUPU\JHR%7R&<A-1.XIW_IE[X)7E)?B'\_LLX"J/7T V#\ 3>
M4XI1Q["ZR<E+\E(F;\7D,:_*9J@)NJ61DD(A+ 5AE8<SL*%P_W_$[M JD2\)
M2(.0JF9^*:BB9@1GAB!IRUH[7[?<%[E8Y$5N<Z3=M\RTD9!O6LE]'@Q%/PJH
MB88!'-%GW.HS_HX^=UB\$(4H4X0[E^2_(\.?P%TTN/[Q^+ESV:/^W*EW>S)^
M_ 93E LZ<Y[:5^'MAX^$:- R=]%IDCCZ3D>3!"YKK=VA[)GLG VM39*8VC@.
MX;TJ7Z4_8!.=#@=C:N-D#/>**3B^P^ T# ;^&T[@DWL@</E*/)#1&HDE?C2W
MQA:U=#<F?/V5/(:]"3RAT ;B7M3TO@)<YB9EJ0+9XB&D42^ WWQ[1&A)*[3D
M1Q/A56WI-L UA21KV>3%&_'$:C'?DMI1Y ,9S[&^)4Z49<UY0DF96[<1U'3)
M-91\I*S.@M^UAF"QIF3@5_&]1D%J(\?Y+GM&T26('=F!V,N@>[K]F\PXK; O
M!]3:/#\NN73QD5,(3_.FUB4GZ9,3[B4G-C@A\0S' ?<',!J,N#.$43SD3@RC
M4<R=!%CT]!A04;8B$4%(*SU3*W\FLCD33T/5G GI,AE-R$%#N4U6M76IC0"0
M<G(W'E$V]BC/2OZ67OH[I8=$O78%E@&G0U^%M+-M#7?N2Y?M<E\ 4NSKO#3D
MY8I,@]Z(<I'V194?6%6Y0F:A+)5%KIM1'8J:%]#_E5+V>< ;M)7M_#]02P,$
M%     @ &H"E5) K0[;>!0  F@\  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C N>&ULE5=M<]I&$/XK.S1MG!D93@*]X-J> =MI,],TGMA-/G3ZX9 .=&-)
M1^X.B/OKNWL2 @+&](M>3KO/OCV[I[M<*?UD<B$L?"^+REQU<FOG%[V>27-1
M<M-5<U'AEZG2);?XJF<],]>"9TZI+'H!8U&OY++J7%^ZM7M]?:D6MI"5N-=@
M%F7)]?-8%&IUU?$[ZX7/<I9;6NA=7\[Y3#P(^]?\7N-;KT7)9"DJ(U4%6DRO
M.B/_8IR0O!/X(L7*;#T#13)1ZHE>/F17'48.B4*DEA XWI;B1A0% :$;WQK,
M3FN2%+>?U^CO7>P8RX0;<:.*KS*S^54GZ4 FIGQ1V,]J];MHX@D)+U6%<5=8
MU;)QW(%T8:PJ&V7TH)15?>??FSQL*23L!86@40B<W[4AY^4MM_SZ4JL5:))&
M-'IPH3IM=$Y65)0'J_&K1#U[_6!5^I2K(A/:O(6[;PMIG^'LD4\*8=Y=]BR:
M(,%>VL"-:[C@!;@^?%25S0W<59G(=O5[Z%KK7[#V;QP<!?S(=1?ZO@<!"X(C
M>/TVWK[#Z_^?>/]45L#?HXFQ&EGRSQ$S@];,P)D9O&0&FR=;% +4%)S)\S%2
M)X,;56([&>X8>?>=GL6A+!]%IT:],'.>BJL.=J(1>BDZ=63G$V<FW38C:C/8
M0@6W^-$JN.$ZD],I?*J0/VKV#*).!%_A!P,Y7PJ8"$%MEZI9)?]%-5D!C@*-
MF-4,UPW2W@ W,%4%=K:Y@,=<"[%3?\#JI;DKWQFJVUPM#*\R\\Y5DRX^?*C2
M8I'5^!2+TT A;*TECHPY#@#;AO &^OT0KP.VHX=-CBF:>3 3%7I8.'V>8;M(
M*BGU?0N1^#$$00*/RJ*@>2UI;\#W_## >Q E<(098<N,\&1FC S.PCG9,U25
M.V,ESAD![[G4\(47BPU_X).3@Y&KT"'*'#?[F&,*&OP,IF1@N3;@DH#%K<=D
M38$55C835FA,(BHHJIZ C+Q#C9GF6)6%(2K0^KC@F$8,3>'86",1?IW,4F6"
M!IO-G73-&-)=N:$ILG,DG,8] /FTR4BVT&O\C08R4"KT3U:93"F65WCGB/99
MFJ?S*4G)"D/"/("F2/QN,H"?X58N92:0,L]2%!DP7*+63"E32X5-(PMJ#HQ[
MKV^0,R4&6&?09]&V*B4/HBZ#9R2U.4*=J*5.=)PZ]<:YSPG:V5S[8@SD9<ZK
MF: <[<@9^+2PQJ(0)O(0@XY:/SQT1NO=?)]'VTZE&X^VA9 J&X] &G# %25O
M0K\+%TV7KOW_NJ;+J*'+A\HB1XQ,8<P+7J5B&]"#6Y&*<B+TF@D^]+TX]KTA
MEOT-Q%V_C[?(&[#0"\($?B-6HVW?BX:Q%_8CFC==?XAE1^@"O_0 ?P6F0I+4
M&0X&-GQ',GXW"*GN4M-ZPABM^E%(]#KHV _\#+U!%'N1[Z,:*B7D5>CYR1!!
MA4ZEH>T8N/U1S_>"Q/?Z$8VGI)M0- 'JL02^(,?1%\J]:/FH8$G4W\<)O3X^
M)R%S]H?D1H3OC!T;>''+VOA4UG[EV@V.'<)NL;7Y_BI1CQO<X>2J,?D2'5=K
MDSOUD6YS(5).% ZM0O))/0-<0NN],BUP6,DI32%'SI?IVX:UQ]^]A1-I// &
M0X;[TK F#$.:-F/F)+[MJ0?=^-4IE;3U3D[>X.[Q%UMHZ@HWB [5\BC8"4-'
M+;3[J^+5\UM3%X6VH"D5H[%=CYQ#]7G(N1:[4^B&$.">K_?'1B031LXJMWG^
M(9$ 6;VSU48$)7SDK&XR7;_OU.X!-R_$&J'#%1;<2FKK'W*$)6%=QGP(XAA;
MF5HR8I''\"EB7K2Y-6#CD\ 2+XD8_N=6 G[Y*0G\X-?VWN#<G.848\Z58TBW
M)R AE!\.O"@^#G5W6G X+)-@4"/U QS=;(@#-/388'!P@O6VSDNET#-W*D3R
MJ$5EZZ-3N]H>/$?U>6LC7I]:L=XSW(&@$%-49=T8?\-T?1*L7ZR:N],7#A(\
MR[G'' _/0I, ?I\J/'PT+V2@/8Y?_P=02P,$%     @ &H"E5,#G\$P8 @
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MGJ/XLK4_TBQ&?A9/R'-+W6PI_RUF* DC1]NQ9C$^D\7./,<^RG8[;]/$L0?
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M\WG48>W;3*/),.JT19V.HFZ8PM-8*E+ ,->TKT\2=KC&;5YPS5JNV?]4H"Q
MVTZ#6VS9G(#8Q#06XJB0LQY,&G=X^R:3>!AWWN+.QW'QG!#FAG"D$AIJ6%/"
M=5WG_;U,.YA]D^0*9AC\[A7!*.@G!T6;\X?_;@2#IWS0%VK>@1RRN5*3X45'
M"T<I/TN#V_ZGE&'O!$RF<?>8'+)*HVF'U+]HP_8.A)ULSX0F' IT"VZGF*>J
MKQ7UP,B#Z\P[:;#/N\<2KV*@K &^+Z0TSP/;[-O+W>H74$L#!!0    ( !J
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MNR;0K78M=.XZQ]_MKO]";:TH5Y"& J#!8 +:TO4T-]&BMGUD*31T)3LLX3=
MI-D WPLA]&YB!+H?2_H'4$L#!!0    ( !J I51V@%WN;P(  $\&   9
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;(U576_:,!3]*U;4AU9:FR](UPHB
M\=%ID]JM:M?M8=J#22[$:FQGM@/LW^_:"1D%BGC!]LT]YYYSXUP&*ZE>=0%@
MR)J70@^]PICJUO=U5@"G^DI6(/#)7"I.#1[5PM>5 IH[$"_]* @2GU,FO'3@
M8H\J'<C:E$S HR*ZYIRJOV,HY6KHA=XF\,06A;$!/QU4= '/8%ZJ1X4GOV/)
M&0>AF11$P7SHC<+;26+S7<(/!BN]M2?6R4S*5WOXD@^]P J"$C)C&2@N2YA
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M0M,^(=2+#9>&M!1$.;@<TPSI=BQ;PZK:W^RULC0G?EG22X;:.=!YH93=&2Y
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M)VE(P[G7C&0V*FM W]=2FMW")NB$^^)_4$L#!!0    ( !J I50:'&K5D04
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MI22EPKR@GZ\Y5Z\WIH/FZ'W^/U!+ P04    "  :@*540N.]_PT#  !E"0
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M=7]\9U]02P$"% ,4    "  :@*54!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !J I528-:F[[@
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( !J I5297)PC$ 8  )PG   3              "  <P!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ &H"E5)4$";06!0  O!0  !@
M             ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( !J I52R4@,=I@4  !D6   8              " @5D-  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  :@*54@?W!&YT"  ",
M!P  &               @($U$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ &H"E5 'CO*K(!   4A   !@              ("!"!8
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( !J I53*P>\A
M*P,  '((   8              " @08;  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    "  :@*547#\^^\T%  !:&0  &
M@(%G'@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ &H"E
M5#%9G\2U!@  T!H  !@              ("!:B0  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( !J I53BO)K-,@8  ,0.   8
M      " @54K  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M"  :@*54=K+9M! '   -$0  &               @(&],0  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ &H"E5")46TVF!   W0P  !D
M             ("! SD  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    "  :@*54^!B_-40%  #O#   &0              @('@/0  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( !J I507>&<9=04
M &L5   9              " @5M#  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ &H"E5-Z'H+]Y!P  QQ(  !D              ("!
M!TD  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  :@*54
M5WNC"5(%   I#   &0              @(&W4   >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( !J I52>,JO3G@4  .,-   9
M      " @4!6  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ &H"E5(2,87\2 P  @ 8  !D              ("!%5P  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  :@*54_^W;M54$   K#
M&0              @(%>7P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( !J I535"Z&LC@4  "(.   9              " @>IC  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ &H"E5!WA[:A-
M!   Y0H  !D              ("!KVD  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    "  :@*54D"M#MMX%  ":#P  &0
M@($S;@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( !J
MI53 Y_!,& (  "X$   9              " @4AT  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ &H"E5+U2_^%0 P  5@P  !D
M         ("!EW8  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    "  :@*54,YA\-18(  !A/0  &0              @($>>@  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( !J I53,N8=Y_04  -,@
M   9              " @6N"  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ &H"E5'H18> + P  G@H  !D              ("!GX@
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  :@*54FB6L
MWTP#  #H"0  &0              @('ABP  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( !J I50D4R@"AP(  &0&   9
M  " @62/  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M&H"E5': 7>YO @  3P8  !D              ("!(I(  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    "  :@*549>T[<=\"  "$"   &0
M            @('(E   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( !J I50Q1P^[1@(  "<%   9              " @=Z7  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ &H"E5"ZG[C?) @
M*@@  !D              ("!6YH  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    "  :@*5408<T$8H#  #$"P  &0              @(%;
MG0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( !J I50:
M'&K5D04  (87   9              " @1RA  !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ &H"E5$+CO?\- P  90D  !D
M     ("!Y*8  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !J I51+BJ +<P$  ' 5   :
M          "  0JV  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( !J I53?(2<;D@$  /D5   3              "  ;6W  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     K "L I L  'BY      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>142</ContextCount>
  <ElementCount>212</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Supplementary Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation</Role>
      <ShortName>Supplementary Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122106 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2128107 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/FairValueMeasurements</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2311303 - Disclosure - Supplementary Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables</Role>
      <ShortName>Supplementary Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/Leases</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/StockholdersEquity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Fair Value Measurements - Fair Value of Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value of Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Supplementary Balance Sheet Information - Investments Available-for-sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails</Role>
      <ShortName>Supplementary Balance Sheet Information - Investments Available-for-sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Supplementary Balance Sheet Information - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails</Role>
      <ShortName>Supplementary Balance Sheet Information - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Supplementary Balance Sheet Information - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails</Role>
      <ShortName>Supplementary Balance Sheet Information - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Stockholders' Equity - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="crdf-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="crdf-20220331.htm">crdf-20220331.htm</File>
    <File>crdf-033122exhibit311.htm</File>
    <File>crdf-033122exhibit312.htm</File>
    <File>crdf-033122exhibit321.htm</File>
    <File>crdf-033122exhibit322.htm</File>
    <File>crdf-20220331.xsd</File>
    <File>crdf-20220331_cal.xml</File>
    <File>crdf-20220331_def.xml</File>
    <File>crdf-20220331_lab.xml</File>
    <File>crdf-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="453">http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy items="28">http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>53
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "crdf-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 11,
   "contextCount": 142,
   "dts": {
    "calculationLink": {
     "local": [
      "crdf-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "crdf-20220331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "crdf-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "crdf-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crdf-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "crdf-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 320,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 29,
   "keyStandard": 183,
   "memberCustom": 9,
   "memberStandard": 22,
   "nsprefix": "crdf",
   "nsuri": "http://www.cardiffoncology.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cardiffoncology.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Fair Value Measurements",
     "role": "http://www.cardiffoncology.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Supplementary Balance Sheet Information",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation",
     "shortName": "Supplementary Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Leases",
     "role": "http://www.cardiffoncology.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122106 - Disclosure - Stockholders' Equity",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128107 - Disclosure - Commitments and Contingencies",
     "role": "http://www.cardiffoncology.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerSharePolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerSharePolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.cardiffoncology.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311303 - Disclosure - Supplementary Balance Sheet Information (Tables)",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables",
     "shortName": "Supplementary Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - Leases (Tables)",
     "role": "http://www.cardiffoncology.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED BALANCE SHEETS",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Basis of Presentation (Details)",
     "role": "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails",
     "shortName": "Organization and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities (Details)",
     "role": "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Fair Value Measurements - Fair Value of Assets and Liabilities (Details)",
     "role": "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
     "shortName": "Fair Value Measurements - Fair Value of Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i9b8194a586f841738340b39f3d565848_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Supplementary Balance Sheet Information - Investments Available-for-sale (Details)",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails",
     "shortName": "Supplementary Balance Sheet Information - Investments Available-for-sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Supplementary Balance Sheet Information - Property and Equipment (Details)",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails",
     "shortName": "Supplementary Balance Sheet Information - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Supplementary Balance Sheet Information - Accrued Liabilities (Details)",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails",
     "shortName": "Supplementary Balance Sheet Information - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "crdf:LesseeOperatingLeaseAreaOfLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.cardiffoncology.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "crdf:LesseeOperatingLeaseAreaOfLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "role": "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "crdf:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Leases - Supplemental Cash Flow Information (Details)",
     "role": "http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails",
     "shortName": "Leases - Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Leases - Future Minimum Lease Payments (Details)",
     "role": "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails",
     "shortName": "Stockholders' Equity - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Stockholders' Equity - Warrants (Details)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails",
     "shortName": "Stockholders' Equity - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "i3e26e9a60f67478f930bec7f58534ab7_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - Stockholders' Equity - Preferred Stock (Details)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails",
     "shortName": "Stockholders' Equity - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ifdc2b0e256004062aef3e08c666721e1_I20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONDENSED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ibad6d99cf2f840ce9e7bed2d46e20230_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ibad6d99cf2f840ce9e7bed2d46e20230_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED STATEMENTS OF CASH FLOWS",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220331.htm",
      "contextRef": "ia1d8da51cc964f8da33b9e65fad3c22a_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 34,
   "tag": {
    "crdf_AccruedClinicalTrial": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trial",
        "label": "Accrued Clinical Trial",
        "terseLabel": "Clinical trials"
       }
      }
     },
     "localname": "AccruedClinicalTrial",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_AccruedDirectorFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued director fees",
        "label": "Accrued director fees",
        "terseLabel": "Director fees"
       }
      }
     },
     "localname": "AccruedDirectorFees",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_AccruedPreferredStockDividend": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Preferred Stock Dividend",
        "label": "Accrued Preferred Stock Dividend",
        "terseLabel": "Preferred stock dividend"
       }
      }
     },
     "localname": "AccruedPreferredStockDividend",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_AccruedResearchAgreements": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research agreements",
        "label": "Accrued research agreements",
        "terseLabel": "Research agreements and services"
       }
      }
     },
     "localname": "AccruedResearchAgreements",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period over which each class of warrants or rights outstanding may be exercised.",
        "label": "Class of Warrant or Right Term of Outstanding Warrants or Rights",
        "terseLabel": "Weighted-Average Remaining\u00a0Contractual Term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right Term of Warrants or Rights [Abstract]",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted average exercise price of each class of warrants or rights outstanding.",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights",
        "periodEndLabel": "Weighted average exercise price of warrants at the end of the period (in USD per share)",
        "periodStartLabel": "Weighted average exercise price of warrants at the beginning of the period (in USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comprehensive Income (Loss) Available To Common Stockholders, Basic",
        "label": "Comprehensive Income (Loss) Available To Common Stockholders, Basic",
        "totalLabel": "Comprehensive loss attributable to common stockholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current",
        "label": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Noncurrent",
        "label": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Noncurrent",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Current",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Current",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Noncurrent",
        "label": "Debt Securities, Available-For-Sale, Noncurrent [Abstract]",
        "terseLabel": "Maturity 1 to 2 years:"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleNoncurrentAbstract",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_EquityIncentivePlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan 2021",
        "label": "Equity Incentive Plan 2021 [Member]",
        "terseLabel": "Equity Incentive Plan 2021"
       }
      }
     },
     "localname": "EquityIncentivePlan2021Member",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to furniture and office equipment.",
        "label": "Furniture And Office Equipment [Member]",
        "terseLabel": "Furniture and office equipment"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Liability",
        "label": "Increase (Decrease) In Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_InducementGrantStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement Grant Stock Options",
        "label": "Inducement Grant Stock Options [Member]",
        "terseLabel": "Inducement Grant Stock Options"
       }
      }
     },
     "localname": "InducementGrantStockOptionsMember",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Annual Rent Increase, Percentage",
        "label": "Lessee, Operating Lease, Annual Rent Increase, Percentage",
        "terseLabel": "Annual rent increase, percentage"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAnnualRentIncreasePercentage",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "crdf_LesseeOperatingLeaseAreaOfLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area Of Lease",
        "label": "Lessee, Operating Lease, Area Of Lease",
        "terseLabel": "Area of lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaOfLease",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LesseeOperatingLeaseMonthlyRentPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Monthly Rent Payment",
        "label": "Lessee, Operating Lease, Monthly Rent Payment",
        "terseLabel": "Monthly rent payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyRentPayment",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LessorAreaOfSublease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor, Area Of Sublease",
        "label": "Lessor, Area Of Sublease",
        "terseLabel": "Area of sublease"
       }
      }
     },
     "localname": "LessorAreaOfSublease",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "crdf_LessorNumberOfSubleases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor, Number Of Subleases",
        "label": "Lessor, Number Of Subleases",
        "terseLabel": "Number of subleases"
       }
      }
     },
     "localname": "LessorNumberOfSubleases",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "crdf_PatentLicenseAndOtherFeesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent, license and other fees payable",
        "label": "Patent, license and other fees payable",
        "terseLabel": "Patent, license and other fees"
       }
      }
     },
     "localname": "PatentLicenseAndOtherFeesPayable",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_PreferredStockDividendAccrued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of preferred stock dividend accrued during the reporting period.",
        "label": "Preferred Stock Dividend Accrued",
        "terseLabel": "Preferred stock dividend payable on Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockDividendAccrued",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_ReleaseOfClinicalTrialFundingCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Release Of Clinical Trial Funding Commitment",
        "label": "Release Of Clinical Trial Funding Commitment",
        "terseLabel": "Release of clinical trial funding commitment"
       }
      }
     },
     "localname": "ReleaseOfClinicalTrialFundingCommitment",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Release Of Clinical Trial Funding Commitment For Services Received",
        "label": "Release Of Clinical Trial Funding Commitment For Services Received",
        "terseLabel": "Release of clinical trial funding commitment"
       }
      }
     },
     "localname": "ReleaseOfClinicalTrialFundingCommitmentForServicesReceived",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Convertible Preferred Stock [Member]",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Convertible Preferred Stock",
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesCConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares at the owner's option.",
        "label": "Series C Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesCConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesDConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D Convertible Preferred Stock",
        "label": "Series D Convertible Preferred Stock [Member]",
        "terseLabel": "Series D Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesDConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesEConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series E Convertible Preferred Stock",
        "label": "Series E Convertible Preferred Stock [Member]",
        "terseLabel": "Series\u00a0E Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesEConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails",
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_ServiceReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants",
        "label": "Service Receivable",
        "negatedTerseLabel": "Service receivables"
       }
      }
     },
     "localname": "ServiceReceivable",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_ServiceReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Receivable",
        "label": "Service Receivable [Member]",
        "terseLabel": "Service Receivable"
       }
      }
     },
     "localname": "ServiceReceivableMember",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expired in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expired in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares issued during the period upon cash exercise of warrants.",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity impact during the period due to the cash exercise of warrants.",
        "label": "Stock Issued During Period Value Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_WarrantsAndRightsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights [Roll Forward]",
        "terseLabel": "Number of Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsRollForward",
     "nsuri": "http://www.cardiffoncology.com/20220331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r18",
      "r131",
      "r132"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable and unbilled receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premiums on short-term investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r31"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees and outside services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r27",
      "r159"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less\u2014accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r41",
      "r42",
      "r43",
      "r313",
      "r326",
      "r327"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r40",
      "r43",
      "r44",
      "r82",
      "r83",
      "r84",
      "r231",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income/(Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r221"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r218",
      "r219",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r193",
      "r195",
      "r224",
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r195",
      "r215",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r80",
      "r117",
      "r120",
      "r126",
      "r144",
      "r229",
      "r232",
      "r243",
      "r298",
      "r312"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r37",
      "r80",
      "r144",
      "r229",
      "r232",
      "r243"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "totalLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTotalLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r137",
      "r151"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r134",
      "r138",
      "r151",
      "r302"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Total available for sale investments",
        "totalLabel": "Fair Market Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r136",
      "r151"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Fair Market Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r136",
      "r151"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Fair Market Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r196",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Acquisition of property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r25",
      "r71"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total included in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r65",
      "r71",
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents\u2014End of period",
        "periodStartLabel": "Cash and cash equivalents\u2014Beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r65",
      "r244"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificate of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r78",
      "r80",
      "r98",
      "r99",
      "r100",
      "r103",
      "r105",
      "r111",
      "r112",
      "r113",
      "r144",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Balance of warrants outstanding at the end of the period (in shares)",
        "periodStartLabel": "Balance of warrants outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r33",
      "r166",
      "r303",
      "r317"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r82",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.0001 par value, 150,000 shares authorized; 43,306 and 41,964 shares issued and outstanding at March\u00a031, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r47",
      "r49",
      "r50",
      "r54",
      "r306",
      "r320"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r185",
      "r192",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Current",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Noncurrent",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of Investments Available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost [Abstract]",
        "terseLabel": "Maturity less than 1 year:"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforsaleAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r69",
      "r116"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPreferredStock": {
     "auth_ref": [
      "r180",
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Preferred Stock",
        "negatedTerseLabel": "Preferred stock dividend"
       }
      }
     },
     "localname": "DividendsPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r55",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r95",
      "r98",
      "r103",
      "r104",
      "r105",
      "r108",
      "r109",
      "r307",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r55",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r98",
      "r103",
      "r104",
      "r105",
      "r108",
      "r109",
      "r307",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average remaining vesting period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase Common Stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails",
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r86",
      "r92",
      "r94",
      "r110",
      "r145",
      "r173",
      "r180",
      "r218",
      "r219",
      "r220",
      "r227",
      "r228",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r236",
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r235",
      "r236",
      "r238",
      "r239",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r185",
      "r186",
      "r191",
      "r192",
      "r236",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0Prices in\u00a0Active Markets\u00a0for Identical\u00a0Assets and\u00a0Liabilities (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r185",
      "r186",
      "r191",
      "r192",
      "r236",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r236",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of the Company\u2019s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r240",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r141",
      "r142",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r152",
      "r153",
      "r154",
      "r155",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r185",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Non U.S. government"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Loss on disposal of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r66",
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable and unbilled receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r262",
      "r264"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Net operating lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Expense and Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (excluding the three months ended March\u00a031, 2022)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30",
      "r80",
      "r121",
      "r144",
      "r230",
      "r232",
      "r233",
      "r243"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r80",
      "r144",
      "r243",
      "r299",
      "r315"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r32",
      "r80",
      "r144",
      "r230",
      "r232",
      "r233",
      "r243"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market fund"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r65",
      "r67",
      "r70"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r45",
      "r48",
      "r52",
      "r70",
      "r80",
      "r85",
      "r87",
      "r88",
      "r89",
      "r90",
      "r93",
      "r94",
      "r101",
      "r117",
      "r119",
      "r122",
      "r125",
      "r127",
      "r144",
      "r243",
      "r304",
      "r318"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r95",
      "r96",
      "r102",
      "r105",
      "r117",
      "r119",
      "r122",
      "r125",
      "r127"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncement and Recent Accounting Pronouncement Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r117",
      "r119",
      "r122",
      "r125",
      "r127"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r257",
      "r264"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r256",
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r254"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r261",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate\u2013operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r260",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term\u2013operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "auth_ref": [
      "r252",
      "r253",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessor's operating leases.",
        "label": "Lessor, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r31"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r38",
      "r39",
      "r41"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized loss on securities available-for-sale"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r46",
      "r49",
      "r51",
      "r53",
      "r173",
      "r245",
      "r250",
      "r251",
      "r305",
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r31"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r60",
      "r62",
      "r135"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r196",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      },
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "negatedLabel": "Preferred stock dividend payable on Series A Convertible Preferred Stock",
        "negatedTerseLabel": "Preferred stock dividend payable on Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.",
        "label": "Preferred Stock, Liquidation Preference, Value",
        "terseLabel": "Liquidation preference"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "verboseLabel": "Shares designated (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical",
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, 20,000 shares authorized; (Note 6)"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r156",
      "r157"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r60",
      "r61",
      "r135"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r60",
      "r61",
      "r135"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Sales of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r27",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r162",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Supplementary Balance Sheet Information"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r26",
      "r158"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, equipment and depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r160",
      "r316"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Components of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r226"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r180",
      "r221",
      "r314",
      "r325",
      "r327"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r86",
      "r92",
      "r94",
      "r145",
      "r218",
      "r219",
      "r220",
      "r227",
      "r228",
      "r322",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r114",
      "r115",
      "r118",
      "r123",
      "r124",
      "r128",
      "r129",
      "r130",
      "r183",
      "r184",
      "r297"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r195",
      "r214",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r195",
      "r214",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r27",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r196",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r200",
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Summary of Stock Option Activity and of Changes in Stock Options Outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions to Estimate Fair Value of Stock Option Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r34",
      "r78",
      "r111",
      "r112",
      "r169",
      "r171",
      "r172",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r170",
      "r171",
      "r172",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Preferred Stock"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r181",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of Warrant Activity and Changes in Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series\u00a0A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted-average assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Authorized shares under the plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of remaining shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at the end of the period (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Cancelled / Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r202",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance outstanding at the end of the period (in shares)",
        "periodStartLabel": "Balance outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance outstanding at the end of the period (in USD per share)",
        "periodStartLabel": "Balance outstanding at the beginning of the period (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r194",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled / Forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r209",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable at the end of the period, intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, weighted average contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Options vested, fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance, ending (in shares)",
        "periodStartLabel": "Balance, beginning (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r14",
      "r300",
      "r301",
      "r311"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r78",
      "r80",
      "r98",
      "r99",
      "r100",
      "r103",
      "r105",
      "r111",
      "r112",
      "r113",
      "r144",
      "r173",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r36",
      "r82",
      "r83",
      "r84",
      "r86",
      "r92",
      "r94",
      "r110",
      "r145",
      "r173",
      "r180",
      "r218",
      "r219",
      "r220",
      "r227",
      "r228",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r110",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r35",
      "r173",
      "r174",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon conversion of Series E Convertible Preferred Stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r36",
      "r173",
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon conversion of Series E Convertible Preferred Stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r22",
      "r23",
      "r80",
      "r133",
      "r144",
      "r243"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r180",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r258",
      "r264"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Operating sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosure of cash flow activity:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r141",
      "r142",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r185",
      "r192",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "negatedLabel": "Change in fair value of derivative financial instruments\u2014warrants",
        "terseLabel": "Gain (loss) from change in fair value of derivative financial instruments\u2014warrants"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase Common Stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r97",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r95",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "Note 1",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "Note 3",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888252"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r332": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r333": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r334": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r335": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r336": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>54
<FILENAME>0001628280-22-012614-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-012614-xbrl.zip
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M:7'P;=W[L_99*X]M[@R.8R^?UXO'^6Z?XW;'=]OS(C++@^51:LLTY<99ZTG
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M4=*8M#1YYK+SB^.2GI7034X^+AF<I$\^.LVE=59J[W$DT)%2*&F?3S[3ZH%
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ME5%<_O%-D!WK^_.K\J10L%#H]Q_6=_<W=]_6*[N;[W9V]RL?:AN;NQ5@@OM
M]T: 35AE9[="Q&_A]]$7.UN5_7]M5J[1Q2NJN/YZOP*'B6'\1D]-FZX_S"<
MP:D,CF/EWY<V6!E%^94(,62H/(/UORN>MSF:!7'#]E<#?(/:\,SC?!D*=HB&
MT?90[,PE"/P\3:I>^$])V^"%2LBJ9!!/$6S8:XJH9+EHC,%"T:6U:EXG4F%D
MN9+[_+8I5^:5,"TB/Z$KAJJGX"=:L47D)_?#^7/$93UH7R-GUA:?H(23.JW#
M\P^/JQLG @A*\[!Y0FIOJL.=@[HXW*\S^"RJ^Q_N$A2Z"^=^&-;:FU]V]D^
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MQ1^/?1$O?5&I,0_5F+S L0>"*1S1NU[7QY!]3^EI%D;"I:LI5Y--6JW8C76
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M&)?"V+WJ\UH<C).Z)1@]!HSV[M )@8UUTAL$K@0CK@2$-HI%1*5T$-MXR3V
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MRCCHO4C!YPBM<_B8.F1S*]0+^W<R-&9H?([]X R-%8+&B91YCCF."8? 8^8
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M9=G:)H?321_G/OZ0%3@#;993A0HY9Z!]0J"=W-TDB#"GO &I;!^@0G!@D&:
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M0=Z)8)$#V& ,J H82"E\Q#89I"9,$8]7TM64L>WU8]L\H0K$6J:P@Y822YE
MVFH4UWY/E9,.874WN/TJ5W@V01^'9O6;:.:E4#32-<"8=H"&X($FV &NO#&"
M1P-5HK5-01=0\2^#6 :Q2KSV/""FD,+88R^537M(2&N$ V08.J39+_<"YP"Q
M;(HN$N$^W40XC"S7S!!  I?1%N71%I7> (Z]B/+D4*;2AUC =0FG#U5FE,LH
MMYPH-P]3\YA[%54A<$&%#(I XU-52,D(U49D-UM5L,W>Q#;)':,D&( =B;:H
M<1R8B&O T""-%H)JE,JZ$KB.X*)*/3XMP-T3:.J:_;.6/D^OX7^-B;EE;KEL
M+?/DSRU7MF6>_+GERK;,DS^W7-F6>?+GEBO;,D_^W')E6^;)GUNN;,L\^7/+
ME6V9)W]NN;(M\^3/+5>V99[\N>7*MLR3/[=<V99Y\N>6*]LR3_[<<F5;YLF?
M6ZYLRSSY<\N5;9DG?VZYLBWSY,\M5[9E,?E_'VC3\O%?U_R^^>_X8_R-:Z?"
MK.\,?&^M/":Y^6_3^WWS\DS:@KXV.AA)T\G)LVZ_F8Z_O>GYEAXTO_L_?C3=
MX&1\:O+:M\J3:6_@U5>TZ7=;P\'=7[FK?^/K]K&G/Q&\[_ G3GWB-X?B^L^3
MWK@S9_JK!Z;G]3>@0^SK&]WZH<_[:[_?>*5VLP.NC]_DJ]_Y@B$\S0M"\C_E
MH4+G;;>G"\$,.\[W4JO8)UV9OM1.>NE\[7\U*?$N8$V@Y9QBQ946ADN+/,/$
M:,V^B+7-PZ0IM6ZH;:>CN9U!_]^_Z\W;Q/@T6E0HZM7,+\YXQ@%LZ;.^?S/^
MY8^QHC<[Q3 47_JCK7M?XR09J4N:(Q-'/(OGE9>OIL\&+*?0:'T</7ET>:.X
M-$:<&]>PW&!QV.^Z##?0G==^=5NV00A[T%U_?0VKA]WU]?158;4T?5V><14;
M!"U+7_D&P<O2UZ<:5Z3XTO3U:>8 )7BFN]YC-56BI-0,S*"LI7E;AH5;7FJT
MX(Z6T)MY%6Y)K?#'U K^/*\M)]Y:W/K6[R/K\;V>=[4B(4C!1<JZ"#.,Q+V%
M+%9HT+;:W6%GD ?MSD';[K;;W4Z>9H\8L3S'[AFQK=C79-?I5JT8L/>ZZ<!>
MI[:MSYH#W<HC=^?('?C>]Z;UM8_>^N;W9"KFP;I[FED[; ];>A!7@/W!B>_5
MHJJ>]?R)[_2;WWVMK,WZ^V^I.NM44KH\CK>.XXX/3=O,X';W:!UV$X05*^>U
MW&U%\FKQ1ZW,X79C^.8N!'M[$=IJ9PR\+ 3[E^X,=>^\5E:"10^J!#L:@#O3
MILV457&9\@O>6E_-:,>=4C;@("FT7GEAO,..<A]'EL BQ2!$>/6*P9X>X:/#
MW?C9/Z>-G;??C@X_H,:A.VE\WOM9?[<7^_BV=?2YT:H?;IU/Y@]LG!Z?U ^_
M_CS^7(?USQ]/&CN?4 /OHJ/3W1]'IZV3>,^3(_SI9WWGKW!9"/8 GC<N+*Q_
M_8(EXL9S" A"#%#E(# (4Z L$R&0 !U6:YL"/;I\VKPJ\,+UYI]6E:L'=[,G
M2)U[ )85PZ9SI"X,P%YI$OOG@[&+"1@3%@7#F0=2\0"H5AIH["U@FG%N W?&
MD[5-M&(@EKG)S-Q$$Q-,$ PS+:F%7%-NI)$86RNM"NYAW.35)SY^/HU'$QH/
MF22::P92_O9(7"0&)M(7$!A$C"M#'8_$A?!U(5=-[3-WR=QEBKLL#. R=WDD
MDI$)))/2414B?FG/(Y)1B8 R4()@0^#&< *Y6T )V QB&<26'L2@MYXJA+&B
M5%-BA)5,:HH\(L:P\!@0RUQM80C')A".,D$I)1Q$I&/1.M,:1/N9@KCZ.!48
MM=21Q-70ND33Y7<RSF6<>PTX-T_)L6C8:.UQM&V4HMAY+7 (3E!L((_&#;X;
MZ'+)L1=QJU^ZUD\M:>SL?1&:>>F8 EB$ "A"(4*># !2"I6S7%(BUS;Q.A+3
MUNGL]<8RUF6LJR36S0-UF#(9A/+2,BH54E![Y*"6'"*)G5T4IWMM]:^?$]S.
M;X(;M9@KAEBJGQCYG!$>*$(]8)&8.TV$5=0OK/QUQKB,<97$N'GXG&#01<VP
M3AE* W**:>F#Y"I:1,+87WC?,I][$<AK3/ YR!GA&@L0N'(@DC@.C"44> TU
M%]&\=3SQ.8+6J6*9T66T>VUH-T^81% P<!NL-Y)R;327UD*/$$:<":ZSEZXB
M&#=!ZQSDWF(90<U0'&W6((!AG #,-'2".D^D7MM$6*XC)I>%ULT=K#I1-GLI
M8*G0%&!TWZ>7;)_Y3K\XA_Z@8-5;!F!98CY&)L?#BAI7J#9[EE.64Y93EE.6
MT^N2TQPDVF$O@C8$<8*HT%9YY:$5+'!-"3;ZRTXZC0+C?T'Q"[F/36^YTV%_
MT$Y990Z[5P<:TU'&O<[H(&,1O5C0B.UK+.*CC^2[WQSXT6&^]_'MN^ZCM]VO
MG>(N_^C6T&?Z/0_];DYMDEL34)S7!K @.:"82: E8X!P* W6F 9OUC8Q?S3S
MSFJ?X3G+*<LIRRG+J3)T)T"!C4#4862I\$X;:$D(D$DK'(0JTYTEISM3WD8A
M*%;8"F"9(( *R(#A#$7ZHY51R*" 2-7X3D[FFUNN;,N52/N03NZEO \I":LM
M\R3UDW.]-CR+O_J?OF>;_>+J#]WKZ2)%Z\,30BSCHOXP\G7[7%B6P[%93EE.
MU3BGC"'WS%&$&2.46:>%"L%@E\ZY8ZKMS#S9]EPH=]C+P\H[PUX<N9+KEH>8
M/X\ ;G<$>CG7RCR4M[$]=609Z6 ]\1YPQ@6@TB)@9!04@XY"'LT<[/G:IK@E
M(CPK<<65.(/M<LCI)39@?H6TA2OA%J#-84X+0^')?1:EG.),(J"14H &%5$X
M, RLHXHPJ"W$*<II'7.2<7C9]#OC<)93EE.6TZK)Z25V6C*O>5%>,[6AXKV7
M"#D"E.404"@4T(8;((0E0B+&B6?5(S9Y2R6W7-F6*W$XH<QD;V]DLF]U^P_;
M.%GB:(@<M9+EE.64Y93EE.64Y93EE.7TNN4T3WX0B#!%6).@K:'4(TT$]H9Z
MI8@4QL^RV71'HI""?=\H(U56D4HUI!I^L!\.]<_L>IG']=*<3H@$O6.*<PV@
MD1)0Z!50AF# M5!6.4H9YFN;7#PB,4C6WXRS64Z/Q=D%.+\SSCX?SDZ=&?"8
M.^<-((&KB+.8 (V@ ]0SXQE$SD)2'9Q=B8#IJYK%99RT:WYO.M]Q.2PZ[Y1F
M.64Y93EE.64Y93EE.64Y93EE.579.Q"[(E0@P2'.*"/4J&AL*BX"B4(.CLR=
MA&!G9 SU+ZVD(EXN^P'F\0.<WY*-V0;M/6< 2X$ 3<73%!,,"&Z$PQX[9M7:
MYG3-ZKGS,&=%K:2B+CQ;2%;4!2GJA,/.$&T<)Q)P*1F@'BF@H_("XK"T6!+K
M&:V,HJY$--Y'W_*ZS&!@X]74K]J@UXP_0WRS^!I%VH-FD3DG1^CE'9\LIRRG
M+*<LIRRG+*<LIX6?QJ-..:,\$I9#"C4U\8=WR#AL.>;!S7<:;T3N]L/VB-H=
M)F;WMB1VVY>\+ILU<Y@U^]O3U3VU9<Q3ZP$QS@"*) 4ZI3*4V ;J7/!&N;5-
M(F&%<A=FW<T8F^64Y53=M7"Q)]/S6O@T:^&DBT\C3:-,%&"!<$"U"<!P1^)T
M<@XA#RG"MFIKX4I$YC7\X.'G;)=X(R'OS&8Y93EE.64Y93EE.64Y93EE.64Y
MO;R<GCD2[XYS>M$JNCJ8EQ/2+<PS<# =I8>MXMI0"C1G#-# $- ..N A%182
M8R07:YML'0E5C0"@K,A5C-3+BOSLBCSAXN/0*B*I P8QDUQ\$!C',/#<4R:#
M8]142Y%7(I+O3]U*E8K6:W7=LR<U@M9K284>$[1GNCWG>V#0/7N3AK[?;35=
M+;W*4N+4?)55J&!<<V\%1YP*P[7@7@FA/?/":(*_[,T62EP63RE3XF;DF:=(
MX.'68'*CW:H@1:1](!*)B#S..B"Y)X!@BT*PEMM4)%"@Z0CBAVTNS*8 +[QE
M^(1:7#V4^^^G$>$<HJL6=MT20K0HX$HG'DZZK3AZ_=W_#)N#\PQ?\\+7!'&*
MW @+3BQ0(J7DYI !J8P DD!C()+0>[2V^>AZ3\L$7IF.S$9'F%6&*8<"<2H:
M3M@$ JD3T7+&P7FM'T9'LI6T.&6?='<PB22'W "M@P,4(Q.574>-USJ*$DK$
MC5K;)&*=,;Q*&I_I2J8K3P%LF:X\&L$FZ JE&DGD#/"">D"MAD [@P"QQDL5
MXO^17]ND&;PR>*TH>%G'@O5:.!T8%=@JBHTT0A(A.:$^/ :\,C=;'++M3W S
MX4($,H@!Y-"G<^@82,L]P())8I7B1./(S3A9)VQ1@:H9WS*^5>*UY]FO(T08
M3!DU*B#J+5'<6,.T199III&Y&^#NV*;+2/?$+J>RNFU$NSW2N/AP_H5S:KC!
M 5C():!"$&"8M4!0195@RDMF4QDXH:;]3G.GR<T8ES&N$J\]#\9Y'+0B5#!,
M(]199"B/AJ>"CAB'I;8+P;@,8W/"6/TFC"FI(T-S&EAM,* H>" Q)" ( WU
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MQX^F&YR,SX!>^U9YSNX-O/J*-OUN:SBX^RM5&5!Q<RBN_TR]+<Z.4N)=P)I
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MFYTDB/W.3B&&8C-Q/VP5<D W5ZC0_.D=N/"];EZ<YEB<+DM>7BU.%#F%)7(
M$LP!A7%=TH(X0*)8O9?><N63]UYBA/]84*K7"C'GK,]/SS3O4^RLP/,H\"2[
M#)Y!(3T!3G$%J$0***P$@%B*$)STGN'%U:A>R5S,"^+#2T&%=OQ9I,/-(MKB
M0>3GEG=_?6"Y</)S?=CC[RV??MGJN*UV-P[01?%Y1LIYD'+:/6BPM%([#*Q3
M$E /(=#$4V ("L1(SXUS:YODT5#Y"^U_*I8SJS&X\HJ[ ):3%?>I%7>2XA!!
M%,*0 Z$% M1*!!13 3@?K1(C+50RE41$T^ZSE]/<57*?%/59@-'](OBX?>8[
M_6+>U_S/]+O/3I1GXQ$')[KG_TR2V+XFB.S>7Q0Z[6_?LNM(1)RD GB+#:#:
M2B"-AB#P8(@32#*H4L%6Q'"%C+#L/ZDZL[A+E;.VSJ.MDUR""\&9(AP$8I.[
M1&A@6," *^.MX!9:H]<V,9<5TM77YC#)'<X=?LT^M.NV7]I*C!9BNSEL%UN,
M_9-X#0Q\KUUK=K[[T2YT]K0]?US>EK6]TEJ_)J[]L-/LVSC*@WXTXM^/!+=W
M):F\_LX3#'-9%3RNP:<V]FOO2UQQA?<^+L F,N5(ETPTY@.+Z[%A+GA-$(_&
M/*&\0L9\=L-5CRQGK7Y1K3Z_J=7&:RJDIT!:) #E!('T$:!(* 8EU];;=*"$
M5DBK7QN'6KH.ORHGZ/:)[GSU*4XPZ&:O]EVWAL6)<Q=O][U(H7 M'4.STQ_T
MA@7TC$)K?NA>3S^4":Z$@V7AOM)/G9Z/0W#AW;4(E4MI]7/$V4+6BJ,I!N@%
MCZS/,D!L"( &X8!&7 .!G;*2*"-ER"%GRZK1SWRZ84Z5SJH[G^I.T#QEJ'/,
M$J ECN0N6 XD,QY@2:@-#&-E5*)YXE4=9%@*_O'1M[SN%Y3#QJNI3[5!+Y&-
M$%\PG5JPW7:[6=@[V=WTY"3#]EQX,Y+)?M@>2>0P">1M*8_M2W&\[?8.?.][
MT_K^1V]]1"J7D6HNI+)3) ,2Y;6Q @C$$\FP$"BF-3!!6"8U@9K0M4U$JA0S
MDMU,U7,S96U^$6V>X!T8,4(-@H"J% %F$(V*3"0(04GH S::DK5-(F&%M/G5
M)\DH/1[]B:.1Q:F.FNZX6JNI3;/UB&.2LQI2+WF/5:*8^X,3WWO,P<B56'2>
M;L=RKV-[:07:\>6_>YU"(I=)B\H357FQF6NQ^39%'3E6C'%G@3<D&KG<&B"1
M=<!! Y'E4 D7C5R6SPF\8B5^N@W*K,1/H\03C#&X0!$5&"@;)* :I5Q 3*70
M7!>8,8&2="R25RG,8)6VR[9LN1^?DF]$&ZG(]II(X[ 3.6/+NVN?YRVQ*E"-
ML< ^7LHE8]0\&'6Z-44T*%><(\2 (-"DW L8&,$(0(@3B*TSR(NU35FE4.2\
M![;$1".K\.-5>()F< ZCJ< ]L#(H0)UA0'&/ ?.$:JVTC;"[MGE+8J_*GB9X
M51Z+]SU_IIMN?!"Q]$MU5]>-\<P94>\#I)%X=DOIY%.*BT.JW2FR8;14V&D(
MH$4!4&L9D-Q(X#1F$:@"9]84QQ3IM&-C]LW[[-.HL$8O/-SF?HW.2CN?TD[0
M"Z(1D4@[H&3:Q2;! VE4 )@&[8WF3%,4E58^)IUQ=F \;#/D<LNKC+LIA@=T
M QC&/W+RR.=V7!0[]+?X5L=2^CO]_3'U=C]\ZOO"RYKA:2YXVIOB% 1::+P0
M  =% ?5: 2FE!8)H@WV04/,BR.;13M;LP:BN+B_>@Y%U^3ET>8)J>*^$,L@#
MPYT&-% !%)61=.CXL6 .DY"<D57*8;)*GHS+_9(S?7ZY6:*M[0W]E7MCQ;P9
MU7)FC"7TOA10R@%7BN?OJSBH?*9H(>@U?:K<1(%%Z0E@I(^8Q2D&V@0%$/$V
M(,9AX=U8T)FB[.1XW4Z.N3=49E?Y[-5\I-Y/GCN/ED:4*HJ*CHK:*@)H33U@
M@J7\]5 RJ9-7D^**>#57V45R+2!XQ5PC+UN);B9[:@Q9YQF3YL*D#]-A'8Q:
M&*(1Q06$@-H4A(:E!,PI*EC\7Y1M"CVKQAG)[ ^I/@/)"ORT"CSI"H&8,8H=
M\,1:D/+: ,E21ANJH-'*">?]VB;&^93S"QU!>2R16 U+Z.4.HMPP?S(8S0%&
MGZ;8A'/*><,)4$I',-)2 !5D2EWK6#1U#(R27=NDTW[9'+1162VN5LQ&UMV%
MZ>X$D: $HT@F*!!0<D"#D4!R3( 0 4EFH% LI%R7%7)(OOI3RXU9RKH^QCUA
MNCWG>R"^X9LDA'ZWU72U\7LM(5A5@W)$L6U'J;WO=;\WG7=_GG^*XKMF FU=
MRBX[7!<':=/)VQ!5 HH(9#P92)2YM.6B#0B<&^]<L$B+M4T$US%=0#7KF75I
MB;P?JXP/3UK./N/#2^##9(:XA/D1ZX$E,N*#A@R8X#$(5EB$O=<XT%3L7LII
MUE,]>!BQH7%'QO.>%<K_ I7:9WKAERXG/W\G7Q'I%+=B9)EJ_";'7-F<.*\@
M3_7M!E<5YM\=J9KT67.@6V6@F&L.AKWL.7W.:+'W^KQ(]GW8W;+_&39[/O*4
MR$P&Y^];NC/8ZKC=^.E9:I()R#P$Y&+Z4+USG N!,1 "NE0L-,6D1Q9"/,)"
M:,BI30:*J$@\2':85MUA.H_NYNC.Q>CT9)274@1!QP!U7 -*G06*<P*"")@%
MXC43J(K1G:^(U]ZNEW4=J43!9E/>Z076-EO>2)$7I1F];IR\KO^VUVU?B:8X
MDUMB6$2K;=UJ]??#UG?=;*6@U92N-H+3@;>CYMD_LC@HFSZ&[QU4A#H*8##)
M?RH0T#P(@'F0 :;J%R1M"<EUC*;#2_*IN5>C^XNG*8O7_<Q@'J[V$PP&>F&<
MLA@X03R@"$%@'$(@2CQ(CI26@E:QYLVK]XR\'_;LB>XOG, LKZU5+4?)W5BU
MX\T@<Y7%@=;T\7XF-5724J PC[87P@%H)RB0GD-A$53>JLA5^+H0%4E DKTI
M%=RQS1I>'0V?H"72.>DI1<!Q$P"%#@/IHL+CP#@BT.J V=HF0G0=*58-%7_U
M/I6D ]F=4C5W2I+*KRRGC%6+Q:KI(_X0.4P94\#3%$P+"01:"0Z<9,IP[C3T
M*:.[6(=R&JJRY^35J/F3>DZRFC^[FD]0$LLYE\PJ(!P)Y>$[Q1D#AG(=K0_K
MF4N5Y->IJI)_]-7[22[#YL]&$98U<U[[;11#_Z\105E $/T\,62O$]\63F/N
M"(V]C$G+H;%/@6S3>0$$-10[I$#D*RJ%QBJ@M%1 .V:-TAQ1 5,RUW7"'EWR
M85XU6B*'RVN#ADK'SV>0>&J0F/3($$@##QHHD0[Y&A]!(G@'.#,FK@O"!)3"
MUQ!:YVH:)>;VR"Q'!/T" Y:?+H+^13OYBOCG[1'T;YL=W;&+B*!?X$F')[O'
M:XN@SQW.'7YUCOJQWZ@6>MUVS?_T/=OL^^2Y_Z%[/9U]]2_EJ_]<#O_N2"(Y
MJFD19+6Q,QW,J!P. EH./%,24$H9T%QY8%60AD8S%O'%9=W-/OGJJO.3^N1_
MK<[9 'VD3D\8H((1C(VE@#%' 4701 ,TRDUR;;B"2$B9#-!US*=C?BKK?U\Z
M=I0[G#N\[!U>)J?#')M>X19/1-[JJH85<(<7^])Y=)<7.]L$#^0/=LHFD%12
M3I@!U*:2A5Y&ZH )!HX88ISURD&YZ+.:>9OK5<'"PJV)A\)"MBT>B0V3B;4%
ME<Q@"[R'#% N))#:,J \#APIY9BQ"[(MGGE_ZZ6I6';+WB1M)[KSU:?LG@5]
M2[72BE_\?X;-[U&%'^F;76%L7CAE2\"<_K][)9J/OC_H->W NW1AJ^-N?G"M
MY?OXOETWG=+8MH9)!KL_RXGP40_\;@C>YMC-!>+[MULJGV E$== .):2_PD!
M4H9RH+&G03 5_ZO7-N4Z@M.Y01_F.ZH,\\L)0BL>X)1Q9HEQ9C)(2B*JK$?
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M:L';_8]5PB5R\&38^45XXN.JK678J3SL3 49:<LU% %@Y0R@$$E@&!4@F+@
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M4Z=[[S"3/,P/&>;#[D"W5BO588F3;V:9+H_*F#3+/'IPU&/N9*4[N:!S@V7
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MPB2#N',!V12R6A(%=C2X%-8Y:7O-$3]+J,%2(5]"#>:']KC'P,>06)06*4$
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MTH!FD<IHK,1)*JYT,@R[Z%426K"\<8HU7R^TMUY,"&;,!:8\2:2H5X@S 38
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M&=BA;K# P";ONJVUM"4L6")62QFD@*.O$L";X0P.2L2C"60TJINF;"DX.:D
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M7R]_'/\X^WK</^M]N8#[@4;P67\99\G)AY-T?GP?K&T=_]FU3PXNQZ<'QS^
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M^:]0LYK_#OTVJ&#-?U\%&.:_9_!UF R6W)&@K(CFORU[^2A=^!;!L["3[P,
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M,E!U(&H.X0:D=M #I1-*\,*2V)ATW$ECL^8^HIM+Y=74]TJ 0!LBQ5P/XH7
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M$,ES]XGX6E2J=<S&N61-LS^70$%%\B//6$LY3K*,E_F0":9_!!!-(@8BX-\
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M/L-3O!Q/ %7?MZSV3+&7T6QE>FNVD.JFQ,1Z:[7YUV94+L\+I0?+4VVF[!^
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M.V1E3QDATLX0.R!V<B5ZR:U.<D@4O^A:VZ@0K#5#A<!05Q\Q/(-C5;GWZ:C
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M]P&U#?XL1WUT\OT@5(_D\ES@LWSD,)GX8<"D $TPB1,^B9J='^Y3KI#[#IX
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MUX?K=L'T6<OJA>S0FV3UEGNYM\4O8U@W.[3?!'DTAG]ZPW[Z_O\#4$L#!!0
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MU[[=QD8.N#T91BR4' CYTF?X]P$_??@?4$L#!!0    ( !J I53NF6(;4QP
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M"UPN1E%(;QQ3$$VB9WLAP+FD02N6B>!>^*B[L&7U^#:#. U -??&<IXA169
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MW8WO !G_7(K1X!@Q7VE'@\XF@#3>1Z9]"+S+VMO:&FO;R-R2WTK19'4_XFJ
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M"&&]W5P: [MG?G4P&?^'9&D+&>\J 7M^SNJY/XM169U-3]Z_4?5="M%!;<^
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MQ\<?_W;E\W_(^:>Y]_[)_-W3CTZ'UWV0OI8_^>_?WGQ,G_$PP' \G85Q.GL
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MWB![>0G3B_GZMQ*HP:4JK3XI<2VJ/I?Y9:5F-Q!A?>M-6JE^8[S(,IML;*(
M-2H"IRWX4#C8E+DU*K'29@-B@WRX4,JW?3K<1>,-:' Q)OUM[A8/>"K&"N7
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MB]S)S=,;I7H8(5OCR-4!8+<] ,Z-\]?C63<<3X=I?J9D($NVCCL.(9L,"H,
MIY&"0">LD#X)TODNDG^I1#\0\?MG7KNTP!JT:94(B+<+%F_W+2\*Q@?>)F5#
MTH#9U9.Y*,B=9!ITM-D%YZ2*.WFMQ'*1'D;$SA'GARQF>GIPT.%!F%V2?&"X
MMXH5"SIP2:NV-.!"(?-(:X7+166]D\<Y[BWQPX#ZT6BW2Z51B\JN=V7^[O3I
MT>SSI*LM>P?6IF1#K?W'X$ Q7^KJ&L&01ZQR%-RX)G=?]"[)#S0^MAQ[],*%
MJ^1VNT+NKV$XJFOEJTDW3X4/HN.1UP/J#A,MDB4C337>@+#9^N MYVRG.7Y9
MH >J;X,95QGO^[NGZ_XIMD6G=2ZU#(DHZ RGT"@$"YY66,@YT')%7J(5;;:3
M^I)@4_=Q;9O)6['XKER[=7+AQ+RG=_3%U'LE@$=DH$RBT$4[#3DE%IW7XDJA
M0#^4/0]B^]<M;)0&DY[,T6!SY?)=)"N@:7F)PB[<;75_\RRQ\QJZ;6]Q9H(6
MV0A@:"D>S(8696EK4"@,BEBRTDVG@RW>?-#*T'=1:8\&GM<,+?I>OQXGFJZ&
M7[$B(P/PDTN! @:E*,BPQM9J..[!E9(@<>55SIQ['5<J$KOQ,9OWD]<QP*2)
M]AKT"+YX;YF07ALM)" /!":E"#ZQ B7RY*01R;<)KBZ@^+G7\?L;9*=JNF^X
MFFP5F1XNS+S[A9EWXLHF+AV\CZ%WZLS/#;(Q#-HE)B!8:4%%@1!=MA!%SD+Q
M>AF>_KG)>Z<+,W>.NW>Q[T8OS.16^U(TKXYD!<9C]1<8^*)LM"SKPIMDE_?]
MPLP[&7SE"S/O8JT>O;NYW_EZG(_27!_S_=%SX$YN+6+6>R>XA$SN;'5I#7FS
M4H!+R65D*2K&5O+<;WW43TR2!K;8\@U2[XD*V'68YV_U>GG4]5_=\MZH%82Y
M=&44E])XQCR3FB*WHD(D9]]HE)K,)XJ\YLJHZQ^RWA+Q?!2F4XI5ZC>>[6=S
MEPJAX"!<J.W?3 *'F:)4+WA)W'(6FU1S7XMF[5VE"VI['[IWW?RJMSS/W[_'
M;CZ !U8;FV*4P)Q*0!&6KJ>,*#Q7,MOH?4C89K=I)7B;G_K69\:5O:C^#=%@
M+^,BRBL9\22CS183>)UY[8Q(43EJ";IV7G>2!]:F)=O-L/:/'FLIOL7>] 5T
M;X8T(^>Y,[!X \<)%_5 SL:<20? !"<5<-*#KT<6;71)AFQ=D+$]098#W#^J
M]&2,!CM?UU'Z7$G9P(3B1.8%^-RQ#V38R'4"OKBGBAGMF]S'>@NN_:/(>JIO
M4;9WMDU<\3W[/M? 8N-7:9]C$!DR1H(F+05^5F=RXF5"C2P4WZ:0=3FF3=5B
M],^#OA2]*P43I[<4GU?5?/?+:!VUE13[,20MZ<2!ED9%"V0- 57D,K>I:5N&
M: =2,.N9_#*5>E%] ]_D/)[C/895$+5,CUR%M)WD1D\VFS11^&:HP E7UDX!
M6FE .<; N^! <&%$=MY$TZ2AP:8H<$N*8&,,N(N>^ZZM^(C=D**EYY/Q5^QF
M0YKI+OH_Q]N#03GNI8OUK$(&56CB\TR03^QS"(%;Z>2EIJ;+.O&L]+SM^I'W
M,<NDK4[[WIQ?0'QV*\103] $ XYY#RH2T:/P"G+DM;C?:&-7JZU9[7G[8/9>
M==IFM#^_#2*/-C-#;C.OYV)I/BM 08\!3ZP4C$EMPEU&^VW/VP>S]ZK3'C<4
MSD%\<1O$@LXRQ@U8$10HKQ$"6OHAA$C,:UY\N(/9;WO>/IB]5YWVWJMO#O'E
M;1"%2J6V;2,?QM<S"#G7TY,*)"J.3$DBK;F#V6][WCZ8O5>=+NT\MR2=>OQR
M_5%/>?_M3_\?4$L#!!0    ( !J I50C#_UIN)4  .)5!@ 5    8W)D9BTR
M,#(R,#,S,5]L86(N>&ULU+U[D]LXEB?Z_WP*WNX;/=41B2H"! FB>V8VTJ\:
MQ[J<7MO5O7,K;BCP=&I;*663DNV<3[\ 2;TE"J ()FLZQF5GDL0Y/Y _'!R<
MQ[_]C^\/L^BK*LKI8O[O?X _QG^(U%PLY'3^Y=__\.OG-R#_P__XCW_YEW_[
M?P#XWR\^OHM>+<3J0<V7T<M"L:62T;?I\C[ZNU3E/R)=+!ZBOR^*?TR_,@#^
MH[KIY>+QJ9A^N5]&*$;H\+?%7U($L<S2!,3F3X 3C0%-TAS07"0TR[0067SS
MY2]$YBA3*0(8<@@P03'(9<) FDG%<IXSR$7UT-ET_H^_V#\X*U5DE)N7U3__
M_0_WR^7C7W[ZZ=NW;S]^Y\7LQT7QY2<4Q\E/ZZO_T%S^_>CZ;TEU-:24_E3]
M=G-I.3UUH7DL_.E___+ND[A7#PQ,Y^62S84=H)S^I:Q^^&XAV++"_*)<T=DK
M[+_ ^C)@?P0@ @G\\7LI__ ?_Q)%-1S%8J8^*AW9__[Z\>W9(>E/]HJ?YNJ+
MG=D/JI@NY*<E*Y;O&%<S(WWUM.73H_KW/Y33A\>96O_LOE#Z]&-G1;'W5"LE
MM5+"S$KYQW.#_72%^#W)NSR6M0?A*G7?]R5C&Z;O>Q/WL^$'%5[@G6&N%KE^
MH5[/Y5#O[F:HJT4/+W%?K\5BR68#O!;;879$GMD?O#-_:X:Q#VHATVJ<AKIW
M1%7?EVHN5<V6>X^.IO+?_V#^-EF5X MCCY-WJBR5NGM4A2'N^9=WRG!N^=D\
MX,5L(?XQ05Q*EC*C!-%FA<J$!$SF":"4Y"F!.F<\FRPW;_A$S<&OG];"5"/Z
M#/<'#ZV79[[>0I6+52&VZ][#[-1B9M8QN_+E/\W9@RH?67.#D=F:"+4:_U&+
M]V\_;;6Y&M#9P##-0B-D!;V)-J)&M:S1;U;:J!+W_S\+X$+L"3:SUL.B.,1E
M(3QQV?LV*TPT*WFE5/,@ Q"*?U*S9;G^"; _ 3%L[(P_.H[XT]$+<5NLE6*%
MN#!#S14_B86QHQZ78&^RK-W91?OEHLN[5,^ $>@/T:*0JC!6\PGE-F^[5-/)
MVFC^;&Z=4 C35$L)4JH%P'F2 D:(-']+5482)C.%7(CB\,%CHX3-3L$*Y\8,
M1UBU<\ U" 3^VMV4=_ZJSVFZ_7[+]0=<*O'CE\77G\PM];=K_G+XR1X];I"/
M\YP2Z\_P[._]/KCUU_SIGA7JA?F$Y<O%PZ.:E]5^Z[8HS#PI.\:+I^TE']B3
M_='M-U;(NT=[87FW6MIMF]T)OYTO"[.)FXJ_L=E*31(8YU3D,4@3NR/E>0HX
MY S05!"59;E 7/@L]<$D'1LE-/)&BZW -]%T+7+TU<KL9T.$FV0W\V,44Q>8
MRRH%@'4QR&A7RVA'S8@_1;O7-:I&E:[6Z*FT-7_9G?F-QM'?6F?>V_@)/BM]
MVDWAA!W4Y J.^:&U%G[ ;NO.&S8MJN>\FI9BMBA7YEN\Y>6R8&(YH1EF&4D)
MH%HG *<9!US'Q@(4!*DX-G_BQ&?I:!ML;.QO9:V_]&A'VNBWM;SG=S_^.+NQ
M=U_H!2;@[L!Y,Z<+(GV27^MX@_*7B^:'%.1T3S<6N5O>J^+]8KY8[T;?SL7B
M0;W^;IE.363.-<GR!&0)Y@!3D8 <8PDXUPPJI"A-E ^/M \W-B:II#6&HQ4Q
M^D'50O[Y)IJKI1^'7$#9C47ZPRXPC]2P[4H:O6TP;(3]<W],XH9*GUQR8<1!
MV<1-^T,^<;RK&Z,8*^EANK164'D[-S;3W Z@YF*JRBU];=VO22)ABF(%D)(0
M8)1R0*6A&:D2E=$DC76L?1C&;_BQ,<Z.])&Q&:,]^?TXQW,>W#@H'+J!.:D5
MV!US)Y";O!MN?;*6IP2#LE@W= Y9K>-3GL?K][.Y<%F^G=>'NC\7B[*<R"0A
M5.4$Q Q1@'FB ,V0!IJP.,.00AK+(?U])V0<&U]6(BH9_3"=1Z75I3QO6@PV
MC\.X]*Z<G=^1,Z_6U-CA4:VK_8G1=CQ^O):I&),'[Y28ORO?70O.?7OMVH;J
MMF+<"E&H2HB'1;&<_G<ET)VV2]-B5:]9'PKU,%T]F&&_JK)>R28TP9"SF "F
M;+R'RC/ (10@AS"7-$=4(C$Y"FRZR#[=I'$B&+>8KC[)9E>':*&CQT;R:&%7
M!?,[8-:B!T,@&T7\%HF.4^>V#@2<B6&H?J- ],.N"G^V,['1HC*ZUWK8(YG+
M4^%-X]<AV2=3=Y1D4#*^#JU#OKWR:1V-<$/.JKPU#]:J*)3\M#2&_2_J@:MB
M(@B$FFH$$&488,@R0#47 #',!,UB&^GM94R?'VML1G$MZI_^"+/XK[=VI_M5
MF2GA,Q5MI(\J\3U-Y1:T'4W>?C ,;;I64D:WAVA%O]6B]N@6< "D5P.R9;AA
M#<'+>A\9= ZW=&.1MW-#7<8,?*7J_[Z=&S*K2,O8A<Q\-H:[++VME'PW97PZ
MFRZ-)!,>$Y0E7 ,!(0=8TA@PF61 I!C+C!*%)/,AF&YBC(U[UC)'C[70U;K/
M:K&CY@3%T_KJ.#]NE!0>]<!LM58@^F&MPI_M3GDS#Q]VYJ%1)-K1I#\NNP[)
M/FFNHR2#,N!U:!V2XY5/ZVA]B7LE5S-UIU\_/,X63TH9COXZ%>K,WGLV:W+1
M[O1')19?YM/_7B>UO%R4R_*S%72"),^I9!P01G* ,9. \C0'"2(:2<U2@;QH
M-8B48V/=DUZTK:_C)FJ.]F1]]L$>ITLVLXK=1,9>-^])]%NEEV=H3)@WP-&6
M?.YY'="!&F9*_:W5D)#W:N<&$718"SDDUD>V==#!.KI+O[+IS#[GS:+XQ&9&
M(K$JJF7KE>++[;\FFB&<B$2!6-D\%Y:;KT;A!% H68HT04*D/@N&Z\!C6P.J
M],6(K:6/]**(2B/_%6Y/URG(\C21F8X!I$H!+%(-K%L:Q)3'*$\SGB$Q66[2
M*Y]G"LXDD?8>0/D+*_ZAEA="S:_#V]&Q' #%P(N>%2S:2F:6LK4.P+S.P+[.
M/;J+/?'IU4'L.O:P+F%/1(Z<P+[W=]QX+-FR,H)>_W,U73[9I6DQK\(^OD_+
M2<P,'<6* (UA"K"F&> B2P'5:2YBJ%)"_:(HVD8;VR)0RQAMA8Q^LV+ZVO6M
M #O:YWW!%IARO!'S-YM=D.C5_&T=<%@SUD7W(W/4Z28_[A"%U)/&JC4VJYI^
MK?::."&$YU0!&DL.S+]RP 12(,,)I4QQR7/H<;I^>I21GIHW<D;%1E!'^_ ,
MENV\< 4T@QW[5'!LA;L*#=ED&%?[I("H[(T3#IU?S!>X9,53G3QKC_;U:FGC
M9849<"K,SF-93,V?9:U+&2T7$5^_6TI:E[2AC+D25:! 5<QK6I8K6Z[*/DPL
M'AYLL(8]U+FQ\1O-P5OU@\K#\8T554C.];S<CGE-Q/8:2Z\H3AIR/7/7(&S:
M+O&:/B]<U8$O+?,6ZM[L^\T<UCD"[Q9EN3'S/B]>5O-6G<7=+V;FL>4+5D[%
MA$N,M#"\RB&2 *<$F4UYK(%"">1")0K&T&5'>)T88]L?[BD2S8P.$5N:[X:O
MEM66W7PSNQ]"HXH'#76?, ?R'F0: I/\_@RLLY*L&G_>[C6CSXNH5B7:U>4F
MJK099#H\5H]!IF6@52;D]/BM#U>CVKJ.='_Z<.O-U0CLK4O7/^W*+/FW\\?5
MLGRGOJI9T@0MI4303"<<("@2@)E@9KD2"BB!,%:(:<:]/ 4M8XW-3_!I^F4^
MU<9NFR^C7^<+;LVVZMNJ13??G!6^#B%+/%,JVB!W\QWT!&3@M62;+G_3P'83
M5:)&28!0,0=,@B3,GQCN>?+ES^M]-EV^Y98NW@-+36_-ID7)5ZMB.O]2GWA5
M(_V]V9V\_JX*,2V5G&@-,PQS":"-.L4LP\8"UAQ@)7*:TD3D;N%A_D./C6O>
MGMGG1:M'\U?5B&U_>W&/=^VDN+@H0D$=VGU105H+'M62-^E234F/M?#11OI@
M,/OX/D+!/9#%^OE>1:IV(4\?S#7+2-;8+\TO'FO\Y:K:VMF?"%;>GWSE?^S+
MK]$%SW:?A]<3!_2'=-%TWU?2Z0D=ZZSL5?M<!^$]O5P5A7E))ZF&4K X!3).
M<X!)E@/&H 2)T+GFN=("4Z\Z*ZW#C6V%V-:JG56AK#.'^-1.*&<Y50HID.?*
M&/R<"<!)+H!,=:HY(I(*-OFJ"KX8'N?=80-NL&O!HL5 B+O9^_VA&'B1/2BJ
M?+.)I'ZZB1II>ZQLXX1*KY5MVD<<MK*-D_9'E6W<[KHVX'G72U$?4KY?+#=K
MQEWQT78BV:DQKC*$*32DGL0Z SAA%#!,$T"DS%6:*DB45QFMSI*,C?D_K1X>
M[*F2L80:F:-;L9Q^M?94%==Z;P->J]S_C?VZ4U"Q:[BR[_RYT=@@LQ)Z&]'H
M8&=D5XM_C9I ":O(S78R%D54*].$&T=!RN=<C6R8Z&)?89XI@K@C9N>CA+L^
ML!OM?B@60BE9OC$J-F.LK?)R G,A<BHTD$F* 98* 8H8!UIHBM-8:V(/&MV9
MM6VPL9'G6M:Z(59W1XH3T&X4V!=\@5EN'[GURK.1M#_B<L&C3VYJ'6]0^G'1
M_)!AG.[IX+G]J*I=SIU^.:N#53[;6)4WJ\J&V)8-LU&K3?C*QR9N92(0QXPJ
M>S*DF=F84P+R1-NDW]30#$H1SIUJ\%\IQ]BHI]&D<NG.]@* =*U-Y>FMU?%P
M,UXQ40ZNW6'@#TQ=:^3O=+16(ZKTB!I%HJTFD5$E6NL2K9499CX\?,##S,M
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M!@B7&F"!<\ R"@'BD!(!,\:Q5\W9,^.,[3,_E3[4S: X@ZNC!7$]6J%-A@Y
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MU:[Y<\\?V"M_0<UCA_RE&[KF>1]VO7Z_6*I- G(&<Q$+9& DN3 <D4' .(6
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M[I,*]_]E/DO@]DG=3G^GUYW:V?I(S1.V\3BOY_(56ZI) M.4*PL,@1Q@21/
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M@3RH0,-%*#\'SGL1S,\B0+?-TYM%81X^_WEA'CVW8NQ'7_^BJNKE*<1*(20
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M2TF;'E9?%^ZCN\?U:FU7.Q>I^^W;LK:CWL_7R^E\-95UG.]$.C8A=NMJ.%<
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MN]<W"96GG)"X4:<)Y!PX6#4=TL<QK@G'NL(!MFH"O"8YKB0EKF)0J:1+V42
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M;OEY^NW[^A_:_:W5K1V5?]-O?]-+.5W9L:=2[[Z[VGQY[V4F#.62:&SY'4J
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MCT9\04?\.>V['?!GK^IACW_0J]5BZ2S[._/E4=2=&B="H9P7KB^"T*X#&N%
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M(<>V;K9+?342AFZP4LQD)/=?XOE)O*R%3$U\W]P5V WJDNLCY[@\<5<@'>R
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MFJ,"*%G*$E7<;C:##);S0XV-OS;B9;.]Q/\9QE0=L/KQ4ARP$K-02TB[3]N
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MN\9]F<:5'DB<[4?I<^W+9$'_7:]<3MJ\KH<@[8]?%^ZC\R54#Q-A-3:4*TJ
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M9#6=4Z@\B2H*7HP#D\DU5D0SD<\$Q**-U(F")C5$E'G'J[>KS^H^>;F_.+M
MP_//N/Q(F^"?EXO?UI^>+CY_"?-O$VFLTE%GB$G6,F?KP24R=EI2W&2+R!Z'
M.W"_DX3MT-%]VO)P\7:!DO>?<#8[IUYP5B1J#MGI*A%'\(Y&@ W6%<NY,'%
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MYS-:,[/%IN'0&5>7RR3]Y\F4B'LY?[M<)%HQ3Q>K]21)+5"3K\F\I%436*$
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M[Q_8/"BMZ')P6ADPM6.PXL9#-(K10N&A..L,8WUUP!B$[:T6HOWOA3@VXGZ
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MS")IQ=!VT17[[W72#B:/;FSFW\)R4VHVZ*S,FP]M.R#S01:.,Q53>2G)<AI
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MV5]02P$"% ,4    "  :@*54&AL1JRH(  #%*0  &0              @ $
M    8W)D9BTP,S,Q,C)E>&AI8FET,S$Q+FAT;5!+ 0(4 Q0    ( !J I50S
MJQ]!' @  *<I   9              "  6$(  !C<F1F+3 S,S$R,F5X:&EB
M:70S,3(N:'1M4$L! A0#%     @ &H"E5,C5KMO_!   T1<  !D
M     ( !M!   &-R9&8M,#,S,3(R97AH:6)I=#,R,2YH=&U02P$"% ,4
M"  :@*54L_OFD_D$  "S%P  &0              @ 'J%0  8W)D9BTP,S,Q
M,C)E>&AI8FET,S(R+FAT;5!+ 0(4 Q0    ( !J I51]^W5R62P! ,:T#P 1
M              "  1H;  !C<F1F+3(P,C(P,S,Q+FAT;5!+ 0(4 Q0    (
M !J I51+IE ?XPL   )V   1              "  :)' 0!C<F1F+3(P,C(P
M,S,Q+GAS9%!+ 0(4 Q0    ( !J I53NF6(;4QP  !\: 0 5
M  "  ;13 0!C<F1F+3(P,C(P,S,Q7V-A;"YX;6Q02P$"% ,4    "  :@*54
M=&&U'T(D   OG0$ %0              @ $Z< $ 8W)D9BTR,#(R,#,S,5]D
M968N>&UL4$L! A0#%     @ &H"E5",/_6FXE0  XE4& !4
M ( !KY0! &-R9&8M,C R,C S,S%?;&%B+GAM;%!+ 0(4 Q0    ( !J I53^
M [S@3E   #6U P 5              "  9HJ @!C<F1F+3(P,C(P,S,Q7W!R
;92YX;6Q02P4&      H "@"F @  &WL"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
